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Part I
Biomarkers in liver 
transplantation

Chapter 1
General introduction and aims 
of the thesis
CJ Verhoeven, LJW van der Laan, J de Jonge, HJ Metselaar
Based on ‘Biomarkers to monitor graft function following liver transplantation’, accepted for 
publication in Biomarkers in Disease: Methods, Discoveries and Applications.
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abstraCt
Liver transplantation (LT) has become the only curative treatment for end-stage liver 
disease since half a century. Patient survival has improved drastically over the years, 
but poor initial graft quality and complications following transplantation still limit 
patient and graft survival. Monitoring and evaluation of graft quality during follow-up 
is achieved by routine biomarker measurements in recipients’ blood, starting directly 
following surgery and in the months and years thereafter. This allows clinicians to early 
detect complications following LT, like early allograft dysfunction and biliary complica-
tions. They are also used as a tool for deciding on further diagnostics or interventions. 
Classic biomarkers are able to assess liver injury (aspartate- and alanine aminotransfer-
ase, lactate dehydrogenase), biliary injury and obstruction (gamma-glutamyltransferase, 
alkaline phosphatase), and liver function (albumin, bilirubin, prothrombin time). Novel 
genetic markers such as microRNAs also show potential as more accurate or specific 
biomarker for various types of injury and functions. Some of these serum biomarkers 
were shown to be promising in predicting disease or severity of injury when measured 
in bile, though widespread implementation in clinical practice has not yet happened. 
Therefore, liver biopsy remains the gold standard for diagnosing acute cellular rejection, 
even with less invasive serum biomarkers that are currently available. Future applica-
tions of biomarkers should enable early assessment of marginal graft function when 
applied to preservation solution in both simple cold storage as well as during ex situ 
machine perfusion. These developments could help to increase the donor pool for LT 
by optimizing and allocating grafts based on favourable biomarker profiles from donors 
with unfavourable clinical characteristics. 
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Definitions of worDs anD terms
Primary sclerosing cholangitis (PsC): auto-immune disease with progressive fibrosis of the 
intra- and extrahepatic bile ducts.
Cholestasis: accumulation of bile due to obstruction of flow to the duodenum or altered bile 
composition. 
non-anastomotic strictures (nas): benign tapering of the intrahepatic and/or (perihilar)-
extrahepatic bile ducts following LT. 
anastomotic stricture (as): isolated benign tapering of the biliary anastomosis following LT. 
early allograft dysfunction (eaD): poor graft function in the first week post LT, based on 
AST or ALT >2000 IU/L, or total bilirubin serum levels >10 µg/L on day 7 post LT, or INR 
>1.6 on day 7 post LT. 
Cholangiocarcinoma (CCa): malignancy of the hepatic bile ducts and cholangiocytes. 
Hepatocellular carcinoma (HCC): malignancy of liver parenchyma and hepatocytes. 
Donation after circulatory death (DCD): procurement of donor organs after circulatory 
arrest of the donor. Associated with warm-ischemic injury of organs. 
Donation after brain death (DbD): procurement of donor organs after disappearance of 
brain stem functions (brain death), while the circulation is still intact. Organs are usually 
of better quality compared to DCD. 
micrornas: small, non-coding RNAs involved in post-transcriptional gene regulation. Poten-
tial novel biomarkers. 
Preservation: storage of organs at cold temperature and suitable fluids to prevent detoria-
tion of the grafts, for optimal quality and functioning following transplantation. 
introDuCtion
The liver is the largest visceral and most multifunctional organ of the human body. It 
produces and drains bile, which is responsible for digestion. Furthermore, the liver me-
tabolizes glucose, proteins like albumin and coagulation factors, amino acids and lipids. 
Detoxification is achieved by the breakdown of hormones like insulin and drugs. Cells 
in the livers’ reticuloendothelial system are responsible for immunological effects and 
protection against certain antigens[1]. This enumeration describes only part of all liver 
functions, but also illustrates the livers’ diverse and essential role for the body. Under 
stable conditions, the liver has 60-70% overcapacity. This allows for resection in healthy 
individuals of up to 70% of liver volume[2]. After such surgery, the liver will regenerate 
to its normal volume within weeks. However, an absent liver function due to acute liver 
failure or chronic end-stage liver disease is not compatible with life and can only be 
cured by liver transplantation (LT).  
12 Chapter 1
It took four years for Thomas Starzl to perform the first successful LT in human in 1967, 
after several unsuccessful attempts since 1963, with most patients dying on the opera-
tion table[3, 4]. Still, the first LT series in human reported a one year survival rate of only 
25%, illustrating the complex surgical technique and severe complications that could 
occur early following LT in those days. One of the major complications limiting patient 
and graft survival was acute rejection of the transplanted organ against the recipient. 
A decade later, survival rates of LT recipients improved drastically after Sir Roy Calne 
introduced cyclosporine, an immunosuppressant drug, into the clinic[5]. 
Nearly 50 years later, LT is regarded standard treatment for end-stage liver disease 
and performed worldwide in various populations suffering from different pathologies. 
Because of optimized surgical techniques and immunosuppressant regimens, graft sur-
vival can now reach beyond 20 years with excellent graft function in some recipients[6]. 
This has also led to an expansion of the designated indications for LT; on-going trials 
investigate the benefit of LT in selected patients with cholangiocarcinoma[7], hepatocel-
lular carcinoma[8], and colorectal liver metastases[9]. However, while the list of patients 
awaiting LT is getting longer, the number of transplantable organs remains scarce. 
Moreover, the quality of transplantable organs is deteriorating due to increasing donor 
age, liver steatosis, viral hepatitis of the donor, and prolonged ischemia times following 
donation after circulatory death (DCD)[10]. All these factors can cause a wide range of 
complications threatening graft and patient survival following LT. Early complications 
mainly consist of infections, graft primary non-function (PNF), early allograft dysfunc-
tion (EAD), biliary complications (i.e. leakage and anastomotic and non-anastomotic 
biliary strictures), and acute rejection. Beside biliary complications, other complications 
at the intermediate and long-term usually consist of recurrence of liver disease that 
initially required LT (like hepatitis C viral infection and primary sclerosing cholangitis), 
the development of malignancies, chronic rejection and liver fibrosis[11]. 
In order to discover these complications in LT recipients timely, monitoring of graft 
function with suitable biomarkers is required. Routine monitoring of minimally- or non-
invasive biomarkers enables early recognition of complications to which physicians can 
adapt their medical policy. Two examples are to obtain histology in case of suspicion 
of allograft rejection or to perform imaging/endoscopic treatment in case of suspicion 
of biliary complications. Therefore, LT recipients are subjected to protocol (blood) mea-
surements depending on their clinical status during follow-up; varying from daily moni-
toring at the intensive care unit directly after surgery, to yearly routine measurements at 
the outpatient clinic. Different patients and underlying diseases require personalized or 
precision monitoring with established biomarkers in liver disease. 
The following paragraphs provide an outline on the definition of biomarkers in the 
field of LT and the different types of biomarkers that are used in clinical practice for 
short and long-term monitoring of graft function. Finally, potentially interesting novel 
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biomarkers are discussed and recommendations are given regarding future applications 
of biomarkers in the context of LT. 
Definition of biomarkers in liVer transPlantation
The term ‘biomarker’, an amalgamation of the words ‘biological marker’, was defined 
in 1998 by a working group of the National Institutes of Health, describing it as “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a thera-
peutic intervention”[12]. Since that time, however, multiple other definitions have been 
introduced that further expanded the interpretation of the term biomarker. This was for 
instance done by a collaboration of the World Health Organization, the United Nations 
and the International Labor Organization, who defined a biomarker as “any substance, 
structure, or process that can be measured in the body or its products and influence or 
predict the incidence of outcome or disease.”[13] Based on the descriptions above, one 
can conclude that biomarkers can be used to measure the effect of treatment as well 
as predict- or be related to a clinical endpoint. Biomarkers are also increasingly being 
used as a primary or secondary outcome measure in experimental or clinical studies, 
and therefore sometimes applied as a surrogate endpoint[14]. Especially in LT, defini-
tions like EAD or PNF are mainly defined by persistently elevated transaminase levels in 
serum, often combined with perturbed coagulation function of the liver. 
Furthermore, the previously described definitions on biomarkers allow to distinguish 
‘dynamic’ markers from ‘static’ markers. In the context of LT, dynamic markers are usually 
molecular markers and liver enzymes that can be measured in serum and which levels 
fluctuate depending on the functional status or degree of injury of the liver graft. As 
an example, immediately after LT, ischemia-reperfusion injury of the graft causes eleva-
tion of serum aspartate- and alanine aminotransferase levels (AST, ALT) above 200 IU/L, 
while a more gradual rise in gamma-glutamyl transferase (GGT) or alkaline phosphatase 
(ALP) starts approximately 24-48h after LT (fig. 1). When a patient has been transplanted 
because of viral hepatitis as underlying pathology, routine measurements of viral load 
during follow-up are part of regular clinical practice. This is because of the reasonable 
chance of recurrence of disease in the new liver graft[15]. Depending on the type of 
complication, treating the cause will ultimately result in normalization of serum levels of 
dynamic markers. Therefore, dynamic markers are variable markers that can be suitable 
for determining whether treatment or interventions are successful.  
Static markers on the other hand are less subjected to change by the (patho-)physi-
ological status of the liver graft. One could think of genetic polymorphisms like single 
nucleotide polymorphisms (SNP’s) of either donors or recipients that are related with 
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certain outcomes following LT. Genetic markers or SNP’s are more often fixed factors 
that do not fluctuate or change by graft injury. However, certain polymorphisms do 
make LT recipients more susceptible for certain complications; several SNP’s involved 
in the innate immunity system have been correlated to a higher incidence of severe 
infections post LT[16]. Also in recipients that were transplanted for cholestatic diseases 
like primary sclerosing cholangitis (PSC), certain SNP’s were identified that cause earlier 
recurrence of severe biliary injury after LT[17]. Because of the predicting capacity for 
outcome rather than their monitoring capacities, in literature, SNP’s are more often 
referred to as ‘risk factors’ instead of biomarkers. 
A separate category of markers are histological markers or markers measured in liver 
biopsies. Up to a decade ago, many transplant centres monitored graft injury and rejec-
tion by evaluating histological changes in by-protocol liver biopsies during follow-up. 
Most dynamic markers for liver injury in serum are related to histological changes of 
the liver parenchyma and bile ducts[18]. However, it usually takes more time to detect 
histological and morphological changes in liver tissue and puncture of the liver is not 
harmless. Therefore, taking liver biopsies is nowadays mainly indicated to confirm sus-
pected graft rejection and recurrence of disease or malignancy based on changes in 
serum biomarkers and imaging. 
The next chapters will focus mainly on dynamic markers in blood and serum and the 
most important histological markers associate with liver injury and function following LT. 
Different biomarkers for Different Cell tyPes
In liver disease, biomarkers are divided in predominantly hepatocellular- or cholestatic 
markers. Liver enzymes as AST and ALT are indicative of hepatocellular injury, while GGT 
and ALP reflect biliary injury or obstruction. Beside these two categories, markers of liver 
function are also of importance for the evaluation of graft quality, especially in the first 
days following LT. Very often, the liver enzymes AST and ALT are used to indirectly asses 
liver function. Strictly spoken they do not represent liver function but are more indicative 
of liver cell death. Thus, for this purpose it is more useful to analyse products that are nor-
mally metabolized or synthesized by the liver, like proteins such as albumin and certain 
coagulation markers. table 1 provides an overview of classic biomarkers per cell type, 
injury or function, which are discussed more extensively in the following paragraphs. 
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biomarkers for hepatocellular injury
Aspartate aminotransferase (AST)
AST is an enzyme involved in the production of proteins and catabolization of amino 
acids, allowing them to cross membranes and enter the citric acid cycle. In humans, 
AST is present in a descending concentration in the following tissues: heart, liver, skel-
etal muscle, kidney, pancreas, spleen, lungs, brain and erythrocytes. Current clinically 
applied techniques however do not trace tissue origin from which AST was released. 
Therefore, it is often necessary to involve other markers as well for the interpretation of 
serum AST in the clinical setting. AST can be measured in serum and plasma obtained 
through venipuncture, remaining stable for at least 24 hours at room temperature. Its 
halftime is approximately 12 hours. Two iso-enzymes of AST can be distinguished that 
occur in separate cellular compartments, namely in the cytoplasm (c-AST) and in the 
mitochondria (m-AST). Following mild tissue injury, particularly c-AST can be elevated 
in serum, while severe injury will also lead to a release of m-AST[19]. In adult healthy 
individuals, the range of AST varies between 31-35 U/l, but usually depends on sex and 
age[20].
Following LT, peak AST in serum is usually reached within the first 24-48 hours after 
surgery, sometimes being a 100-fold increased or higher. In particular when a liver graft 
is of poor quality, for instance due to increased warm ischemia time, high donor age, or 
liver steatosis, peak AST can reach extreme values during the first week post-LT (>1000 
U/l). Although transaminase levels usually decrease quickly following LT, one should 
be careful with interpreting this as graft recovery. Massive hepatocellular necrosis can 
result in hepatic failure, which should be evaluated based on the capacity of the graft’s 
coagulation function and bile production. Therefore, both markers for hepatocellular 
injury (AST, ALT) as well as cholestatic markers (ALP, GGT) and functional markers (PT, 
INR, albumin, bilirubin) should always be evaluated together directly following LT. 
table 1. Conventional biomarkers  used in liver transplantation for graft monitoring.
Category biomarkers
Hepatocellular injury AST, ALT, LDH
Cholangiocyte injury & cholestasis GGT, ALP, Bilirubin
Liver function Albumin, Bilirubin, PT, INR
Recurrence or new onset HCC AFP
Recurrence or new onset CCA CA 19-9
AST = aspartate aminotransferase, ALT= alanine aminotransferase, LDH = lactate dehydrogenase, GGT = 
gamma-glutamyl transferase, ALP = alkaline phosphatase, PT = prothrombin time, INR = international nor-
malized ratio, HCC = hepatocellular carcinoma, AFP = alpha-fetoprotein, CCA = cholangiocarcinoma, CA 
19-9 = cancer antigen 19-9.
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Alanine aminotransferase (ALT)
Alanine aminotransferase (ALT) catalyses the transfer of the amino group L-alanine to 
α-ketoglutarate, resulting in the production of pyruvate and L-glutamate. High concen-
trations occur in the hepatocyte cytoplasm, whereas only low concentrations are found 
in heart and kidney tissue[21]. Therefore, ALT is considered to be more liver specific 
compared to AST. However, because of their differences in intra-lobular distribution, 
elevation of AST levels is usually faster than ALT. Nevertheless, serum or plasma ALT has 
proven to be of value in the diagnostic process of various liver disease. For instance in 
acute viral hepatitis, serum ALT can quickly rise up to twenty-fold its normal range, while 
levels of AST remain lower or show only mild increase. At the same time the ALT/AST 
ratio, which is <1 in healthy individuals, becomes >1[22]. Chronic (viral) hepatitis results 
in milder elevations of AST and ALT. When levels of AST become higher then ALT, one 
should be aware of cellular necrosis. 
Despite being markers of hepatocellular injury, biliary obstruction can also result in 
liver injury and therefore increased levels of AST and ALT. Furthermore, peak serum 
ALT levels in the first week following LT have been associated with the development 
of severe biliary complications[23]. A possible explanation for this finding could lay 
within the distribution of ALT in the liver acinus; the bile ducts and hepatic artery are 
located peri-portally (zone 1). Ischemic injury in this zone will cause release of ALT into 
the serum. Zone 3 on the other hand is located peri-centrally, is less oxygenated, and 
contains higher concentrations of AST[18]. It remains unclear whether serum levels of 
AST are also related to the development of biliary complications. 
Just like AST, the reference value of ALT depends on sex and age, but normally does 
not rise above 50 U/l. Be aware that halftime of ALT in plasma or serum is however lon-
ger, approximately fifty hours. 
Lactate dehydrogenase (LDH)
This enzyme catalyses the conversion of lactate into pyruvate and vice versa. Pyruvate, 
the product of glycolysis, is converted to lactate under anaerobic conditions. The inverse 
reaction takes place in the liver and results in gluconeogenesis. LDH is present in the cell 
cytoplasm of practically all organs in the human body, making it widely applicable but 
thereby also less attractive for diagnostic purposes. Also distinguishing between the five 
different isotypes of LDH, which differ in characteristics as halftime, does not seem to 
give additional diagnostic benefit. Furthermore, haemolysis can give an overestimation 
of LDH activity in serum. The normal range of LDH in healthy adults is  below 225 U/l.
[24].
Despite these apparent shortcomings, LDH is still used as a clinical biomarker in the 
follow-up of liver transplant recipients. Strong elevations of LDH in serum or plasma di-
rectly after liver transplantation are usually indicative for the severity of ischemia-reper-
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fusion injury of the graft. When strong elevations of LDH prolong and are accompanied 
with high levels of other transaminases one should be aware of serious complications, 
like hepatic artery thrombosis[25]. But experimental studies also suggest the measure-
ment of LDH in bile to assess the amount of biliary or cholangiocyte injury[26]. However, 
this application of LDH is currently not used in standard clinical practice. 
biomarkers for biliary obstruction or cholestasis
Gamma-glutamyl transferase (GGT)
The enzyme GGT is a carboxypeptidase located in cellular membranes. It transfers gamma-
glutamyl gluthathione to acceptor aminoacids, peptides or water. Furthermore, it transfers 
amino acids across the cellular membrane. The hepatopancreatobiliary system is the larg-
est contributor of GGT levels in serum, but high concentrations of GGT are also present in 
kidney tubular epithelium and prostate tissue. Lower tissues are found in spleen, brain and 
heart. The liver excretes GGT via the bile. Therefore, biliary obstructions can cause strong 
elevations of GGT in serum[27]. Together with alkaline phosphatase (ALP), GGT is useful 
to screen whether recipients have developed significant biliary complications following 
LT, in particular anastomotic and non-anastomotic strictures (AS and NAS respectively). 
In contrast to ALP, GGT is not elevated in bone disease[28]. Increased serum levels of 
cholestatic markers are an indication to perform further imaging to determine the cause 
of obstruction, generally via endoscopic retrograde cholangiopancreaticography (ERCP) 
or via magnetic resonance cholangiopancreaticography (MRCP). 
In healthy adults, GGT serum levels are below 35-40 U/l. Directly following LT, levels 
of GGT are often not elevated, but start to rise within the first post-operative days. If a 
recipient develops AS, levels of GGT and ALP are expected to be high, up to 400 to 500 
U/L. Stenting of the biliary anastomosis will give a rapid normalization of serum levels, 
as illustrated in the right panels of fig. 1. When a liver graft is affected by NAS, levels of 
GGT and ALP can strongly fluctuate, but will increase over time, since these strictures are 
more stubborn to treat by stents or percutaneous drains. When a mild rise in cholestatic 
markers is accompanied by a rise in hepatocellular markers, one should also think of 
(recurrence of chronic) hepatitis[29].
A paradoxical finding confirmed by multiple researchers is that higher levels of GGT 
early following LT are associated with improved 90-day survival in recipients, while recipi-
ents who died before the 90th post-operative day had lower GGT serum levels[30]. After 
the first 90 days however, high levels of GGT are associated with impaired 5-year survival. 
It has been suggested that high levels of GGT early following surgery are the result of a 
proper systemic response to reactive oxygen species that are released after graft reperfu-
sion. A different hypothesis states that the increase of GGT is correlated to regeneration of 
hepatocytes following LT[31]. Direct evidence for this hypothesis is however not available. 
18 Chapter 1
Alkaline phosphatase (ALP)
The enzyme ALP is responsible for dephosphorylation of multiple types of molecules. 
It is bound to plasma membrane lipoproteins of tissues throughout the entire body. 
Serum ALP is mostly derived from liver parenchyma, biliary epithelium (cholangiocytes), 
and bone osteoblasts. To a lesser extent, serum ALP can also originate from intestinal 
mucosa, placenta, and kidney tissue[32]. The isoenzymes of intestinal and placental ALP 
are different from ALP in other tissues. It is possible to distinguish between the different 
isoenzymes for instance by elektropheresis. In clinical practice, however, ALP is gener-
ally tested together with GGT to differentiate. Strong elevation of both ALP and GGT 
indicates biliary obstruction, whereas extrahepatic obstruction causes a stronger rise in 
ALP compared to intrahepatic obstruction. Other hepatic causes for elevation consist of 
alcoholic abuse, hepatitis and cholestatic disease. A sole elevation of ALP without rise 
in GGT levels indicates extrahepatic pathology, like bone disease or hyperthyroidism. 
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figure 1. biomarker dynamics in blood and serum following lt. The left panels show biomarker dynam-
ics in recipients with normal early graft function, the median panels show elevated biomarker levels in se-
rum during PNF/EAD, the right panels show increased cholestatic markers in AS. Data represent biomarker 
serum levels of individual patients following LT and were derived from the database of the Erasmus Medical 
Center Rotterdam, The Netherlands.
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In adults, serum values of ALP are <125 U/l. The halftime of most ALP isoenzymes is 3-7 
days, while the halftime of intestinal ALP is <8 hours.
biomarkers to assess graft function
Albumin
Albumin is one of the most abundant proteins in human serum and plasma beside blood 
coagulation factors. It is involved in pH homeostasis, maintaining oncotic pressure, and 
the transportation of blood compounds, hormones and drugs. Synthesis takes place in 
the liver and therefore, serum albumin is considered to be an important marker for liver 
function. Over twenty structural variants of albumin exist, and its half time is approxi-
mately 20 days. In healthy adults, serum/plasma levels are usually between 35-55 g/l, 
but levels can be influenced by body fluid distribution, for instance by dehydration[33].
In particular hypoalbuminemia has been associated with liver disease and, follow-
ing LT, with impaired graft function. A higher degree of graft injury, mirrored by high 
postoperative transaminase levels, often negatively affects liver graft function. However, 
the increased use of marginal grafts for LT has gained more interest for pure functional 
markers; because despite extensive injury, some marginal grafts manage to function 
well in recipients. Therefore, experimental studies with graft machine preservation focus 
on the assessment of liver function already prior to graft implantation in recipients[34]. 
But also following LT, early allograft dysfunction is estimated by a lack of markers that 
normally result from good liver function, like conjugated bilirubin and INR (coagula-
tion). However, serum albumin is not included in this definition.[35] Though albumin 
could be of use for assessing graft function, one should also be aware for other causes 
of hypoalbuminemia, like inflammation, malnutrition/malabsorption, malignancies and 
hypothyroidism. Furthermore, albumin levels can remain in the normal range when 
patients suffer from biliary obstruction. 
Bilirubin (indirect and direct)
Bilirubin is the yellow-coloured breakdown product of haemoglobin when erythrocytes 
are degraded. A vast majority of bilirubin is derived from aged erythrocytes (over 85%), 
but ineffective erythropoiesis by bone marrow and certain hepatic enzymes can also 
contribute to bilirubin formation. When heme is degradated by splenic macrophages, 
unconjugated bilirubin is formed, which is not soluble in water and cannot be excreted. 
Subsequently, unconjugated bilirubin is bound to albumin and is transported to the 
liver, where hepatocytes conjugate bilirubin with glucuronic acid (90% diglucuronic, 
10% monoglucuronic). This step makes bilirubin soluble in water and suitable for excre-
tion via the hepatobiliary system. Once transported to the intestine and colon, conju-
gated bilirubin is hydrolysed and reduced to urobilinogen by bacteria, and excreted via 
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the faeces. A small part of the urobilinogen (2-5%) is resorbed into the enterohepatic 
circulation and excreted via the urine[36]. 
Human plasma or serum contains four fractions of bilirubin; unconjugated bilirubin 
(30%), unconjugated bilirubin bound to albumin (35%), monoconjugated bilirubin 
(25%), and di-conjugated bilirubin (10%). ‘Indirect’ bilirubin consists of unconjugated 
bilirubin and the fraction of bilirubin not-covalently bound to albumin. ‘Direct’ bilirubin 
usually refers to fractions of conjugated bilirubin and bilirubin that is covalently bound 
to albumin. In clinical practice, total bilirubin and direct bilirubin are measurable in hu-
man serum or plasma. Total bilirubin consists of conjugated as well as unconjugated 
forms of bilirubin. Based on these measurements, the indirect bilirubin can be calculated 
with the formula: indirect bilirubin = total bilirubin – direct bilirubin. In healthy adults, 
total bilirubin levels are <20 µmol/l, and direct bilirubin levels are <5 µmol/l. Jaundice 
usually occurs when serum bilirubin exceeds 50 µmol/l[37]. 
Based on total and direct bilirubin, one can distinguish different causes for hyperbiliru-
binemia. Strong elevation of unconjugated bilirubin indicates pre-hepatic pathophysiol-
ogy like hemolysis, or dysfunction of hepatocytes and conjugation at the hepatic level. 
However, most complications that can occur following LT will cause conjugated hyper-
bilirubinemia. At the hepatic level, hepatocyte injury due ischemia-reperfusion injury, EAD 
or PNF, is accompanied by a rise in bilirubin and liver transaminases. These changes can 
occur early after LT. In case of intrahepatic cholestasis, for instance due to biliary strictures, 
but also extrahepatic bile duct obstruction (post-hepatic level), hyperbilirubinemia is 
accompanied by a rise in ALP and GGT. Recurrence of (viral) hepatitis can elevate both 
conjugated and unconjugated serum bilirubin. Thus, by measuring conjugated and 
unconjugated hyperbilirubinemia and comparing serum levels with hepatocellular and 
cholestatic markers, one can distinguish between different complications following liver 
transplantation. When hepatocellular function is impaired, bilirubin levels also become 
measurable in urine and are per definition pathologic[38]. When possible, collection of 
bile following liver transplantation can also be used for determining biliary bilirubin levels, 
that can mirror hepatocyte function but also cholangiocyte injury[39]. 
Prothrombin time (PT) and international normalized ration (INR)
Synthesis of tissue factors for sufficient blood coagulation is an important function of the 
liver. A lack of tissue factors in blood plasma could indicate severe liver disease or, in case 
of transplantation, graft failure. To assess the degree of graft failure or graft (dys)function 
following LT one could measure individual coagulation factors, but instead, PT and INR 
are commonly used as general indicators; 
Prothrombin time measures the time it takes for blood plasma to form a fibrin clot 
after adding tissue factor. In healthy individuals, PT is usually between 12-15 seconds, 
but it depends on the standards of the laboratory performing the analysis. A prolonged 
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PT could indicate a deficiency in the production of coagulation factors I (fibrinogen), II 
(prothrombin), V, VII and X, which are all part of the extrinsic coagulation cascade. Logi-
cally, the use of anticoagulant drugs should be taken into account when interpreting PT. 
Immediately after LT, PT is usually prolonged and can reach up to 100 seconds. When PT 
does not decrease or normalize in the first post-operative week, this could indicate severe 
graft dysfunction with risk of developing serious complications and impaired patient 
survival. Urgent re-transplantation can be lifesaving in these cases. As mentioned before, 
the analysis and subsequent interpretation of PT is very institutionally dependent[40]. 
Therefore, a standardized PT-ratio, also known as the international normalized ratio 
(INR), is used more often to determine early allograft dysfunction. Outside the context 
of LT, INR is often used as a tool to monitor patients on vitamin-K antagonists. The INR 
standardizes PT values of patients by calibrating reagents to an international sensitivity 
index (ISI) and by comparing patients’ PT value with the mean PT of healthy individuals 
(normal), with the formula INR=(PTpatient/PTnormal)ISI[41]. At one week following LT, INR is 
used as one of the parameters to evaluate early allograft dysfunction; an INR ≥ 1.6 is con-
sidered to be a risk factor for shortened graft and recipient survival[35]. Importantly, the 
cut-off of 1.6 seems to be a predictor of graft failure for grafts that were obtained from 
brain death donors as well as those obtained from circulatory death donors. Therefore, 
it has been suggested to give more weight to INR as a predictor of graft failure following 
LT[42].   
biomarkers for reCurrenCe of Disease following liVer 
transPlantation
Beside the threat of cellular damage due to severe ischemia-reperfusion injury, biliary in-
jury, and rejection, the recurrence of disease for which recipients were transplanted is also 
an important factor for graft loss. In particular recurrence of PSC, HCC, and viral hepatitis-B 
and -C are notoriously recurring diseases in the transplanted graft[43]. Furthermore, over 
the last years patients with unresectable cholangiocarcinoma are transplanted, but sur-
vival rates are limited due to recurrent or metastatic disease[44]. Several biomarkers are 
clinically available to monitor recurrence of the above-mentioned diseases in LT recipients, 
which are described shortly in the following paragraphs.
Cholestatic markers in recurrence of PSC
Primary sclerosing cholangitis  is an autoimmune related disorder that causes chronic 
inflammation and strictures of the (mainly intrahepatic) bile ducts. This progressive dis-
ease occurs more frequently in men compared to women and has been associated with 
ulcerative colitis[45]. Incidence is highest in the US and north European countries. The 
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time of onset until end-stage liver disease is approximately twelve years and currently, 
LT is the only curative treatment for PSC. Unfortunately, recurrence of disease occurs in 
up to 20% of the PSC recipients, sometimes requiring re-transplantation[46]. 
Clinical symptoms of recurrence of PSC consist of obstructive jaundice, bacterial 
cholangitis, fever, and fluctuating elevations of liver enzymes and cholestatic serum 
markers. Cholangiography shows typical intra- or extrahepatic strictures, beading and 
irregularities. Histological features consist of fibrous cholangitis or fibro-obliterative 
lesions. Because of the overlap in clinical presentation with NAS, one of the criteria of 
recurrent PSC prescribes this diagnosis should be excluded if it develops within the first 
90 days following LT[47]. Beside recurrence, PSC patients also have an increased risk to 
develop CCA . Therefore, it could be plead to monitor these recipients for cancer antigen 
19-9 (CA 19-9), a potential marker of CCA. table 2 illustrates expected serum levels of 
classic biomarkers in PSC. 
table 2. Serum biomarkers during different pathophysiological states of the liver graft following LT. Values 
represent which serum levels can be expected for the various outcomes or diagnoses following LT. Except 
for PNF and EAD, these values are an indication and can diverge between different LT recipients. 
biomarker Healthy 
liver
Pnf / eaD* as nas aCr rec PsC (rec) HCC, 
CCa
ast (u/l) <50 >2000 
within 7 days 
post LT
= 50-400 100-1000 50-400 =↑
alt (u/l) <50 >2000 
within 7 days 
post LT
= 50-200 100-1000 50-200 =↑ 
total bili 
(µmol/l)
<20 ≥170 on day 
7 post LT
= ↑ ↑, up to 300 ↑, up to 
300
↑, up to 300 =↑
albumin (g/l) 35-55 ↓ = =↓ ↓ = =↓
ggt (u/l) <40 = ↑ ↑ 
up to 500
↑, up to 200 ↑, up to 
300
↑, up to 200 =↑
alP (u/l) <125 = ↑ ↑
up to 400
↑, up to 200 ↑, up to 
300
↑, up to 200 =↑
inr or Pt (sec) 12-15 ≥1.6  on day 
7 post LT
= Prolonged Prolonged Prolonged =↑
afP (mcg/l) <10-15 <10-15 <10-15 <10-15 <10-15 = ↑ ↑
Ca 19-9 (u/ml) Neg Neg ↑ prior to 
stenting
↑ Neg If >100, higher 
risk of CCA
↑
*EAD (and PNF) are defined by serum biomarkers in the first week post LT and consist of one of the follow-
ing: serum AST or ALT > 2000 U/L in the first postoperative week, or total bilirubin levels ≥10 mg/dL (=170 
µmol/L) on day 7 post LT, or INR ≥1.6 on day 7 post LT. 
Legend: PNF, primary non-function; EAD, early allograft dysfunction; AS, anastomotic stricture; NAS, non-
anastomotic stricture; ACR, acute cellular rejection; Rec, recurrence; PSC, primary sclerosing cholangitis; HCC, 
hepatocellular carcinoma; CCA, cholangiocarcinoma; = normal levels, ↑ increased levels, ↓decreased levels.
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Cancer antigen 19-9 (CA 19-9) in recurrence of CCA
Cholangiocarcinoma is a rare disease that accounts for less than three percent of all gas-
trointestinal malignancies, but which has a poor prognosis due to its aggressive nature. 
Transplant centres recently started exploring the success of LT for perihilar CCA, either 
with or without use of neoadjuvant chemo(radio)therapy[7]. In particular patients suf-
fering from PSC have a 398-fold increased risk to develop CCA compared to the general 
population[48]. 
A potential serum marker to screen for (recurrent) CCA in PSC patients is CA 19-9. This 
carbohydrate structure is found in pancreatic tissue as well as on epithelial cells of the 
stomach and gallbladder. It can be secreted into serum by cancer cells. Beside cholangio-
carcinoma, increased serum levels of CA 19-9 have been associated with pancreatic- and 
colon cancer, but also with benign causes of biliary obstruction. Therefore, when assess-
ing the risk of malignancy based on CA 19-9 serum levels, one should take into account 
whether cholestasis or cholangitis is present (preferring a cut-off value of ≥300 U/mL) 
or absent (better discrimination with a cut-off of ≥37 U/mL)[49]. It is recommended to 
evaluate CA 19-9 levels after recovery of cholangitis. However, the optimal cut-off value 
for CA 19-9 remains inconclusive. A lower cut-off at 37 U/mL can be undesirable in terms 
of specificity, but higher cut-off values are at the expense of sensitivity[50]. Current 
guidelines recommend a cut-off between 100-127 U/mL. Another important limitation 
of CA 19-9 is that its biosynthesis depends on the activity of fucosyltransferase-2 and 
fucosyltransferase-3 (FUT2 and FUT3, respectively). Individuals with inactive FUT3 do 
not express CA 19-9 on their epithelial cells. In contrast, FUT2 inactivity increases CA 
19-9 expression. These genetic variations in FUT2 and FUT3 are not uncommon and 
strongly influence the optimal cut-off level for CA 19-9 in individuals[51]. 
Finally, one could plea for use of CA 19-9  during follow-up after LT, since post-trans-
plant CA 19-9 levels are predictive of recurrence of CCA (HR 1.8). This could influence the 
timing of adapted medical policy[44].  
Alpha-fetoprotein (AFP) in recurrence of HCC
The glycoprotein AFP is mainly produced in the fetal liver and yolk sac during gestation. 
In the first months after birth, plasma levels of AFP decrease and become undetectable 
at the age of approximately one year. In healthy adults, AFP levels are usually <10-15 
µg/L[52]. Experimental animal studies have shown a role of AFP in estradiol transport 
and preventing virilisation of female foetuses, but its function in humans remains largely 
unknown. After malignant degeneration, cells from various tissues are able to produce 
AFP. These cells can originate from the yolk sac, the gonads, hepatocytes and certain 
gastric cells[53]. 
In patients with HCC, pre-transplant levels of AFP were shown to be predictive of 
recurrence of HCC during follow-up. Therefore, it has been suggested to incorporate 
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pre-transplant AFP levels in the Milan criteria, which are currently used for screening 
of HCC patients to undergo LT[54]. A rise in AFP levels during follow-up has also been 
associated with the recurrence of disease[55, 56]. However, no clear correlation exists 
between AFP levels and tumor size, stage or prognosis. Current guidelines advise to 
measure AFP every three to six months for two years combined with imaging in patients 
transplanted for HCC. After that, annual monitoring is sufficient. If AFP levels show a 
strong elevation, further diagnostics for possible recurrence should be undertaken. 
Patients with chronic HBV or HCV infection have an increased risk to develop HCC. 
Serum levels of AFP can be elevated without the presence of an intrahepatic malignant 
process. However, AFP levels >500 mcg/L increase the risk of HCC[57].  Half-life of AFP 
is five to seven days and are expected to decrease within 25 to 30 days after effective 
therapy. 
biomarker DynamiCs in Various ComPliCations following lt
After discussing the specific markers for recurrent disease, the next paragraphs will pro-
vide an outline on biomarker dynamics that can be expected for common complications 
that can occur following LT (summarized in table 2). 
graft primary non-function (Pnf) and early allograft-dysfunction (eaD)
Incidence of PNF is 5-8% and despite being one of the most severe complications fol-
lowing LT, no formal definition of PNF exists. Usually, the diagnosis of PNF is ascertained 
by exclusion and in retrospect, the transplanted liver fails to start functioning in the first 
post-operative days and requires liver re-transplantation, or otherwise will inevitably 
result in the patients’ death[58]. Risk factors of PNF can be for instance donor related 
(high donor age, steatosis, small for size) or procedure related (prolonged cold or warm-
ischemia times, DCD, (hepatic artery)-thrombosis)[10, 59]. However, in up to 50% of the 
cases, the exact cause of PNF remains unknown. Complete failure of the graft in PNF 
results in extremely elevated liver enzymes in serum, impaired or absent bile produc-
tion, encephalopathy and coagulopathy within the first 72 hours following LT.     
A complication similar to PNF is early allograft dysfunction (EAD). In 2010, Olthoff et 
al. formulated and validated criteria in order to determine EAD based on one or more of 
the following serum biomarker levels in the first week post-transplant; bilirubin ≥10mg/
dL on day 7, INR ≥1.6 on day 7, and ALT or AST levels >2000 IU/L within the first 7 days . 
Though EAD is a risk factor for impaired graft and patient survival, in contrast to PNF it 
will not inevitably result in liver re-transplantation or patient death. One could consider 
PNF as an excessive form of EAD and therefore it might be questioned whether the two 
definitions should be fused. Furthermore, liver grafts obtained by DCD usually have 
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poor immediate function and elevated serum biomarker levels compared to donation 
after brain death (DBD). It has been suggested to adjust the definition of EAD for this 
category of LT in order to better assess the risk for graft failure[42]. Especially since DCD 
is responsible for a significant contribution of the donor pool in many (particularly West-
ern) countries, early prediction of EAD for this category could benefit graft and patient 
outcome. The median panels of fig. 1 shows examples of biomarker dynamics during 
the first post-operative week in LT recipients suffering from PNF and EAD. Such dynam-
ics are usually accompanied with extensive ischemic necrosis at the histological level.
acute cellular rejection (aCr) 
As explained before, the introduction of cyclosporine significantly improved graft sur-
vival by lowering the degree of cellular rejection. Nevertheless, in individual patients 
it remains a challenge to lower immunosuppressant’s use in order to avoid related 
complications on one hand, and to prevent ACR on the other hand. ACR is the result 
of a T-cell mediated immune response directed against tissue of the donor graft and 
mostly occurs within the first 90 days following LT (early ACR). However, low serum 
levels of immunosuppressant drugs have also been associated with ACR even years 
after transplantation[60]. Clinical symptoms in recipients consist of fever, abdominal 
pain, hepatomegaly and sometimes ascites. Laboratory test can show increased serum 
levels of hepatocellular and cholangiocyte-injury markers as well as bilirubin. The gold 
standard for diagnosing ACR however remains liver biopsy.    
In 1995, experts formulated the so-called histological Banff-criteria to evaluate the 
degree of ACR in liver biopsies, also known as the rejection activity index[61]. This index, 
outlined in table 3, scores the extend of inflammation and lymphocytic infiltration into 
(i) the portal triads, (ii) the bile ducts, and (iii) the venous endothelium. To date, this 
index is used as part of standard clinical practice. In the early days, tissue biopsies were 
taken frequently post-LT to monitor for ACR, but are now only indicated based on clini-
cal symptoms. 
Because of the low specificity of regular laboratory tests for ACR and the invasiveness 
of liver biopsies, many other surrogate-biomarkers have been investigated to monitor 
for ACR, among which interleukins, intercellular adhesion molecules, and many other. 
None have make it into clinical practice jet. A potential novel biomarker reported for 
ACR but also for other complications following LT are microRNAs (miRNAs), which will 
be discussed separately later.  
biliary complications
Biliary complications are very common after LT and can vary in nature, location and time 
of onset. The most common biliary complications consist of biliary leakage, anastomotic 
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biliary strictures (AS) and non-anastomotic biliary strictures (NAS), which will all be 
discussed shortly. 
Leakage of the biliary anastomosis usually occurs early following LT and the cause is 
either technical or because of insufficient blood supply to the biliary tree resulting in 
biliary necrosis. Suspicion for biliary leakage rises when patients have pain and feel ill 
due to irritation of the peritoneum. Abdominal free bile collections can be imaged by 
ultrasound but is more sensitive with ERCP, which is also useful for therapeutic stent-
ing[62]. Biliary leakage is often accompanied by AS. 
Benign local narrowing or tapering at the site of the biliary anastomosis, also known 
as AS, occurs in approximately 5-10% of LT recipients. Shortly after LT, the biliary anas-
tomosis can be edematous due to surgical trauma and/or ischemia. The development 
of AS does not depend on the type of biliary anastomosis[63]. It is usually detected by 
elevated cholestatic markers in serum combined with clinical symptoms in recipients. 
Diagnosis and therapy of AS are accomplished by ERCP (fig. 2a) and depending on the 
severity of the stricture, the bile duct can be cannulated by single or multiple stents 
(in case of duct-duct) or by percutaneous drains (in case of hepaticojejunostomy). If 
repeated attempts via the endoscopic or percutaneous route fail, AS can also be treated 
surgically[64]. Anastomotic strictures can occur early but also later following LT. Some 
table 3. Banff scoring criteria or rejection activity index to evaluate histological graft rejection. 
Category Description score
Portal inflammation Mostly lymphocyte involving, but not noticeably expanding, a minority of the 
triads.
1
Expansion of most or all triads, by a mixed infiltrate containing lymphocytes 
with 
occasional blasts, neutrophils and eosinophils. 
2
Marked expansion of most or all triads by a mixed infiltrate containing 
numerous blasts and eosinophils with inflammatory spillover into the peripheral 
parenchyma. 
3
bile duct 
inflammation/
damage
A minority of the ducts are cuffed and infiltrated by inflammatory cells and show 
only mild reactive changes such as increased nuclear:cytoplasmic ratio of the 
epithelial cells
1
Most or all of the ducts are infiltrated by inflammatory cells. More than an 
occasional duct shows degenerative changes such as nuclear pleomorphism, 
disordered polarity, and cytoplasmic vacuolization of the epithelium. 
2
As above for two, with most or all of the ducts showing degenerative changes or 
focal luminal disruption. 
3
Venous endothelial 
inflammation
Subendothelial lymphocytic infiltration involving some, but not a majority of the 
portal and/or hepatic venules.
1
Subendothelial infiltration involving most or all of the portal and/or hepatic venules 2
Subendothelial infiltration involving most or all of the portal and/or hepatic 
venules as above for two, with moderate or severe perivenular inflammation 
that extends into the perivenular parenchyma and is associated with perivenular 
hepatocyte necrosis. 
3
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recipients have recurrence of AS for which they need progressive stenting[65]. Success-
ful treatment of AS will result in a rapid decrease of cholestatic markers in serum and 
patients can recover without residual symptoms. An example of cholestatic biomarker 
dynamics in AS is provided in the right panels of fig 1.
Beside the biliary anastomosis, some liver grafts develop strictures of the intrahepatic bile 
ducts or extrahepatic hilar region, which are called NAS[66]. The method of post-mortem 
donation strongly influences the risk for a liver graft to develop NAS; ~10% of DBD grafts 
vs. ~30% of DCD grafts[67, 68]. Furthermore, it is known that thrombosis of the hepatic 
artery, the major supplier of blood to biliary tree, will inevitably lead to NAS. Therefore, 
warm ischemia is thought to play a key-role in the pathophysiology of NAS. In contrast 
to AS, the (multiple) strictures in NAS and their anatomical localization are often less ac-
cessible for biliary stents or drains (fig. 2b). Therefore, liver retransplantation is indicated 
in 10-15% of all LT recipients due to NAS[69]. Large HAT usually indicates immediate liver 
re-transplantation. In serum, NAS give elevation of cholestatic markers and only in few 
cases, normalization of biomarker levels to baseline is achieved. Eventually, NAS will lead 
to such severe cholestasis that patients will become ill and liver function will be affected. 
noVel biomarkers in tHe fielD of liVer transPlantation
micrornas (mirnas) as novel biomarker
In the last decade, miRNAs have gained interest in the field of biomarker research. Mi-
croRNAs are short, hairpin-shaped RNAs with the potential to regulate gene-expression 
by inhibiting messenger RNA translation (fig. 3). MiRNAs are highly cell-type abundant 
and can be release via active and passive mechanisms into the circulation and other body 
A B C 
figure 2. Visualization of biliary complications following lt. (A) ERCP showing an isolated stricture at 
the biliary anastomosis, pointed out by the white arrow, with dilatation of the common bile duct and slim 
intrahepatic bile ducts. (B) ERCP showing dilated intrahepatic bile ducts throughout the entire liver graft 
with loss of normal architecture due to NAS. (C) Biliary cast removed from the hilar region of a liver graft that 
was formed due to biliary obstruction and which is often seen in NAS. The length of the cast is displayed 
in cm. Pictures are derived from the database of the Erasmus Medical Center Rotterdam, The Netherlands.   
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fluids in which they remain stable up to 24 hours. These characteristics make miRNAs 
attractive candidate biomarkers for various disease. Beside their biomarker potential, 
the knowledge regarding miRNA induced gene-expression and regulation is increasing, 
though not yet fully understood[70]. 
For various liver diseases, particularly miR-122 has been related to hepatocellular liver 
injury. Serum levels of miR-122 increase earlier than conventional transaminase levels, 
which was shown in patients with viral hepatitis as well as in LT recipients who devel-
oped ACR[71, 72]. Therefore, hepatocyte-derived miRNAs (HDmiRs) might be suitable 
early markers for severe hepatocellular injury following LT, as is the case in grafts devel-
oping EAD or PNF. In contrast to liver transaminases, which are mainly injury markers, 
HDmiR-122 secretion into bile has also been correlated to good bilirubin excretion of 
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figure 3. microrna structure and biogenesis. Biogenesis of miRNAs by cells. Immature precursor miR-
NAs are formed inside the cell nucleus. In the cell cytoplasma, miRNAs reach their mature form and are able 
to inhibit mRNA translation, thereby regulating gene expression. Illustration from Winter et al.[80]. 
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hepatocytes into bile[39]. Therefore, HDmiR-122 and perhaps other HDmiRs might also 
be suitable markers for graft function. 
Cholangiocytes have a different expression of miRNAs compared to hepatocytes 
[73]. Therefore, cholangiocyte-derived miRNAs (CDmiRs) could be more sensitive or 
specific in the detection of biliary complications. Already at time of graft preservation, 
CDmiRs are released in response to ischemia-induced biliary injury that causes severe 
complications in LT recipients during follow-up[74]. Beside changes in expression, also 
the composition of miRNAs in bile is changed during biliary obstructions[75]. 
Despite the growing evidence of their utility, miRNAs as biomarker are currently not 
part of clinical practice in liver disease. Future research should focus on validation of 
sensitivity and specificity of previously identified CDmiRs and HDmiRs. Another chal-
lenge for implementing miRNAs as a routine laboratory test lays within the technical 
aspect of measuring miRNAs. This is now done by real-time quantitative polymerase-
chain-reaction (RT-qPCR), which takes approximately three hours before miRNAs are 
isolated and analysed. This issue could be facilitated by improving accelerated PCR-
techniques. Because of the highly sensitive analysis of qPCR, mild elevations of miRNA 
levels in blood or other body fluids can be determined quite accurately. Despite the fact 
that much is still unknown about miRNAs as therapeutic target, the first clinical series 
in human showed that inhibition of HDmiR-122 reduces viral load in HCV patients[76]. 
Whether CDmiRs are potentially interesting in (prevention of ) cholestatic disease needs 
to be explored by future research.
key facts of micrornas
 • MicroRNAs (also called miRNAs or miRs) are 20-23 nucleotide long, hairpin-shaped 
RNA. Up to 30% of the human genes is regulated by miRNAs via inhibition of mRNA 
translation.
 • A single miRNA is responsible for the regulation of multiple genes. 
 • The first reports on the presence of miRNAs in Caenorhabditis-elegans date from 
2001 and since then, over a 1000 different miRNAs have been discovered in mam-
mals.
 • Various cell types express distinct sets of miRNAs that are related to metabolism, 
oncology, endocrinology, the vascular system, and infection. 
 • Tissue-abundant miRNAs are released from cells into the circulation and other 
body fluids under different (patho)physiological conditions via active and passive 
mechanisms. 
 • In contrast to mRNA, extracellular miRNA are protected from degradation in fluids, 
making them attractive for non-invasive biomarker research. 
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Potential aPPliCation to Prognosis, otHer Diseases or ConDitions
The previous paragraphs provided an overview of different types of biomarkers that 
are regularly used in liver disease and how these should be interpreted in the context 
of LT. Routine monitoring of graft quality based on biomarkers helps clinicians to 
decide whether or not to perform additional (mostly more invasive) tests like ERCP or 
liver biopsy. Biomarker levels can be reason to adjust therapy, for instance to increase 
immunosuppressant dosage when high transaminase levels indicate cellular rejection. 
But also as a definition of outcome, biomarkers play an important role in predicting 
prognosis early after LT. 
Some important complications that can occur following LT, like EAD and biliary stric-
tures, are often related to marginal quality of the liver graft already at time of transplan-
tation. As mentioned before, grafts obtained by DCD have a higher risk to develop EAD 
and NAS. For this reason, DCD liver grafts from elderly donors (over 60 years of age) are 
often rejected for LT. However, some of the rejected DCD grafts might have functioned 
well in recipients. With the increasing number of marginal grafts for LT, there is a need 
to improve- and simultaneously to objectify graft quality in an earlier phase of LT. The 
prolonged time-window between graft procurement and graft implantation, known as 
the preservation period, is in particular useful for this purpose. Many studies showed 
that during static cold-storage, liver grafts can still release some injury markers that have 
been associated with outcome. A novel technique designed to preserve and improve 
graft quality is machine perfusion (MP)[77]. With MP, the liver graft is flushed ex situ on 
a pump that recirculates preservations solution (perfusates) before implantation into 
the recipient. Many different techniques of MP have been investigated with variations in 
solutions, temperature, oxygenation, single-portal or dual portal-hepatic artery perfu-
sion, flow pressure and more. The first clinical studies with MP show promising results 
regarding prevention of hepatic and biliary injury[78]. However, during MP it remains 
a challenge to objectify that marginal grafts show enough recovery to be transplanted 
and which should still be rejected for LT. Multiple options are available to assess graft 
quality during MP with the use of biomarkers in graft perfusates and produced bile, 
depending on the applied technique[11]. 
Despite the potential of biomarkers to assess graft quality during preservation, their 
clinical application is still experimental and the decision to accept a graft for LT is mainly 
driven by clinical donor variables and the macroscopic aspect on inspection by the 
donor surgeon. Beside donor variables, some researchers plea for implementation of 
recipient variables as well in allocation algorithm’s, since recipient factors as age, MELD 
score and gender can strongly influence survival[79]. Because of the limited number of 
performed LTs annually in transplant centres, many biomarker studies omit validation of 
potential biomarkers in multiple cohorts. This will however delay the implementation 
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of biomarkers to assess graft quality during preservation. Furthermore, criteria for EAD 
should be adapted for DCD liver grafts; despite their worse biomarker profile post-LT, 
multiple DCD grafts show good recovery during follow-up. The current criteria might be 
insufficient to distinguish grafts that will eventually function properly in recipients from 
the ones that actually cause PNF. This could also be the case for other types of donation, 
like living donor LT, for which other literature is recommended.  
summary Points anD DisCussion
To conclude, this overview discussed routinely measured biomarkers and more novel 
ones for evaluation of graft injury and function in the follow-up of LT recipients and 
their dynamics at time of various complications and (recurrence of ) disease. It is evident 
that biomarkers can indicate hepatocellular injury, biliary obstruction and liver function. 
Evaluation of biomarkers can play a key-role in the early recognition of complications 
and provide an objective tool to monitor graft quality after transplantation. As in recent 
years, many new potential biomarkers have been discovered. Therefore, this overview 
is incomplete and limited to established serum biomarkers. Furthermore, it should be 
emphasized that experienced clinical knowledge and imaging techniques of the liver 
are two other key factors in clinical decision making, and determining the need of inter-
vention will rarely be based on biomarkers solely. Much likely, LT recipients will start with 
monitoring of graft function through biomarker measurements in the home situation as 
part of individualized medicine. Finally, novel application of biomarker measurements 
during graft preservation seems promising in early evaluation of graft quality that could 
help extend the donor pool for LT.    
aims anD outline of tHis tHesis
The aim of this thesis is to evaluate conventional and novel biomarkers on their perfor-
mance to assess graft quality and predict outcome in LT. The rising incidence of severe 
complications like NAS, which is strongly related to DCD, urges for predictive biomark-
ers in an earlier phase of LT. For example during graft preservation and by identifying 
recipients or donors with an increased risk for complications. 
To identify potentially relevant markers, part i of this thesis provides an overview of 
the literature on conventional and novel biomarkers. Chapter 1 discusses the various 
definitions of biomarkers and which biomarkers are generally applied for graft monitor-
ing during follow-up. Subsequently, chapter 2 is a systemic review of the literature on 
which conventional and novel markers are useful to assess graft quality prior to graft 
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implantation during graft preservation by static cold storage or MP. This chapter also 
provides a brief overview on the different techniques of MP and the pros and cons of 
using different biomaterials as perfusates, biopsies and bile. 
Part ii focuses on biomarkers that can be useful to assess the risk of developing biliary 
complications, in particular NAS. Since many years, researchers hypothesize whether 
liver grafts obtained by DCD have an increased tendency to form microthrombi in their 
microvasculature at time of graft preservation that could explain the higher incidence of 
NAS. Therefore, some transplantation centres apply potentially harmful intraoperative 
fibrinolytic therapy that can cause major blood loss in recipients. In chapter 3, we inves-
tigate whether there is histological evidence to support the hypothesis of microthrombi 
formation in DCD that could justify fibrinolytic therapy. Beside diminished blood supply, 
immunological factors have also been associated with the development of NAS. This is 
particularly the case in patients who suffer from auto-immune diseases, like PSC. Because 
of the clinical similarities between PSC and NAS, a shared underlying pathophysiologi-
cal mechanism has been suggested. A polymorphism of the fucosyltransferase-2 (FUT2) 
gene has been associated with PSC, by altering the glycosylation of cholangiocytes that 
enhances bacterial translocation. Chapter 4 investigates the association between FUT2 
polymorphism and the development of NAS in a large cohort of LT donors and recipients. 
Part iii entirely focuses on the discussion of aforementioned miRNAs in the setting of 
LT. First, the potential advantages and applications of extracellular miRNAs as dynamic 
markers in liver disease and transplantation are evaluated based on the literature in 
chapter 5. Most studies on extracellular miRNAs investigated release in serum, since this 
is an attractive and easily obtainable medium. However, the presence of miRNAs in bile 
could also be of importance in liver disease and interesting for biomarker purposes. In 
chapter 6, we therefore examine the release of hepatocyte and cholangiocyte-derived 
miRNAs, so-called HDmiRs  and CDmiRs, into bile and serum of LT recipients to gain 
more insight into the mechanisms of release during different pathophysiological states 
of the liver. Extracellular HDmiRs and CDmiRs are also released during graft preserva-
tion, that are detectable in preservation solutions for flushing the graft. The features 
of these HDmiRs and CDmiRs in perfusates and their capacity to predict the develop-
ment of NAS is subject of chapter 7. Although extracellular miRNAs are highly stable 
in biofluids, reliable detection can be challenged if samples are contaminated with 
components that are able to inhibit reverse transcriptase-quantitative polymerase chain 
reaction (RT-qPCR), like heparin. In chapter 8 we investigate whether perfusate samples 
contain traces of heparin that are used during organ retrieval. In addition, the effect 
of heparinase I to counteract the inhibition of RT-qPCR is studied, in order to optimize 
miRNA detection in perfusates. Since heparin is partly excreted by the kidneys, chapter 
9 investigates whether miRNA detection in urine samples from hospitalized transplant 
patients is inhibited and whether detection can be optimized by treating samples with 
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heparinase I. This is particularly relevant for future biomarker studies on urinary miRNAs, 
which are becoming increasingly popular because of their non-invasiveness. 
Finally, the results of this thesis are summarized in part iV - chapter 10, including a 
general discussion with recommendations for future research. 
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summary
A global rising organ shortage necessitates the use of extended criteria donors (ECD) 
for liver transplantation (LT). However, poor preservation and extensive ischemic in-
jury of ECD grafts has been recognized as an important factor associated with primary 
non-function, early allograft dysfunction, and biliary complications after LT. In order to 
prevent for these ischemia-related complications, machine perfusion (MP) has gained 
interest as a technique to optimize preservation of grafts and to provide the opportu-
nity to assess graft quality by screening for extensive ischemic injury. For this purpose, 
however, objective surrogate biomarkers are required which can be easily determined 
at time of graft preservation and the various techniques of MP. This review provides an 
overview and evaluation of biomarkers that have been investigated  for the assessment 
of graft quality and viability testing during different types of MP. Moreover, studies 
regarding conventional graft preservation by static cold storage (SCS) were screened to 
identify biomarkers that correlated with either allograft dysfunction or biliary complica-
tions after LT and which could potentially be applied as predictive markers during MP. 
The pros and cons of the different biomaterials that are available for biomarker research 
during graft preservation are discussed, accompanied with suggestions for future re-
search. Though many studies are currently still in the experimental setting or of low 
evidence level due to small cohort sizes, the biomarkers presented in this review provide 
a useful handle to monitor recovery of ECD grafts during clinical MP in the near future. 
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introDuCtion
Graft quality at time of liver transplantation (LT) is a major determinant of early graft 
performance and thereby strongly influencing graft survival and morbidity during 
recipient follow-up[1]. Over the last decade, grafts from extended criteria donors (ECD) 
had to be used increasingly for LT due to organ shortage. The quality of these grafts has 
been shown to be variable[2, 3]. Although some ECD liver grafts turn out to function 
properly in recipients, their use has also been associated with impaired graft survival 
due to primary non function (PNF), early allograft dysfunction (EAD) and severe biliary 
complications like ischemic-type biliary lesions (ITBL, fig. 1)[4, 5]. 
Though pathophysiology between PNF, EAD and biliary complications is assumed to 
differ, extensive ischemic- and preservation injury has been recognized as a shared risk 
factor in these entities[1, 6]. Primary non-function occurs in up to 5-8% of LT’s and neces-
sitates immediate re-transplantation in all cases. Though PNF may be caused by technical 
failure resulting in inadequate blood flow through the graft[7], the association between 
unfavourable donor risk factors and PNF suggests that its cause is likely multifactorial[8]. 
Early allograft dysfunction is typically characterized by increased serum transaminase 
levels in recipients during the first postoperative week[9], but unlike PNF, liver grafts 
showing EAD do not always need immediate re-transplantation[10]. The most common 
complication associated with ischemic- and preservation injury are biliary complica-
tions. Dependent on the type of graft (donation after brain death; DBD vs. donation 
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figure 1. incidence of ischemia/preservation related complications after lt. Estimation of the inci-
dence of PNF, EAD and ITBL in separate DBD and DCD grafts, based on cohort- and case-matched studies[5, 
9-11, 76, 86, 110]. Percentages represent the mean incidence ± standard error. Studies used to calculate the 
incidence of EAD maintained the criteria formulated by Olthoff et al.[9, 10]. Definitions of PNF and ITBL can 
be found in the supplementary information.
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after circulatory death; DCD), up to 50% of recipients develop complications due to bile 
leakage, anastomotic strictures, ITBL, bile duct necrosis, and cast formation[11, 12]. The 
various times of onset and different nature of biliary complications suggest that they 
are caused by different underlying mechanisms, including surgical trauma, DCD, high 
donor age, prolonged ischemia time, cytotoxicity of bile salts and immune factors[6, 11].
Prediction models as the donor risk index were developed to estimate the risk of graft 
failure in recipients and to match high-risk grafts to suitable recipients[13]. Furthermore, 
earlier research on the topic of predicting graft function after LT has focussed mainly on 
clinical characteristics from donors and recipients, including  the model for end-stage 
liver disease-score (MELD)[14-16]. However, models that are mainly based on such 
characteristics are unable to assess the degree of injury that is caused by the process of 
graft procurement, cold preservation and reperfusion. Moreover, the under-utilization 
of grafts with unfavourable donor characteristics like advanced donor age, DCD and 
African race, can lead to an undesirable diminution of the donor pool[17]. 
Therefore, machine perfusion (MP) is increasingly being investigated as a novel tech-
nique to improve graft preservation of particularly ECD grafts. Through MP, ischemia 
related complications like PNF, EAD or ITBL can be reduced or even prevented and 
potentially allow for expansion of the extended criteria donor pool to be utilized for 
LT. Other potentially beneficial features of MP consist of the possibility to add supple-
ments during perfusion that could further benefit graft quality[18, 19], or even attempt 
for restoration of ischemic injury[20, 21]. Beside safety and technical feasibility of MP, 
investigators pronounce on the need of sensitive biomarkers that can distinguish poor 
quality grafts from those that will function properly after implantation[22, 23]. Next to 
other well-known risk factors for impaired graft quality as illustrated in fig. 2, the time 
required for ex vivo MP provides the opportunity to monitor graft quality by measure-
ment of biomarkers in perfusates and biopsies, which could be a helpful decision tool 
for improving the accuracy of selecting grafts for LT. This purpose however demands for 
objective surrogate biomarkers that are easily obtainable at time of graft preservation 
and is challenged by the various techniques of MP currently investigated. 
In this review, we provide an overview of potentially useful biomarkers that were 
identified through a systematic search of the literature (supplementary information), 
in order to assess graft viability testing during various techniques of MP. Because of the 
limited experience with clinical MP in LT, biomarker studies regarding conventional graft 
preservation by static cold storage (SCS) that correlated with either PNF, EAD or biliary 
complications after LT and which could potentially be applied as predictive markers 
during MP were also included. Finally, the pros and cons of the different biomaterials are 
discussed, accompanied with suggestions for future research.    
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Different maCHine PreserVation strategies
Because of easier accessible logistics and lower costs, SCS has become the standard 
preservation technique in clinical practice of LT to date. The low temperature during 
SCS delays metabolic processes in order to restrict ischemic injury. However, especially 
ECD grafts seem more vulnerable for prolonged ischemia, increasing morbidity and 
mortality in recipients after LT. Therefore, during the last ten years, various techniques 
by MP have been investigated in pre-clincal and clinical setting in order to further op-
timize graft quality and thus improve outcome of ECD liver transplantation. The main 
differences in the setup of MP are determined by pumping-temperature, the route- and 
pressure of recirculating preservation solution, and whether oxygen is administered 
(fig. 3). As summarized in table 1, several studies already performed MP on human 
liver grafts. Hypothermic MP (HMP) without the administration of oxygen comes closest 
to conventional preservation by SCS, but is believed to improve preservation through 
continuous recirculation of solution to all segments of the liver and the removal of rem-
nant metabolites from the graft (fig. 4). Guarrera et al.[24] performed the first clinical 
series of non-oxygenated HMP in humans (n=20) using standard criteria donors. In this 
study, HMP was shown to be safe and analysis of perfusates and biopsies demonstrated 
an attenuation of ischemic injury markers during preservation[25-27]. Furthermore, the 
Donor Graft transportation  
& preservation Recipient 
- Age 
- DBD 
- DCD 
- Lifestyle (BMI, smoking) - Genetics 
- Graft size 
- Cold ischemia time 
- Preservation fluid 
- Steatosis 
- Biliary hypoxia 
- ABO/HLA/genetic incompatibiliy - Viral status 
- Underlying disease 
- Infections 
- Reperfusion 
       injury 
Factors influencing outcome after liver transplantation 
- Race 
Outcome 
- Primary non-function 
- Early allograft dysfunction 
- Biliary complications 
Short term: 
Intermediate/long term: 
- Chronic rejection 
- Recurrence of disease 
- Malignancies 
- De novo hepatitis 
- Warm 
ischemia 
time 
- Acute rejection 
- Biliary complications 
- Fibrosis 
figure 2. risk factors for outcome following lt. Risk factors in donors, recipients and during the trans-
plantation and transportation procedure influcening graft quality and graft/recipient outcome. 
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authors suggest that HMP could have beneficial effect on the incidence of EAD and bili-
ary complications in recipients after LT. The feasibility of HMP was also investigated by 
Monbaliu et al.[28], who used HMP as a screening-tool to distinguish transplantable from 
non-transplantable ECD human liver grafts that were rejected for LT. Beside Guarrera et 
al, the second reported clinical trial using MP prior to LT is from Dutkowski et al.[29]. 
In contrast to Guarrera et al., this study used hypothermic oxygenated MP (HOPE) for 
the preservation of ECD grafts. Previous experimental studies from this group showed 
beneficial effects of HOPE on biliary injury and endothelial damage[30, 31].  Protective 
mechanisms of HOPE seem to be based mainly on the down regulation of mitochondrial 
and nuclear activity prior to reperfusion. Moreover, the used low-pressure perfusion at 3 
mmHg caused less endothelial injury compared to more physiological pressures around 
8 mmHg. Notably, grafts were perfused solely through the portal vein due to practical 
considerations and to prevent further damaging of the usually fragile hepatic artery[32]. 
Reactive oxygen species that are generated during ischemia can induce injury to mi-
tochondria, which effects appear to exacerbate after hypothermic conditions[33, 34]. 
Some researchers believe that reconditioning of the tissue by MP at higher temperatures 
can prevent this[35, 36]. Moreover, (sub)normothermic MP (SNP) is seen as a preferable 
SCS HMP HOPE SNP COR NMP 
Delay 
metabolism 
and  
decrease 
oxygen  
need 
Delay 
metabolism, 
decrease 
oxygen  
need and 
eliminate 
harmful  
factors 
Delay 
metabolism, 
energetic 
recovery 
and 
eliminate 
harmful  
factors 
Graft 
reconditioning, 
energetic 
recovery and 
eliminate 
harmful  
factors 
Attenuate 
inflammation, 
energetic 
recovery 
and 
 eliminate 
harmful 
factors 
Mimic 
physiology, 
maintain 
energy charge 
  and  
evaluate cell 
function 
Bile: production + composition 
Tissue biopsies: histology and energy charge 
Perfusates: release of cell-type specific injury markers 
Flow: 
 Temperature: 
Oxygenated:: 
4°C 4°C 4°C 20°C 4-25°C 37°C 
Mechanism: 
Preservation: 
No Yes Yes Yes Yes Yes 
No No Yes Yes Yes Yes 
Biomarkers: 
figure 3. mechanisms of various machine preservation strategies. Different techniques of graft preser-
vation can be used to protect against ischemic injury, to recondition the graft before reperfusion or even to 
maintain physiology. The various techniques have different potentially protective underlying mechanisms. 
Via all techniques, graft quality could be evaluated through markers in tissue biopsies or perfusate analysis. 
The (sub)normothermic conditions also allow for the analysis and evaluation of bile. SCS = static cold stor-
age, HMP = hypothermic machine perfusion, HOPE = hypothermic oxygenated machine perfusion, SNP 
= subnormothermic perfusion, COR = controlled oxygenated rewarming, NMP = normothermic machine 
perfusion. 
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model for viability testing because metabolic function can be judged, for instance 
through bile output during warm MP[37, 38]. Although not yet performed in clinical 
LT, op den Dries et al. performed a feasibility study of normothermic perfusion (NMP) 
on four discarded human donor livers, which showed no harmful effects on liver tissue 
after 6 hours of pumping[37]. Also in large animal models, graft NMP improved survival 
compared to SCS [35, 39]. Finally, an alternative for perfusion with constant temperature 
is controlled oxygenated rewarming (COR) of primarily cold stored liver grafts. Gradual 
increase of the MP temperature is thought to minimize re-oxygenation injury that is 
normally triggered by immediate rewarming of the graft, like in reperfusion and NMP. 
First results of COR in animal models indicate that post-reperfusion recovery is more 
successful in grafts that were subjected to COR compared to HMP, SNP and SCS[40]. 
Gradual rewarming in this study however did not exceed 20-25°C because of potentially 
toxic effects of the preservation solution at higher temperatures.
Many experimental studies have been performed on the different techniques of MP, of 
which some also attempted to identify biomarkers for graft quality assessment (table 2). 
Donor Death 
(DBD/DCD) 
Procurement Transport & Storage Back-table Implantation Reperfusion 
Donor/recipient 
risk factors 
Functional tests 
post-reperfusion 
HMP/HOPE:  
attenuate and  
assess injury 
Cu
m
ul
at
iv
e 
gr
af
t i
nj
ur
y 
Biomarkers during preservation  
(bile, tissue, perfusates) 
(Sub)normthermic MP:  
functional assessment  
and recovery 
Static cold storage: 
delay injury mechanisms  
figure 4. Cumulative graft injury & evaluation points for graft quality. Already in an early phase of LT, 
known risk factors in donors and recipients could be used for deciding to accept a graft for transplantation 
and for which recipient. In order to determine the degree of preservation injury, biomarkers can be mea-
sured in tissue, perfusates or bile during various preservation methods. The cumulative injury of grafts that 
are preserved by hypothermic MP (either oxygenated or non-oxygenated) is believed to be less compared 
to static cold stored grafts (SCS). Mimicking normal physiological functions through (sub)normothermic MP 
is hypothesized to even recover injury of ECD grafts, for instance steatosis, and to provide a better assess-
ment of graft function. After graft reperfusion, other functional tests are available in order to monitor graft 
quality during follow-up.
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One would expect that these various MP techniques require different biomarkers for the 
assessment of graft quality. In the next paragraphs, we highlight on the most promising 
biomarkers for viability testing in MP of which some have been shown also to be predic-
tive for early graft function after clinical LT (table 3). 
biomarkers for Viability assessment During maCHine Perfusion
Production and composition of bile
Beside using bile output as a parameter for outcome after reperfusion[32], some studies 
also investigated whether bile production during MP is a useful indicator for graft viability 
and the secretory function of hepatocytes and cholangiocytes; Brockmann et al. identi-
fied bile outflow during NMP as a discriminative variable for early graft survival[35]. Op 
den Dries et al.[37] also demonstrated the production of bile by human liver grafts under 
normothermic conditions. Based on this small series, they conclude that bile production 
during NMP is the most important parameter for viability[41], although no strong cor-
relations could be made since these grafts were not actually transplanted. Vairetti et al. 
demonstrated that bile is also produced during colder SNP[36]. More importantly, this 
study showed that bile outflow during MP was no guarantee for improved bile flow after 
graft reperfusion. Boehnert et al. emphasized that evaluation of solely bile flow during 
MP might be biased due to the secretion of serum-like fluids from the injured biliary 
mucosa, which could falsely increase bile volume[23, 42]. In order to correct for this bias, 
they measured lactate dehydrogenase (LDH) in bile as a marker for biliary epithelial in-
jury and found its content in bile to be lower after NMP compared to SCS, while bilirubin 
and phospholipid concentrations were higher[23]. Impaired secretion of phospholipids 
gives a surplus of free bile salts  which are toxic for cholangiocytes. A higher ratio of bile 
salts/phospholipids, rather than bile production solely, has been associated with the 
development of ITBL[43, 44]. Also the secretion of HCO3- into bile, involved in local pH 
regulation, has been described as a marker for cholangiocyte function. The evidence of 
bile outflow or -composition as a marker at temperatures below 20°C is however mar-
ginal. Since lower temperatures shut-down metabolic cellular processes, bile parameters 
are probably more informative under (sub)normothermic conditions. 
liver enzyme release as indicator of hepatocyte injury
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and LDH are the most 
frequently studied biomarkers in liver disease. Both AST and LDH are enzymes that are 
mainly present in the cell cytoplasm of various tissues, including liver, and they are often 
used as general injury markers to monitor graft function after LT. For a more specific 
assessment of hepatocyte injury, ALT is often determined. In their clinical trial, Guarrera 
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et al. found perfusate levels of AST and ALT measured during HMP to strongly correlate 
with post-transplant peak AST and ALT serum levels in recipients. This suggests that 
injury that becomes apparent after graft implantation, can already be detected during 
HMP. Monbaliu et al. distuingished transplantable from non-transplantable grafts based 
on AST levels in perfusates during HMP[28]. But also during NMP, the release of AST and 
ALT were predictive for recipient survival in a large animal model[35]. Moreover, hepatic 
enzyme release during MP strongly correlated with donor warm-ischemia time, which 
in turn has been associated with poor graft quality[45]. The value of enzyme release into 
perfusates to predict PNF and EAD has also been confirmed by clinical LT studies with 
conventional SCS (table 3)[46-48]. 
energetic recovery status by adenine nucleotides
Cold temperatures and the absence of oxygen supply to tissue causes the shutdown 
of adenine nucleotide metabolism, which causes failure of ion transport by electron 
pumps on the cell membrane[49]. Therefore, Minor et al. investigated whether oxygen-
ation during MP could recover energy status by measuring the energy charge potential 
and adenosine triphosphate (ATP) levels in tissue[40]. At the end of various MP methods 
and already before reperfusion, oxygenated tissue showed a higher energy charge po-
tential and increased ATP levels compared to cold stored livers. This study furthermore 
demonstrated that hypothermic conditions hampered energetic recovery compared to 
(sub)normothermic conditions. In clinical LT, decreased ATP levels have been shown to 
increase the risk for graft PNF or EAD; Kamiike et al.[50] used expression of ATP and total 
adenine nucleotides in peri-transplant liver biopsies to predict graft viability, based on 
functional outcome within the first days after LT. Compared to other nucleotides, ATP 
was demonstrated to be most sensitive for ischemia, as its expression decreased faster. 
However, a reduction of total adenine nucleotide levels in liver biopsies was more predic-
tive for PNF after LT than ATP levels solely. Following revascularization, good functioning 
grafts also showed a better recovery of ATP and total adenine nucleotide levels. These 
levels were inversely related to the period of warm ischemia during graft implantation. 
Similar studies performed by Lanir et al.[51] and Hamamoto et al.[52], confirmed lower 
(total) adenine nucleotide levels in biopsies that were obtained during respectively 
cold storage and post-reperfusion, which also correlated with the development of PNF. 
Moreover, Hamamoto et al. found increased levels of Xanthine in perfusates also to be 
associated with PNF. These findings suggest that assessing energetic recovery of grafts 
in tissue and perfusates might be a good predictor for graft viability during MP in both 
hypo- as (sub)normothermic conditions.  
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endothelial injury markers: hyaluronic acid & thrombomodulin
The absence of blood and oxygen causes ischemic- and preservation injury to cells of 
the liver sinusoids[53]. Hyaluronic acid (HA) is a high-molecular weight glycosaminogly-
can (4 - 8 million kD) formed by the cellular plasma membrane[54] and its uptake mainly 
occurs by sinusoidal endothelial cells of the liver[55]. In clinical LT, a disruption of the 
hepatic micro-vascular integrity by preservation injury was shown to reduce the uptake 
of HA from the circulation, causing levels of HA in the liver to rise, which subsequently 
lead to EAD[56]. Comparable studies by Bronsther et al.[57] and Rao et al.[58] provided 
stronger evidence for HA to be associated with PNF and diminished graft survival after 
LT; levels over 400 μg/L in the perfusate had a highly negative predictive value of 95%. 
Furthermore, these studies demonstrated a correlation between HA levels in perfusates 
and post-operative AST and ALT levels in recipients. In the setting of NMP, Brockmann 
et al. found HA levels during NMP as one of their most significant predictors for graft 
viability after LT in a large animal model[35]; the mean level of HA in perfusates of suc-
cessful grafts was 108 ng/ml, while non-succesful grafts released much higher HA levels 
(6087 ng/ml). 
Another endothelial cell marker is Thrombomodulin (TM), which has potential anti-
coagulant effects if it forms a complex with thrombin. When the vascular endothelium 
of liver sinusoids is injured for instance by graft preservation, TM is inactivated by 
cleavage into smaller fragments of so-called soluble thrombomodulin (sTM) and it is 
subsequently released from the cell surface[59-64]. Suehiro et al.[65] found TM levels 
over 20 FU/ml in perfusates to be sensitive for identifying grafts with PNF or EAD after 
LT. These grafts showed a higher expression of TM on liver sinusoidal endothelial cells 
at the end of cold storage. In a smaller study performed by Sido et al, intraoperative 
sTM levels were measured in blood to assess graft endothelial reperfusion injury[60]. 
After reperfusion, sTM levels correlated significantly with release of liver enzymes and 
increased adherence of leukocytes in liver tissue. In clinical LT, however, only one study 
investigated TM as a predictor for outcome and graft quality[65] and no data are known 
on the potential use of TM as a marker for viability testing in the setting of MP. 
inflammatory markers, kupffer cells  and proteolytic enzymes 
Graft ischemia induces an inflammatory cascade that attracts leukocytes and neutro-
phils to the site of tissue injury and subsequent leakage of proteolytic enzymes, causing 
breakdown of cells and surrounding tissue post-reperfusion[66]. In a retrospective study 
that derived from the first clinical trial applying HMP for LT, Henry et al. investigated the 
effect of HMP on the expression of several injury markers[26]. Oxidative stress markers 
as Hypoxia-inducible factor-1α and -1β were significantly decerased in biopsies that 
were taken at the end of HMP, compared to SCS grafts. Also the expression of inflam-
matory markers like tumor necrosis factor-α (TNF- α ) were significantly lower in grafts 
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already at time of HMP. The authors hypothesize that these pro-inflammatory factors are 
eliminated through the diluting effects of HMP, thereby also reducing the production 
of down-stream chemokines and adhesion molecules like intercellular adhesion mol-
ecule-1 and P-selectin. This hypothesis was supported by the observation that at the end 
of HMP, less infiltrating kupffer cells (CD68 positive) were present in tissue compared to 
SCS biopsies. Berberat et al.[67] found several inflammatory genes in post-reperfusion 
biopsies predictive of graft outcomes; high expression of TNF-α was correlated with 
shortened graft survival, while high c-reactive protein expression correlated with the 
need of interventions after LT. A linear combination of five down regulated vascular 
genes was superior in forecasting graft related complications, with a positive predictive 
value of 72% and negative predictive value of 96%. Calmus et al.[68] also demonstrated 
a strong correlation between ongoing proteolysis during SCS and EAD; increased levels 
of free amino acids that were released from the liver into perfusates showed good 
positive- and negative-predictive value (respectively 100% and 95%) for EAD in the first 
postoperative week. As Henry et al. and Calmus et al. show, it is feasible to measure 
inflammatory markers and proteolytic enzymes during cold graft preservation prior to 
reperfusion. However, the strongest effect on these markers usually becomes apparent 
after revascularization of the graft[25] and therefore it would be highly interesting to 
observe the predictive value of these markers in normothermic conditions. Up to now, 
many MP studies only investigate such markers after reperfusion[25, 32]. 
tissue hemorrhage and cell necrosis 
The degree in which tissue is affected by graft ischemia varies and is usually reflected 
by histopathological changes. Xu et al. investigated these histological changes during 
NMP of porcine liver grafts[38]. A remarkable finding was that the degree of necrosis and 
apoptosis in biopsies taken after warm ischemia and subsequent cold storage, appeared 
to be reversed after 4h of NMP. This not only suggests that histological evaluation at 
time of NMP might be a useful indicator for graft viability, it also indicates that NMP has 
the potential to recover ischemic damage. This has also been suggested by other NMP 
studies that performed histological evaluation after reperfusion[23, 39]. The prognostic 
value of necrosis and apoptosis occurring during SCS was also evaluated in different 
tissues from clinical studies; Khettry et al. demonstrated extensive hemorrhage and/or 
necrosis of 10-50% in the donor gallbladder mucosa to have a high positive- and nega-
tive predictive value for PNF and impaired graft survival, whereas vascular congestion 
was present in all donor gallbladders[69]. In addition, Abraham et al. identified apoptotic 
cells and zone 3 hemorrhage in post-reperfusion liver tissue to have good discriminative 
power for PNF (AUC=0.90 and 0.77 respectively)[70]. 
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Degree of graft steatosis
Beside DCD, steatotic livers form another important source within the category of ECD 
grafts that could benefit from improved preservation and subsequent graft outcome by 
MP. Bessems et al.[20] found improved functional parameters in steatotic rat livers after 
HMP compared to normal preservation by SCS. Similar beneficial effects were observed 
by Vairetti et al, who concluded that subnormothermic temperatrues are preferred over 
colder temperatures for the recovery of steatotic grafts[71]. Despite exciting results on 
MP for optimizing the quality of steatotic grafts, these studies were not informative on 
potential biomarkers prior to reperfusion. However, a more recent study by Jamieson 
et al. measured a decrease in lipid deposits during NMP of rat livers which correlated 
with a reduction in the degree of steatosis[21]. Previous clinical studies showed the 
value of histological macro vesicular steatosis to predict graft PNF, which has been 
extensively reviewed earlier[72]. Dutkowski et al.[73] integrated the degree of steatosis 
in a balance of risk score with other risk factors for graft failure, consisting of recipient 
age, MELD-score, re-transplantation, cold ischemia, and donor age. This score indicates 
that one should be reluctant with the use of moderate to severe steatotic liver grafts 
(>30%) in recipients with a balance of risk-score ≥9, but microvesicular steatosis has not 
been related to poorer outcome. Though histological scoring in steatotic grafts seems 
promising in the setting of both MP and SCS, in general, one should be aware for the 
risks of intra- and inter observer variability that hampers a standardized histological 
evaluation.[74] 
markers for biliary inJury
As previously explained, bile ducts of particularly ECD grafts have been shown to be 
vulnerable for ischemic injury and are responsible for a high percentage of graft loss 
(fig. 1). Therefore, biliary complications are also an important outcome for several MP 
studies. Up to now, MP studies on human liver grafts (table 1) have shown that MP 
is not harmful for bile ducts, but most studies are too small to demonstrate whether 
a significant benefit actually exists[24, 29, 37]. Schlegel et al. recently demonstrated 
beneficial effects of HOPE on biliary fibrosis, but no markers were investigated during 
HOPE on their predictive capacity for biliary injury[31]. Several clinical studies however 
identified markers in tissue and perfusates during SCS that were able to predict biliary 
complications.
Peribiliary epithelial damage and vascular injury
Brunner et al. developed a bile duct damage-score based on the degree of injury in 
the epithelium of the extrahepatic bile duct and diminished epithelial barrier integrity 
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measured by tight junction proteins[12]. Samples of common bile duct tissue showing 
more than 10% of destructed epithelium or/and subepithelial connective tissue at the 
beginning of cold preservation were predisposed to develop major biliary complica-
tions and diminished graft survival. Also Hansen et al.[75] scored extrahepatic bile duct 
specimens and found arteriolonecrosis causing mural necrosis to be the most prominent 
risk factor for ITBL. Similar observations were recently reported in a larger cohort studied 
by op den Dries et al.[76]. Additionally, the investigators found that grafts that would 
develop ITBL, lost over 50% of cells within deep peribiliary glands that are located along 
the common bile duct and which are involved in cholangiocyte proliferation in response 
to injury[77, 78]. Based on their findings, the authors formulated the hypothesis that 
ITBL results from an insufficient regenerative capacity of injured cholangiocytes by 
peribilary glands, caused by arteriolonecrosis in the bile duct wall, rather than being 
the result of extensive epithelial injury alone[79]. Remarkably, the degree of injury in 
peribiliary glands did not differ between DBD and DCD grafts. Beside changes in the 
arterial vasculature of the peribiliary plexus, a case-control study by Farid et al. showed 
changes in the luminal size of the portal vein branch (PVB) in liver tissue specimens to be 
more pronounced after reperfusion[80]; a smaller PVB size was seen in grafts that later 
developed ITBL. This supports earlier findings on the importance of portal blood flow, 
which is responsible for approximately 40% of the blood supply in the common bile 
duct, for the risk to develop ITBL[81, 82]. Unfortunately, differences in PVB size became 
apparent only after reperfusion. 
Cholangiocyte-derived micrornas
MicroRNAs (miRNAs) are small regulatory RNAs with high cell-type specificity and their 
resistance against RNAse mediated degradation in different media and conditions 
makes them an attractive candidate for biomarker research[83-85]. Hepatocyte-derived 
miRNAs (HDmiRs) were identified as sensitive markers in serum for acute graft rejec-
tion and more recently, our group reported that lower levels of cholangiocyte-derived 
miRNAs (CDmiRs) in perfusates during SCS are predictive of ITBL in both DBD and DCD 
grafts[86, 87]. In this study, miRNAs remained stable in University of Wisconson (UW) 
and histidine-tryptophan-ketoglutarate (HTK) perfusates, also after incubation at room 
temperature. Preliminary data show that miRNAs can also be measured during MP (data 
not shown). Furthermore, HDmiRs and CDmiRs are also released into bile[88]. Interest-
ingly, a very recent study shows that recipients developing ITBL have an altered miRNA 
composition in bile[89]. 
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DisCussion
As dynamic preservation is now entering the clinic, researchers emphasize on the need 
of predictive and sensitive biomarkers that are able to objectively assess graft qual-
ity during MP. Biomarkers could help to enlarge the donor pool by objectively screen 
liver grafts that initially would be discarded based on their predisposing characteristics. 
Several experimental studies already demonstrated that a combination of biomarkers 
measured during MP could be used as a damage index for ECD grafts[45, 90]. However, 
since the clinical application of MP is still in its infancy, the introduction of such damage 
scores based on surrogate biomarkers should be studied in larger cohorts. Prospective 
randomized clinical trials on MP would offer the best opportunity for unbiased evalua-
tion of potential biomarkers, provided that sampling of materials during MP is executed 
accurately. Moreover, such trials could also definitely answer the question which MP 
strategy is most capable of optimizing ECD graft quality. 
The requirements for a biomarker to make it into clinical practice are that its mea-
surement should be easy and relatively fast, with a high sensitivity and specificity for 
outcome. Moreover, biomarkers should be measurable in biomaterials that are avail-
able at time of graft preservation, so its discriminative capacity could be used in graft 
screening and allocation[91]. Biopsies from liver or extrahepatic bile duct specimens 
can be collected during preservation and are suitable for histological evaluation and 
quantification of injury based on (low) expressed biomarkers. It should however be 
emphasized that biopsies are obtained invasively and only represent a small part of the 
liver or bile duct, which could lead to incorrect interpretation when injury is unequally 
distributed throughout the tissue (table 4). Moreover, inter- and intra-observer vari-
ability can hamper a standardized evaluation of histological markers. The collection of 
perfusates form an attractive non-invasive alternative for a variety of markers during 
conventional preservation and MP. Another advantage of using perfusates over tissue 
biopsies is that larger volumes can be collected and markers released into perfusates 
are believed to represent the condition of the entire liver parenchyma rather than only 
a small part of the liver. Limitations consist of difficulties in the normalization of mark-
ers; most MP systems use a recirculating perfusion system, in which biomarkers can 
accumulate. Therefore, perfusate levels of conventional biomarkers like AST could differ 
from standards in clinical practice. This also applies to perfusion temperature; hypother-
mic conditions will cause a delayed metabolism of the liver and requires an adjusted 
evaluation of biomarkers and cut-off values compared to normothermic, physiologic 
conditions .
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A limitation for many biomarkers in general is that their quantification can be labour 
intensive and time consuming. Some techniques, for instance polymerase chain reac-
tion, are however progressing in terms of accelerated measurements, which makes 
them applicable in the prolonged time-window created by MP[92, 93]. 
In general, biomarkers can be used either to determine graft injury or graft function. 
Up to now, most biomarkers concern markers for injury, while bile production currently 
is the only marker for liver function. Robust markers of function rather than injury are 
however of importance, because severe ischemic injury not necessarily means that a 
graft will not function properly following LT. Additional markers of function could consist 
of subtrates which do not naturally occur in the body, but are cleared by the liver. For in-
stance the plasma disappearance rate of intravenously administered indocyanine green 
(PDR-ICG) or 13C-labeled methacetin (LiMAx test), which are predictive of PNF, EAD and 
hepatic artery thrombosis after LT [94-97]. However, results of such tests are influenced 
by perfusion flow rates[98, 99]. Moreover, functional markers require a metabolically 
active liver, which can only be achieved under (sub)normothermic conditions (fig. 4).     
Beside biomarkers for injury and function, it is evident that donor- and recipient risk 
factors can influence outcome after LT (fig. 2). Genetic polymorphisms in both donors 
and recipients have been identified that increase the risk for recipients to develop ITBL 
or bacterial infections after LT[100-102]. Therefore, genetic profiling could be helpful 
in matching donors to equivalent recipients[91]. Moreover, information on donor and 
recipient risk factors are usually available in an early stage of LT[103]. 
table 4. Materials for biomarker measurement during graft preservation. Summary on the advantages and 
disadvantages between the different biomaterials that can be used to asses graft quality at time of MP or 
during SCS prior to LT. 
biomaterial advantages Disadvantages
Tissue Histological evidence for graft quality
Large amount of cells 
Invasive
Only local representation 
Risk of inter- or intra obser variability
Perfusate Non-invasive
Larger quantities available
Suitable application for various types of MP
Timing; short before implantation
No standardized workup between LT 
centers
Bile Non-invasive
Indicative for hepatocyte and cholangiocyte 
function
Suitable application for MP
Less informative during hypothermic 
conditions 
smaller quantities available
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ConCluDing remarks anD future DireCtions
The limited experience of MP in clinical LT hampers the evaluation on which MP strategy 
is most optimal for graft quality and the evaluation of potential biomarkers for quality 
assessment. Another factor that hampers evaluation of biomarkers is the inconclusive-
ness between studies on outcome definitions; investigators maintain different criteria 
for comparing cohorts, making it impossible to perform a reliable meta-analysis on 
outcomes describing corresponding markers. More clear international guidelines on 
outcome definitions are therefore recommended, as was previously initiated by Olthoff 
et al.[9]. Comparing biomarkers during MP and conventional SCS, we can however 
conclude that non-invasive measurement of injury markers into perfusates and the as-
sessment of liver function based on the production of bile are well-possible in MP. For all 
markers, however, one should take into account the baseline differences that can exist 
between donors, liver grafts and MP techniques that influence biomarker measurements 
and pleas for custom criteria and cut-off values in the evaluation of biomarkers[10]. This 
review forms a starting point for future studies on quality assessment by biomarkers and 
graft screening in the changing setting of graft preservation and MP in clinical LT in the 
coming years.  
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key points
 • The increased use of extended criteria grafts demands for more objective and 
sensitive biomarkers to evaluate the large discrepancy of graft quality in LT.
 • Measurement of prudent biomarkers during machine preservation (MP) could be 
helpful in the prediction of early graft performance after LT. 
 • During MP, surrogate biomarkers for graft quality could help select the most opti-
mal preservation technique before implantation.
 • Research shows discriminative potential of a variety of biomarkers for graft injury 
and function, but requires robust validation in larger cohorts before applicable in 
the clinic. 
 • Non-invasive evaluation of biomarkers released into perfusates during MP is an 
attractive alternative for invasively obtained tissue biopsies. 
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suPPlementary information 
metHoDs 
literature search
Two systematic literature searches in Embase, Ovid Medline and Cochrane were per-
formed to identify potentially relevant studies regarding biomarkers in machine per-
fusion (MP) and in conventional static cold-storage LT (SCS) that were published until 
January 2014, as described in supplementary table 1 and table 2. The search regarding 
biomarkers in MP consisted of the following key elements: liver transplantation, biologi-
cal markers and machine perfusion/preservation. The search regarding biomarkers in 
conventional LT consisted of: liver transplantation, biological markers and preservation. 
All elements were searched using the corresponding thesaurus terms (EMTREE or MeSH) 
or words in title or abstract. 
For studies regarding biomarkers in liver MP, we mainly focussed on studies using 
human liver grafts. Because of the low incidence of clinical MP, we also included experi-
mental studies on liver MP that have been performed in animal models. To amplify and 
validate whether biomarkers in MP are useful, we also searched for comparable data in 
clinical LT studies using conventional SCS for graft preservation. Inclusion criteria were 
as follows: (i) Biomarkers should be measured in donor graft material, and (ii) should be 
obtained during graft preservation, and (iii) they should be associated with impaired 
graft quality resulting in impaired graft viability (in case of MP) or be predictive for PNF, 
EAD, or the occurrence of biliary complications after static cold storage in LT (see defini-
tions). Studies describing steatosis as a marker for early graft dysfunction were excluded, 
since this has been reviewed extensively earlier. The Oxford Centre for Evidence-based 
Medicine Level of Evidence scale was used to assess methodological quality of poten-
tially relevant publications. 
supplementary table 1. search terms used for identifying biomarkers using MP.
Database search terms
Embase, Medline and 
Cochrane
(‘liver perfusion’/de OR ((liver/exp OR (liver OR hepatic):ab,ti) AND ((machine* OR 
hypotherm* OR cold OR normoterm* OR warm* OR subnormotherm* OR oxygenated) 
NEAR/3 (perfusion* OR preservation*)):ab,ti)) AND (marker/de OR ‘biological marker’/
de OR ‘molecular marker’/de OR ‘biochemical marker’/de OR ‘genetic marker’/exp OR 
‘pharmacological biomarker’/de OR biomarker*:ab,ti OR marker*:ab,ti)
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Definitions
Primary non-function was defined as the occurrence of liver re-transplantation or 
patient death within the first week after LT. For EAD, most studies maintained differ-
ent criteria, but usually consisted of the following parameters: elevation of AST and/
or ALT above a defined cut-off value (1500-2000) within the first week after LT, elevated 
international normalized ratio on day 7 after LT, elevated bilirubin levels on day 7 after 
LT, or graft loss within the first month after LT. Biliary complications following LT included 
bile duct leakage, necrosis, anastomotic strictures and ITBL. Ischemic-type biliary lesions 
were defined as (i) symptomatic, non-anastomotic strictures and associated dilatations 
of the intrahepatic or extrahepatic hilar bile duct(s) after LT, which (ii) were confirmed 
supplementary table 2. search terms used for identifying biomarkers during graft SCS. 
Database search terms
Embase (‘liver transplantation’/exp OR ((liver* OR hepatic*) NEAR/3 (Transplant* OR graft* )):ab,ti)  
AND (marker/de OR ‘biological marker’/de OR ‘molecular marker’/de OR ‘biochemical 
marker’/de OR ‘genetic marker’/exp OR ‘pharmacological biomarker’/de OR biomarker*:ab,ti 
OR marker*:ab,ti) AND (‘preoperative period’/exp OR ‘perioperative period’/de OR 
‘intraoperative period’/de OR prediction/de OR ‘predictive value’/de OR (((pre OR before 
OR per OR prior OR intra OR during OR peri) NEAR/6 (transplant* OR surg* OR donat* OR 
operat*)) OR pretransplant* OR pertransplant* OR predonat* OR perdonat* OR presurg* OR 
persurg* OR intrasurg* OR preoperat* OR peroperat* OR perioperat* OR intraoperat* OR 
predict* OR (early NEXT/1 marker*)):ab,ti) NOT ([Animals]/lim NOT [humans]/lim)
Medline (liver transplantation/ OR ((liver* OR hepatic*) ADJ3 (Transplant* OR graft* )).ab,ti.)  AND 
(exp Biological Markers/ OR biomarker*.ab,ti. OR marker*.ab,ti.) AND (“preoperative period”/ 
OR “perioperative period”/ OR “intraoperative period”/OR (((pre OR before OR per OR 
prior OR intra OR during  OR peri) ADJ6 (transplant* OR surg* OR donat* OR operat*)) OR 
pretransplant* OR pertransplant* OR predonat* OR perdonat* OR presurg* OR persurg* OR 
intrasurg* OR preoperat* OR peroperat* OR perioperat* OR intraoperat* OR predict* OR 
early marker*).ab,ti.) NOT (exp Animals/ NOT humans/)
Cochrane (((liver* OR hepatic*) NEAR/3 (Transplant* OR graft* )):ab,ti)  AND (biomarker*:ab,ti OR 
marker*:ab,ti) AND ((((pre OR before OR per OR prior OR intra OR during OR peri) NEAR/6 
(transplant* OR surg* OR donat* OR operat*)) OR pretransplant* OR pertransplant* OR 
predonat* OR perdonat* OR presurg* OR persurg* OR intrasurg* OR preoperat* OR 
peroperat* OR perioperat* OR intraoperat* OR predict* OR early marker*):ab,ti)
Pubmed (((liver*[tiab] OR hepatic*[tiab]) AND (Transplant*[tiab] OR graft*[tiab] )))  AND 
(biomarker*[tiab] OR marker*[tiab]) AND ((((pre[tiab] OR before[tiab] OR per[tiab] 
OR prior[tiab] OR intra[tiab] OR during[tiab] OR peri[tiab]) AND (transplant*[tiab] OR 
surgery[tiab] OR surgical[tiab] OR donat*[tiab] OR operat*[tiab])) OR pretransplant*[tiab] OR 
predonat*[tiab] OR presurg*[tiab] OR persurg*[tiab] OR intrasurg*[tiab] OR preoperat*[tiab] 
OR peroperat*[tiab] OR perioperat*[tiab] OR intraoperat*[tiab] OR predict*[tiab] OR early 
marker*[tiab])) AND publisher[sb]
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by cholangiography and in the presence of a patent hepatic artery as demonstrated by 
Doppler ultrasonography, and (iii) requiring endoscopic or percutaneous interventions 
of the biliary system or liver retransplantation in recipients. 
literature screening
The selection of relevant publications was performed by three stages of evaluation 
performed by two authors independently (CV and WF) and a final random check by two 
others (GK and LL). At first, studies were excluded if they concerned duplicate studies in 
the three databases, animal research (except for MP studies), reviews and conference 
abstracts (supplementary fig. 1, stage 1). At the second stage, manuscript abstracts 
were evaluated for their relevance; research papers describing organ transplantation 
other than deceased donor LT, or not using biomarkers at time of graft preservation 
were excluded. The remaining studies were completely reviewed at stage 3. 
Stage 1: 
Initial literature search 
n=3130 
Stage 2: 
Abstract evaluation 
n=2279 
Stage 3: 
Complete manuscript review 
n=108 
Included studies 
n=42 
Exclude double studies & 
irrelevant animal studies 
n=851 
Exclude irrelevant papers 
based on abstract 
n=2171 
Exclude irrelevant papers 
based on complete 
manuscript; n=66 
supplementary figure 1. Inclusion scheme for relevant publications.
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Methodological quality of clinical studies was assessed by using the Oxford Centre for 
Evidence-based Medicine Level of Evidence scale (CV and GK). 
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Liver grafts procured from 
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abstraCt
Microthrombi formation provoked by warm ischemia and vascular stasis is thought to 
increase the risk of non-anastomotic biliary strictures (NAS) in liver grafts obtained by 
donation after circulatory death (DCD). Therefore, potentially harmful intraoperative 
thrombolytic therapy has been suggested as a preventive strategy against NAS. Here, 
we investigated whether there is histological evidence of microthrombi formation dur-
ing graft preservation or directly post-reperfusion in DCD livers and the development of 
NAS. Liver biopsies collected at different time points during graft preservation and post-
reperfusion were stained in triplo with hematoxylin-eosin (HE), Von Willebrand Factor 
VIII (VWF), and Fibrin Lendrum (FL) to evaluate the presence of microthrombi. In a first 
series of 282 sections obtained from multiple liver segments of discarded DCD grafts, 
microthrombi were only present in 1-3% of the VWF stainings, without evidence of 
thrombus formation in paired HE and FL-stainings. Additionally, analysis of 132 sections 
obtained from matched, transplanted brain death (DBD) and DCD grafts showed no dif-
ference in microthrombi formation (11.3% vs. 3.3% respectively, P=0.082), and no rela-
tion to the development of NAS (P=0.729). Furthermore, no microthrombi were present 
in perioperative biopsies in recipients who developed early hepatic artery thrombosis. 
Finally, the presence of microthrombi did not differ before or after additional flushing 
of the graft with preservation solution. Conclusion: The results of our study derogate 
from the hypothesis that DCD livers have an increased tendency to form microthrombi. 
It weakens the explanation that microthrombi formation is a main causal factor in the 
development of NAS in DCD, and that recipients could benefit from intraoperative 
thrombolytic therapy to prevent NAS following liver transplantation.   
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introDuCtion
Biliary complications following liver transplantation (LT) are associated with high morbid-
ity and mortality rates in recipients[1, 2]. In particular non-anastomotic strictures (NAS) 
located in the hilar and intrahepatic regions of the liver, which appear in 15-30% of the 
LT recipients, have been associated with shortened graft survival[3]. In severe cases, the 
distribution of NAS makes them less accessible for endoscopic or percutaneous interven-
tion and often requires a more extensive treatment[4, 5]. Eventually, re-LT due to NAS is 
necessary in up to 15% of LT recipients, underscoring the severity of this condition[6].  
Several risk factors have been identified for the development of NAS, but its 
pathogenesis is still not fully understood. Immune-mediated risk factors such as ABO-
incompatibility[7], CMV infection[8], and primary sclerosing cholangitis as underlying 
disease[9, 10] increase the risk of NAS. A second category of risk factors include bile salt 
toxicity against cholangiocytes[11-13]. However, as the incidence of NAS is significantly 
higher in grafts donated after circulatory death (DCD) compared to those donated after 
brain death (DBD), a leading role has been attributed to ischemia-reperfusion injury[2, 
3, 6, 9]. Possible mechanisms for NAS in DCD livers could be the detrimental effects of 
insufficient flushing of the graft on the biliary epithelium or to the microcirculation of 
the peribiliary plexus (PBP)[14, 15]. 
The involvement of vascular obstruction, in particular the hepatic artery that provides 
the majority of blood supply to the PBP, and the development of NAS has been demon-
strated by multiple studies. Hepatic artery thrombosis (HAT) was shown to be a major 
risk factor for severe NAS, often requiring re-LT in recipients due to graft failure[16, 17]. 
Although conflicting data exists on the occurrence and pathophysiology of HAT[18], 
some studies suggest that their incidence is higher in DCD grafts[19]. Experimental 
studies showed a positive correlation between the length of warm ischemia time and 
bile duct injury due to occlusion of the PBP, induced by post-transplant hepatic arterial 
ischemia[20, 21]. Beside the hepatic artery, 40% of the microvascular blood flow origi-
nates from the portal vein, which when obstructed can also cause severe NAS[22-24]. 
In contrast to DBD grafts, DCD grafts experience additional warm ischemia time with 
no-flow status in the period between cardiac arrest and in situ cold perfusion. Due 
to the diffuse presentation of NAS and its relation with compromised blood flow, it is 
hypothesized that DCD grafts have an increased tendency to form microthrombi in the 
microcirculation of the liver during warm ischemia time[25]. This could subsequently lead 
to inadequate flushing of the capillary network with suboptimal cold preservation and 
exacerbation of ischemic injury following reperfusion[26]. In order to improve the flush 
of the microcirculation, an additional arterial back-table pressure perfusion has been 
recommended[14]. Additionally, some transplant centers advocate the use of thrombo-
lytic agents in preservation solutions to prevent formation of microthrombi[27]. Several 
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studies suggest that arterial perfusion of DCD livers with urokinase or tissue plasminogen 
activator prior to implantation may reduce the incidence of NAS[25, 28]. However, such 
management could result in severe complications, such as perioperative bleeding, mak-
ing many centers reluctant to use thrombolytic agents in the transplantation setting. 
To date, only a limited number of studies have performed a histological evaluation 
of microthrombi formation in DCD livers, with the primary emphasis on extrahepatic 
bile duct tissue[15, 29]. Therefore, it remains questionable whether the aforementioned 
hypothesis on the role of intrahepatic formation of microthrombi in NAS is correct and 
whether it justifies intraoperative treatment with aggressive thrombolysis. To address 
this question, we performed a comprehensive histological study on the presence of 
microthrombi formation at time of graft preservation and following reperfusion in liver 
tissue biopsies from; (i) a series of extended criteria DCD liver grafts that were discarded 
for human LT, and (ii) a series of transplanted DCD and DBD liver grafts that developed 
NAS or HAT following LT. 
materials anD metHoDs
study design and donor livers
For the current study, we retrospectively analyzed two series of prospectively col-
lected liver biopsies. The first series of biopsies were obtained from extended criteria 
DCD donors that were discarded for human LT between July 2012 and December 2013 
(see supplementary information for further inclusion details). As these grafts were 
discarded for human LT, a more extensive sampling of biopsies was possible. In order to 
correlate the formation of microthrombi with the development of NAS, a second series 
of biopsies obtained from liver grafts transplanted between January 2007 and December 
2012 were analyzed as well. Microthrombi formation was compared between DCD and 
DBD grafts and between grafts that developed NAS or remained free of biliary complica-
tions. Biopsies were selected from LT procedures with comparable donor-, recipient- and 
procedural characteristics, so matched groups would only differ based on graft type and 
outcome, namely DBD – no NAS, DBD – NAS, DCD – no NAS, and DCD – NAS. Finally, 
biopsies from explanted liver grafts that developed HAT and required re-transplantation 
were analyzed as a control group. An illustration of the inclusion of liver grafts and the 
study design is provided in fig. 1a. 
graft procurement, graft preservation, and collection of tissue biopsies
All liver grafts in this study were procured via standard procedure and conformed to 
Dutch organ retrieval protocols. Details regarding organ retrieval and liver perfusion 
are described in the supplementary information. fig. 1b provides an outline of the time 
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points for collecting the first series of biopsies that were obtained from central and 
peripheral segments of the left and right liver lobes of discarded DCD grafts by an 18G 
Tru-Cut® biopsy needle. Biopsies were retrospectively selected for histological evalua-
tion if they were available from similar liver segments at a minimum of two different 
time points per discarded DCD graft. fig. 1C provides an outline of the collection time 
points for the second series of biopsies from transplanted DBD and DCD grafts, which 
were wedges of liver tissue from the left lateral segment. All collected biopsies from 
Discarded DCD
n=16
Included livers for peri-
transplant biopsy collection
A
DBD / control
n=5
DBD / NAS
n=5
DCD / NAS
n=5
DCD / control
n=5
DCD / HAT
n=4
n=94 biopsies
n=282 sections
n=40 biopsies
n=120 sections
n=4 biopsies
n=12 sections
Circulatory death Graft cold storage (~8 hours) Benching
T=0 T=2T=1
T=3T=2
Circulatory or
brain death Graft cold storage (~8 hours) Benching
Graft 
implantation
Reperfusion
B
C
figure 1. Study design. (A) Inclusion scheme of liver grafts for the collection of peri-transplant liver tissue 
biopsies. (B) Schematic illustration of time points for collection of the first series of liver biopsies obtained 
from DCD grafts discarded for human LT. Directly following organ retrieval, needle biopsies were taken 
(t=0) with an 18G Tru-Cut® biopsy needle from left and right-sided liver segments before grafts were trans-
ported to our center. During transportation, grafts remained cold stored for at least 6-8 hours and subse-
quently, biopsies were taken from similar segments as at time of organ retrieval (t=1). In order to mimic the 
normal transplantation procedure, after cold storage, the liver was additionally flushed ex situ with 1000 
ml UW or HTK solution, depending on the preservation fluid initially used during procurement. After this 
second flush, the final series of biopsies were taken (t=2). (C) Comparable to discarded grafts, transplanted 
livers also received an additional ex situ perfusion with 1000 ml of UW or HTK upon arrival at the operating 
room. This was followed by flushing with 600ml of human albumin solution (Albuman human albumin 
40g/l, Sanquin, The Netherlands). Next, a wedge of liver tissue from the anterior side of the left lateral seg-
ment was taken at the end of cold ischemia (comparable to t=2 in discarded DCD livers). After implantation, 
a paired wedge of liver tissue was collected following graft arterial and venous reperfusion (t=3). Explant 
biopsies from four DCD grafts that developed HAT following LT were used as a control group. 
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both discarded as well as transplanted liver grafts were directly fixated in 4% formalde-
hyde for a minimal duration of 24 hours and subsequently embedded in paraffin blocks 
(FFPE-blocks). All FFPE-blocks were stored at the department of Pathology in our center 
according to the latest regulations of the International Organization for Standardiza-
tion (ISO) for optimal preservation of the blocks with less risk of protein degradation 
for histochemical staining and immunohistochemistry. For more detailed information 
regarding the collection of biopsies, see the legend of fig.1. 
stainings and histological scoring for microthrombi
All biopsies were cut into 4μm sections and evaluated on the presence of microthrombi 
using three different staining protocols; hematoxylin-eosin (HE), Fibrin Lendrum (FL) 
histochemical staining and immunohistochemistry for von Willebrand Factor VIII (VWF), 
performed with anti-Factor 8 polyclonal antibody  (Dako, Glostrup, Denmark). Placental 
tissue and endothelial tissue of maximally two to three years old were used as positive 
controls for FL and VWF staining’s, respectively. This is comparable to the age of FFPE-
blocks used for the second series of biopsies from transplanted DBD and DCD grafts. 
For the VWF staining, deparaffinization and staining of sections was processed auto-
mated by a Ventana BenchMark ULTRA Stainer (Ventana, Tucson Arizona, USA) accord-
ing to manufacturers’ instructions at the department of Pathology. Peroxidase-coupled 
antibodies were detected using 3,39 - diaminobenzidine as a substrate and the slides 
were counterstained with haematoxylin. This staining method has been validated for 
use in patient care, and human placenta was used as a positive control for every section. 
For the FL staining, sections were deparaffinized and rehydrated by graded alcohol 
series. Subsequently, sections were stained at room temperature with the following 
solutions: Weigert’s Iron Haematoxylin for core staining (10 min.), 1% acid alcohol for 
differentiation (30 sec.), Martius Yellow for erythrocyte staining (3 min.), Crystal Ponceau 
solution for Fibrin staining (5 min.), Phospotungstic acid solution for collagen (2 times 
5 min.), and Methyl blue solution for connective tissue staining (5 min.). Between each 
staining step, sections were thoroughly rinsed with tap water. After staining, sections 
were rapidly dehydrated through ascending ethanol series, cleared in xylene substitute, 
and covered with pertex. Endothelial tissue was used as a positive control. 
For the HE staining, sequentially sliced sections were cut, deparaffinized and stained 
using a fully automated Ventana Discovery Stainer (Ventana, Tucson Arizona, USA) ac-
cording to the manufacturers’ instructions for HE staining. All sections were evaluated 
for the presence of microthrombi by two experienced liver transplant pathologists (MD 
and KB) who were blinded to the clinical data. 
Definitions
Definitions of HAT and NAS are provided in the supplementary information. 
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statistical analysis
Statistical analysis was performed using SPSS statistics 20 (SPSS Inc, Chicago, IL, USA). 
Group comparisons were performed using Mann-Whitney U or Kruskal-Wallis-test for 
continuous data and X2-test for categorical data. P-values < 0.05 were considered statis-
tically significant. 
results
Donor characteristics of discarded, extended criteria DCD liver grafts 
For the analysis of the first series of biopsies, 16 extended criteria DCD liver grafts, dis-
carded for human LT, were included in this study. Donor demographics and procedural 
variables are summarized in table 1. The primary reasons for discarding the liver graft 
for transplantation were donor age >60 years (62.5%; median of 64 years), followed by 
high donor BMI >28 (12.5%). The majority of the livers were obtained from male donors 
(62.5%) and UW was more frequently used for preservation than HTK (62.5%). Clinical 
blood values of the donors were comparable to those in transplanted liver grafts (listed 
in table 2). Median first warm ischemia time from circulatory arrest until cold perfusion 
was 17 minutes, while the functional first warm ischemia time from saturation <70% or 
systolic blood pressure <50 mmHg until cold perfusion was 29 minutes. 
no histological evidence of microthrombi formation during preservation of 
extended criteria DCD grafts
From 16 DCD grafts, 94 liver biopsies were collected at three different time points during 
graft preservation (fig. 1a-b). With a standard of three sections per biopsy, a total of 282 
sections were available to analyse for the presence of microthrombi; 63 sections at t=0, 
111 sections at t=1 and 108 sections at t=2. All included liver biopsies contained a me-
dian of 23 portal triads (IQR 14-33) suitable for histological evaluation. A more extensive 
collection of biopsies was possible after graft arrival at the hospital, explaining the larger 
number of biopsies at t=1 and t=2. 
In sections stained with HE and FL, no microthrombi could be identified by both 
pathologists (fig. 2a-C). Only 4 out of 282 sections (1.4%) showed positive staining for 
VWF in arterial vessels within the portal triad (fig. 2e). However, paired HE and FL sec-
tions did not provide convincing evidence of thrombus formation (fig. 2D and f). Two 
positive stainings were found at t=0, prior to graft transportation and cold storage (fig. 
2J). Additional positive stainings were found at the end of cold storage (t=2) and after 
additional flushing at the back table (t=3). The formation of microthrombi showed no 
preference for central, peripheral, left or right liver segments.  
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fig.2H and 2i show stainings in endothelial and placental tissue, which served as posi-
tive controls. As a positive control for HE staining, a biopsy obtained from an explanted 
graft that developed HAT after initial LT was analyzed. fig. 2g shows a positive control 
for HE staining, with an arterial thrombus in the hilar region of the liver graft at day six 
following LT. However, analysis of wedge biopsies from the same graft at the end of cold 
ischemia and post-reperfusion did not reveal any microthrombi formation. 
table 1. Clinical variables of extended criteria DCD grafts that were discarded for human LT. 
 number (n=16) 
Donor characteristics
Age (yr)  64 (54-70)
Male/Female  10/6
Body mass index  25 (22-33)
Cause of death
     Cardiovasculair event  2 (12.5%)
     Cerebrovasculair accident  5 (31.3%)
     Trauma  4 (25%)
     Other  5 (31.3%)
Clinical blood values at time of donation
     AST (U/L) 49 (29-90)
     ALT (U/L) 35 (18-65)
     GGT (U/L) 55 (25-111)
     Total bilirubin (µmol/L) 7 (5-8)
Procedure variables  
Preservation solution and volume (cc)  
     UW (n=10) 10000 (-)
     HTK (n=6) 8000 (7250-9000)
First warm ischemia time (min)1  17 (14-18)
Functional 1st warm ischemia time (min)2  29 (21-35)
Reasons for discarding
     Donor age >60 yr 10 (62.5%)
     Donor BMI >28 2 (12.5%)
     Elevated donor transaminases 1 (6.3%)
     No cardiac arrest 60 min following switch-off 1 (6.3%)
     Hypoperfusion 1 (6.3%)
     Steatosis 1 (6.3%)
1 Time from circulatory arrest until cold perfusion
2  Time from saturation <70% or systolic blood pressure <50 mmHg until cold perfusion (min)
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; UW, 
University of Wisconsin solution; HTK, histidine-tryptophan-ketoglutarate solution; BMI, body mass index. 
For numerical variables, values represent the median (interquartile range), for categorical variables, values 
represent the number (percentage). 
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figure 2. Histological grading of liver biopsies from discarded DCD liver grafts for the presence of micro-
thrombi. Panel a-C: portal triad in a liver biopsy with no signs for thrombus formation in none of the in triplo 
stained sections. Panel D-f: portal triad in a liver biopsy with a small amount of fibrin in the portal vein (D), 
doubtful thrombus formation in VWF  immunostaining (E) and negative in FL (F). Magnifications x10. Panel 
g-i: positive control for HE with thrombus formation in the branch of a hepatic artery in the hilar region 
of a liver that developed HAT following LT (G). Positive controls for thrombus detection with VWF staining 
in endothelial tissue (H) and FL staining in placental tissue. (I) Magnifications x20. Panel J: number (%) of 
sections with positive staining for microthrombi per time point and per staining in discarded DCD grafts. 
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Donor and recipient characteristics of transplanted liver grafts 
To validate our findings from discarded grafts in the clinical setting and test the hypothesis 
of microthrombi formation causing NAS, a second series of biopsies obtained from twenty 
liver grafts was also evaluated. Biopsies from ten grafts that developed NAS were com-
pared with biopsies from ten grafts that remained free of biliary complications. Groups 
were matched for graft type to analyze the occurrence of microthrombi in DCD compared 
to DBD grafts. Out of ten recipients who developed NAS, re-transplantation was required 
in seven. Three other recipients needed frequent endoscopic treatment with stent place-
ment and biliary dilatation or surgical revision. As a positive control group, biopsies of four 
explanted DCD livers from recipients who developed early HAT were included, in which 
we expected to find microthrombi in the liver microvasculature. These recipients had to 
undergo re-transplantation within the first 2-6 days following primary LT.
As shown by table 2, groups were matched with respect to donor variables (graft type, 
age, donor risk index), recipient variables (age, MELD score) and procedural variables 
(ischemia times, preservation solution, intraoperative blood loss). Indications for LT did not 
differ between groups (p=0.665) and consisted of acute liver failure (n=3), hepatitis C virus 
(n=8), cholestatic liver disease (n=3), alcoholic steatohepatitis (n=3), non-alcoholic steato-
hepatitis (n=4), Wilson disease (n=1), polycystic liver disease (n=1) and porphyria (n=1). 
Interestingly, the international normalized ratio (INR), a marker for standardized pro-
thrombin time or coagulation activity in blood, was not different between groups (table 
2, P=0.687). Also intra-operative blood loss and the volume of blood transfusions did not 
significantly differ (P≥0.290). However, serum of levels of AST and ALT were significantly 
increased directly post-surgery in recipients who developed NAS and HAT (P=0.017 and 
P=0.036, respectively). Injury markers at time of donation were not different between groups. 
no histological evidence of microthrombi formation during preservation and 
post-reperfusion in liver grafts that developed nas  
Of each transplanted liver, a wedge of liver tissue was collected at two perioperative time 
points (fig. 1C); one biopsy at the end of cold ischemia (t=2) and one post-reperfusion 
(t=3). Just like the first series, sections from this second series of biopsies were stained 
in triplo, providing a total of 120 sections for histological evaluation of microthrombi. 
fig. 3b shows the number of sections that were positive for (partial) microthrombi 
formation, stratified for graft type (DBD vs. DCD) and outcome (development of NAS vs. 
controls). Out of 120 sections, seven showed partial microthrombi formation (5.8%); four in 
VWF sections, of which three also showed had a positive HE staining. Again, all FL stainings 
were negative for microthrombi. Microthrombi formation was not increased in DCD grafts 
compared to DBD grafts (fig. 3C, 3.3% vs. 11.3%, respectively, P=0.083). Furthermore, 
the formation of microthrombi did not differ between grafts that remained free of biliary 
complications and those that developed NAS (8.3% in controls vs. 6.6% in NAS, P=0.729). 
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table 2. Clinical variables of grafts that developed NAS, HAT, or remained free of biliary complications. 
Groups were matched for donor, recipient and procedural variables. 
Control
 (n=10)
nas
(n=10)
Hat
(n=4)
P-value
Donor characteristics
Donor risk index 2.1 (1.6-2.4) 2.0 (1.8-2.5) 2.0 (1.8-2.4) 0.99
Age (yr) 55 (46-69) 57 (51-62) 45 (41-61) 0.31
Body mass index 24 (23-28) 26 (24-26) 23 (22-24) 0.13
DBD/DCD 5/5 5/5 0/4 0.18
Male/female 5/5 4/6 2/2 0.93
Cause of death 0.42
     Cardiovascular event 0 1 0
     Cerebrovascular accident 5 8 3
     Trauma 3 0 1
     Other 2 1 0
Clinical blood values at time of 
donation
     AST (U/L) 43 (28-127) 46 (32-79) 41 (16-87) 0.65
     ALT (U/L) 38 (11-61) 34 (23-62) 30 (10-52) 0.62
     GGT (U/L) 30 (21-34) 52 (23-85) 91 (40-143) 0.09
     ALP (U/L) 58 (46-68) 60 (46-122) 58 (45-69) 0.80
     Total bilirubin (µmol/L) 7 (6-10) 10 (7-14) 7 (5-7) 0.20
Recipient characteristics
Age (yr) 52 (36-61) 54 (41-57) 51 (44-61) 0.96
Male/female 5/5 5/5 3/1 0.66
MELD score 23 (20-26) 22 (20-31) 22 (18-28) 0.82
Clinical blood values directly 
post LT
     AST (U/L) 754 (558-1089) 2474 (1458-5133) 2165 (1554-7589) 0.02
     ALT (U/L) 572 (457-810) 1742 (812-3585) 1466 (733-4370) 0.04
     GGT (U/L) 50 (33-128) 117 (54-150) 149 (86-304) 0.24
     ALP (U/L) 71 (48-90) 72 (57-133) 75 (62-161) 0.67
     Total bilirubin (µmol/L) 110 (54-147) 74 (41-132) 57 (13-115) 0.41
     INR 1.8 (1.7-2.7) 2.1 (1.7-3.0) 2.2 (1.9-2.8) 0.69
Procedure variables
Cold ischemia time 345 (284-388) 367 (343-445) 360 (339-444) 0.45
First WIT (min)1 12 (10-19) 18 (16-26) 17 (12-19) 0.18
Functional 1st WIT (min)2 28 (17-32) 30 (22-36) 23 (15-26) 0.35
Second WIT (min) 28 (25-32) 31 (26-37) 30 (23-42) 0.56
Preservation UW/HTK 3/7 6/4 0/4 0.09
Preservation volume (cc) 8500 (5750-15500) 8000 (5000-10625) 12500 (7750-
15000)
0.40
Blood loss (cc) 3050 (1575-5563) 3500 (1950-6050) 4800 (3525-8400) 0.40
Blood transfusion (cc) 4047 (1554-5381) 4675 (1995-9388) 6333 (4621-6994) 0.29
1 Time from circulatory arrest until cold perfusion.
2  Time from saturation <70% or systolic blood pressure <50 mm Hg until circulatory arrest (min).
For numerical variables, values represent the median (interquartile range). For categorical variables, values 
represent the number (percentage). 
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Comparable to the first series, the formation of microthrombi was not significantly differ-
ent between various time points of biopsy collection (5% at t=2 vs. 10% at t=3; P=0.298). 
Finally, we also evaluated the formation of microthrombi in the microvasculature of four 
DCD liver grafts (n=12 sections) which developed early HAT following LT. Macroscopic 
investigation of the explanted liver grafts and microscopic evaluation of hilar sections 
showed clear formation of partially obstructive thrombi in the arterial vessels, resembling 
the positive control in the first series. In biopsies outside the hilar region, however, none of 
the three stainings showed any formation of microthrombi in the microvasculature of grafts 
Staining (nr. 
sections)
DBD - NAS 
(n=30)
DBD - control 
(n=30)
DCD - NAS
(n=30) 
DCD - control
(n=30) 
H&E 1 (3%) 2 (6%) 1 (3%) 0 (0%)
VWF VIII 1 (3%) 3 (10%) 1 (3%) 0 (0%)
Fibrin Lendrum 0 (0%) 0 (0%) 0 (0%) 0 (0%)
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figure 3. Histological grading of liver biopsies obtained from transplanted liver grafts that developed NAS 
or remained free of biliary complications, which were matched for clinical variables such as graft type. (A) 
The panels represent the in triplo staining of a biopsy for HE, VWF and FL. (B) Shown are the number (%) of 
positive staining for microthrombi per staining, per graft type and per outcome in transplanted livers. (C) Mi-
crothrombi formation was not significantly increased in DCD grafts (P=0.083). The number of positive stain-
ings was similar between grafts that remained free of biliary complications and those that developed NAS 
(P=0.729). Finally, formation of microthrombi was not significantly increased following reperfusion (P=0.298).
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that developed HAT. Moreover, biopsies from the implantation procedure at the end of cold 
ischemia and post-reperfusion did not show any signs of microthrombi formation as well. 
DisCussion
This study shows that neither preservation with standard flushing, nor vascular stasis 
during warm ischemia increases the risk of microthrombi formation in DCD grafts during 
LT. Previous studies hypothesized that prolonged warm-ischemia with no flow-status 
in the period between circulatory arrest and in situ cold perfusion causes the forma-
tion of microthrombi in the microcirculation of DCD livers. Additionally, suboptimal 
preservation due to an inadequate flush of the liver microcirculation could exacerbate 
ischemic injury and cause NAS in LT recipients. This caused several transplant centers to 
perform additional flushing of the hepatic artery with thrombolytic agents. However, 
the results presented here show no histological evidence of microthrombi formation in 
DCD livers that would justify the use of potentially harmful, intraoperative fibrinolytic 
therapy during LT. Furthermore, in DBD nor DCD grafts could we correlate the presence 
of microthrombi to the development of NAS. 
Based on the results of four clinical studies that have investigated the administration 
of tissue plasminogen activator (tPA) and urokinase during LT, it still remains inconclu-
sive whether such treatment prevents the development of NAS in recipients[25, 27, 
28, 30]. The first and largest study by Lang et al.[27] performed a double flush of the 
hepatic artery with urokinase in DCD grafts during the benching procedure. They found 
a significantly decreased incidence of intrahepatic NAS (1.4%) in grafts pre-treated with 
urokinase (n=140) compared to untreated grafts (5.9%, n=220). A more recent study by 
Seal et al.[28] also found a lower incidence of intrahepatic NAS in 85 DCD grafts which re-
ceived tPA just before anastomosis and reperfusion of the portal vein and hepatic artery 
(3.5% vs. 21.2% in 33 controls). The benefit of tPA in this study was demonstrated in two 
different transplant centers. In contrast, two other studies could not demonstrate ben-
eficial effects of tPA and urokinase. Pietersen et al. recently described similar incidences 
of NAS in DBD and DCD grafts that were treated with arterial urokinase administration 
immediately before implantation (18%)[30]. Three studies did not experience increased 
risk of excessive postoperative bleeding in recipients. This complication was however 
present in 64% of the recipients in a study by Hashimoto et al.[25], who investigated 
the administration of tPA into the hepatic artery during the back-table procedure in a 
small series of 22 DCD grafts. Even after tPA treatment, six grafts developed biliary com-
plications, of which two developed NAS. This underlines the potential danger of using 
anti-coagulative therapy during LT, even after researchers attempted to wash-out re-
maining thrombolytic agents by additional flushing with perfusate solution before graft 
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implantation. Nonetheless, unfavorable donor factors and previous laparotomy could 
also contribute to bleeding complications as argued by Seal et al. The main limitations 
of the aforementioned studies were the retrospective character, lack of randomization 
and short follow-up in treatment groups. The use of historical controls could bias the 
outcome of the tPA and urokinase intervention studies, because there is evidence of an 
overall improvement in DCD outcomes regardless of whether tPA is used. Therefore, the 
potential benefit demonstrated by these studies might be based on factors as center 
experience, procurement technique and donor-recipient selection rather than tPA 
or urokinase treatment. A decisive answer on the usefulness of thrombolytic therapy 
would require a randomized study, but this still will not provide direct evidence for the 
hypothesis of increased microthrombi formation in DCD grafts.       
To our knowledge, the current study is the first that performed a comprehensive 
histological analysis of microthrombi formation in intrahepatic liver tissue biopsies with 
two additional stainings specific for coagulation activity. Biopsies were obtained from 
multiple liver segments of extended criteria DCD grafts discarded for LT and DCD grafts 
that developed NAS. Taking into account that even though NAS is more prevalent in 
the extrahepatic bile duct, it particularly causes severe problems when occurring in the 
intrahepatic bile ducts[31]. Previous studies on the topic of histological parameters and 
NAS mainly focused on biopsies from the extrahepatic bile ducts. Two studies analyzing 
the microcirculation of the extrahepatic bile ducts demonstrated that no microthrombi 
were found in 31,3% and 26,3% of the microcirculation of the extrahepatic bile ducts 
after reperfusion, respectively[15, 29]. However, arteriolonecrosis and the loss of 
peribiliary gland mass, but not the formation of microthrombi, were associated with  the 
development of NAS. In addition, Op den Dries et al. found that the formation of micro-
thrombi in the peribiliary plexus did not differ between DBD and DCD liver grafts[15, 
32]. Altoghether, these findings lead to a new hypothesis, stating that arteriolonecrosis 
of the common bile duct disables cholangiocyte regeneration by peribiliary glands. The 
histological injury found at the distal end of the extrahepatic bile duct was representa-
tive for proximal, intrahepatic large bile ducts[33]. Also, a study performed by Brunner 
et al. found severe epithelial injury and diminished epithelial barrier integrity in bile 
ducts from DBD grafts that developed biliary complications following LT[34]. Beside 
the current study, Farid et al. investigated perioperative intrahepatic liver histology and 
NAS. They reported a smaller luminal size of the portal vein branch in post-reperfusion 
biopsies from DBD livers that developed NAS, supporting an earlier observation that 
diminished portal flow is also involved in biliary blood supply[24]. However, this study 
also found no thrombi in the intrahepatic arterial or venous vasculature. All the afore-
mentioned studies observed a negligible degree of microthrombi formation at time 
of graft preservation that was not related to the development of NAS, supporting the 
results of the current study.
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To determine whether microthrombi formation is indeed more prevalent in DCD 
grafts, biopsies from matched DBD grafts were also evaluated. This confirmed our find-
ing from the first series that DCD grafts do not appear to have an increased tendency 
to form microthrombi during preservation. It furthermore weakened the hypothesis 
that microthrombi formation is the main underlying cause of NAS. It seems unlikely that 
the microthrombi that we found in a minority of cases of particularly DBD grafts, which 
only covered part of the vascular lumen, were of clinical significance. Recipients from 
these DBD grafts, that remained free of biliary complications, had significantly lower 
serum levels of AST and ALT post-operatively compared to the NAS group, suggesting 
that the present microthrombi did not cause additional injury. Higher postoperative 
transaminase levels in recipients who developed NAS, however, is in concordance with 
other studies[35, 36]. This further supports the thought that injury, and not increased 
coagulation, is the leading factor in the pathophysiology of NAS. 
Until now, most clinical studies investigating the presence of microthrombi used HE-
staining as the gold standard for histological scoring[15, 29]. Although HE provides in-
sight on the degree of tissue and epithelial disruption, as well as morphological features 
of cells, it might be less specific for detecting the presence of coagulation factors[37, 38]. 
In order  to minimize the chance of missing microthrombi formation, we also applied 
additional stainings with Von Willebrand Factor VIII and Fibrin Lendrum. At the tissue 
level, Von Willebrand Factor VIII marks endothelial cell activation, which occurs earlier in 
the coagulation cascade, whereas Fibrin deposits occur at the end of the cascade. The 
fact that all biopsies were negative for FL staining suggests that no older microthrombi, 
that could have formed during graft procurement, are present after cold storage or 
even following reperfusion. However, the fact that we mainly observed microthrombi 
in the VWF staining’s demonstrates possible increased endothelial activity earlier in the 
coagulation cascade. It is unlikely that these more fresh microthrombi will transform 
into fibrin clots in a later phase, since the VWF positive staining’s in our study were not 
related to the development of NAS.
The current study contains several limitations, most importantly the possibility of 
sampling bias as biopsies only provide a local representation of the liver tissue. In par-
ticular for the scoring of microthrombi, certain areas of the liver might be overlooked 
when analyzing biopsies. Also, the included number of discarded livers was limited. 
Furthermore, there might be inter- or intra-observer variability of histological findings. 
We tried to deal with these issues by collecting a large number of biopsies from multiple 
liver segments, by staining sections with various coagulation-specific markers, and have 
evaluation performed by two independent pathologist. The large amount of biopsies 
taken from both extended criteria as well as transplanted DCD grafts showed a uniform 
absence of microthrombi in the microcirculation of all liver segments. Whether addi-
tional staining of the larger intra- and extrahepatic bile ducts with FL and VWF could 
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provide more insight into microthrombi formation in the peribiliary vascular plexus 
should be investigated by future research. Beside histological evaluation, Vendrell et 
al. investigated coagulation profiles in the blood of DCDs by thromboelastometry as-
says[39]. They found hyperfibrinolysis induced by all DCDs, suggesting no increased ten-
dency of microthrombi formation. Although we did not perform thromboelastography, 
postoperative INR values in recipients from our study suggest no increased coagulation 
activity in DCD grafts that developed NAS. Another limitation is that the collection of 
intrahepatic liver biopsies from multiple segments, like the first series of DCD grafts, is 
invasive and disruption of the tissue could cause severe perioperative complications[40]. 
Therefore, it is not justified to collect such intrahepatic biopsies in grafts that are suitable 
for clinical LT. However, recent studies already initiated a shift in methods to assess graft 
quality away from histology by measuring early and non-invasive biomarkers during 
graft preservation)[35, 40]. 
In conclusion, the results of our study suggest that DCD livers do not appear to have 
an increased tendency to form microthrombi during graft preservation or following 
graft reperfusion. Also, formation of microthrombi was not associated with the develop-
ment of NAS or HAT. Thus, in our opinion, the absence of histological evidence for micro-
thrombi formation contradicts with the use of intraoperative thrombolytic therapy that 
could contribute to additional, unnecessary risks for complications in recipients after LT. 
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suPPlementary information
materials anD metHoDs
study design and donor livers
For the first series, discarded DCD livers were procured and included in this study be-
tween July 2012 and December 2013, when the following criteria were fulfilled; (i) if 
donor age was between 18-80 years, (ii) if the deceased donor was officially registered 
as an organ donor or, in case of unknown registration, if the next of kin gave permission 
for organ donation, (iii) if organs other than the liver were procured for transplantation, 
(iv) if the liver was not accepted for transplantation due to medical reasons, and (v) if 
the next of kin gave informed consent to use the donor liver for scientific research. The 
criteria for using discarded livers from deceased donors for scientific research are exten-
sively described in a study protocol that was accepted by the medical ethical committee 
in our center, as well as by the Dutch Committee on Organ Donation and the Dutch 
Transplantation Foundation. The donor livers included in this study were procured in the 
same way as livers used for clinical LT. 
In a second series, we investigated microthrombi formation and the development 
of NAS in transplanted liver grafts, by retrospectively analyzing perioperative biopsies 
which were collected as part of standard clinical practice during LT at our center. Biopsies 
were selected from both DBD and DCD grafts that were matched for clinical parameters 
and were transplanted between January 2007 and December 2012. The use of donor 
materials was approved by the Medical Ethical Committee and all patients provided 
informed consent for the use of clinical information for medical research. 
organ retrieval and liver perfusion
During each multi-organ retrieval, a standard in situ pressurized perfusion of the liver 
was performed via the aorta with University of Wisconsin solution (UW; Viaspan, Du-
ramed Pharm Inc, Pomona, NY) or histidine-tryptophan-ketoglutarate solution (HTK; 
Custodiol HTK, Essential Pharmaceuticals, LLC, Pennsylvania, USA) in order to remove 
remnant blood. Heparin was added to the first bag of preservation solution in a dose of 
25,000 to 35,000 IU. An additional ex situ perfusion via the portal vein was performed 
during the back-table procedure with 1000 ml of UW or HTK depending on the preserva-
tion fluid that was initially used during retrieval. In transplanted livers, this step was 
followed by flushing with 600 ml of human albumin solution (Albuman human albumin 
40g/l, Sanquin, The Netherlands) just prior to implantation of the graft. Surgical implan-
tation procedures were identical between DBD and DCD grafts, with initial portal vein 
reconstruction and reperfusion.  
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Definitions
Non-anastomotic biliary strictures (NAS) were defined as (i) symptomatic strictures 
and associated dilatation of the intrahepatic or hilar bile duct(s) after LT, which (ii) 
were confirmed by cholangiography and in the presence of a patent hepatic artery 
as demonstrated by Doppler ultrasonography, and (iii) which required endoscopic or 
percutaneous interventions of the biliary system or liver re-transplantation in recipients. 
Transplant recipients without biliary complications during follow-up were defined as 
controls. 
Hepatic artery thrombosis (HAT) was defined as the (complete) absence of blood flow 
through the arterial vessels of the donor liver from the site of the common hepatic artery 
of the donor’s site, proven by duplex ultra-sound and/or CT-angiography. Donor and 
recipient characteristics and clinical parameters were obtained from the LT database of 
the institution. 
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abstraCt
background. Non-anastomotic biliary strictures (NAS) are a common cause of graft loss 
after liver transplantation (LT). Similarities in clinical manifestation between NAS and 
primary sclerosing cholangitis (PSC) suggest a shared pathophysiology. The aim of this 
study was to investigate whether a polymorphism affecting fucosyltransferase-2 (FUT2) 
secretor status, a recently discovered risk factor for PSC and inflammatory bowel disease, 
is associated with the development of NAS after LT.
materials and methods. In DNA obtained from 418 LT procedures, genotyping for 
FUT2 was performed in 255 donors, 356 recipients and 193 paired donors-recipients. 
results. As expected, FUT2 non-secretor status was more prevalent in patients with 
underlying PSC compared to non-PSC patients (33% vs. 22%, P=0.034). FUT2 non-secretor 
status in donors and non-PSC recipients was not associated with NAS. In patients with 
PSC, however, recipient FUT2 non-secretor status was the most important independent 
risk factor for NAS (cox-regression HR: 2.34, P=0.034), with an incidence of 56% already 
during the first five years after LT (log-rank P=0.002). Analysis of paired donor-recipient 
genotypes showed that transplantation of a graft from a FUT2-secretor donor into a 
FUT2 non-secretor PSC recipient further increased the risk for developing NAS (P=0.002). 
Finally, FUT2 non-secretor status was higher among patients with ulcerative colitis, but 
coexistence of ulcerative colitis with PSC did not increase the risk of NAS. 
Conclusion. Donor FUT2 non-secretor status has no effect on the risk of NAS. However, 
FUT2 non-secretor status of PSC recipients is an independent risk factor for NAS after LT. 
This is possibly related to an increased bacterial translocation or an aggravated immune 
response induced by FUT2 mismatching between donors and recipients.
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introDuCtion
Non-anastomotic biliary strictures (NAS) are a common complication after liver trans-
plantation (LT) and have a detrimental effect on patient morbidity and graft survival. 
Narrowing of the bile ducts typical for NAS can be centrally located in the (sub)hilar 
region, but it can also occur more diffusely throughout the graft[1]. Therefore, NAS 
often present themselves through severe obstructive jaundice in LT recipients, requir-
ing expensive and physically invasive endoscopic treatment, or even necessitate re-
transplantation in 15% of the cases[2, 3]. 
Although the exact pathophysiology of NAS is not fully understood, previous studies 
identified several risk factors. Most importantly, grafts obtained by donation after circu-
latory death (DCD) have an up to three-fold increased risk to develop NAS compared to 
grafts obtained by donation after brain death (DBD)[4]. It is hypothesized that prolonged 
warm ischemia of the graft, typically associated with DCD, damages biliary epithelium 
and peribiliary glands. Subsequently, this damage is said to cause insufficient regenera-
tive capacity of bile ducts[5]. Longer after LT, also immunological factors contribute to 
deformations of the bile ducts. These immunological factors include various genetic 
polymorphisms and underlying autoimmune diseases in recipients.[6, 7] In particular 
recipients who are transplanted because of primary sclerosing cholangitis (PSC) are 
prone to develop NAS both early as well as late  after LT[8, 9]. 
The high incidence of PSC in Nordic countries makes this disease the leading indica-
tion for LT in the North European region[10]. PSC is characterized by irregular sclerosis of 
the intrahepatic bile ducts, it has been associated with inflammatory bowel disease (IBD) 
such as ulcerative colitis[11], and it affects males more often than females (3:2). Just as 
with NAS, patients suffering from PSC are often treated for biliary obstructive jaundice 
through endoscopic retrograde pancreatico-cholangiography (ERCP) or percutaneous 
transhepatic cholangiography (PTC). 
Genome-wide association studies identified various single nucleotide polymorphisms 
(SNPs) associated with the development of PSC[12]. In particular a mutation in the 
fucosyltransferase-2 (FUT2) gene, responsible for the glycosylation of proteins, accel-
erates the disease course in PSC and reduces the transplantion-free survival of these 
patients[13, 14]. This rs608133 mutation (G>A) causes a truncated, dysfunctional FUT2 
protein on the surface of epithelial cells throughout the body. It is thought that these so 
called FUT2 non-secretors have a perturbed composition of their cellular glycocalyx and, 
therefore, are less resistant against the translocation of bacteria and other pathogens 
from the intestinal epithelium to extra-intestinal sites such as the liver and bile ducts. 
Subsequently, translocation of bacteria to the liver may result in inflammatory responses 
and fibrosis[15, 16]. 
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Similarities in the clinical manifestation between PSC and NAS suggest a potential 
overlap in pathophysiological mechanisms. Since FUT2 non-secretor status is associated 
with PSC, this raised the hypothesis that the rs608133 polymorphism might also be 
associated with the development of NAS. Therefore, in this study we investigated the 
association between FUT2 non-secretor status and the development of NAS in a large LT 
cohort by genotyping both donors and recipients.
materials anD metHoDs
study design 
In this longitudinal cohort study, DNA samples were collected prospectively during 
consecutive, adult LTs between February 1990 and December 2011 at the Erasmus Uni-
versity Medical Center, Rotterdam. Available DNA samples from donors and recipients 
were retrospectively genotyped for the FUT2 mutation rs608133. The primary outcome 
measure of this study was the time to diagnosis of NAS following LT, which was com-
pared between different categories based on FUT2 status of donors, or recipients, or 
of paired donors and recipients. Secondary outcome measures were graft and recipi-
ent survival. Besides the association between FUT2 status and development of NAS in 
the entire cohort, a sub analysis was performed in PSC and non-PSC recipients, since 
pathophysiologic effects of mutations in FUT2 have been described particularly in the 
context of PSC. Cases of hepatic artery thrombosis (HAT) or primary non-function (PNF) 
directly after LT were excluded. Partial- or split liver LTs were excluded as well because 
of their small number and the unique surgical procedure that is different from whole LT. 
Donor and recipient characteristics and clinical parameters were obtained from the LT 
database of the institution. The Medical Ethical Committee of the Erasmus MC approved 
the use of donor and recipient DNA and all patients provided informed consent for the 
use of clinical information and their materials for medical research.
Definitions
Non-anastomotic biliary strictures were defined as described previously[17], namely as 
(i) symptomatic tapering or narrowing with associated dilatation of the intrahepatic or 
(sub)hilar bile ducts after LT, (ii) confirmed by cholangiography or MRCP and in the pres-
ence of a patent hepatic artery as demonstrated by Doppler ultrasonography, and (iii) 
which required endoscopic or percutaneous interventions of the biliary system or liver 
re-transplantation in recipients. The ‘no NAS’ group consisted of transplant recipients 
without biliary complications during follow-up and recipients who had biliary complica-
tions other than NAS, such as isolated anastomotic strictures and bile leakage. 
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Time to event was calculated from the date of LT until the date of intervention associ-
ated with NAS (i.e. biliary stenting by ERCP, bile drainage by PTC or surgical intervention). 
Graft survival was calculated from the date of LT until the date of re-LT or recipient death. 
Patient survival was calculated from the day of LT until the date of death. The final date 
for collection of follow-up was 20th February 2016, 4.2 years after inclusion of the last LT 
patient. 
sample collection and genotyping 
Donor DNA was obtained from splenocytes that were sampled together with the liver 
after graft procurement. Recipient DNA was derived from peripheral blood collected 
from patients at time of hospital admission just prior to surgery. DNA was isolated using 
the Wiyard Genomic DNA Purification Kit (Promega Corp., Madison, Wisconsin, USA), 
according to the manufacturers’ instructions and stored at -20°C until further use. SNP 
genotyping for rs601338 was performed by LGC Genomics, Teddington, UK (http://
www.lgcgroup.com/genotyping), using a PCR based KASP genotyping technology and 
as previously described by De Mare-Bredemeijer et al.[18]. 
statistical analyses
Results of continuous data are expressed as medians (interquartile range; IQR) unless 
stated otherwise. Statistical analysis was performed using SPSS statistics 20 (SPSS Inc, 
Chicago, IL, USA). Analyses on both ungrouped as well as grouped FUT2 genotypes were 
performed. For the grouped analysis, donors or recipients with a homozygous mutation 
(=AA) were considered to be FUT2 non-secretors, while donors or recipients with either 
GA or GG genotype were considered as FUT2 secretors. Group comparisons were per-
formed using Mann-Whitney U tests for continuous data and two-sided chi-square test 
for categorical data. Associations with the time to diagnosis of NAS were conducted by 
Kaplan-Meier analysis and log-rank test. Prediction analyses were constructed through 
backward stepwise Cox proportional hazards regression analysis. P-values smaller than 
0.05 were considered as statistically significant. 
results
Donor and recipient characteristics
Between November 1989 and December 2011, 721 adult LTs were performed in our 
center. All transplantation procedures were ABO-compatible. From 453 transplanta-
tions, DNA from either donor, recipient or from both donor and recipient was available 
for FUT2 genotyping, as illustrated by the inclusion scheme in fig. 1. After exclusion of 
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cases of HAT (n=26), PNF (n=6) and split LTs (n=3), 418 LT procedures were included for 
final analysis, consisting of 385 primary LTs and 33 re-LTs. 
DoLTs., recipient and procedural variables are listed in table 1. The median duration of 
follow-up of the entire study cohort in years was 9.2 (5.0-14.7). Out of 418 transplants, 73 
resulted in the development of NAS (17.5%), with a median time to diagnosis of 380 days 
(102-1345) after transplantation. In primary LTs, viral hepatitis was the main indication 
for LT in the no NAS group, while PSC was the main indication in the NAS group. NAS was 
the main indication for re-LT (19 out of 33 re-LTs), and the incidence of recurrence of NAS 
was significantly higher in this group (8 out of 19 re-LTs for NAS, P=0.002). Graft survival 
was significantly lower in the NAS group than in the no NAS group (5.3 versus 9.1 years), 
though recipient survival was similar. In the NAS group, biliary anastomosis was more of-
ten performed via  hepaticojejunostomy (P<0.001). Also, NAS occurred more frequently 
in DCD grafts, which in most cases were preserved using HKT solution (P=0.004). Male to 
male transplantation occurred more frequently in the NAS group (P<0.001). 
figure 1. inclusion scheme for genotyping of donor and recipient Dna. From transplantations per-
formed between November 1989 and December 2011, DNA from either donors, recipients or both was 
available from 453 LT. Thirty-five cases were excluded due to HAT, PNF or partial LT. For final analysis, FUT2 
genotype was available of 255 donors, 356 recipients and 193 paired donors and recipients, in a total number 
of 418 LT’s. 
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table 1. Donor and recipient characteristics and procedural variables between recipients who developed 
NAS and those who did not develop NAS following LT. 
no nas (n=345) nas (n=73) P-value
Donor characteristics
Age (yr) 46 (33-55) 47 (35-57) 0.391
Men/women 166/179 43/30 0.094
Rhesus (neg/pos) 54/291 8/65 0.305
CMV (neg/pos)* 164/180 42/30 0.125
Recipient characteristics
Age (yr) 50 (41-58) 47 (36-55) 0.056
Men/women 207/138 49/24 0.256
Rhesus (neg/pos) 46/299 13/60 0.318
CMV (neg/pos)* 154/190 36/36 0.345
Primary LT (n=385), indication
    Viral hepatitis 90 (26.1%) 7 (9.6%) 0.003
    PSC 56 (16.2%) 31 (42.5%) <0.001
    Alcoholic 50 (14.5%) 9 (12.3%) 0.717
    Cryptogenic 29 (8.4%) 2 (2.7%) 0.106
    PBC 22 (6.4%) 4 (5.5%) 0.833
    ALF 19 (5.5%) 6 (8.2%) 0.326
    AIH 16 (4.6%) 3 (4.1%) 0.896
    Other 38 (11.0%) 3 (4.1%) -
Re-LT (n=33), indication
    NAS 11 (3.2%) 8 (11.0%) 0.002
    Other    14 (4.1%) 0 (0%) -
Graft failure ending in re-LT (%) 9 (2.6%) 27 (37%) <0.001
Graft survival (yr) 9.1 (4.8-14.9) 5.3 (2.2-10.0) <0.001
Recipient survival (yr) 9.4 (5.0-15.1) 8.7 (4.8-12.3) 0.331
Procedural variables
Graft type (DBD/DCD) 318/27 58/15 <0.001
Preservation solution 0.004
    UW 289 49
    HTK 54 23
    Other 2 1
cold ischemia time (min) 451 (359-590) 449 (396-555) 0.759
2nd warm ischemia time (min) 36 (26-59) 32 (26-44) 0.150
Biliary anastomosis 
    Duct-to-duct/Roux-Y 281/64 43/30 <0.001
Recipient/donor 
Sex match <0.001
    male/male 99 (28.7%) 37 (50.7%)
    male/female 108 (31.3%) 12 (16.4%)
    female/male 67 (19.4%) 6 (8.2%)
    female/female 71 (20.6%) 18 (24.7%)
Rhesus match 0.493
    neg/neg 8 (2.3%) 1 (1.4%)
    neg/pos 38 (11%) 12 (16.4%)
    pos/neg 46 (13.3%) 7 (9.6%)
    pos/pos 253 (73.3%) 53 (72.6%)
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fut2 non-secretor status is more common in PsC recipients 
From 418 included LTs, FUT2 genotype was determined in 255 donors, 356 recipients and 
193 paired donors-recipient. The distribution of FUT2 genotype in donors and recipients 
is displayed in fig. 2a. The proportion of donors with homozygous FUT2 non-secretor 
status (AA-genotype) was 17.6% and allele frequency in donors was in Hardy Weinberg 
equilibrium (P=0.979). In recipients, however, the proportion of homozygous FUT2 
non-secretors was higher (24.4%) and the Hardy Weinberg equilibrium was violated 
(P=0.006). The high incidence of patients suffering from PSC in our cohort (20.8%, table 
1) could contribute to this observation. Indeed, the proportion of homozygous recipient 
FUT2 non-secretor status was higher among PSC patients than in non-PSC patients (fig. 
2b, 33.3% vs. 21.8%, respectively, P=0.034).
PsC recipients with fut2 non-secretor status have a higher incidence of nas 
following transplantation
Mutation of the FUT2 gene is common in the general population and thus, the impact 
of FUT2 secretor status in donors as well as recipients on the development of NAS could 
be studied. When analyzing the entire cohort, FUT2 genotype in donors (n=255) was 
not associated with the development of NAS following LT (supplementary table 1 and 
supplementary fig.1a, P=0.993). In recipients, occurrence of NAS was most frequent 
in homozygous non-secretors (AA-genotype), but did not significantly differ from the 
other genotypes (supplementary table 1 and supplementary fig.1b, P=0.152). 
Incidence of NAS was however comparable between recipients heterozygous for FUT2 
mutation and those without the mutation. Therefore, all cases of GA and GG-genotypes 
were clustered as ‘FUT2 secretors’ for following analyses, while AA-genotypes were 
clustered as ‘FUT2 non-secretors’. 
table 1. Donor and recipient characteristics and procedural variables between recipients who developed 
NAS and those who did not develop NAS following LT.  (continued)
no nas (n=345) nas (n=73) P-value
CMV match 0.314
    neg/neg 71 (20.6%) 21 (28.8%)
    neg/pos 83 (24.1%) 15 (20.5%)
    pos/neg 92 (26.7%) 21 (28.8%)
    pos/pos 97 (28.1%) 15 (20.5%)
* In both the No NAS and the NAS group, one donor and recipient CMV status was missing.
CMV, cytomegalovirus; PSC, primary sclerosing cholangitis; PBC, primary biliary cirrhosis; ALF, acute liver 
failure; AIH, auto-immune hepatitis; re-LT, liver retransplantation; NAS, non-anastomotic biliary strictures; 
DBD, donation after brain death; DCD, donation after circulatory death; UW, University of Wisconsin solu-
tion; HTK, histidine-tryptophan-ketoglutarate solution.
Continuous data are presented as medians (IQR), categorical data are presented as numbers (%). 
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We subsequently analyzed the influence of FUT2 non-secretor status on the devel-
opment of NAS for separate PSC and non-PSC recipients. As shown by fig. 3a and b, 
grafts obtained from donors with FUT2 non-secretor status did not increase the risk 
of developing NAS in both non-PSC and PSC recipients (P=0.696 and P=0.379, respec-
tively). However, when analyzing recipient genotype (fig. 3C and D), NAS developed 
already within the first 5 years following LT in up to 50% of the patients with PSC and 
FUT2 non-secretor status, against 10% of the PSC recipients with FUT2 secretor status 
and the non-PSC recipients in general (P=0.002). In the PSC group, 86% of the cases 
of NAS developed after the first 90 days following LT, which is usually set as a cut-off 
for diagnosis of recurrence of PSC[19]. These results suggest that NAS  observed in PSC 
recipients might in fact reflect recurrence of disease.   
Next, the effect of NAS and recipient FUT2 status on graft and patient survival was 
analyzed for both cohorts. The development of NAS was associated with significantly 
impaired graft survival in both non-PSC and PSC patients (supplementary fig. 2, log-rank 
P<0.001 and P=0.015, respectively). FUT2 non-secretor status in the recipient, however, did 
not significantly reduce graft survival (log-rank P=0.076 in non-PSC and P=0.306 in PSC). 
Recipient survival was similar for the NAS and the no NAS group and was not affected by 
recipient FUT2 non-secretor status (log-rank P=0.096 in non-PSC and P=0.843 in PSC). 
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figure 2. Distribution of fut2 genotype in donors and recipients with different underlying disease. 
(A) Distribution of donor FUT2 genotype was in Hardy-Weinberg equilibrium. In recipients, however, the 
number of FUT2 non-secretors (AA-genotype) was higher and the Hardy-Weinberg equilibrium was vio-
lated (P=0.006). (B) Distribution of recipient FUT2 status in non-PSC and PSC patients. The incidence of FUT2 
non-secretor status was significantly higher in PSC patients (P=0.034), probably explaining the violation of 
the Hardy-Weinberg equilibrium in recipients.
106 Chapter 4
0 5 10 15 20 25
0
20
40
60
80
100
Donor FUT2 genotype in  
non-PSC recipients 
Donor FUT2 genotype in  
PSC recipients 
0 5 10 15 20 25
0
20
40
60
80
100
0 5 10 15 20 25
0
20
40
60
80
100
Recipient FUT2 genotype in  
PSC recipients 
0 5 10 15 20 25
0
20
40
60
80
100
Recipient FUT2 genotype in 
non-PSC recipients 
GA/GG 170 107 61 31 3 0
AA 35 23 15 11 2 0
40 23 10 3 1 0
10 6 5 2 0 0
Years after transplantation Years after transplantation 
(no. at risk)
A B
C D
GA/GG 215 136 85 53 11 2
AA 60 42 29 16 3 0
52 37 17 4 2 0
29 10 5 2 0 0
Years after transplantation Years after transplantation 
(no. at risk)
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
of
 N
AS
 (%
) 
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
of
 N
AS
 (%
) 
AA 
GA/GG 
P=0.696 P=0.379 
P=0.383 P=0.002 
AA 
GA/GG 
AA 
GA/GG 
GA/GG 
AA 
figure 3. Cumulative incidence of nas between fut2 secretors versus fut2 non-secretors. (A and B) 
Transplantation of a graft obtained from a FUT2 non-secretor donor did not lead to a higher incidence of 
NAS following LT in non-PSC patients, nor did it in PSC patients. (C) In non-PSC patients, recipient FUT2 non-
secretor status was also not associated with a higher occurrence of NAS. (D) In PSC patients, however, the 
incidence of NAS was 60% and significantly faster in the first five years following LT in FUT2 non-secretors 
(AA), while it was 10% in FUT2 secretors (GA or GG). 
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recipient fut2 non-secretor status is an independent risk factor for nas in PsC 
recipients
In order to identify other risk factors for NAS, we compared demographic data based on 
recipient FUT2 genotype for separate non-PSC and PSC recipients (table 2). Variables with 
a P-value ≤0.2 were selected for univariate Cox regression analysis. Variables that were 
significant with univariate analysis were subsequently included for multivariate analysis. 
As shown by table 3, FUT2 non-secretor status was the strongest independent risk 
factor for the development of NAS in PSC recipients (HR: 2.34, P=0.034). We also foud a 
tendency for an increased risk of NAS when PSC recipients were transplanted with a DCD 
graft, though this was not statistically significant. Remarkably, sex mismatch between do-
nor and recipient was a protective factor against NAS in PSC recipients (HR: 0.23, P=0.02), 
while the risk was highest in male-to-male transplantation (table 2). In non-PSC recipients, 
transplantation with a DCD graft was the only independent risk factor the development of 
NAS (HR: 2.51, P=0.048). In univariate analysis, viral hepatitis as indication for LT seemed to 
lower the risk for the development of NAS in non-PSC patients (HR: 0.39, P=0.022), while 
NAS on itself as indication for re-LT was predisposing for recurrence of NAS in this group 
(HR: 3.37, P=0.049). These factors however lost significance in multivariate analysis. 
Finally, a separate analysis was performed on re-LTs. Out of 30 re-LTs with available 
recipient FUT2 status, n=8 recipients developed NAS (26.7%). Overall, recipient FUT2 
non-secretor status did not increase the risk of (recurrent) NAS after re-LT (P=0.234). 
When analyzing separate PSC recipients (n=11), three out of four recipients who devel-
oped NAS were FUT2 non-secretor. This however remained insignificant due to the small 
number of cases in this group (P=0.554).   
fut2 mismatch between donors and recipients is an additional risk factor to 
develop nas
In addition to separate donor and recipient FUT2 status, the association between paired 
donor-recipient FUT2 genotypes and the occurrence of NAS was analyzed. Of the 193 
paired donor-recipient genotypes, 149 pairs were in the non-PSC group and 44 pairs 
were in the PSC group. For both groups, the incidence of NAS for different combina-
tions of FUT2 secretor status between donors and recipients is displayed in fig. 4. In 
non-PSC recipients, there was no association between the incidence of NAS and (mis)
match in FUT2 secretor status (fig. 4a). In PSC recipients, however, incidence of NAS 
was significantly higher when a graft from a FUT2 secretor donor was transplanted into 
a FUT2 non-secretor recipient (D+R- group); 80% versus ≤21.4% in the other donor-
recipient combinations (P=0.002, fig. 4b). In addition, the median time to develop NAS 
in recipients with this unfavorable FUT2 combination was only 1 year, compared to 6.4 
years in other FUT2 combinations (log-rank <0.001). The hazard to develop NAS with the 
D+R- combination was 8.7 (95% CI: 2.9-26.5, P<0.001). However, the limited number of 
data made it impossible to perform a reliable multivariate analysis. 
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table 2. Donor, recipient and procedural variables for the development of NAS for separate non-PSC recipi-
ents and PSC recipients. Data are based on FUT2 secretor status in recipients. 
Non-PSC recipients PSC recipients
No NAS 
(n=239) NAS (n=36) P-value
No NAS 
(n=52) NAS (n=29) P-value
Donor characteristics
Age (yr) 46 (33-54) 47 (35-55) 0.453 47 (36-56) 46 (34-58) 0.768
Men/women 107/132 17/19 0.783 29/23 20/9 0.244
Rhesus (neg/pos) 40/199 4/32 0.391 7/45 2/27 0.367
CMV (neg/pos)* 110/128 19/17 0.707 28/24 21/7 0.074
Recipient characteristics
Age (yr) 50 (41-58) 51 (36-59) 0.642 48 (39-58) 44 (32-49) 0.056
Men/women 142/97 21/15 0.902 35/17 24/5 0.134
Rhesus (neg/pos) 36/203 8/28 0.275 4/48 5/24 0.190
CMV (neg/pos)* 94/145 18/18 0.224 35/17 14/14 0.129
FUT2-genotype
   GA and GG vs. AA 185/54 30/6 0.422 40/12 14/15 0.009
Viral hepatitis (no/yes) 157/82 30/6 0.034
Previous NAS 6 (2.5%) 4 (11%) 0.010 3 (5.8%) 4 (13.4%) 0.218
Procedural variables
Graft type (DBD/DCD) 219/20 29/7 0.037 50/2 24/5 0.040
Preservation solution 0.195 0.150
   UW 204 27 41 18
   HTK 33 9 11 10
   Unknown 2 0 0 1
cold ischemia (min) 459 (360-610) 445 (393-534) 0.649 455 (347-566) 454 (401-638) 0.317
2nd warm ischemia (min) 38 (28-63) 35 (28-45) 0.292 29 (23-52) 32 (25-40) 0.828
Biliary anastomosis
   Duct-to-duct/Roux-Y 230/9 33/3 0.211 6/46 3/26 0.870
Recipient/donor
Sex match 0.333 0.001
   male/male 65 13 17 20
   male/female 77 8 18 4
   female/male 42 4 12 0
   female/female 55 11 5 5
Rhesus match 0.395 0.324
   neg/neg 5 0 2 1
   neg/pos 31 8 2 4
   pos/neg 35 4 5 1
   pos/pos 168 24 43 23
CMV match 0.570 0.080
   neg/neg 43 9 21 11
   neg/pos 51 9 14 3
   pos/neg 67 10 7 10
   pos/pos 77 8 10 4
* In non-PSC recipients, one donor CMV status was missing. In PSC-recipients, one donor and recipient CMV 
status was missing.
PSC, primary sclerosing cholangitis; NAS, non-anastomotic biliary strictures; CMV, cytomegalovirus; FUT2, 
fucosyltransferase-2; DBD, donation after brain death; DCD, donation after circulatory death; UW, University 
of Wisconsin solution; HTK, histidine-tryptophan-ketoglutarate solution.
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table 3. Cox regression analysis of potential risk-factors for the development of NAS in non-PSC recipients 
and PSC recipients. Factors from univariate analysis with a P-value <0.05 were included for multivariate 
analysis.
Univariate Multivariate
HR P-value (95% CI) HR P-value (95% CI)
Variables in PSC recipients
FUT2 non-secretor status (AA) 3.05 0.003 (1.47-6.35) 2.34 0.034 (1.08-5.08)
Graft type (DCD) 4.58 0.009 (1.73-12.1) 2.74 0.079 (0.98-7.67)
Gender mismatch 0.21 0.001 (0.07-0.62) 0.23 0.002 (0.08-0.67)
Recipient sex (male) 2.38 0.058 (0.90-6.29)
CMV status donor (positive) 0.56 0.175 (0.24-1.34)
CMV status recipient (positive) 1.70 0.167 (0.81-3.58)
Recipient/donor CMV mismatch 1.12 0.770 (0.53-2.36)
Recipient age 0.98 0.146 (0.95-1.01)
Preservation solution (HTK) 2.08 0.079 (0.95-4.56)
Variables in non-PSC recipients
Indication viral hepatitis 0.39 0.022 (0.16-0.94) 0.45 0.060 (0.19-1.10)
Indication NAS 3.37 0.049 (1.19-9.55) 3.19 0.063 (1.09-9.32)
Graft type (DCD) 2.68 0.036 (1.17-6.14) 2.81 0.030 (1.21-6.53)
Preservation solution (HTK) 2.07 0.077 (0.97-4.41)
FUT2, fucosyltransferase-2; DCD, donation after circulatory death; CMV, cytomegalovirus; HTK, histidine-
tryptophan-ketoglutarate solution; NAS, non-anastomotic biliary strictures. 
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figure 4. Paired donor-recipient fut2 status and incidence of nas. (A) In non-PSC patients there was 
no unfavourable donor-recipient combination of FUT2 genotypes causing a higher incidence of NAS. (B) In 
PSC patients, particularly the transplantation of a graft with donor FUT2 secretor status into a recipient with 
FUT2 non-secretor status was associated with a higher incidence of NAS, up to 80%. The tables below the 
graphs show the total number of paired donors-recipients per group. Abbreviations: D = donor, R = recipi-
ent, + = FUT2 secretor (GA or GG genotype), - = FUT2 non-secretor (AA genotype).
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relation between inflammatory bowel disease, PsC and fut2 status
Previous studies showed an association between PSC and inflammatory bowel disease 
(IBD). Moreover, FUT2 non-secretor status is a known genetic risk factor for IBD and 
might be associated with a “leaky gut”. This led to the hypothesis that increased bacterial 
translocation could be involved in the pathophysiology of PSC. As shown in fig. 5a, 
also in our study cohort, a strong correlation existed between IBD and PSC: in particular, 
ulcerative colitis was common among PSC recipients (56%) while it was almost absent 
in non-PSC recipients (0.7%, P<0.001). And as shown by fig. 5b, in the entire cohort a 
higher incidence of FUT2 non-secretors was observed in patients with ulcerative colitis 
No IBD Crohn Colitis ColitisCrohnNo IBD
non-PSC
PSC
FUT2 secretor
FUT2 non-secretor
***
*In
ci
de
nc
e
(%
)
In
ci
de
nc
e
(%
)
A B
No NAS NASPSC &
Colitis
PSC &
Crohn
PSC & 
No IBD
FUT2 secretor
FUT2 non-secretor
ns
In
ci
de
nc
e
(%
)
C
ns
PSC without colitis
PSC with colitis
D
In
ci
de
nc
e
(%
)
figure 5. association between PsC, ibD and nas.  (A) Incidence of PSC without coexisting IBD or with 
Crohn’s disease or ulcerative colitis (n=81). In particular ulcerative colitis was associated with PSC, occurring 
in 56% of PSC patients (P<0.001). (B) Association between IBD and FUT2 non-secretor status for the entire 
cohort (n=356). The percentage of FUT2 non-secretors was higher in patients with ulcerative colitis than 
in those with Crohn’s or without IBD (p=0.021). (C) Association between combined PSC and IBD and FUT2 
non-secretor status (n=81). The percentage of FUT2 non-secretors was not significantly higher in PSC recipi-
ents with coexisting ulcerative colitis (P=0.155). (D) Comparable incidence of NAS between PSC recipients 
with or without coexisting ulcerative colitis (P=0.070). 
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than in patients with Crohn’s disease or without IBD. In PSC recipients with coexistent 
ulcerative colitis, the number of FUT2 non-secretors was however similar to FUT2 secre-
tors (fig. 5C), and the incidence of NAS was comparable between PSC patients with or 
without coexisting ulcerative colitis (fig. 5D, P=0.070). 
It has been suggested that colectomy in PSC patients is protective for the recurrence 
of disease following LT[20]. Since many cases of NAS in PSC patients are possibly caused 
by recurrence of disease, we also investigated whether colectomy was protective against 
development of NAS. Out of 81 PSC recipients, 16 patients were subjected to colectomy; 
in 9 patients prior to development of NAS and in 7 patients after development of NAS. 
Two out of nine PSC recipients that had undergone colectomy developed NAS, while 
seven did not develop NAS (P=0.487). 
DisCussion
This study shows that patients suffering from PSC with a homozygous polymorphism in 
the FUT2 gene have a higher risk to develop NAS following LT.. This so-called FUT2 non-
secretor status was more common among PSC patients, in whom it was an independent 
risk factor for the development of NAS particularly during the first five post-operative 
years. Moreover, analysis of paired donor-recipient genotypes showed that FUT2 mis-
match further increased the risk of NAS, namely up to 80% when PSC recipients with 
FUT2 non-secretor status received a graft from a donor with FUT2 secretor status. In 
non-PSC recipients, transplantation with a DCD graft was the most important risk factor 
for development of NAS, as demonstrated by others before[21]. The results of our study 
not only confirm the pathophysiological role of altered glycosylation in PSC as identified 
by previous studies, it is the first that shows FUT2 genotype is an independent risk factor 
for outcome following LT in PSC.   
Fucosyltransferase-2 is an enzyme that catalyzes transfer of fucose into glycoproteins, 
which are expressed on the surface of epithelial cells throughout the body. The first 
studies on the biological role of FUT2 mainly concerned its function in the biosynthesis 
of blood group antigens[22]. But in the more recent years, the focus has moved to 
dysfunction of FUT2; the non-sense mutation caused by rs608133 creates a truncated 
FUT2 protein. Approximately 20% of the general population is FUT2 non-secretor, with 
inactivity of both alleles[23]. A strong correlation has been found between Crohn’s 
disease and FUT2 non-secretors[24]. Possible effects of FUT2 dysfunction in Crohn’s 
disease are altered host-microbe interactions due to a lack of fucosylation that causes 
epithelial barrier dysfunction[16]. Moreover, FUT2 non-secretors have a different, less 
diverse bacterial composition in their intestine[25]. These factors may lead to increased 
bacterial translocation to extra-intestinal sites which may explain the involvement of 
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FUT2 dysfunction in other diseases such as chronic pancreatitis[26] and auto-immune 
disorders as psoriasis[27, 28] and Behcet’s disease[29]. Remarkably, the correlation 
between FUT2 dysfunction and ulcerative colitis is less clear, with contradictory results 
in various studies[24, 30]. While in the current study, we observed a higher frequency of 
FUT2 non-secretors in LT recipients also suffering from ulcerative colitis than recipients 
with Crohn’s disease or patients without IBD. This observation could however be biased 
by the transplant population, which mainly consisted of PSC recipients with ulcerative 
colitis. 
Beside the intestine, FUT2 non-secretion also affects the bacterial composition of 
bile, as demonstrated by Folseraas et al.[13]. This finding supports the hypothesis that 
in patients with PSC, adhesion of specific bacteria to the cholangiocyte epithelium 
could provoke (recurrent episodes of ) cholangitis. Since the intestinal epithelium is 
also affected by the mutation, bacteria from the intestinal site could also translocate 
to the liver via the portal vein. The detection of Enterococcus, Escheria coli and Candida 
in bile of LT recipients with post-transplant biliary complications has been associated 
with shortened retransplantation-free survival[31]. A recent study by Rupp et al. showed 
an increased frequency of cholangitis by biliary Candida infection in PSC patients 
with heterozygous FUT2 carriers[14]. Dominant stenosis occurred more frequently in 
homozygous-mutated patients. To investigate whether bacterial translocation from the 
intestine also played a role in our cohort of PSC recipients, we tried to correlate NAS 
with the presence of IBD. The incidence of NAS was however comparable between PSC 
patients with and without coexisting IBD. Also, the preventive effect of colectomy on the 
recurrence of NAS that was shown by previous studies, was not proven to be effective 
against NAS in our study [20]. This could however be due to the limited number of PSC 
patients with colectomy in our study cohort.
A different mechanism that could explain the biliary injury in FUT2 non-secretors 
is the increased vulnerability of cholangiocytes for bile salt toxicity. In a physiologic 
situation, cholangiocytes are protected against the potential toxicity of bile acids by 
the excretion of HCO3-, also known as the bicarbonate umbrella[32]. Together with a 
glycocalyx layer on the apical membrane of cholangiocytes, the alkaline environment 
in the biliary lumen is maintained[33]. It is believed that the absence of FUT2, as is the 
case in non-secretors, can perturb the integrity of the biliary glycocalyx and bicarbonate 
umbrella and thereby increase the toxic effects on the biliary epithelium by bile salts. 
Multiple studies in both humans and animals demonstrated the relation between bile 
salt toxicity and bile duct injury in the context of LT[34, 35]. Whether absence of FUT2 
further exposes cholangiocytes to bile acids remains unknown and should be confirmed 
by future research.      
Another hypothesis on the pathophysiology behind FUT2 and NAS raised after 
analysis of paired donor-recipient FUT2 genotypes. In particular the combination of 
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donor FUT2 secretor with recipient FUT2 non-secretor showed a strong effect on the 
development of NAS. This raises the question whether FUT2 mismatch aggravates an 
immune response by the provision of fucose-positive antigens to recipients who have 
not been exposed to such antigens before. Strikingly, an experimental study by Gock et 
al. demonstrated that skin and heart grafts from transgenic mice with overexpression of 
human α1,2-fucosyltransferase were rapidly rejected by wildtype recipients[36]. This in 
contrast to mice that were matched for fucosyltransferase expression and that showed 
a much better graft survival. Histological evaluation of rejected grafts indicated that 
altered glycosylation patterns can trigger the innate as well as the adaptive immune 
system. This study supports our hypothesis that FUT2 mismatch could lead to an aggra-
vated immune-response. In addition, the possibility of popularization of the donor liver 
with recipients cells should also be considered. Hove et al. demonstrated chimerism 
of recipient cholangiocytes in the donor bile duct after transplantation[37]. Although 
this migration of recipient cells is supposed to induce tolerance, the displacement of 
fucosylated donor cholangiocytes by the non-fucosylated ones of the recipient could 
also activate immune responses, leading to NAS or recurrence of PSC.
This brings up an important point of the discussion; are the NAS observed in our cohort 
of PSC recipients in fact recurrence of the underlying disease? Already in 1999, Graziadei 
et al. formulated a definition for the diagnosis of recurrence of PSC after LT[19]. All PSC 
recipients in our cohort had a confirmed diagnosis of PSC prior to transplantation and the 
vast majority developed NAS at least after 90 days of follow-up. This, together with the fact 
that we found a correlation between NAS and FUT2 in patients with PSC only, strongly sug-
gests that NAS in our cohort of PSC recipients was in fact caused by a recurrence of disease. 
Nevertheless, few cases occurred before the limit of 90 days post LT. But if recurrence of PSC 
is triggered by a powerful immune response, as hypothesized in the previous paragraph, 
perhaps the cut-off in days for the definition of recurrence of PSC should be revised.  
The most important limitation of our study is the small cohort size. Although the 
study included donor and recipient DNA from a total of 418 LTs, paired donor-recipient 
samples were only available in 193 cases. Also, the number of patients in the PSC cohort 
was relatively small with 81 recipients. Despite this, we found a clear correlation between 
PSC, NAS and FUT2 non-secretor status. It did however hamper the performance of a 
reliable multivariate analysis for the matched donor-recipient genotype analysis. Finally, 
our study does not contain an independent validation cohort. But the data presented 
here do confirm the findings of previous large GWAS-studies in the context of LT, which 
makes this study a validation study on itself[13].      
In conclusion, this study demonstrates that FUT2 non-secretor status is a risk factor for 
the development of NAS or recurrence of disease in patients with PSC during the first 
years following LT. This is potentially related to an aggravated immune response due to 
FUT2 mismatch between donors and recipients.   
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supplementary table 1. Association of donor or recipient FUT2 genotype with NAS.
Donor FUT2 genotype No NAS (n=214) NAS (n=41)
AA 38 7
GA 104 20
GG 72 14
P=0.994
Recipient FUT2 genotype No NAS (n=291) NAS (n=65)
AA 66 21
GA 130 21
GG 95 23
P=0.132
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supplementary figure s1. Association between FUT2 genotype in donors and recipients and time to di-
agnosis of NAS.
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supplementary figure s2. Association between NAS and graft survival in non-PSC and PSC recipients.
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abstraCt
Ongoing research is being conducted in the field of transplantation to discover novel 
non-invasive biomarkers for assessment of graft quality before transplantation and 
monitoring of graft injury after transplantation. MicroRNAs (miRNAs) are among the 
more promising in this field. MiRNAs are small non-coding RNAs that function as impor-
tant regulators of gene expression in response to cellular stress and disease. An advan-
tage that makes miRNAs attractive candidates for biomarker research is their fast release 
from cells in response to stress and injury, which can occur via different routes. In the 
context of liver transplantation (LT), non-invasive measurement and stability of extracel-
lular miRNAs in blood, bile and graft perfusates has been linked to cell-type specific 
injury and early graft outcome following LT. Furthermore, specific intrahepatic miRNA 
expression patterns have been associated with graft survival and recurrent disease, like 
hepatitis C virus related fibrosis and hepatocellular carcinoma. Therefore, miRNAs with 
strong predictive value and high sensitivity and specificity might be successfully applied 
to assess hepatic injury and to diagnose (recurrent) liver disease before, during and after 
LT. In this review, the current features and future prospects of miRNAs biomarkers in and 
out of the liver are discussed.
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introDuCtion
Liver transplantation (LT) remains the only curative treatment for end-stage liver 
disease. Both short and long-term patient and graft survival however remain far from 
satisfactory, despite substantial advances in immunosuppressive therapy and surgical 
techniques[1, 2]. The increased need for use of marginal donors due to allograft short-
age, transplantation of recipients with increasingly higher MELD scores, and recurrence 
of liver disease are major factors that are negatively influencing outcome following 
LT[2]. Ongoing research is conducted in the field of transplantation to discover novel, 
non-invasive biomarkers for assessment of graft quality before transplantation and 
monitoring graft injury after transplantation. MicroRNAs (miRNAs) are among the more 
promising in this field. 
MicroRNAs are a class of newly discovered small non-coding RNAs, which serve as 
important regulators of post-transcriptional gene expression and as such control many 
cellular processes[3]. They exert down-regulating effects by preventing translation of 
messenger RNA (mRNA) into functional proteins. Increasing evidence establishes the 
important role of miRNA expression in physiological as well as pathophysiological pro-
cesses, including tissue injury and repair[4-11]. 
Although the gene regulating function of miRNAs is complex and far from fully unrav-
eled, their unique features make them attractive candidate biomarkers for prognostic 
and diagnostic purposes in liver disease and LT. Profiles of miRNAs that are expressed 
by various cell types, like hepatocytes, cholangiocytes and endothelial cells, allow for 
the study of cell-type specific injury or stress[12-14]. Moreover, in response to injury, 
cell-type specific miRNAs can be released into the circulation and other body fluids via 
different routes, which has been demonstrated by multiple studies[13-18]. Surprisingly, 
these extracellular miRNAs remain fairly stable, despite the abundance of RNA degrad-
ing enzymes[7, 19-23].
For LT, both miRNA expression patterns in tissue (the Ins) as well as miRNA release 
into serum, bile and graft preservation solutions (the Outs) have been linked with com-
plications that form major threats for patient and graft survival. These include severe 
ischemia-reperfusion injury (IRI), acute rejection, hepatitis C virus (HCV) re-infection, 
and recurrence of hepatocellular carcinoma. MicroRNAs with strong predictive value 
and high sensitivity and specificity might be successfully applied to assess graft quality 
and monitor graft function during different phases of clinical LT. Moreover, they could 
be valuable contributors to existing decision-making models like the donor risk index 
and the Milan criteria, which are currently used for the selection of respectively suitable 
donors and recipients in order to optimize graft and patient survival. 
In this review, we discuss recent literature with special attention towards the use of 
miRNAs as biomarkers to assess graft quality in LT, to monitor graft function shortly after LT 
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and for diagnosis of recurrent disease after LT. Emphasis is put on the biological relevance 
of miRNAs in response to cell stress and the associated release of miRNAs from cells.
miCrornas as master regulators of Cellular stress
Approximately 30% of all human genes are believed to be regulated by miRNAs, of which 
over 1000 types have been identified to be expressed by different cells. A distinct set 
of miRNAs was found to be expressed by hepatocytes and cholangiocytes of the liver, 
including miR-30a1, miR-30c, miR-30e, miR-122, miR-133a, miR-148a, miR-191, miR-192, 
miR-194, miR-198, miR-200c, miR-222, miR-296, miR-710, and miR-711[15, 24-28]. The 
most abundantly expressed miRNA in liver tissue is miR-122[12, 28]. This miRNA has been 
shown to be an important regulator of cholesterol metabolism[29], iron homeostasis[30] 
and as a crucial host factor for hepatitis C virus (HCV) infection and replication[31, 32]. 
General miRNA-induced gene regulation is a two-way process that is able to respond 
rapidly to specific cellular needs, especially under circumstances of cellular stress where 
they play a central role[33]. Not only do miRNAs regulate gene expression, they are 
sometimes also regulated themselves by stress signals such as NF-kB and p53 during for 
instance inflammation and DNA damage[34]. Furthermore, miRNAs have been shown 
as important mediators of metabolic stress for example during hypoxia, hyperglycemia, 
hypertriglyceridemia & hypercholesterolemia, and caloric restriction[35]. Furthermore, 
this regulation due to repression by miRNAs is a reversible process. For instance, the 
mRNA for cationic amino acid transporter 1 (CAT-1), which is normally repressed by 
miRNA-122, is relieved from repression during cellular stress (amino acid deprivation) 
to allow increased CAT-1 protein formation by translation of preexisting mRNA[33], sug-
gesting an important role for miRNAs as regulators of cellular stress.
CirCulating mirnas, tHeir release anD tHeir extraCellular 
stability
The presence of tissue-specific, extracellular miRNAs in the circulation has made them 
an important subject for non-invasive biomarker research. Already in the early 1970’s 
it was reported that, beyond expectation, intact free stable RNA could be found in the 
 1 Under a standard nomenclature system, names are assigned to experimentally confirmed miRNAs before publi-
cation of their discovery. The prefix “miR” is followed by a dash and a number, the latter often indicating order of 
naming. For example, mir-123 was named and likely discovered prior to mir-456. Species of origin is designated 
with a three-letter prefix, e.g., hsa-miR-123 is a human (Homo sapiens). MiRNAs with nearly identical sequences 
except for one or two nucleotides are annotated with an additional lower case letter. For example, miR-123a 
would be closely related to miR-123b.
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blood circulation, suggesting that such RNAs had to be relatively resistant to degrada-
tion by RNases[36]. More recently, circulating miRNAs have also been demonstrated to 
exert unexpected stability. Even after prolonged times at room temperature and after 
repeated cycles of freezing and thawing, miRNAs in serum, plasma and graft perfusate 
samples remained insensitive from degradation[7, 13, 14, 19]. But miRNAs can also be 
detected in other body fluids, including amniotic fluid, breast milk and colostrum, bron-
chial lavage, cerebrospinal and peritoneal fluid, bile, saliva, tears, urine, pleural fluid, and 
seminal fluid[17, 18, 37], suggesting protection against degradation.
The general observation is that stability of circulating miRNAs exceeds the stability of 
circulating mRNA. This has been attributed to either packing of miRNAs in small particles 
or their association with (lipo)protein complexes, protecting miRNAs from RNase activ-
ity. According to literature, the largest portion of circulating miRNAs in plasma or serum 
is present in a protein-bound form. They have been shown to bind to the Ago2-protein 
in particular, which is a catalyzing component in the RNA-induced silencing complex 
(RISC)[22, 38]. The involvement of proteins in stabilizing extracellular miRNAs has been 
demonstrated in serum samples treated with proteinase K, which results in degradation 
of proteins and subsequently diminished stability of extracellular miRNAs[22]. The exact 
mechanism by which miRNA-protein complexes are formed and excreted in the setting 
of LT is unknown. Furthermore, it is currently unknown what the faith of liver-derived 
miRNAs is once they have been released from cells. One interesting hypothesis is that re-
leased miRNAs can be taken up by cells inside or outside the liver and thereby remotely 
regulate gene expression in recipient cells[39]. However, this hypothesis requires further 
research in order to demonstrate a biological role of extracellular miRNAs.
In addition to the protein-bound form, a smaller portion of miRNAs is transported 
in small particles like exosomes, microvesicles and apoptotic bodies[20-23]. All these 
particles contain a lipid layer surrounding the miRNAs cargo to protect their content. 
Apoptotic bodies are released by cells during programmed cell death and are relatively 
large in size compared to microvesicles and exosomes. Microvesicles again are larger in 
their size compared to exosomes and are released from living cells by bleb formation of 
the lipid layer. The smallest particles known to carry miRNAs are exosomes. These small 
particles are produced in endosomes and are released from cells by fusing with the lipid 
cell membrane[20-23]. Recent studies have already shown that genetic exchange, and 
even transmission of HCV, through exosomes is possible[20, 39]. Hypothetically, these 
small vesicles could be involved in signal transduction and intercellular communication 
mediated by miRNA exchange.
Finally, stable forms of extracellular miRNAs have recently been found in association 
with high-density lipoproteins (HDL) and low-density lipoproteins (LDL)[23, 40]. The 
exact method of binding between miRNAs and lipoproteins is not understood. Some 
studies suggest that this association occurs within the circulation, where miRNAs are 
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picked up by lipoproteins, rather than packaged in HDL and LDL particles in the cell[23, 
40]. A summary of all routes of cellular miRNA release is illustrated in fig. 1. 
For most miRNAs found in circulation, it appears that excretion is caused by a selec-
tive and active mechanism of controlled release rather than a passive or coincidental 
leakage[22]. In vitro studies show differences in ratios of intracellular miRNAs and their 
release through small particles; some miRNAs were effectively excreted, while others 
were retained completely by the same cells, suggesting selective packaging and excre-
tion mechanisms[20, 41, 42]. In case of lipoprotein-associated miRNAs, it was shown that 
levels varied in certain diseases, underlining their potential as biomarkers[23, 43]. This 
specific controlled release further strengthens the hypothesis that released miRNAs are 
involved in regulatory, pathophysiologic mechanisms.
Hepatocytes 
Liver sinusoid 
Bile duct 
Risc-Ago2 
microvesicles 
Ischemia-
reperfusion 
exosomes 
HDL 
HDL 
MiR-Ago2 
HDL 
lipoproteins 
Rejection Infection Oncogenesis 
HDL 
figure 1. Mechanisms of miRNA release from (injured) cells. Mature miRNAs inside the cell cytoplasm are 
bound to the RISC-argonaute2 complex. Cell stress induced by for instance ischemia-reperfusion, infection, 
rejection and oncogenesis, can cause active release or secretion of miRNAs into the circulation. Extracel-
lular circulating miRNAs have been found in vesicles and smaller exosomes, or bound to lipoproteins (HDL 
and LDL) and argonaute2. Recently, miRNAs were also described to be released from the liver into bile. (Not 
included in this figure; miRNA release through apoptotic bodies).
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CirCulating miCrornas as non-inVasiVe biomarkers for liVer 
inJury in a non-transPlant setting
Current research concerning circulating miRNAs as biomarkers has mainly focused 
on liver disease and liver-failure prior to transplantation. This has encouraged further 
investigation of miRNAs as biomarkers in the setting of LT, though the total number 
of published studies for this field is still limited. Markers for liver disease however, 
could be relevant for predicting or diagnosing recurrent disease after LT. Therefore, this 
paragraph discusses relevant studies regarding circulating miRNAs in a non-transplant 
setting (table 1).
Globally, viral hepatitis is one of the most important indications for LT. A study by 
van der Meer et al. demonstrated that serum levels of previously described hepatocyte-
abundant miR-122 and miR-192 are elevated in HCV infected patients. Interestingly, 
table 1. A summary of literature is given of identified miRNAs and their potential as biomarkers of liver 
injury in a non-transplant setting.
manuscript medium mirnas Description
van der Meer et 
al. [44]
Serum miR-122
miR-192
Sensitive detection of liver injury by miRNAs even when 
transaminases are low in HCV infected patients
Cermelli et al. [45] Serum miR-16 
miR-34a 
miR-122
Increased levels in patients with HCV infection and NAFLD
Positive correlation of miR-122 and miR-34a with liver enzyme 
levels and histological fibrosis stage and inflammation activity
Roderburg et al. 
[46]
Serum miR-29 Lower circulating levels in patients with liver fibrosis
Roderburg et al. 
[47]
Serum miR-571 Levels closely correlated with disease stages during alcoholic or 
HCV induced liver cirrhosis
Gui et al. [48] Serum miR-885-
5p
Increased levels in patients with HBV, HCC and liver cirrhosis
Xu et al.  [49] Serum miR-21 
miR-122 
miR-223
Elevated levels in patients with HCC but also in patients with 
chronic hepatitis
Li et al. [50] Serum let-7f  
miR-25 
miR-375
Differentiation between HBV infected patients with concurrent 
HCC and healthy controls and patients with only HBV or HCV 
infection
Specificity of 96% and sensitivity of 100% for predicting HCC with 
miR-375
Zhou et al. [51] Serum miR-21 
miR-26a 
miR-27a 
miR122 
miR-192 
miR-801
Combined miRNA profile with high diagnostic accuracy for 
predicting HCC in HBV infected patients
Li et al. [52] Serum miR-221 Elevated levels correlated with HCC tumor size, cirrhosis, tumor 
stage, and significantly diminished patient survival by 2.5 times
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these miRNAs were also able to identify patients with normal transaminase levels during 
active HCV infection[44]. In patients with HCV infection and non-alcoholic fatty liver dis-
ease (NAFLD), not only miR-122, but also miR-34a and miR-16 were found to be elevated 
in serum compared to controls[45]. These levels of miR-122 and miR-34a correlated with 
liver enzyme levels and histological fibrosis stage and inflammation activity in both HCV 
and NAFLD patient groups. Roderburg et al. showed lower serum levels of miR-29 in mice 
and humans with liver fibrosis compared to healthy controls [46] and that serum levels 
of miR-571 were closely correlated with the stage of disease during alcoholic or HCV 
induced liver cirrhosis[47]. The findings from these studies indicate a higher sensitivity 
of serum miRNAs compared to conventional transaminases in screening liver injury, and 
the potential of miRNAs as biomarkers for monitoring fibrosis and severity of cirrhosis. 
Studies by other groups show that miR-885-5p2 is significantly increased in serum 
of patients with hepatocellular carcinoma (HCC), liver cirrhosis, and hepatitis B virus 
(HBV) infection compared to controls, but does not differentiate between the different 
types of liver disease[48]. Similarly, levels of miR-21, miR-122, and miR-223, which are 
commonly deregulated in HCC tissue, were elevated in serum of patients with HCC 
compared to healthy controls, but also in patients suffering from chronic viral hepatitis 
without known HCC[49]. This illustrates the problem that some serum miRNAs can only 
differentiate patients with liver injury from healthy controls, but not specify for the 
nature of the injury. 
In contrast, a different study shows that serum miRNAs could specifically identify HBV 
infection. Serum levels of miR-25, miR-375, and let-7f clearly differentiated between 
patients with combined HBV infection and concurrent HCC from healthy controls and 
patients with only HBV or HCV infection. Serum levels of miR-375 achieved specificity 
and sensitivity of respectively 96% and 100% for predicting HCC, making it a useful 
marker for HCC in HBV infected patients[50]. A comparable study in three independent 
cohorts identified a different set of circulating miRNAs (miR-122, miR-192, miR-21, miR-
223, miR-26a, miR-27a, and miR-801) that provided high diagnostic accuracy for predict-
ing of HCC in HBV infected patients[51]. Li et al. found that increased serum levels of 
miR-221 correlated with HCC tumor size, cirrhosis, tumor stage, and diminished patient 
survival by 2.5 times, suggesting its prognostic usefulness[52]. 
In general, these studies demonstrate the potential of miRNAs as predictive, diag-
nostic, and prognostic biomarkers in liver diseases, which are common indications for 
LT, with higher sensitivity and specificity compared to transaminases. However, small 
sample sizes and the lack of prospective studies make most current miRNA biomark-
 2 When two mature microRNAs originate from opposite arms of the same pre-miRNA, they are denoted with a 
-3p or -5p suffix. In the past, this distinction was also made with ‘s’ (sense) and ‘as’ (antisense). When relative 
expression levels are known, an asterisk following the name indicates an miRNA expressed at low levels relative 
to the miRNA in the opposite arm of a hairpin. For example, miR-123 and miR-123* would share a pre-miRNA 
hairpin, but more miR-123 would be found in the cell.
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ers still premature. This is indicative of the limitations of current biomarker discovery 
research. Whether miRNAs as biomarker could be utilized in the clinical setting of LT 
therefore remains to be determined. However, the strong correlation of specific miRNAs 
with the degree of histological inflammation, fibrosis and cirrhosis suggests that they 
could prove useful for various purposes in LT, such as screening for (and thus early treat-
ment of ) recurrent disease, identification of specific post-transplant complications and 
safe tapering of immunosuppressive drugs to minimize side effects.
CirCulating miCrornas as non-inVasiVe biomarkers in liVer 
transPlantation
As mentioned earlier, outcome after LT has improved considerably over the last decades, 
but patient and graft survival and quality of life could still be improved[14, 53-56]. Out-
come after LT is often compromised as a result of various causes such as inadequate graft 
selection and consequent primary non-function or delayed graft function, recurrence 
of disease, ischemic cholangiopathy, and life-long usage of immunosuppressive drugs 
and its complications[2, 55, 57, 58]. The need for non-invasive biomarkers to monitor 
graft quality before, during and after LT therefore remains. Despite this need, only a 
limited number of studies have been conducted so far in the field of LT, which results are 
summarized in table 2.
In an earlier study by our group, a diminished expression of hepatocyte-abundant 
miR-122 and miR-148a in allograft tissue during LT was shown to significantly correlate 
with the length of graft ischemia time. At the same time, serum levels of these miRNAs 
increased and correlated with traditional markers of liver injury after LT. Furthermore, 
during episodes of histologically proven acute cellular rejection, miRNAs rised earlier 
compared to transaminases during injury and normalized more rapidly after treatment, 
showing that miRNAs are promising candidates for very early detection of liver injury 
after transplantation[13]. More recently these findings were confirmed in a rat model, 
showing plasma levels of miR-122, miR-146a and miR-192 to be significantly increased 
during acute rejection. Interestingly, the researchers suggest miR-146a to be more 
specific in detecting of acute rejection because this miRNAs was higher abundant in 
portal lymphocytes within the liver, compared to levels of miR-122 and miR-192 that 
were assumed to represent more general hepatic injury[59]. 
More recent work from our team shows that pre-transplant perfusates, that are used 
for cold storage of liver allografts, contain stable extracellular miRNAs originating from 
hepatocytes (miR-122, miR-148a) as well as cholangiocytes (miR-30e, miR-222, miR-296). 
Profiles of these miRNAs were independent predictors for the development of ischemic 
cholangiopathy after LT. The proof of concept that miRNAs could be used as early bio-
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markers already before graft implantation to predict graft quality could be a valuable 
feature for the selection of allografts in the future[14, 60]. 
Not only blood or perfusates, but also measurement of miRNAs in bile can be of use 
after LT. Very recently, Lankish et al. showed that bile levels of miR-517a, miR-892a and 
miR-106a* were elevated in patients with ischemic cholangiopathy and could distin-
guish between ischemic cholangiopathy and other causes for biliary obstructions[61]. In 
particular for biliary complications, miRNA composition in bile rather than serum might 
better reflect ongoing injury of cholangiocytes[62].
Although miRNA biomarkers clearly have potential for clinical application in the set-
ting of LT, the number of studies on this topic should be expanded as their numbers 
are limited. During transplantation, miRNAs in perfusates can be used for diagnostic 
and in the future also maybe for therapeutic, purposes. Hence, not only selection of 
good quality grafts might benefit, but also alleviating ischemia-reperfusion injury might 
be an option once the biology of miRNAs has been unraveled. Furthermore, detection 
of circulating miRNAs in bile and serum can be equally useful for post-transplantation 
follow-up, such as monitoring for recurrent disease.
table 2. A summary of literature is given of identified miRNAs and their potential as biomarkers of liver 
injury in a transplant setting.
manuscript medium mirnas Description
Farid et al. [13] Peritransplant 
liver tissue and 
posttransplant 
serum
miR-122 
miR-148a 
miR-194
Reduction of miR-122 and miR-148a in liver tissue negatively 
correlated with length of ischemia time
Correlation of serum miR-122, miR-148a and miR-194 levels 
with transaminases
Early detection and quick response of miR-122 and miR-148a 
during acute rejection and its treatment
Verhoeven et al. 
[14]
Pretransplant 
graft perfusates
miR-30e 
miR-122 
miR-148a 
miR-222 
miR-296
Profiles of combined cholangiocyte and hepatocyte-derived 
miRNAs predictive for development of post-transplant 
ischemic cholangiopathy
Hu et al.  [59] Plasma and
portal 
lymphocytes
miR-122 
miR-146a 
miR-192
Increased plasma levels of all miRNAs during acute rejection
Specific higher expression of miR-146a in portal lymphocytes
Lankisch et al. [61] Posttransplant 
bile
miR-517a 
miR-892a 
miR-
106a*
Elevated in bile after development of ischemic 
cholangiopathy after liver transplantation
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tissue mirna exPression Patterns anD HePatitis C reCurrenCe after 
liVer transPlantation
Recurrence of disease is the most important cause of graft loss after LT and its preven-
tion could lead to decreased need of re-LT and significant improvement of outcome 
after LT. One major determinant for patient and graft survival after LT is the recurrence 
of HCV infection. Several studies investigated whether miRNA profiles in liver tissue in 
recipients can be used to predict the severity and time to develop fibrosis caused by 
recurrence of HCV and whether microRNAs can monitor response to antiviral therapy. 
One study investigated slow vs. fast progressing fibrosis in recipients with recurrent 
HCV after LT. Recipients with slow progression of liver fibrosis at 12 months after LT 
(Ishak score <F2) showed up-regulated expression of miR-146a, miR-19a, miR-20a and 
let-7e in graft liver biopsies compared to recipients with fast progression (Ishak score 
≥F2 at 12 months)[63]. In addition, the investigators were also able to distinguish fast 
progressing HCV re-infection from acute cellular rejection using miRNAs, which can 
usually be clinically challenging after LT but is essential as therapies for both conditions 
differ significantly.
A similar study compared miRNA expression between non-progressors (Knodell 
fibrosis score F0-F1) and progressors (F3-F4) in liver allograft tissue biopsies that were 
collected during clinical recurrence of HCV. In a training set of 27 recipients, a profile of 9 
differentially expressed miRNAs was identified of which 7 could be validated successfully 
in an independent set of recipients. In particular miR-155 and miR-30c were respectively 
up- and down regulated in progressors and were described as key-regulator miRNAs 
for the development of fibrosis through ingenuity pathway analysis[64]. Why these two 
comparable studies did not identify common miRNAs is unclear.
Another study investigated which miRNAs target HCV receptors and relate to HCV 
infection and response to antiviral therapy after LT. Different from the previous two 
papers, the investigators did not use gene-array analysis for identification of potentially 
relevant miRNAs, but miRNAs were selected by target prediction software. High viral 
load at time of HCV recurrence was significantly associated with increased expression of 
miR-122. Furthermore, in patients with sustained virological response, miR-122 expres-
sion significantly increased when recipients responded to antiviral therapy, next to five 
other miRNAs. Pretreatment profiles in tissue were however not predictive for success 
of antiviral therapy[65]. 
These identified miRNAs could serve as diagnostic methods, but more importantly, 
their biological function should be further investigated as this can give vital insight into 
the process of recurrence of HCV after LT and why its clinical course can differ consider-
ably between recipients. These insights in biological functions will inevitably be useful 
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in recipient and graft matching and the development of novel therapeutic strategies in 
order to minimize (the effects of ) recurrence of HCV.
tissue mirna Profiles anD reCurrenCe of HePatoCellular 
CarCinoma after liVer transPlantation
Another important recurrent disease associated with diminished patient survival after 
LT is HCC. The Milan criteria, often used for the selection of patients suffering from HCC 
in need of a LT, have been shown to be only moderately successful in the reduction of 
recurrence of HCC in recipients following LT[66]. Therefore, studies have been conducted 
to investigate the predictive or prognostic value of miRNAs for HCC recurrence after LT.
In a study by Han et al., miRNA gene-array analysis in primary HCC liver samples 
identified 18 miRNAs that were expressed differentially in recipients who developed 
HCC recurrence (n=5) and recipients who did not (n=5). Six miRNAs with the strongest 
fold-change, miR-19a, miR-886-5p, miR-126, miR-223, miR-24, and miR-147 were suc-
cessfully validated in 105 primary HCC samples of the same center and in 50 patients 
from another transplant center. Especially the combination of all six miRNAs showed 
high sensitivity and specificity and was demonstrated to be an independent predictor 
for HCC recurrence in patients transplanted within the Milan criteria as well as outside 
of the Milan criteria[67]. Based on this multiple-miRNA based profile, recipients could 
be divided into having a low-risk signature with a better recurrence-free and overall 
survival compared to recipients with a high-risk signature. In addition, in another study, 
high levels of miR-155 in HCC tissue were demonstrated to promote cell invasion result-
ing in poor overall en recurrence-free survival[68].
The same research group performed further clinical and experimental studies on 
the correlation between miR-126 and HCC recurrence. A lower expression of miR-126 
in primary HCC was associated with an increased incidence of HCC recurrence and 
impaired patient survival[69]. Moreover, in vitro and in vivo experiments showed that 
over-expression of miR-126 could inhibit HCC cell migration and invasion, thereby 
suppressing HCC metastasis. The involvement of several miRNAs, including miR-96, miR-
139-5p, miR-126*, and miR-142-3p in HCC recurrence was demonstrated by Sato et al. in 
an elaborate study[70]. Patients in this study were all operated within the Milan criteria 
but received resection as therapy for HCC instead of LT.
Based on these findings, stricter clinical and radiological follow-up can be granted in 
recipients identified as high-risk patients for recurrence of HCC, so that early identifica-
tion of recurrence will result in earlier therapeutic intervention probably resulting in 
higher quality of life and longer survival. 
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miCrornas anD reCurrenCe of otHer HePatiC PatHology after 
liVer transPlantation
Recurrence of other liver diseases after LT, such as primary sclerosing cholangitis (PSC), 
primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-HCV viral 
hepatitis, auto-immune hepatitis (AIH), and a variety of metabolic diseases could also be 
useful. However, in our search of literature currently no studies were found concerning 
the use of microRNAs after LT in other hepatic diseases, and thus we are unable to report 
on this topic in this review. 
Current CHallenges anD future aPPliCations 
As discussed earlier, the analysis of miRNAs for biomarker purposes can be performed 
in many different biomaterials and at different stages of LT. Ideally, liver biopsies should 
be avoided, as they impose a risk to the patient due to their invasive nature. Much of the 
earlier described research however has used liver biopsies for identification of miRNAs 
as they are easier to detect in tissue. Detection of miRNAs in body fluids and graft perfu-
sion fluid can be cumbersome due to lack of generally accepted protocols for isolation, 
detection and normalization, and the lack of adequate reference genes. Further investi-
gation on technical standards in detecting miRNAs in fluids is thus needed for discovery 
of new biomarkers. But most importantly also the verification of earlier identified mark-
ers is crucial. Validation of biomarkers is critical before translation of non-invasive or 
minimally-invasive form can be applied in the clinic and can replace existing suboptimal 
and/or invasive markers. Therefore, it is not expected that in short-term, non-invasive 
diagnostics will replace liver biopsies taken for the purpose of histologic assessment. 
Invasive diagnostic methods however, do not necessarily always pose a risk. Some-
times, invasively acquired material is already conveniently available due to the nature 
of the therapy, like tumor tissue that was collected from liver resection specimens[67, 
68, 71]. Though invasive diagnostics in these cases do not pose an additional risk, non-
invasive biomarkers could still be useful as the expected prognosis could be known 
beforehand, and patients be followed-up easier and non-invasively. Another complicat-
ing factor of using biopsies as a source for miRNA identification is the fact that biopsies 
only represent local expression instead of systematic changes. Therefore, using this 
technique, many interesting miRNAs could be overlooked and this might also explain 
the limited overlap in identified miRNAs by the different studies. Moreover, in diseases 
that tend to have patchy distribution, such as ischemic cholangiopathy, the chances of 
a sample error are high.
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As mentioned earlier, the absence of generally accepted protocols and technologies 
specifically designed to analyze large amounts of circulating miRNAs at once have 
significantly hampered research. However, novel technologies now available allow 
quantification of hundreds of circulating miRNAs at once in a more standardized fashion 
and have already lead to the discovery of many biomarkers[72-78], thereby opening 
new possibilities in the setting of transplantation.
Novel non-invasive biomarkers could be used for earlier detection and treatment of 
disease possibly preventing the need for transplantation or used for quantifying the 
response of novel therapies for diseases. During transplantation, biomarkers will aid in 
selecting appropriate good quality allografts[14]. Whereas after transplantation, they 
could be utilized for individually tailoring the need of immunosuppression, allowing a 
better balance between effects (prevention of graft rejection) and side effects (long-
term nephrotoxicity, infection and malignancy)[58], or be utilized for early detection of 
recurrent disease. 
The miRNAs discussed in the present study can not only serve as biomarkers but could 
also give more insight into mechanisms of several clinical entities, such as recurrence of 
disease or ischemia-reperfusion injury and its repair. This however remains difficult, as 
target prediction of miRNAs is achieved by in silico algorithms on the basis of (partial) 
complementarity and one unique miRNA usually has many hundreds of potential targets. 
These targets need to be confirmed through in vitro studies, as many predicted targets 
do not show any regulation by the miRNA expected to regulate[79]. No technique is cur-
rently available for mass target verification, which is time consuming, and thus usually 
a small number of targets are selected on the basis of hypotheses. This inevitably leads 
to a selection bias in studies and does not give a complete picture of the biology in a 
certain situation. This currently makes it difficult to quickly relate a certain miRNA to a 
certain biological function elucidating the pathogenesis.
Another potential role for miRNAs could be their therapeutic appliance. Recent litera-
ture implicates that released miRNAs serve as a way of cell-to-cell communication and 
that they can trigger remote (regenerative) responses following injury and disease[21, 
80-85]. Studies have already demonstrated the use of anti-sense, anti-miRNA technol-
ogy with surprising therapeutic results[11, 86]. This application of miRNAs could be used 
not only for treatment of (recurrent) disease, but possibly also for optimizing allograft 
quality by treatment of grafts after organ retrieval but prior to transplantation. However, 
as discussed, actual regulation of targets by miRNAs cannot be calculated reliably and 
one should therefore be careful that many other unwanted targets are not affected 
when applying the miRNAs therapeutically, which can lead to severe side effects. 
Finally, when applying miRNAs for diagnostic utility, besides plasma and serum, many 
other non-invasively obtainable substrates, as mentioned earlier, contain miRNAs, but 
they have not been investigated thoroughly[14, 17, 18, 37]. All these substrates present 
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possible sources of non-invasive diagnostic possibilities and should be researched. All 
in all, miRNAs represent a very promising field not only for diagnostic but also future 
therapeutic possibilities and therefore extensive research on miRNAs as biomarkers, 
their role in regulation and pathogenesis, and finally therapeutic appliance is justified 
and warranted. 
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abstraCt
background and aims. Extracellular microRNAs (miRNAs) in serum and bile are currently 
under intense investigation for biomarker purposes in liver disease. However, the direc-
tions and pathways by which miRNAs are released from hepatic cells remains largely 
unknown. Here, we investigated the release of hepatocyte and cholangiocyte-derived 
miRNAs (HDmiRs and CDmiRs) into blood and bile during various (patho)physiological 
hepatic conditions. 
methods. MiRNA release was analyzed using longitudinally collected tissue and 
paired bile and serum samples (n=124) that were obtained from liver transplant recipi-
ents during follow-up. 
results. Cell-type specificity of HDmiRs and CDmiRs was confirmed in liver and com-
mon bile duct biopsies (P<0.001). Analysis of paired bile and serum samples showed up 
to 20-times higher miRNA-levels in bile compared to serum (P<0.0001). Fractionation 
of bile showed the majority of miRNAs being present in the unpelletable supernatant, 
where protein-conjunctions protect miRNAs against degradation (P<0.0001). During 
episodes of liver injury and histologically proven rejection in liver transplant recipients, 
relative HDmiR-levels in bile decreased while its levels in serum increased (P≤0.015). 
Simultaneously, relative CDmiR-levels in bile significantly increased, while their levels 
in serum decreased. Related to liver excretory function, a strong positive correlation 
was observed between HDmiR-122 levels and bilirubin excretion into bile (R=0.694, 
P<0.0001), whereas CDmiRs showed an inverse correlation (P<0.05). 
Conclusion. During impaired excretory function and injury, the liver shows polar-
ized release of extracellular HDmiRs and CDmiRs. This sheds new light on the biology 
of hepatic miRNA release which is relevant for the interpretation of hepatic miRNAs as 
biomarkers.
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introDuCtion
MicroRNAs (miRNAs) are important regulators of post-transcriptional gene expression and 
as such control many cellular processes[1]. Previous studies have shown the involvement 
of miRNAs in physiological as well as pathophysiological processes[2-6]. In addition, the 
fact that certain miRNAs are cell-type abundant makes them attractive for biomarker 
research[7]. Recent studies have investigated the release of such specific miRNAs into 
the circulation and proposed their use as highly sensitive and specific markers for cellular 
injury[8, 9]. Moreover, some studies suggest that miRNAs released upon injury might serve 
as a danger signal that can trigger remote regenerative responses[10-14]. Despite the 
increasing knowledge on miRNAs as potential biomarkers, though, our understanding on 
the underlying mechanisms of miRNA release in response to injury remains incomplete. 
Because of their cell-type abundancy, extracellular miRNAs are increasingly being in-
vestigated as non-invasive biomarkers in serum for various liver disease[7, 15]. Recently, 
in concordance with other human and animal studies[8, 9, 16], our team has demon-
strated the specific release of hepatocyte-derived miRNAs (HDmiRs) in blood during 
liver injury, chronic hepatitis C infection and acute rejection after liver transplantation 
(LT)[17, 18]. These miRNAs were shown to be stable, early, and sensitive markers of 
liver injury. In addition to HDmiRs, miRNAs derived from cholangiocytes (CDmiRs) were 
diagnostic in patients with cholangiocarcinoma[19]. Moreover, CDmiRs were shown to 
be predictive of severe biliary injury already at time of graft preservation in LT[20]; in 
contrast to HDmiRs, grafts that developed biliary complications following LT contained 
lower levels of CDmiRs in perfusates. These findings suggest that during injury, there is a 
polarized release of HDmiRs and CDmiRs by hepatocytes and cholangiocytes[21]. 
The hypothesis that dynamics in miRNA release are different between hepatocytes and 
cholangiocytes was recently suggested by Lankisch et al., who found that during injury, 
cholangiocytes release miRNAs to bile rather than to blood[22]. The first report on miRNAs 
in bile by Shigehara et al. found miR-9 to be a potential biomarker for biliary tract cancer 
and showed that miRNAs were protected against RNAse activity in bile[23]. In addition, Li 
et al. used miRNAs in extracellular vesicles in bile for the identification of diagnostic miR-
NAs in cholangiocarcinoma[24]. Yet, these studies did not address the dynamics behind 
miRNA release into both bile and serum. Thus, the question remains whether polarized 
cells like hepatocytes and cholangiocytes can control miRNA release into both serum and 
bile. This knowledge is of importance for the interpretation of miRNAs as injury markers 
in the circulation or, as suggested by previous studies, a role of miRNAs as gene regula-
tors in the entero-hepatic circulation and biliary homeostasis[25-27].  
For this purpose, we investigated the following aspects of extracellular miRNAs in bile 
and serum: (1) the presence and stability of HDmiRs and CDmiRs in fresh human bile 
samples, and (2) the directional or polarized release of HDmiRs and CDmiRs into bile and 
serum during impaired liver excretory function and liver injury. 
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materials anD metHoDs
tissue, blood and bile sampling
First, abundance of HDmiRs and CDmiRs was evaluated by comparing expression of 
these miRNAs in liver biopsies (n=10) and common bile duct specimens (CBD, n=8) 
which were collected from donor livers at the end of cold ischemia during human LT. 
Tissue samples were snap frozen and stored at -80°C until further use. In order to inves-
tigate polarized release of HDmiRs and CDmiRs during different (patho)physiological 
conditions, we analyzed paired serum and bile samples (n=62 each, n=124 in total) that 
were collected from ten LT recipients during the first three weeks of follow-up after 
transplantation. Serum was withdrawn by venipuncture, while bile was collected from 
a T-tube that was inserted routinely into the common bile duct during LT. Samples were 
processed within two hours of withdrawal to prevent any degradation or contamination 
and were stored at -80˚C. Standard serum liver tests (AST, ALT, alkaline phosphatase, 
gamma-GT and bilirubin) were obtained. Bilirubin levels were also determined in bile for 
the assessment of liver excretory function. 
Fresh bile samples were obtained from donor gallbladders during the benching proce-
dure for centrifugal fractionation and protease treatment (n=7) and miRNA stability assays 
(n=4). Directly after collection, large components were removed from bile by a two-step 
centrifugation protocol; samples were centrifuged for 10 min at 453g at 4°C, followed by 
15 min of centrifugation at 3220g at 4°C. Bile samples were stored at -20°C until further use. 
During recipient follow-up, liver biopsies were taken for histological evaluation. 
Samples were stained for hematoxylin-eosin (HE) and cytokeratin 19 (CK19) and scored 
for rejection in correspondence with the rejection activity index[28] by an experienced 
pathologist as part of regular clinical practice. The use of all human samples was ap-
proved by the Medical Ethical Council of the Erasmus MC and all patients provided 
informed consent for the use of materials for medical research.
key points
 • Release of hepatocyte and cholangiocyte-derived miRNAs can be used to distin-
guish between biliary injury and hepatocyte injury.
 • In bile, the majority of extracellular miRNAs are in the unpelletable fraction and 
protected against degradation through conjunctions with proteins.  
 • Different hepatic (patho)physiologic conditions, like impaired hepatic excretory 
function, histologically proven acute rejection, and biliary injury, affect the direc-
tional release of hepatocyte and cholangiocyte-derived miRNAs into serum and bile. 
 • These new insights into the dynamics of miRNA release are of importance for the 
interpretation of miRNA-based biomarkers for liver injury and disease.   
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fractionation, protease and rnase-treatment of bile samples
For fractionation of bile, 4 ml of cell-free bile was diluted with 8 ml of sterile PBS and a 
baseline sample was taken. More detailed information regarding centrifugation steps 
of bile and protease-K and diethylpyrocarbonate (DEPC) treatment are available in the 
legend of fig.1 and the supplementary information. 
rna isolation, reverse transcription and real-time quantitative Polymerase 
Chain reaction (rt-PCr)
More detailed information on RNA isolation and RT-qPCR is provided in the supplemen-
tary data.
statistical analyses
Statistics for non-parametric correlations were generated by Spearman’s Rank Correla-
tion test, using relative miRNA levels that were calculated by threshold cycle values 
(2-CT). Because of the lack of well-validated reference miRNAs in both bile and serum, 
for comparative statistics (Kruskal-Wallis, Mann-Whitney U and Wilcoxon matched pair 
test), we used relative miRNA levels that were normalized by setting their total in each 
sample at 100% to correct for any differences in bile and serum concentration[20]. In 
tissue biopsies, relative miRNA levels were normalized using a previously described ref-
erence gene[18, 20], RNU43 (2-ΔCT), which was equally expressed between CBD and liver 
tissue (supplementary fig. s1a). P-values <0.05 were considered significant. Figures 
represent the median ± interquartile range (IQR). Analyses were conducted using IBM 
SPSS Statistics for Windows, Version 20.0 (Armonk, NY: IBM Corp.) and GraphPad Prism 
version 6.0 (GraphPad Software, San Diego, California, USA).
results
levels of HDmirs and CDmirs in liver and bile duct tissue 
The cellular origin of miRNAs in serum or bile is of importance to discriminate between 
injury of different cell types. Therefore, we first validated the abundance of HDmiRs and 
CDmiRs, as identified by previous studies[19], in liver biopsies (n=10) and CBD speci-
mens (n=8) that were collected during LT. MiR-122 and -148a were previously reported 
as hepatocyte-abundant, while miR-30e, -200c and -222 were reported as cholangiocyte 
abundant. As illustrated by supplementary fig. s1b, expression of miR-122 was over a 
1000-fold higher in liver tissue compared to CBD (median ± IQR; 128 ± 20 vs. 0.02 ± 0.8, 
P=0.0021). Although less abundant than miR-122, also the expression of miR-148a was 
significantly higher in liver tissue (5.6 ± 0.9 vs. 1.3 ± 0.2, P=0.0003). In bile duct tissue, 
miR-222 was expressed highest and showed up to 17-fold higher levels compared to liver 
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tissue (0.5 ± 0.5 vs. 8.5 ± 1.6, P=0.0002). The discrepancy in expression of miR-200c was 
even higher, up to 70-fold; 0.04 ± 1.6 in liver vs. 2.8 ± 0.5 in CBD. The results demonstrate 
that miR-122 and miR-148a are more abundant in hepatocytes, while miR-200c and miR-
222 are more specific for cholangiocytes (supplementary fig. s1b). The expression of 
miR-30e did not significantly differ between liver and CBD tissue.  
fractioning and stability of HDmirs and CDmirs in bile
To investigate the direction of HDmiR and CDmiR release into bile and blood in vivo, 
n=62 paired serum and bile samples (n=124 in total) were analyzed that were collected 
from ten recipients during the first three weeks after LT. Donor and recipient characteris-
tics are listed in supplementary table 1. As shown in fig. 1a, HDmiR-122 was the most 
abundant miRNA in serum as well as in bile. Of the three tested CDmiRs, CDmiR-222 was 
the most abundant in bile. Only a small portion was accounted for by miR-148a, while 
miR-200c was virtually absent in serum. Overall, relative levels of all HDmiRs and CDmiRs 
were significantly higher in bile compared to serum. 
In order to determine the subcellular localization of HDmiRs and CDmiRs, bile samples 
obtained from human donor gallbladders (n=7) were fractionated. In short, cell-free 
bile samples (sample S0) were sequentially centrifuged at 20,000g to obtain a pellet 
enriched with mitochondria, lysosomes and peroxisomes (sample P1). Subsequently, 
the supernatant was centrifuged at 100,000g to obtain a pellet enriched with micro-
somes and membrane fragments (sample P2). Finally, the supernatant was centrifuged 
at 140,000g to obtain a pellet with exosomes, ribosomes and viruses (sample P3). As 
shown in fig. 1b, all pellets contained only a small percentage of HDmiRs and CDmiRs 
compared to the unfractioned baseline sample (S0); approximately 0.9% of the miRNAs 
was present in P1, 1.2% in P2 and 1.9% in P3. In contrast, over 96.4% of the miRNAs 
were found in the non-pelletable supernatant after the final spinning step (sample S3). 
These percentages were similar between all tested CDmiRs and HDmiRs. The stability of 
extracellular miRNAs has been linked to the formation of miRNA-protein complexes[20, 
29]. In order to test whether miRNAs in bile are indeed bound to proteins, samples of 
unpelletable bile supernatant (S3) were treated with Proteinase-K for protein degrada-
tion (ProtK treated S3). As shown within the dotted square in fig. 1b, up to 89% of the 
miRNAs became undetectable after degradation of proteins in bile (P<0.0001). 
To further test the stability of biliary miRNAs, bile samples spiked with synthetic 
C.elegans cel-miR-39 and cel-miR-238 were incubated at room temperature up to 24h 
(n=4). As shown by fig. 1C, both HDmiRs and CDmiRs remained stable for at least one to 
four hours in bile. However, spiked-in control miRNAs cel-miR-39a and cel-miR-238 were 
almost completely degraded within the first five minutes after incubation, consistent 
with previous studies[20, 23]. To investigate whether degradation was caused by RNase 
activity, stability of miRNAs was also determined in an RNase-free environment by treat-
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ing bile with diethylpyrocarbonate (DEPC). As shown by fig. 1D, HDmiRs and CDmiRs 
remained more stable (up to 24 hours) in bile when samples were treated with DEPC. 
These findings suggests that the majority of biliary miRNAs is present in the unpellet-
able biliary fraction, where they remain stable and protected against RNAse activity 
through protein conjunctions. 
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figure 1. (A) Distribution of HDmiRs and CDmiRs in n=62 paired serum and bile samples. In general, miRNA 
levels in bile were higher compared to miRNA levels in paired serum samples. (B) Cell-free bile samples (sam-
ple S0, n=7) were fractionated by centrifugation at increasing speeds of 20,000g, 100,000g and 140,000g, 
in order to obtain pellets enriched with mitochondria, lysosomes and peroxisomes in pellet 1 (sample P1), 
microsomes and membrane (fragment)s in pellet 2 (sample P2) and exosomes, ribosomes and viruses in pellet 
3 (sample P3). The supernatant after the final centrifugation step (sample S3) contained soluble proteins and 
protein complexes. The fractionation of bile showed that all pellets only contained a very small percentage of 
the tested HDmiRs and CDmiRs compared to the baseline sample (S0), while the majority of miRNAs is present 
in the supernatant (S3). When proteins in biliary supernatant were degraded by Prot-K treatment, up to 89% 
of miRNAs become undetectable (ProtK treated S3). This suggests that most miRNAs are bound to proteins 
for protection against RNAse activity and degradation. (C) Stability of miRNAs in bile (n=4). Levels of HDmiRs 
and CDmiRs in bile remained relatively stable up to 4 hours (closed symbols), while exogenously spiked-in 
cel-miR-39 (open squares) and cel-miR-238 (open circles) degraded within 5 minutes after incubation at 37°C. 
(D) Eliminating RNAse activity in bile samples  by DEPC treatment resulted for all tested miRs in stability  for 
at least 24 hours in bile (closed symbols), whereas untreated bile showed a gradual decrease for all miRNAs 
tested (open symbols). Figures represent the median ± IQR. **P<0.01, ***P<0.001, #P<0.0001.
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release of mirnas into bile and serum during impaired liver function 
To investigate the effect of impaired liver function on the release of HDmiRs and CDmiRs, 
paired bile and serum samples were compared between grafts with good bilirubin excre-
tion into bile versus grafts with impaired bilirubin excretion (table 1). Bile samples con-
taining low concentrations of bilirubin (≤1000 IU/L, n=14) were considered to represent 
poor liver excretory function, while bile samples with bilirubin concentrations >1000 
IU/L (n=36) indicate good excretory function[30]. As shown in fig. 2a, livers with good 
bilirubin excretion had higher levels of HDmiR-122 in bile (P<0.0001). When liver excre-
tory function was impaired, however, levels of HDmiR-122 in bile drastically lowered. 
Simultaneously, CDmiR-levels in bile increased. Interestingly, out the five tested miRNAs, 
three of them showed no differences in miRNA levels in paired serum samples (table 1, 
fig. 2b). This could indicate that miRNAs in bile rather than serum better reflect the func-
tional status of the liver. In particular levels of HDmiR-122 in bile were strongly correlated 
with bilirubin secretion to bile (P<0.001, R=0.695). This correlation is displayed in more 
detail by fig. 2C, showing highly similar dynamics of HDmiR-122 and bilirubin levels in 
bile in six individual patients. The opposite dynamics between HDmiR and CDmiR secre-
tion to bile suggest that their release is polarized, dependent on liver excretory function. 
table 1. MicroRNA levels in paired bile and serum samples during impaired liver function and liver injury.
 
relative biliary mirna levels (%)
(median ± iQr)  
relative serum mirna levels (%)
(median ± iQr)  
Impaired excretrory function
microrna Bile bili >1000 
µmol/L (n=36)
Bile bili <1000  
µmol/L (n=14)
P-value Bile bili >1000 
µmol/L (n=36)
Bile bili <1000   
µmol/L (n=14)
P-value
HDmiR-122 81 (73-87) 2 (1-44) <0.0001 56 (42-69) 62 (46-77) 0.319
HDmiR-148a 3 (3-4) 5 (3-6) 0.006 8 (5-10) 4 (2-7) 0.022
CDmiR-30e 3 (2-3) 8 (5-11) <0.0001 18 (9-23) 10 (6-20) 0.106
CDmiR-200c 7 (4-11) 24 (13-30) <0.0001 0.2 (0.1-0.4) 0.0 (0.0-0.1) 0.006
CDmiR-222 6 (4-9) 42 (15-64) <0.0001 19 (12-29) 19 (11-33) 0.825
Cellular liver injury
microrna Serum AST <50 
U/L (n=21)
serum AST >50 
U/L (n=41)
P-value Serum AST <50 
U/L (n=21)
Serum AST >50 
U/L (n=41)
P-value
HDmiR-122 83 (80-88) 75 (42-84) 0.015 42 (27-57) 58 (51-76) <0.0001
HDmiR-148a 3 (3-4) 3 (2-4) 0.557 10 (7-12) 11 (6-20) 0.001
CDmiR-30e 2 (2-3) 3 (2-5) 0.315 21 (18-25) 11 (6-20) <0.0001
CDmiR-200c 7 (4-9) 10 (5-19) 0.035 0.2 (0.0-0.4) 0.1 (0.0-0.2) 0.024
CDmiR-222 4 (3-6) 7 (4-18) 0.011 26 (14-36) 16 (12-27) 0.045
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HDmir and CDmir release into bile and serum during liver injury 
To analyze the direction of miRNA release during liver injury, pairs of bile and serum 
samples from LT recipients were analyzed at time of liver injury with elevated serum 
transaminase levels (serum AST>50 IU/L, n=41) and compared to samples at time of 
limited liver injury (serum AST<50 IU/L, n=21). The median miRNA levels of HDmiRs and 
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figure 2. (A) Directional release of HDmiRs and CDmiRs into bile and (B) into serum during good versus im-
paired bilirubin excretion. Livers that excreted ≤1000 IU/L bilirubin into bile were considered to have poor 
excretory function (n=14), while livers that excreted >1000 IU/L bilirubin into bile were considered to have 
a proper excretory function (n=36 paired samples). Figures represent the median ± IQR of relative miRNA 
levels. (C) Correlation between HDmiR-122 and bilirubin levels in bile. Dynamics between bilirubin levels in 
bile and HDmiR-122 levels in bile were similar, suggesting a relation between HDmiR-122 and hepatocyte 
excretory function (P<0.001, R=0.694). Each graph represents values in an individual recipient during the 
first three weeks of follow-up after liver transplantation.
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CDmiRs in paired serum and bile samples are summarized in table 1. As illustrated by 
fig. 3a, during injury there was a polarized release of HDmiR-122 and CDmiR-222 into 
bile (P≤0.015). This inverse relation was also observed in serum (fig. 3b), showing an in-
crease in HDmiR-122 (P=0.0002) while CDmiR-222 was decreased (P=0.045). In contrast 
to excretory function, miRNAs in serum rather than bile showed the biggest discrepancy 
at time of liver injury (table 1). 
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figure 3. (A) Directional release of HDmiRs and CDmiRs into bile and (B) into serum during early (cellular) 
liver injury. Samples were divided into two groups: the low transaminase group with serum AST ≤50 IU/L 
(n=21) and the high transaminases group with serum AST >50 IU/L (n = 41). (C, D) During the first three 
weeks of follow-up, approximately three liver biopsies were taken per patient for histological evaluation. 
Biopsies were routinely stained for HE and CK19 and scored by the rejection activity index (RAI-score). 
Paired analysis of biopsies and bile samples (n=21) showed that levels of HDmiR-122 in bile significantly 
diminished when the rejection activity was higher, while levels of CDmiR-222 increased (C). This correla-
tion became even more apparent when looking at the ductular component of the RAI-score (D). All figures 
represent the median ± IQR. 
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To further investigate the release of HDmiRs and CDmiRs during injury, levels of these 
miRNAs were correlated with the degree of rejection. From the ten recipients in our 
study, a total of n=21 biopsies were evaluated within the first three weeks following 
LT by an experienced pathologists, according to the BANFF scoring criteria. Based on 
histology and clinical parameters, recipients received adjusted immunosuppressive 
treatment in order to clear cellular rejection. As shown by fig. 3C, levels of HDmiR-122 
in bile showed a modest though significant inverse correlation with the total rejection 
activity index (RAI) score (P=0.042, R=-0.448). Oppositely, higher levels of biliary CD-
miR-222 were positively associated with the RAI score (P=0.038, R=0.456). This contrast 
between HDmiR and CDmiR release into bile became even more apparent when we 
correlated their levels to the degree of ductular rejection (fig. 3D, P=0.015, R=-0.524 
for HDmiR-122 and P=0.033, R=0.466 for CDmiR-222). These correlations were absent in 
paired serum samples (data not shown). Interestingly, biliary levels of CDmiR-222 mildly 
correlated to serum levels of gamma-GT (P=0.045, R=0.258). Conventional markers as 
serum gamma-GT and alkaline phosphatase, however, did not correlate to histological 
ductular injury (data not shown). supplementary fig. s2 shows an example of a liver 
biopsy taken at two different time points during follow-up, and which was evaluated 
based on H&E and CK19 staining.
DisCussion
This is the first study showing that release of HDmiRs and CDmiRs into bile and blood 
is polarized in response to stress, impaired excretory liver function and during mild or 
severe liver cell injury. In recipients early after LT, good bilirubin excretion into bile was 
accompanied with high HDmiR-122 excretion into bile, while this was impaired when 
excretory function was poor. At the same time, opposite dynamics were observed for 
CDmiRs. Also during episodes of cellular liver injury and rejection, inverse dynamics in 
HDmiR-122 and CDmiR-222 release into both bile and serum were found. The correlation 
between bilirubin and HDmiR-122 excretion suggest that besides being a marker for 
injury, HDmiR-122 might also be involved in the conjugation and exocrine function of 
hepatocytes. Moreover, the polarized release of HDmiRs and CDmiRs into bile and serum 
suggests active rather than passive underlying release mechanisms and this provides 
us with new information on the dynamics of extracellular miRNAs in liver disease. In 
fig. 4, we illustrated proposed mechanisms of miRNA release during various (patho)
physiologic conditions of the liver that are supported by our findings. 
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Previous studies reported on miRNAs in bile solely. The first report on biliary miRNAs 
identified miR-9 as a potential biomarker for biliary tract cancer[23]. The investigators 
also verified the presence of HDmiR-122, CDmiR-200c and CDmiR-222 in bile, which 
were identified earlier in liver and bile duct tissue[19]. Also, despite the RNA hostile 
environment of human bile, miRNAs were found to be highly stable and protected from 
degradation. The current study not only confirmed that miRNAs can remain stable in 
bile for a certain period of time, but also that this is probably due to the fact that most 
miRNAs are bound to proteins in the unpelletable biliary supernatant. This is in accor-
dance with earlier findings regarding stability of extracellular miRNAs in plasma and 
serum[29]. The most well-studied protein responsible for miRNA stability is Argonaute-2 
(Ago2)[29, 31]. In the cell cytoplasm, miRNAs are loaded onto Ago2 and together they 
form the RNA-induced silencing complex (RISC). Subsequently, this RISC is guided to 
Lymphocyte
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miR-222
X
X
Acute liver injury & rejection
Hepatocyte Bile duct
miR-122
Bilirubin
erythrocyte
miR-222
Good liver function
miR-122
Bilirubin
miR-222
X
Impaired liver function
figure 4. Illustration of suggested mechanisms and routes of miRNA release from hepatocytes and chol-
angiocytes in different (patho)physiological conditions. (A) During normal graft function, there is good 
excretion of HDmiR-122 and bilirubin by hepatocytes into bile. Levels of CDmiRs, like miR-222, remain low 
in bile when liver function is sufficient. (B) When excretory function is impaired, the excretion of HDmiR-122 
and bilirubin into the bile is inhibited. There is, however, no release of HDmiR-122 and CDmiR-222 into the 
circulation. (C) During cellular injury and rejection, a similar mechanism of miRNA release is seen as during 
impaired function. The polarized release of HDmiRs and CDmiRs is however also directed into serum.  Re-
lease of HDmiRs is more pronounced into serum while CDmiRs are mainly released into bile.
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target mRNA by specific miRNAs. Being the active component of the RISC, Ago2 is able 
to inhibit messenger RNA (mRNA) translation through cleavage[32]. Other proteins 
that have been associated with miRNA stability are nucleoplasmin and high-density 
lipoproteins[33, 34]. It, however, remains unclear which protein is mainly responsible for 
miRNA stability in bile. Furthermore, in our study, approximately 10% of the initial biliary 
miRNAs remained detectable after protein degradation, suggesting protection against 
degradation in a different manner. Perhaps a minority of miRNAs is bound to complexes 
that have not yet been discovered. Nevertheless, it cannot be ruled out that fragments 
as vesicles, exosomes, or apoptotic bodies were incompletely removed from the biliary 
supernatant even after centrifugation at 140,000g. 
Besides biliary miRNAs in the unpelletable fraction, a recent paper by Li et al. reported 
on biliary miRNAs located in extracellular vesicles as potential diagnostic markers for 
cholangiocarcinoma[24]. The investigators plea for the analysis of miRNAs present in 
extracellular vesicles rather than those in whole bile, in order to better discriminate 
between cholangiopathologies. Evidence that using whole bile is inferior for designing 
biomarker assays was however not provided. Furthermore, based on the results from 
previous studies as well as shown here, the percentage of miRNAs present in vesicles like 
exosomes appeared to be very low[23]. By only looking at miRNAs in the vesicle fraction, 
over 90% of the miRNA signal in bile would be overlooked and ignored for analysis[35]. 
In addition to characterizing of biliary miRNAs, the studies from Shigehara at al. and 
Li et al. also confirmed that CDmiR-222 is a potentially relevant marker for cholangi-
opathy[23, 24]. Earlier work from our group showed CDmiR-222 release to be lower in 
preservation solutions that were used to flush grafts which later developed ischemic-
type biliary lesions after LT[20]. Based on this observation, earlier we hypothesized that 
cholangiocytes release their miRNA content into bile rather than into blood. The results 
of the current study support this hypothesis by the polarized release of HDmiRs and 
CDmiRs into bile during impaired function and graft rejection. 
Furthermore, the observation that HDmiR-122 is released into serum at time of injury is 
in accordance with other studies[17, 18, 36]. The finding that HDmiR-122 is also excreted 
into bile and strongly correlates with cellular excretory function, however, is new. This 
suggests a role of HDmiR-122 in biliary hemostasis via the entero-hepatic circulation. 
Other miRNAs that have been linked to biliary homeostasis are miR-506, miR-222 and 
miR-199a-3p; miR-506 was found upregulated in cholangiocytes of patients with pri-
mary biliary cirrhosis, causing impaired biliary secretory function by diminished anion 
exchanger 2 activity[27]. In esophageal adenocarcinoma cells, CDmiR-222 expression 
and farnesoid-X receptor (FXR) activity were affected by bile acids[26]. FXR has also been 
linked to protection of hepatocytes by repressing miR-199a-3p[25]. On the other hand, 
some miRNAs were reported to regulate expression of FXR, thereby increasing the risk 
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for cholangiocarcinoma[37]. The exact mechanism by which HDmiR-122 is involved in 
the context of biliary homeostasis should be explored by future research. 
The current study contains several limitations. First, we did not confirm the results 
from our human data in an in vitro model. Investigating polarized miRNA release ap-
pears unsuitable in hepatocyte or cholangiocyte cell-lines. Thereby, it also remains dif-
ficult to judge whether miRNAs are either passively or actively released to bile. For future 
research, the design of 3D organ-like structures could serve this purpose for specific liver 
pathologies[38]. In particular organoids appear to have a ductular phenotype during 
their differentiation, that could be of interest for in vitro molecular research of bile ducts 
and directional release of miRNAs[39]. Finally, the bile and serum samples used in this 
study were obtained from only ten LT recipients. However, the longitudinal collection 
of multiple samples (n=124) was particularly useful for studying the biology of extracel-
lular miRNAs in terms of dynamics and directions of release.  
The results from this study are important for understanding miRNA biology and sub-
sequent development and interpretation of new diagnostic assays. We observed that 
injury to cholangiocytes causes a release of CDmiRs into bile rather than into serum. So, 
counterintuitively, serum of patients with a higher degree of cholangiocyte injury con-
tained lower levels of CDmiRs. Moreover, bile could be considered as a novel diagnostic 
medium or so-called liquid biopsy for biomarkers. For instance when patients suffering 
from cholangiocarcinoma need interventions via the endoscopic or percutaneous route, 
the collection of bile is accessible and perhaps less sensitive for sampling bias, as can be 
the case with brush cytology[40]. But also in the context of LT, novel organ preservation 
techniques like machine perfusion create a prolonged time window in which graft qual-
ity could be evaluated more objectively; the production of bile during machine perfu-
sion is potentially useful for assessing liver graft viability[41]. In addition, measurement 
of miRNAs in bile or perfusates during machine perfusion might be informative on graft 
function or the degree of biliary injury, which are the main causes of graft failure after 
LT[42, 43]. 
In conclusion, this study demonstrates the polarized release of hepatocyte and chol-
angiocyte abundant miRNAs into bile and serum during impaired graft function and 
liver injury following LT. These findings shed new light on the underlying biology as 
well as the interpretation of extracellular miRNAs as biomarkers for hepatic injury and 
function.
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suPPlementary information
fractionation and rnase and protease treatment of bile samples
For fractionation of bile, 4 ml of cell-free, -20°C stored bile extracted from human organ 
donor gallbladders was diluted with 8 ml of sterile PBS and a baseline sample was taken 
(sample S0). In short, larger components, ie. mitochondria, lysosomes and peroxisomes, 
were pelleted by centrifugation at 20.000g for 20 min at 4°C (sample P1). The superna-
tant was then transferred to a new tube and centrifuged at 100.000g for 1 hour at 4°C in 
order to obtain a pellet enriched with microsomes and membrane fragments (sample 
P2). Finally, the remnant supernatant was centrifuged a third time for two hours at 
140.000g at 4°C to obtain a pellet containing exosomes, ribosomes and viruses (sample 
P3). The pellets were resuspended in 400 µl sterile PBS and mixed with 1400 µl Qiazol 
lysis agent (Qiagen, Hilden, Germany) and stored at -80°C until further use. 400 µl of the 
remaining, unpelletable, supernatant was mixed with 1400 µl of Qiazol and stored at 
-80°C until further processing (sample S3).
Protein degradation was tested in samples of biliary supernatant after centrifugation 
(sample S3). Samples of 400 µl of bile supernatant were incubated for 1 hour at 37°C 
with Proteinase-K (Roche Diagnostics, Almere, The Netherlands) in a final concentration 
of 0.1 mg/ml. 
For RNAse inactivation, cell-free, -20°C stored bile samples were treated with diethyl-
pyrocarbonate (DEPC; Sigma-Aldrich, Zwijndrecht, The Netherlands) in a final concen-
tration of 0.02% for 3 hours at room temperature. To remove traces of DEPC completely, 
samples were boiled for 15 minutes, and aliquots were stored at -20°C until further 
use. Immediately prior to incubation at 37°C, samples were spiked with 2 fmol each of 
artificial C. elegans miR-39 (cel-miR-39) and miR-238.
rna isolation 
Total RNA was extracted using the miRNeasy mini kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s protocol with minor modifications. For the isolation of miRNAs 
from tissue, 750µl of Qiazol lysis was added to approximately 10mg of snap frozen liver 
and bile duct specimens and homogenized by extensive vortexing with glass beads. For 
the isolation of miRNAs from serum and bile, 1.5ml of Qiazol lysis reagent was added to 
200 µl of serum or bile and mixed extensively by vortexing. In case of supernatant or pel-
let from the fractioning experiment, 1400 µl of Qiazol lysis agent was added to 400 µl of 
bile (S0), supernatant (S3), or pellet (P1, P2, P3) as mentioned earlier. After 5 minutes of 
resting at room temperature, 200µl or 280 µl of chloroform was added respectively, and 
the samples were again mixed vigorously by vortexing. After centrifugation (15 minutes, 
16.000 RCF at 4˚C), 700 µl of aqueous RNA containing layer was obtained, which was 
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further processed according to the manufacturer’s protocol (Qiagen).  RNA content was 
quantified, handled and stored as described previously[1].
reverse transcription and real-time quantitative Polymerase Chain reaction 
(rt-PCr)
RNA samples were analyzed for HDmiRs and CDmiRs as previously reported[2-4]. As 
HDmiRs, miR-122 and miR-148a were determined and for CDmiRs, miR-30e, miR-200c 
and miR-222 were analyzed.
The TaqMan microRNA reverse transcription kit (Applied Biosystems, Carlsbad, CA, 
USA) was used to prepare cDNA for multiple miRNAs in one reaction, using a modified 
protocol as reported previously[4]. In short, for every multiplex cDNA reaction 0.4 µl 
dNTP mix, 1.35 µl Multiscribe RT enzyme, 2.0 µl 10x RT Buffer, 0.25 µl RNase Inhibitor, 1.0 
µl of each RT primer and 7.5 µl of template RNA were used. The total reaction volume 
was adjusted to 20 µl with nuclease free water. All cDNA reactions were performed ac-
cording to the manufacturer’s instructions (Applied Biosystems).
For the analysis of paired serum and bile samples from LT recipients, PCR reactions 
were carried out in duplo on 384 wells plates to prevent inter-plate variability and con-
sisted of 5 µl TaqMan Universal PCR Master Mix, 0.25 µl microRNA-specific PCR primer 
(Applied Biosystems) and 2,5 µl of the previously prepared cDNA (1:10 dilution). The final 
volume of every PCR reaction was adjusted to 10 µl with nuclease free water and the 
PCR reactions were run according to the manufacturer’s instructions for 45 cycles. For 
stability and protein degradation experiments and the analysis of cell-line and porcine 
bile and perfusate samples, PCR reactions were performed as described previously[1].
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supplementary figure s1. (A) RNU43 was equally expressed in common bile duct (CBD, n=8) and liver 
tissue (n=10) and was used as a reference gene for comparing hepatocyte and cholangiocyte-derived miR-
NAs in these two types of tissue. (B) Confirmation of hepatocyte- and cholangiocyte abundance of HD-
miR-122, HDmiR-148a, CDmiR-30e, CDmiR-200c and CDmiR-222 in liver biopsies (n=10) and common bile 
duct tissue (CBD; n=8). RNU43 levels were used for normalization. HDmiR-122 was the most abundant in 
liver tissue, while CDmiR-222 expression was highest in tissue of CBD.** P<0.01, ***P<0.001.
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Day 6 post LT, RAI I Day 10 post LT, RAI 7 
supplementary figure s2. For each LT recipient, liver biopsies were taken at different time points during 
follow-up. Displayed are two biopsies taken at day 6 and day 10 following LT. The rejection activity index 
(RAI) was evaluated based on H&E and CK19 staining.
supplementary table 1. Characteristics of LT donors and recipients.
Variable number
Donor characteristics
Age (mean ± SD) 44.4 ± 8.6
Sex (m/f ) 5/5
BMI (mean ± SD) 23.3 ± 1.9
Donor lab (mean ± SD)
   AST (IU/L) 43.8 ± 30.4
   ALT (IU/L) 20.6 ± 12.0
   Gamma-GT (IU/L) 26.2 ± 35.9
   Bilirubin (µmol/L) 27.0 ± 42.1
   Natrium (mmol/L) 146.9 ± 5.8
Graft type (DBD/DCD) 10/0
Cause of death
   CVA 6
   Trauma 3
   Suicide 1
Graft preservation (UW vs. HTK) 10/0
Graft cold ischemia time in min (mean ± SD) 519.0 ± 137.1 
Recipient characteristics
Age (mean ± SD) 46.2 ± 9.9
Sex (m/f ) 7/3
Indication for LT
   HCV 2
   HBV 2
   Auto-immune (PSC, PBC, AIH) 3
   Alcoholic 2
   PNF 1
RAI first 21 days post LT (mean ± SD) 4.2 ± 2.5
Abbreviations: BMI; body mass index - DBD; donation after brain death – DCD; donation after circulatory 
death – CVA; cerebral vascular accident – UW; university of Wisconsin solution – HTK; histidine tryptophan 
ketoglutarate – HCV; hepatitis C virus – HBV; hepatitis B virus – PSC; primary sclerosing cholangitis – PBC pri-
mary biliary cirrhosis – AIH; auto-immune hepatitis – PNF; primary non-function – RAI; rejection activity index. 
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abstraCt
background & aims. Ischemic-type biliary lesions (ITBL) are the second most com-
mon cause of graft loss after liver transplantation. Though exact pathophysiology of 
ITBL is unknown, bile duct injury during graft preservation is considered to be a major 
cause. Here we investigated whether the release of cholangiocyte-derived microRNAs 
(CDmiRs) during graft preservation is predictive of the development of ITBL after liver 
transplantation. 
methods. Graft preservation solutions (perfusates) and paired liver biopsies collected 
at the end of cold ischemia were analysed by RT-qPCR for CDmiR-30e, CDmiR-222 and 
CDmiR-296 and hepatocyte-derived miRNAs (HDmiRs) HDmiR-122 and HDmiR-148a. Mi-
croRNAs in perfusates were evaluated on their stability by incubation and fractionation 
experiments. MicroRNA profiles in perfusates from grafts that developed ITBL (n=20) 
and grafts without biliary strictures (n=37) were compared.
results. MicroRNAs in perfusates were proven to be stable and protected against 
degradation by interacting proteins. Ratios between HDmiRs/CDmiRs were signifi-
cantly higher in perfusates obtained from grafts that developed ITBL (P<0.01) and were 
identified as an independent risk factor by multivariate analysis (P<0.01, HR: 6.89). The 
discriminative power of HDmiRs/CDmiRs in perfusates was validated by analysis of 
separate brain death (DBD) and cardiac death donors (DCD; P≤0.016) and was superior 
to expression in liver biopsies (C=0.77 in perfusates vs. C<0.50 in biopsies). 
Conclusion. This study demonstrates that differential release of CDmiRs during graft 
preservation is predictive of the development of ITBL after liver transplantation. This 
provides new evidence for the link between graft-related bile duct injury and the risk for 
later development of ITBL.  
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introDuCtion 
Biliary strictures after liver transplantation – in particular non-anastomotic strictures, 
which are more diffusely distributed throughout the liver graft – can cause considerable 
morbidity, graft loss, and mortality[1, 2]. Hepatic artery thrombosis (HAT) after liver trans-
plantation can result in such non-anastomotic strictures[3, 4]. However, similar patterns 
of diffuse biliary strictures and dilatations may occur in the presence of normal arterial 
circulation, which are often referred to as ischemic-type biliary lesions (ITBL)[3, 5]. Up to 
31% of liver transplant recipients suffer from ITBL [6]. In contrast to isolated strictures 
at the site of the biliary anastomosis, treatment of ITBL by biliary stenting through the 
percutaneous or endoscopic route is often ineffective and retransplantation is necessary 
in up to 15% of liver transplant recipients[7]. This renders ITBL the second most common 
cause of graft loss after liver transplantation[7, 8].
Previous studies report on various factors to be associated with ITBL, including primary 
sclerosing cholangitis (PSC) as indication for liver transplantation[9], blood type incompat-
ibility between donor and recipient[10], concomitant cytomegalovirus infection[11], grafts 
donated after cardiac death (DCD)[7], prolonged cold ischemia time[7], and insufficient 
flushing of the peri-biliary capillary plexus during graft preservation[12, 13]. However, 
these risk factors for ITBL and other factors related to graft quality lack specificity and are 
unable to predict outcome of individual grafts prior to transplantation. The increased use 
of marginal donors due to relative organ shortage[7] however emphasizes the need for 
biomarkers to forecast ITBL, since many of these marginal grafts, in particular grafts from 
DCD donors, are more likely to develop ITBL. Conversely, marginal grafts that are currently 
rejected for transplantation because of presumed high chances of developing ITBL could 
be used successfully in the future if they are diagnosed with a favourable biomarker profile. 
MicroRNAs (miRNAs) have recently emerged as promising candidates for biomarker 
research[14]. This class of small non-coding RNAs can regulate gene expression by 
repressing messenger-RNA translation; specific miRNA profiles have been associated 
with a variety of pathologic conditions in humans, such as malignant, metabolic and au-
toimmune diseases[15-17]. In addition to their altered expression in tissues, gene-array 
studies have identified cell-type abundant miRNAs excreted in serum, plasma, urine and 
other body fluids, which were proven to be detectable and stable[18-22]. Moreover, their 
feature as early and sensitive marker was demonstrated in mice with drug-induced liver 
injury, in which hepatocyte-derived miRNAs (HDmiRs) in serum increased earlier than 
conventional transaminase markers[23]. This has been confirmed in acute and chronic 
hepatitis patients[24, 25]. In liver transplant recipients, HDmiRs in serum were found to 
be an early and sensitive marker of acute rejection after transplantation[26]. 
Despite this relationship between hepatocyte injury and HDmiR release, the role of 
cholangiocyte-derived miRNAs (CDmiRs) and their release during biliary injury is un-
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known. Since ITBL are thought to be related to ischemic injury of the bile ducts, we 
hypothesized this may lead to the release of CDmiRs during cold storage that can be 
detected in graft preservation solution or so called perfusates. Grafts are flushed at the 
back-table just prior to implantation to remove unwanted products accumulated in 
the graft during cold-storage. These flushes or perfusates are believed to represent the 
condition of the entire liver parenchyma rather than only a small part of the liver, as is 
typically the case with liver biopsies. The fact that they contain biological material from 
the donor exclusively renders perfusate an attractive medium to assess graft quality 
prior to transplantation without the influence of recipient factors[27, 28]. 
The aim of our study was to determine whether it is feasible to detect CDmiRs and 
HDmiRs in graft perfusates, whether their levels are associated with the development of 
ITBL after transplantation, and whether they have the potential to serve as accurate and 
stable biomarkers.
materials anD metHoDs
Explanations on study design, definition of ITBL, sample collection & processing, RNA 
isolation, RT-qPCR, stability assay and statistical analyses are listed in the supplementary 
information. Detailed information on the fractionation assay is also provided in the leg-
end of fig. 2a.
results
recipient and donor characteristics 
Between April 2010 and March 2012, perfusates from 75 consecutive liver transplanta-
tions were collected at the end of cold ischemia time. Samples were retrospectively ana-
lyzed for the presence of two HDmiRs (HDmiR-122 and HDmiR-148a) and three CDmiRs 
(CDmiR-30e, CDmiR-222 and CDmiR296). The selection of these particular miRNAs was 
based on microarray data from literature[29] (table 1). Levels of miRNAs in graft perfus-
table 1. MicroRNA primer sequences.
microrna mature microrna sequence
Hsa-miR-122 UGGAGUGUGACAAUGGUGUUUG
Hsa-miR-148a UCAGUGCACUACAGAACUUUGU
Hsa-miR-30e UGUAAACAUCCUUGACUGGAAG
Hsa-miR-222 AGCUACAUCUGGCUACUGGGU
Hsa-miR-296 AGGGCCCCCCCUCAAUCCUGU
MicroRNAs are predictive of ischemic-type biliary lesions 169
ates from grafts that developed ITBL and grafts that did not develop biliary strictures 
after liver transplantation were compared.
Recipient and donor characteristics are shown in table 2. Out of 75 liver transplanta-
tions, 20 recipients developed ITBL (26,7%) with a median time to event of 57 days after 
transplantation (=ITBL group). Thirty-seven recipients remained free of biliary strictures 
table 2. Recipient and donor characteristics.
non-itbl
(n=37)
itbl
(n=20)
total 
(n=57)
p-value
recipient characteristics
Demographics
      median (SD) age (y) 52.0 (11.2) 52.5 (10.4) 52.0 (10.8) ns
      male/female 24/13 11/9 35/22 ns
      PSC (%) 9 (24) 2 (10) 11 (19) ns
Clinical blood values 24 hours post-surgery
      median (SD) AST 843 (1673) 2005 (2465) 1271 (2038) 0.006
      median (SD) ALT 713 (1202) 1398 (1656) 978 (1431) 0.012
      median (SD) AF 84.0 (68.1) 78.0 (85.7) 80.5 (74.6) ns
      median (SD) yGT 73.0 (73.1) 89.0 (108.6) 81.0 (86.4) ns
      median (SD) Bili 57.0 (101.0) 56.0 (107.3) 56.5 (102.3) ns
Anastomosis
      Duct to duct/Roux-Y 29/8 18/2 47/10 ns
Median days of follow-up(SD) 526 (218) 408 (368) 487 (218) ns
Median days to event (SD) 57 (74)
Donor characteristics
Demographics
     median (SD) age (years) 52.0 (15.7) 51.0 (17.8) 51.0 (16.3) ns
     male/female 17/20 9/11 26/31 ns
     median BMI 23.0 (3.7) 22.0 (2.8) 22.6 (3.4) ns
Graft type
      DCD / DBD 5/32 9/11 14/43 0.006
Graft preservation
      HTK / UW 11/26 11/9 22/35 0.052
      median (SD) cold ischemia time (min)      389.0 (115.3) 405.0 (86.7) 392.0 (106.9) ns
Laboratory results at time of donation
      median (SD) AST 52.5 (27.9) 36.5 (62.6) 44.0 (43.1) 0.042
      median (SD) ALT 31.0 (44.0) 24.0 (49.7) 30.0 (45.8) ns
      median (SD) AF 67.5 (60.2) 57.0 (18.1) 62.5 (50.1) ns
      median (SD) yGT 30.0 (104.7) 28.5 (42.6) 30.0 (88.1) ns
      median (SD) Bili 9.0 (18.3) 8.0 (7.6) 9.0 (15.5) ns
n.s., not significant
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and associated interventions during follow-up (=non-ITBL group). Median follow-up of 
the entire study cohort was 487 days. Subjects who were never at risk for ITBL due to 
immediate re-transplantation (HAT n=6; primary non-function n=4) or with biliary inter-
ventions due to causes other than ITBL (anastomotic strictures n=4; recurrent disease 
n=2; rejection n=2) were excluded for analysis. 
Recipients who developed ITBL received a DCD graft more often than recipients 
without biliary strictures (9 out of 20 in the ITBL group vs. 5 out of 37 in the non-ITBL 
group, P=0.006) and graft preservation tended to be performed more frequently with 
HTK (11 out of 20 in the ITBL group vs. 11 out of 37 in the non-ITBL group, P=0.052). 
Donors’ serum AST levels were higher in the non-ITBL group (P=0.042) and 24-hour 
post-operative serum AST and ALT levels were increased in recipients who eventually 
developed ITBL (P≤0.012). 
Detection and stability of mirnas in perfusates 
To study the release of miRNAs during graft preservation specifically, perfusate samples 
cleared of cells were used for analysis. It was feasible to detect levels of both HDmiRs 
and CDmiRs in cell-free perfusates through quantitative RT-PCR (fig. 1a). Comparing 
relative miRNA levels, HDmiR-122 levels were higher in liver tissue than in perfusates 
(P=0.033). This in contrast to levels of HDmiR-148a (P=0.008) and CDmiR-222 (P=0.010), 
which were lower in liver tissue compared to perfusates (fig. 1b). Levels of HDmiRs and 
CDmiRs in perfusates did not correlate to expression in paired biopsy samples. These 
differences between perfusates and liver tissue could indicate selectivity in the release 
of miRNAs from both hepatocytes and cholangiocytes.
As shown in fig. 1C, HDmiRs and CDmiRs in cell-free perfusates remained stable up to 
24 hours after storage at room temperature. In contrast, an exogenously added Caenho-
rhabditis elegans miRNA (cel-miR-39) degraded within 5 minutes of incubation (P<0.01), 
suggesting that HDmiRs and CDmiRs are protected against RNAse activity in perfusates. 
To further investigate the stability and fractionation of released miRNAs in perfusates, 
separate cell and subcellular fractions were prepared by sequential centrifugation steps 
(fig. 2a). As shown in fig. 2b, the fraction of HDmiRs and CDmiRs present in cell debris 
and vesicles was only small. The largest fraction of miRNAs however was found in the 
remaining perfusate supernatant, containing protein complexes, ribosomes and macro-
molecules. Acetone precipitation showed that over 90% of miRNAs in the supernatant 
is attached to protein complexes (fig. 2C) of which the majority is larger than 100 kD, 
as was demonstrated by perfusate concentration (supplementary fig. 1). The conjunc-
tion between miRNAs and proteins, rather than their embedding in small vesicles, could 
explain miRNA stability and their protection against RNAse activity in perfusates.
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figure 1. relative HDmir and CDmir levels in perfusates and tissue biopsies. (A) RT-qPCR results for 
CDmiR-222 and HDmiR-148a in n=29 perfusates. (B) Relative levels of HDmiR-122 (P=0.033), HDmiR-148a 
(P=0.008) and CDmiR-222 (P=0.010) were significantly different between 33 paired perfusate- and biopsy 
samples, indicating selectivity in miRNA release. (C) Stability of HDmiRs and CDmiRs in perfusates after 
incubating samples at room temperature for different time points (n=3). Both HDmiRs and CDmiRs in 
perfusates remained stable up to 24 hours of incubation. The synthetic exogenously spiked-in cel-miR-39 
however was degraded within five minutes (*P<0.05, **P<0.01). All figures demonstrate the mean ± SEM. 
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figure 2. microrna fractions in perfusates. To investigate in which different fractions miRNAs are pres-
ent in perfusate, separate cell and subcellular fractions were prepared by different centrifugations steps 
(A); fresh perfusates were centrifuged at low speed (1,000g for 10 min.) to pellet intact cells. Second, a 
centrifugation step at medium speed (20,000g for 20 min.) was performed to pellet nuclei, cytoskeletons 
and other organelles. Finally, centrifugation at high speed (80,000g for one hour) was performed to pellet 
small vesicles and exosomes. The remaining supernatant contained proteins, ribosomes, viruses and large 
macromolecules. (B) Percentages of HDmiRs and CDmiRs in different perfusate fractions (n=7). The dotted 
line delineates fractions in perfusates after standardized workup, as was done for the cohort study. (C) After 
the final spin, acetone precipitation of the supernatantshowed that over 90% of miRNAs was bound to 
proteins (n=4). Shown are the mean ± SEM. 
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ratios between HDmirs and CDmirs in perfusate are predictive for the 
development of itbl
Relative levels of HDmiRs and CDmiRs in perfusates were compared between grafts that 
developed ITBL (n=20) and grafts without biliary strictures (n=37). Since we did not have 
a reliable reference miRNA that could be measured consistently in perfusates, we instead 
used the ratio of HDmiRs/CDmiRs to normalize data and calculate relative CDmiR levels. 
As shown in fig. 3a, levels of HDmiR-122 but not HDmiR-148a were higher in perfusates 
from grafts that developed ITBL after liver transplantation (P=0.032). Levels of CDmiRs 
however were all significantly lower in these perfusates (P≤0.006). These low CDmiR 
levels resulted in high ratios of HDmiRs/CDmiRs and CDmiRs in perfusates obtained 
from grafts that developed ITBL (P≤0.004, fig. 3b). 
Univariate analysis (table 3) revealed that high HDmiR/CDmiR ratios (HR≤4.98) and 
the type of donor (HR: 3.21, P=0.01) were possible risk factors to develop ITBL. The type 
of preservation fluid used during graft procurement also tended to increase the risk of 
ITBL (HR 2.24, P=0.059). Multivariate analysis identified ratios of HDmiR-148a/CDmiR-
30e, -222 and -296 as independent risk factors for ITBL (table 3). This model also dem-
onstrated discriminative power of miRNAs in perfusate, calculated by C-statistics, since 
values reached up to 0.89 and were not below 0.60. To validate our findings, incidence 
of ITBL  in the entire study cohort and in separate DBD and DCD grafts was compared 
between grafts with high HDmiR/CDmiR ratios in perfusate vs. grafts with low HDmiR/
CDmiR ratios (fig. 4). This revealed that in DBD grafts, ratios between HDmiR-148a/
CDmiR-30e had strong discriminative power (P=0.001) with high negative predictive 
value (90%) whereas in DCD grafts, ratios of HDmiR-148a/CDmiR-296 showed the stron-
gest separability (P=0.011) with a positive predictive value of 100%.  
table 3. Cox regression analysis and C-statistics on HDmiR/CDmiR ratio’s in perfusate and the development 
of ITBL.  
univariate multivariate
HDmir/CDmir ratio HR p-value (95%CI) HR p-value (95%CI) C  (low. limit - up. limit)
HDmiR-122/CDmiR-30e 1.67 0.004 (1.18-2.35) 1.39 ns -
HDmiR-122/CDmiR-222 2.04 0.002 (1.29-3.22) 1.62 ns -
HDmiR-122/CDmiR-296 1.94 0.002 (1.27-2.96) 1.65 ns -
HDmiR-148a/CDmiR-30e 3.22 0.001 (1.64-6.43) 6.89 0.003 (1.97-25.06) 0.77 (0.64-0.89)
HDmiR-148a/CDmiR-222 4.98 0.001 (1.91-12.95) 3.38 0.025 (1.28-11.11) 0.76 (0.63-0.88)
HDmiR-148a/CDmiR-296 3.45 0.001 (1.65-7.20) 4.03 0.025 (1.19-13.62) 0.74 (0.62-0.87)
In the multivariate statistical model, separate HDmiR/CDmiR ratios were adjusted for graft type (DBD vs. 
DCD), the type of solution used for graft preservation (UW vs. HTK) and the interaction between variables. 
The adjusted models were also used for the calculation of discriminative power by C-statistics. 
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figure 3. Distribution of relative HDmir and CDmir-levels and ratios between HDmirs/CDmirs in 
perfusates. (A) Comparison of relative HDmiR- and CDmiR-levels in perfusates obtained from grafts that 
developed ITBL (n=20) and grafts that did not develop biliary strictures (non-ITBL group, n=37). (B) Due to 
the lack of reliable reference RNAs in solutions, CDmiR levels were normalized to HDmiR levels using a ratio. 
The HDmiR/CDmiR ratios of all perfusate samples were significantly different between ITBL and non-ITBL 
grafts. Figures demonstrate the median ± interquartile ranges. *P<0.05, **P<0.01, ***P<0.001.
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no correlation between HDmir and CDmir levels in graft perfusate and their 
expression levels in liver tissue 
From the first 24 transplantations, paired liver biopsies were available and tested for 
miRNA expression. Six grafts developed ITBL and 18 remained free of biliary strictures. 
No differences were found in HDmiR and CDmiR expression, nor in ratios of HDmiRs/CD-
miRs between ITBL and non-ITBL groups (supplementary fig. 2a and 2b). In contrast 
to graft perfusates, HDmiR/CDmiR ratios expressed in liver tissue had no discriminative 
power (C<0.5) and univariate cox regression analysis showed no significantly increased 
risk for the development of ITBL after transplantation (HR=1.06, P=0.487). Also donor 
type (DBD vs. DCD) did not significantly affect expression levels of HDmiRs or CDmiRs 
(data not shown). Accordingly, it is known that hypothermic conditions preserves mRNA 
patterns and prevents changes in gene expression. 
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figure 4. increased incidence of itbl in grafts with high HDmir/CDmir ratios in perfusates. Through 
a grid search on HDmiR/CDmiR values within the inter-quartile range, different cut-off values could be 
obtained to distinguish grafts with an increased incidence of ITBL from grafts without biliary complications 
in the entire study cohort and for separate DBD and DCD grafts. (A) In the entire study cohort (n=57), inci-
dence of ITBL was threefold higher in grafts that released high ratios of HDmiR-148a/CDmiR-30e and four-
fold higher in grafts that released high ratios of HDmiR-148a/CDmiR-296. (B) In DBD grafts (n=43), incidence 
of ITBL was significantly higher in grafts with high levels of HDmiR-148a/CDmiR-30e (P=0.001) and HDmiR-
148a/CDmiR-296 (P=0.016). (C) In DCD grafts (n=14), all grafts except one developed ITBL when perfusates 
contained high ratios of HDmiR-148a/CDmiR-30e. Grafts releasing high HDmiR-148a/CDmiR-296 levels 
showed significant higher incidence of ITBL during follow-up (P=0.011). 
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DisCussion
This study shows that CDmiRs are released during graft preservation and that their 
profiles in perfusates are predictive of ITBL. High ratios of HDmiRs/CDmiRs in perfusate 
increased the risk for a graft to develop ITBL within a year after transplantation up to four 
fold, which was validated in a separate analysis of DBD and DCD grafts. Furthermore, 
we showed that miRNAs remained stable in perfusates for at least 24 hours. Given the 
stability of miRNAs in perfusates and their superior discriminative power to expression 
in tissue biopsies, our data indicate that they could be used as novel biomarker to assess 
bile duct integrity during cold storage prior to liver transplantation.  
To our knowledge, we are the first to report on a potential marker that is able to assess 
graft biliary injury and predict the development of ITBL prior to liver transplantation. One 
advantage of miRNAs as injury markers is that many are expressed in a cell type specific 
fashion. In the current study, we used miRNAs that were reported to be highly abundant 
in cholangiocytes[29]. Distinctive cell-type abundant miRNAs have been identified that 
were able to diagnose graft rejection and ischemia-reperfusion injury[18, 30, 31]. In liver 
transplant recipients, HDmiR-122 and HDmiR-148a were found to be released into the 
circulation and were elevated in patient serum during episodes of graft rejection, prior 
to the elevation of AST and ALT in serum[26]. Furthermore, CDmiR-222 and CDmiR-296 
have been associated with injury to vascular endothelial cells and protection against 
ischemia-reperfusion injury in kidney transplantation[32, 33]. As diagnostic markers, 
miRNA profiles have been shown to be able to distinguish normal cholangiocytes from 
cholangiocarcinoma cells, and tumor derived miRNAs in bile were proven to be more 
sensitive in diagnosing cholangiocarcinoma than carcinoembryonic antigen[29, 34].
There are several benefits to use perfusates for diagnostic assays. As perfusates 
are non-invasively obtained from total vascular perfusion during cold ischemia, they 
represent injury events of the whole liver and therefore lack the sampling bias that is as-
sociated with tissue biopsies. Furthermore, perfusates can represent graft quality prior 
to transplantation without any influencing recipient factors in an early phase of liver 
transplantation[27, 28]. Since liver biopsies only provide information about that specific 
part of the liver, it may be less useful for the detection of bile duct injury as ITBL, which 
is known to occur focally and often does not affect the entire graft evenly. Therefore, 
it can be argued that perfusates provide more accurate information about conditions 
predisposing to ITBL than biopsies. Previous studies have reported the successful use 
of perfusates to predict graft survival and graft dysfunction by measuring hyaluronate 
and aminotransferases[35-37] and recent experimental studies describe the identifica-
tion of perfusate markers in hypothermic machine perfusion of marginal grafts[38, 39]. 
These markers however concerned hepatocyte injury and associated graft primary non-
function, but failed to detect the degree of biliary injury in liver grafts. 
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The current study supports the notion that the release of miRNAs from cells is an 
active and selective process. For instance, the relative levels of CDmiRs and HDmiRs 
in liver tissue were significantly different from their levels in perfusates (fig. 1b), sug-
gesting that the release of miRNAs from cells is selective and does not just reflect the 
relative abundance of miRNA observed in the cells. This selectivity is consistent with the 
observed release of HDmiRs into serum, reported earlier[26]. Furthermore, concentra-
tions of different miRNAs in perfusates did not correlate with donor or recipient serum 
transaminases or the length of cold ischemia time, which makes the hypothesis that 
miRNAs in perfusates represent leakage after cell damage less likely. Though one would 
expect increased levels of miRNAs following injury, the opposite was the case in the 
current study; relative levels of CDmiRs were found to be significantly lower in perfus-
ates obtained from grafts that developed ITBL. This finding leads to several underlying 
hypotheses: the number of cholangiocytes could be lower already during cold preserva-
tion in grafts that will develop ITBL. This however seems unlikely, since no difference 
in CDmiRs expression was found in liver biopsies taken at the end of cold ischemia 
between ITBL and non-ITBL groups. Based on recently obtained insights on polarized 
release of miRNAs by cells[40], a more plausible explanation would be a shift of miRNA 
release into bile influenced by cholangiocyte-injury. Furthermore, measurement of 
immature pre-miRNAs or apoptotic cholangiocyte markers, such as CK19, could be an 
alternative method to investigate gene regulation and cholangiocyte deregulations in 
tissue biopsies. However, markers like CK19 are also highly expressed by liver-derived 
mesenchymal stem cells and therefore could lack specificity[41]. These hypotheses were 
not further explored in the current study and need to be  investigated through future 
research. 
A majority of HDmiRs and CDmiRs in perfusates were associated with protein 
complexes. Of the cell-free fractions, an average of 7% of miRNAs were found in the 
organelle or microvesicle fractions, whereas the remaining  93% of miRNAs were present 
in the unpelletable supernatant fraction (fig. 2b) which were predominantly associated 
with proteins (fig. 2C). This could explain miRNA stability in the RNAse-rich environ-
ment of graft perfusates even hours after incubation at room temperature. Studies on 
the characterization of extracellular miRNAs revealed that proteins like Argonaute2 are 
mainly responsible for the stability of circulating miRNAs[21, 22]. Targeted release of 
miRNAs from cells through selective microvesicle and exosome secretion seems less 
likely, since only a minority of miRNAs was present in these fractions in the current study 
(fig. 2b).  It is however important to emphasize that different methods are available 
for the isolations of exosomes and microvesicles. Particularly for the quantification of 
miRNAs, modified exosome precipitation methods appear to be more suitable than 
conventional ultracentrifugation up to 200,000g[42]. In the current study, centrifugation 
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steps did not exceed 80,000g and therefore it cannot be ruled out whether a fraction of 
the protein-bound miRNAs in the perfusate supernatant was derived from exosomes. 
Several other limitations should be considered in the present study. Firstly, the num-
ber of liver transplantations performed by our center annually hampers the validation of 
miRNA performance to predict ITBL in an independent cohort in short term. The sample 
size of our study was however sufficient to validate our findings in a sub analysis of DCD 
and DBD grafts. Secondly, the median recipient follow-up for 17 months is relatively 
short, since other groups have described different clinical presentations of ITBL varying 
from early onset to late onset up to 18 years after transplantation[3, 6]. The vast major-
ity of ITBL however occur within the first year after transplantation[6, 7, 43], which was 
also the case in the present study. Thirdly, wedge biopsies that were used in this study 
were taken from the periphery of the liver and were used to compare expression of 
miRNAs in tissue with their levels in perfusates. It can be argued that biopsies do not 
reflect ischemic bile duct injury adequately, since ITBL is usually more prominent in the 
center of the liver[43]. As argued earlier, we therefore strongly believe that particularly 
for ITBL, perfusates are more representative than random biopsies, taken from either the 
center of the liver or from the periphery. It should be emphasized that for the present 
study, analysis was performed on perfusates that were obtained after the second flush 
of the graft with human albumin solution, during the back-table procedure. The use 
of these second flush perfusates implies that a considerable amount of miRNAs that 
were released during graft preservation might be lost for analysis during the first flush. 
Therefore, miRNA levels in the perfusate after the second flush might only represent the 
release of miRNAs at the end of cold storage, rather than their release during the entire 
preservation procedure. However, analysis on miRNA levels in perfusates obtained from 
the first flush provided similar trends in HDmiR/CDmiR ratios between ITBL and non-
ITBL groups, though their discriminative power was less pronounced (data not shown). 
Finally, our study included only a limited number of CDmiRs and thereby possibly 
overlooks other miRNAs which could indicate biliary injury or predict ITBL even more 
sensitively. As shown in fig. 3, extensive overlap in HDmiR/CDmiR levels exists between 
ITBL and non-ITBL groups, which might be detrimental for assessing graft quality on an 
individual level. More sensitive and specific CDmiRs could be identified by MicroRNA 
geneArray analysis. Sclerosing and tapering of the biliary tree in the pathophysiology of 
ITBL however complicates the application of accurate techniques for miRNA isolation, 
like laser capture micro dissection from bile duct tissue. Therefore, we are currently at-
tempting genome-wide miRNA gene array analysis on perfusate samples, though rela-
tive low RNA yields render this procedure technically challenging. Preliminary results 
from our ongoing research however do confirm that the CDmiRs investigated in this 
study are up to eight-fold higher in common bile duct tissue compared to liver tissue, 
while expression of HDmiRs is almost zero (data not shown). 
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In conclusion, this study demonstrates that differential release of CDmiRs during graft 
preservation is associated with biliary injury and predictive for the development of ITBL 
after liver transplantation. Our findings provide new possibilities to assess graft quality 
prior to transplantation, though future research is warranted to unravel the true merits 
of miRNAs in predicting or preventing the development of ITBL after liver transplanta-
tion.
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suPPlementary information
materials anD metHoDs
study design 
In this longitudinal cohort study, perfusates and paired liver tissue biopsies were col-
lected prospectively during liver transplantations from adult recipients between April 
2010 and March 2012 at the Erasmus University Medical Center, Rotterdam. Available 
perfusates and biopsies were retrospectively analyzed for the presence of two HD-
miRs (HDmiR-122 and HDmiR-148a) and three CDmiRs (CDmiR-30e, CDmiR-222 and 
CDmiR296). The selection of these particular miRNAs was based on microarray data 
from literature[1]. Through RT-qPCR, we confirmed that expression of CDmiRs are up 
to eight-fold higher in choledochus tissue compared to expression in liver tissue, while 
HDmiR levels are almost zero (preliminary results, data not shown). Levels of miRNAs in 
graft perfusates from grafts that developed ITBL and grafts that did not develop biliary 
strictures after liver transplantation were compared. 
Definition of itbl
Ischemic-type biliary lesions were defined as (i) symptomatic strictures and associated 
dilatation of the intrahepatic or hilar bile duct(s) after liver transplantation, which (ii) 
were confirmed by cholangiography and in the presence of a patent hepatic artery 
as demonstrated by Doppler ultrasonography, and (iii) which required endoscopic or 
percutaneous interventions of the biliary system or liver retransplantation in recipients. 
Imaging was reviewed by both a transplant hepatologist (HJM) and a transplant surgeon 
(GK) who were blinded to the presence of miRNAs in perfusates. Transplant recipients 
without biliary complications during follow-up were defined as non-ITBL. Time to event 
was calculated from the date of liver transplantation until the date of intervention as-
sociated with ITBL (i.e. biliary stenting by ERCP and/or bile drainage by PTC). Donor and 
recipient characteristics and clinical parameters were obtained from the liver transplan-
tation database of the institution. The Medical Ethical Committee of the Erasmus MC 
approved the use of donor materials and all patients provided informed consent for the 
use of clinical information for medical research. 
sample collection and processing 
Perfusate samples were obtained during the back-table procedure. After a standard 
in situ perfusion of the liver with University of Wisconsin solution (Viaspan, Duramed 
Pharm Inc, Pomona, NY) or Histidine-tryptophan-ketoglutarate (Custodiol HTK, Essential 
Pharmaceuticals, LLC, Pennsylvania, USA ), liver grafts were procured and transported 
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to our center. Upon arrival at the operating room, an additional ex situ perfusion of the 
portal venous system of the graft was performed with 1000 ml of UW or HTK depending 
on the preservation fluid initially used during harvesting. This was followed by flush-
ing with 500 ml of human albumin solution (Albuman human albumin 40g/l, Sanquin, 
The Netherlands) just prior to implantation of the graft. Flushing was performed under 
normal hydrostatic pressure. Perfusates were collected directly after the second flush 
with albumin and cold stored at -4°C until further processing. Paired biopsies, consisting 
of wedges of liver tissue obtained from the anterior side of the left lateral segment of 
the liver graft, were taken at the end of the cold ischemia time and directly snap-frozen 
for storage at -80°C.
rna isolation 
Graft perfusates were cleared of cells and cell debris by a first centrifugation (445g at 
4°C for 15 minutes) and a second centrifugation of 10 ml supernatant at 3,166g at 4°C 
for 15 min. In order to optimize signaling for RT-qPCR on lower abundant miRNAs, cell-
free perfusate samples were concentrated with a 100 kD Amicon filter (supplementary 
fig. 1); Of cell-free perfusates, 3 mL was centrifuged at 3,166g at 4°C for 30 minutes, 
obtaining a volume of supernatant of approximately 750 μl. Total RNA was extracted 
from 100 μl concentrated supernatant perfusate by adding 1.5 ml of Qiazol Lysis reagent 
to homogenize samples. Chloroform (300 μl) was added, and after centrifugation (15 
minutes at 20,817g) an aqueous RNA-containing layer of 700 μl was obtained, which was 
further processed according to the manufacturer’s protocol (Qiagen, Hilden, Germany). 
Extraction of total RNA from liver biopsies (approximately 10 mg of tissue per biopsy) 
was performed following the manufacturer’s instructions and normalized to a concen-
tration of 50 ng/7.5 μl, using a NanoDrop 2000 spectrophotometer (Thermo Scientific, 
Waltham, Ma, USA).
reverse transcription and real-time polymerase chain reaction (rt-PCr)
After RNA isolation, sample-specific cDNA was prepared using the Taqman microRNA 
Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). In a modified proto-
col, every multiplex cDNA reaction consisted of 0.4 μl dNTP mix, 1.35 μl Multiscribe RT 
enzyme, 2.0 μl 10x RT Buffer, 0.25 μl RNase inhibitor, 1.0 μl of each RT primer, and 7.5 μl 
of diluted template RNA. The total reaction volume was adjusted to 20 μl with nuclease 
free water. The sequences of the primers used for RT-PCR are summarized in table 1. All 
cDNA and PCR reactions were performed according to the manufacturer’s instructions 
and carried out in duplicate. Each PCR reaction consisted of 10 μl TaqMan Universal PCR 
Master Mix, 0.5 μl microRNA-specific PCR primer (Applied Biosystems) and 5.0 μl of the 
previously 1:10 diluted cDNA. The final volume of every PCR reaction was adjusted to 20 
μl with nuclease-free water. 
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Because of the lack of a detectable conventional reference gene, relative perfusate 
miRNA levels were calculated by threshold cycle values (2-Ct) and normalized by setting 
their total at 100% to correct for any differences in perfusate concentration. Subse-
quently, ratios of HDmiRs/CDmiRs in graft perfusate were determined. In tissue biopsies, 
relative miRNA levels were normalized by a reference gene, RNU43 (2-ΔCt). 
microrna stability and fractionation 
MicroRNA stability was assessed by measuring miRNA degradation in graft perfusates 
over time. From three liver transplantations, samples of 400 μl cell-free graft perfusate 
were incubated at room temperature and total RNA was extracted at scheduled time 
points after incubation, varying from 0 to 24 hours. Samples were spiked with 40 μl of 
synthetic Caenorhabditis elegans miR-39 (cel-miR-39) to investigate nuclease activity 
and to test for exogenous miRNA stability.  After isolating RNA using previously de-
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supplementary figure 1. Concentration of perfusates improves mirna detection. Perfusate samples 
obtained from n=3 different liver transplantations were cleared from cells by centrifugation. Of the cell-free 
perfusate, 3 mL was concentrated by 100 kD Amicon Ultra filters. After concentration, 100 µL of the super-
natant and 100 µL of the flow-through were used for miRNA isolation and to test for respectively increased 
signaling in the supernatant and the amount of miRNAs passing the 100 kD filter. Compared to paired 
non-concentrated perfusate samples, miRNA detection was two to four-fold higher after concentration. 
The fraction of miRNAs in the flow-through that passed the filter was less than 5%, suggesting that most 
miRNAs in perfusates are bound to (protein) complexes ≥100 kD.
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scribed methods, relative levels of HDmiRs and CDmiRs were determined. To investigate 
the location of released miRNAs in graft perfusate, separate cell and subcellular fractions 
were prepared by sequential centrifugation steps (fig. 2a). For this, 50 ml fresh unpro-
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supplementary figure 2. expression of HDmirs and CDmirs in liver biopsies. Comparison of HDmiRs, 
CDmiRs, and HDmiR/CDmiR ratios in liver biopsies of grafts that did (n=6) or did not (n=18) develop ITBL. 
Tissue miRNA levels were determent by RT-qPCR and normalized to the RNU43 reference RNA. (A) Both 
HDmiRs and CDmiRs showed no significant differences in expression in biopsies of ITBL or non-ITBL grafts. 
(B) HDmiR/CDmiR ratios were also not significantly different between ITBL or non-ITBL grafts. Shown are the 
median ± interquartile ranges of normalized miRNA expression.
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cessed (and non-concentrated) perfusate was centrifuged for 10 minutes at 1,000g to 
pellet intact cells. A second centrifugation step of 20,000g for 20 minutes was performed 
to obtain a pellet with nuclei, cytoskeletons, and other organelles. A final centrifugation 
for 1 hour at 80,000g was performed to spin down small vesicles and exosomes. The 
remaining supernatant contained miRNA fractions associated with protein complexes, 
ribosomes and large macromolecules. RNA was extracted from each pellet fraction and 
400 μl of the final supernatant; miRNA levels were quantified as a percentage of the total 
of HDmiRs and CDmiRs in a sample. The percentage of miRNAs bound to protein com-
plexes was determined by adding 1600 μl acetone to 400 μl supernatant of perfusate. 
After one hour at -20oC, the supernatant was centrifuged for 10 minutes at 15,000g at 
4oC. The remaining pellet was air-dried and dissolved in 700 μl Qiazol. The acetone was 
evaporated from the solution and further dissolved in 700 μl Qiazol. MicroRNAs in these 
protein fractions were isolated and measured using previously described methods. 
statistical analysis 
Statistical analysis was performed using SPSS statistics 20 (SPSS Inc, Chicago, IL, USA) 
and SAS 9.2 PROC GENMOD (SAS institute, Cary, NC). Correlations were estimated using 
Spearman’s Rank correlation test. Group comparisons were performed using Mann-
Whitney U tests for continuous data and log-rank tests for categorical data. C-statistics 
were calculated to test for discriminative power. Prediction analyses were constructed 
through Cox proportional hazards regression analysis. P-values smaller than 0.05 were 
considered significant.
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To the editor, 
Ischemic-type biliary lesions (ITBL) are a major complication after liver transplantation 
(LT), which can lead to severe obstructive jaundice in recipients and impaired graft 
survival. Previously, we showed the potential of extracellular microRNA (miRNA) profiles 
in flush-outs of preservation solutions, so called perfusates, to predict the develop-
ment of ITBL after LT[1]. We demonstrated that particularly the ratio of hepatocyte and 
cholangiocyte-derived miRNAs (HDmiRs/CDmiRs) was predictive for the development 
of ITBL. As a follow-up to our previous study, here we would shortly like to elucidate on 
new means to further optimize detection of miRNAs  in perfusates and improve their 
accuracy as biomarkers. 
Recently, Plieskatt et al.[2] showed the inhibitory effects of heparin on the quantifica-
tion of circulating miRNAs by reverse-transcriptase quantitative polymerase chain reac-
tion (RT-qPCR). These inhibitory effects could be best negated by treating RNA samples 
with heparinase I during the RT-step. In the setting of liver transplantation, in our center 
graft procurement in the donor is performed with a standard amount of approximately 
30,000 IU heparin. Directly following organ retrieval, the graft is thoroughly flushed 
with preservation solution, which is repeated at the end of cold storage. Because of the 
strong connection with endothelial cells[3], traces of heparin might still be present in 
the liver even after multiple flushes with preservation solution. Therefore, it remained 
unknown whether perfusates at the end of cold storage contain heparin and whether 
the amount of heparin would be sufficient to interfere with RT-qPCR detection of miR-
NAs. To investigate this, we tested the presence of heparin by re-evaluating our earlier 
analysis of miRNA profiles in graft perfusates after treating samples with heparinase 
I. To do so, specific cDNA for HDmiR-122, HDmiR-148a, CDmiR-222, and CDmiR-296 
was synthesized in the presence of 6 IU of heparinase I. A synthetic C.elegans miRNA 
(Cel-miR-39) was added as an internal control for sample variation during the RT step. 
Relative expression levels were calculated and normalized for Cel-miR-39 levels. 
Heparinase I treatment improved detection of miRNAs in all perfusates (n=57). As 
shown by fig. 1a, the median decrease in Ct-value by qPCR was 1.15 for HDmiR-122 
(IQR: 0.31-2.46), 2.65 for HDmiR-148a (IQR: 2.13-4.90), 1.28 for CDmiR-222 (IQR: 0.82-
2.07) and 1.50 for CDmiR-296 (IQR: 0.58-3.38). The decrease in Ct-values after heparinase 
I treatment was significantly stronger for HDmiR-148a compared to the other miRNAs. 
This could be explained by the low detection levels of HDmiR-148a before heparinase I 
treatment, which was even >35 Ct in a small number of samples. Heparinase I treatment 
also effected the ratios between HDmiR-148a/CDmiR-222 and HDmiR-148a/CDmiR-296, 
which significantly increased after heparinase I treatment (fig. 1b).    
Out of the 57 patients included for this study, n=22 developed ITBL and n=35 re-
mained free from biliary complications. After heparinase I treatment, the ratio between 
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HDmiRs/CDmiRs remained higher in perfusates obtained from grafts that developed 
ITBL compared to the non-ITBL group (fig. 1C, P≤0.012). This distribution of perfusate 
HDmiR/CDmiR ratios between ITBL and non-ITBL grafts was almost identical to that ob-
served without heparinase I treatment. However, the re-evaluation of the cox-regression 
analysis on the heparinase I treated samples showed that ratios of HDmiRs/CDmiRs 
became a stronger predictor for ITBL (fig. 1D). Furthermore, ratios between HDmiR-122 
and CDmiRs also appeared to be independent predictors, which was not the case in 
our already published results. The incidence of ITBL was up to six-fold higher in grafts 
with high HDmiR/CDmiR ratios (fig. 1e-g). In grafts donated after brain death (DBD), 
HDmiR-148a/CDmiR-296 had a high negative predictive value of 88%. In grafts donated 
after circulatory death (DCD), in particular HDmiR-122/CDmiR-296 had high positive 
predictive value (90%).  
These findings show that some perfusate samples can be contaminated with traces 
of heparin that are sufficient to inhibit miRNA detection. This inhibitory effect can how-
ever effectively be counteracted by treating isolates of perfusate RNA with heparinase 
I during the RT-step in qPCR analysis. Therefore, we would like to emphasize that in 
PCR-based biomarker research, one should always take into account the possibility of 
inhibitory components like heparin. For future applications of miRNAs as biomarker, HD-
miRs and CDmiRs may provide valuable predictive information. Thus, with the growing 
interest in the use of machine perfusion and assessment of graft quality, counteracting 
the interference of heparin in perfusate must be reckoned with[4, 5].
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figure 1. (A) After heparinase I treatment, the median decrease in Ct-level was stronger in HDmiR-148a 
compared to other miRNAs. (B) Ratios of HDmiR-122/CDmiR-222 and HDmiR-122/CDmiR-296 were not 
significantly changed by heparinase I treatment. However, due to the stronger effect of heparinase I on 
HDmiR-148a, ratios of HDmiR-148a/CDmiR-222 and HDmiR-148a/CDmiR-296 increased. (C) Increased ra-
tios of HDmiRs/CDmiRs in perfusates from grafts that developed ITBL compared to those that remained 
free from biliary complications after heparinase I treatment. The distribution between the two groups was 
almost identical to samples that were non-heparinase treated samples (data not shown). (D) Heparinase I 
treatment further strengthened miRNA ratios as independent predictor of ITBL. (E-G) Increased incidence 
of ITBL in grafts with high HDmiR/CDmiR ratios in perfusate. *** P<0.001.
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abstraCt 
MicroRNAs (miRNAs) have emerged as promising biomarkers due to their association 
with cell stress and diseases and their easy detection and stability in many body fluids. 
Because of the sensitivity, the method of choice to detect miRNAs is quantitative reverse 
transcribed quantitative polymerase chain reaction (RT-qPCR). Therapeutics, in particu-
lar circulating anti-coagulants, are notorious for their inhibitory effect on RT-qPCR-based 
measurements. The effect of heparin contamination on inhibition of RT-qPCR on miRNAs 
isolated from urine has, however, never been investigated. We obtained urine samples 
from healthy controls and from heparinized patients undergoing major surgery (live 
kidney donation or liver transplantation) (n=27). Samples were spiked with synthetic 
miRNAs to monitor RNA loss during work-up and levels of endogenous and spiked-in 
miRNAs were quantified by RT-qPCR. We showed that endogenous miRNAs in urine were 
protected from degradation but levels differed substantially within surgery groups. Vari-
ability in detection levels of spiked-in miRNAs was low in non-hospitalized controls, but 
was high in both surgery groups, and the difference in miRNA levels correlated well with 
the heparin concentration in urinary samples. Treatment of urinary RNA with heparinase 
I during RT-qPCR strongly reduced this variation in a dose dependent manner. Hepari-
nase I should therefore be considered as standard step for detection of miRNA in urine 
from hospitalized individuals.
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introDuCtion
MicroRNAs (miRNAs) are small RNA molecules of approximately 19-23 nucleotides 
in length that play an important role in the regulation of gene expression.[1]  As an 
estimated 30-60% of all genes are post-transcriptionally regulated by these molecules 
and the possibility of sensitive quantification, miRNAs have a favorable position as 
biomarker for many diseases and physiological processes.[2] Two important prerequi-
sites for a molecule to be considered as a biomarker for routine applications, being (i) 
ease of attainment, and (ii) stability during sample isolation, storage, and subsequent 
processing for analysis, apply to miRNAs. Although the majority of miRNAs are located 
intracellularly, a significant amount of miRNAs are released from cells into body fluids 
like blood, lymph, saliva, bile and urine.[3] These extracellular miRNAs also remain stable 
in environments like bile and graft preservation solution,[4, 5] despite high RNAse and 
protease activity present in these liquids. Due to non-invasive sampling and stability, 
urinary miRNAs can also be considered an excellent source for biomarker identification.
[6] This has been acknowledged for various medical fields like urology, nephrology, and 
oncology of the urinary tract. Recent data show that urinary miRNAs are also discrimi-
native in systemic diseases and malignancies, expanding the potential applications of 
urinary miRNAs as biomarker.[7, 8] 
Polymerase chain reaction (PCR) and reverse transcription (RT) are among the most 
powerful tools in molecular biology and frequently used for detection of diagnostic and 
prognostic DNA and RNA biomarkers. Though sequence specific amplification through 
PCR improves miRNA detection, some factors can actually inhibit this molecular approach 
and thus interfere with detection. The existence of RT-qPCR inhibiting components 
have been described decades before the invention of PCR and this technique became 
a common practice in RNA quantification and DNA amplification.[9, 10] The currently 
known RT-qPCR inhibitors represent a very diverse group of chemical substances, both 
organic and inorganic, with different modes of action. They can interfere with sample 
processing, nucleotide extraction, substrate and enzyme degradation, or polymerase 
inhibition.[11]
In the clinical setting, therapeutics are considered one of the main concerns for PCR 
inhibition. Particularly anticoagulants often administered during hospital stay or used in 
plasma sampling are notorious PCR inhibitors.[12-14] Recently, Boeckel et al. described 
the inhibitory effect of heparin on the amplification of miRNA in human blood samples 
to be dose dependent with complete inhibition occurring at levels as low as 2x10-5 IU/
µl.[15]  Heparin is a highly sulfated disaccharide polymer ranging in weight from 3-30 
kDa. Two distinct mechanisms are known for eliminating heparins from the circulation, 
which depends on the size and concentration of molecules: i) The reticuloendothelial 
system for high doses of unfractionated heparin (UH) and ii) renal clearance for lower 
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doses of UH and low molecular weight heparins (LMWH).[16] Urinary excretion of UH 
and LMWH after systemic administration is well documented and the remaining antico-
agulant activity well characterized.[17-19] However, to what extend these degradation 
products can interfere in the non-invasive measurement of biomarkers such as miRNAs 
has not been documented. 
The aim of the current study was to investigate the excretion of LMWH and UH into 
urine and determine their effects on miRNA detection levels by RT-qPCR. Subsequently, 
we examined the effectiveness of heparinase I digestion to restore detection of urinary 
miRNA.
materials anD metHoDs
Drugs and reagents
All reagents used were laboratory grade and pharmaceuticals were in-house manu-
factured by  the hospital pharmacy (UH 500 IU/mL; protamine-sulfate 1000 IU/mL) or 
clinical grade, commercially available, LMWH (Fraxiparine® (GlaxoSmithKline, Zeist, The 
Netherlands)).
Patient and healthy control characteristics
Urine samples were obtained from the following groups: Post-surgically from liver 
transplant recipients that were heparinized prior to (heparinized, n=10) or after urine 
collection (non-heparinized, n=9) and who were operated between March 1st 2014 and 
March 1st 2015; Pre-surgically from healthy, heparinized kidney donors prior to surgery 
between June 1st 2009 and July 1st 2010 (n=10); From volunteering healthy controls 
(n=6). Seven combined urine and kidney biopsy samples were obtained between 21st 
January and February 19th of 2015 as part of the PROTECT Trial (NTR3663). Collection 
and use of urine and biopsy material from hospitalized individuals was approved by 
the Medical Ethical Council of the Erasmus MC and all participants provided informed 
consent  for the use of these materials for medical research. Baseline characteristics are 
presented in table 1. 
sample preparation and storage
Urine was obtained from liver transplant recipients within 24 hours after transplantation 
while on the intensive care unit, directly from a urinary catheter in a vacutainer without 
additives (Becton-Dickenson, Breda, the Netherlands). Urine from live kidney donors 
was collected the morning prior to kidney donation. Urine from healthy individuals was 
first-morning urine. Samples were cleared from large fragments and cells by centrifuga-
tion for 15 min 3,200g at  4°C and subsequently stored at -20 °C or -80°C until further use. 
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rna isolation
Total RNA was isolated from urine using the Qiagen miRNeasy kit as described by the 
manufacturer with some minor modifications (Qiagen, Venlo, The Netherlands). In short, 
200 µL cell-free urine was lysed using 1400 µL Qiazol. After adding 280 µL chloroform, 
samples were  centrifuged for 15 min at 12000xg at 4°C. Subsequently, 800 µL of the 
aqueous layer was used for further processing. RNA was eluted from the column with 30 
µL RNAse-free water and stored at -80°C. Urine samples were spiked with 200 amol of 
artificial Caenorhabditis elegans miR-39 (Cel-miR-39) and miR-238 (Cel-miR-238) (Sigma 
Aldrich, Zwijndrecht, The Netherlands) during the lysis procedure or Cel-miR-54 during 
table 1. Baseline characteristics.
    Healthy controls Liver transplant recipients  
   
No heparin 
(n=6)
Heparinized 
(n=10)
No heparin 
(n=9)
Heparinized 
(n=10)
p value*
Median age (IQR) 45.9 (35.5-48.7) 58.8 (42.8-62.6) 56.4 (51.9-58.8) 47.5 (30.0-59.2)  n.s.
Sex          
  Male (%) 3 (50) 7 (70) 8 (89) 7 (70)  n.s.
  Female (%) 3 (50) 3 (30) 1 (11) 3 (30)  
             
heparinized individuals#          
  LMWH 0 10 0 7  
  UH 0 0 0 5  
liver function          
 
median Alk. Phos. 
(IQR)
ND 75.5 (68.75-94.5) 54 (37-143) 104 (67.75-157.25)  n.s.
  median γGT (IQR) ND 22 (20.25-31.25)
59 (23.35-
113.25)
68 (47.75-163.25) 0.0098
  median AST (IQR) ND 23.5 (18.5-32.25)
304 (232.5-
697.75)
757.5 (411-895.75) <0.0001
  median ALT (IQR) ND 20.5 (17.5-22.5)
350 (264.5-
545.25)
640 (354-915.25) <0.0001
  median PT-INR (IQR) ND ND 1.6 (1.6-1.9) 1.95 (1.8-2.88)  n.s.
renal function          
 
median serum urea 
(IQR)
ND 5.4 (4.73-5.83) 10.8 (8.9-13) 13.25 (8-17.85) 0.0001
 
median serum creat. 
(IQR)
ND 75.5 (66.75-81.5) 110 (66-136) 97.5 (67.5-117.5) n.s. 
*:p-values are determined by a 1-way ANOVA between 3 or more groups. For PT-INR a non-parametric t-test 
was used
#: 2 Liver transplant recipients received both LMWH and UH prior to surgery
ND: Not Measured. N.s.: not significant
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cDNA synthesis from biopsy material. When required, RNA concentrations were deter-
mined using a BioAnalyzer 2100 (Agilent Technologies, Middelburg, the Netherlands).
Heparinase i treatment
5 µL of isolated total RNA was added to a reaction mixture consisting of 6 IU Heparinase 
I (New England Biolabs, Ipswich, MA) in 2.5 µL with RNAse-free water. Heparinase I was 
co-incubated during the RT step for cDNA synthesis as described hereafter. 
reverse transcriptase and quantitative real-time polymerase chain reaction
cDNA was synthesized using the Taqman microRNA Reverse Transcription Kit (Applied 
Biosystems/Life technologies, Carlsbad, CA) as described previously[5], using 5 µL of iso-
lated total RNA. cDNA was diluted to 100 µL with water and stored at -20°C. PCR reactions 
were conducted on a Applied Biosystems StepONE plus real-time PCR machine (Applied 
Biosystems) according to the manufacturer’s guidelines with 45 cycles of amplification. 
Reactions consist of 6 µL Taqman Universal PCR Master mix (Life technologies), 0.5 µL 
miRNA specific primer, 0.5 µL sterile milliQ water and 5 µL of diluted cDNA. Threshold 
levels were manually set at 0.25 for all microRNA assays, and the upper Cq limit for reli-
able detection was set at 35 cycles.
Colorimetric heparine assay
UH and LMWH content in urine was determined using a chromogenic anti Xa-activity 
assay[20] according to the manufacturer’s instructions (HemosIL™ liquid heparin test kit, 
Instrumentation Laboratory, Breda, The Netherlands) on a Sysmex CS5100 coagulation 
analyzer (Siemens, the Hague, the Netherlands)  with minor adjustments. The presence 
of antithrombin and plasma proteins was assured by diluting the cell-free urine with an 
equal volume of normal plasma prior to the assay.
statistical analysis
Statistical analysis was performed using Graphpad Prism 5.0 (Graphpad Software, San 
Diego, CA). Spearman’s Rank Correlation Test was used to generate correlation results. 
Group comparisons were analyzed using the Wilcoxon matched pair test or Mann-
Whitney U-test for non-paired samples. p-values <0.05 were considered significant.
results
stability of mirnas in urine
Since stability during storage and isolation is an essential prerequisite for a good biomarker, 
we set out to determine whether extracellular miRNAs in urine remained present and were 
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not degraded. Urine samples from three healthy controls with adequate detection levels 
of miRNA-30e were spiked with 0.2 fmol of synthetic Cel-miR-39, and incubated at 37°C for 
0, 7, 15, 60, 240 and 1440 minutes. After isolation, total RNA samples were analyzed for the 
variation in detection levels of  endogenous miRNA miR-30e and the synthetic, spiked-in 
miRNA Cel-miR-39. As shown in fig. 1, the endogenous miR-30e remained stable with 
levels of approximately 60% compared to baseline still detectable after 24 hours. The 
spiked-in Cel-miR-39, on the other hand, showed a strong decrease with levels dropping 
to less than 1% compared to baseline already after 7 minutes of incubation. 
Detection of endogenous and spiked-in mirnas in urine of heparinized and 
non-heparinized individuals
Five different miRNAs that were described in literature as being present in urine of 
healthy individuals as well as patients with acute kidney injury (miR-18a, -30e, -92a, 
-155, and -637), were selected for further analysis in our study cohorts. These miRNAs 
showed less than five-fold difference between healthy controls and patients, Cq values 
did not exceed 32, and no false melting curves were present in any of the samples.[21] 
Out of these five miRNAs, miR-30e and miR-92a were selected because only these two 
miRNAs were detectable in most of the urine samples used in this study. As shown in 
fig. 2a, Median (IQR) Cq values in urine were 29.53 (28.84-30.65) and 31.51 (31.03-32.8) 
for miR-30e and miR-92a, respectively, but were significantly higher in the heparinized 
group as compared to the non-heparinized group (p≤0.001) with median values (IQR) of 
32.32 (31.01-34.11) and 34.70 (32.88-36.19). This observation was further supported and 
substantiated when the same urine samples were spiked with synthetic Cel-miR-39 and 
miR-238. RT-qPCR for these synthetic miRNAs resulted in median Cq values (IQR) in the 
non-heparinized group of 24.88 (24.13-25.11) and 26.6 (25.06-26.75) for Cel-miR-39 and 
Cel-miR-238, respectively but in the heparinized group results were 28.43 (26.49-28.90) 
and 30.16 (27.01-30.09) (p<0.001, fig. 2b). 
figure 1. stability of endogenous 
mirnas in urine.  Mean stability of 
endogenous miRNA miR-30e (closed 
circles) and spiked-in Cel-miR-39 
(open circles) of healthy control sam-
ples (n=3) after increasing incubation 
times at 37°C.
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Heparin is a potent inhibitor of rt-qPCr analysis in urinary rna samples and 
can be counteracted using heparinase i
To confirm that heparin is indeed able to inhibit RT-qPCR analysis of urine samples, we add-
ed increasing amounts of UH and LMWH to urine of a healthy, not-heparinized individual, 
as well as 50 amol Cel-miR-39 during lysis. Isolated RNA was analyzed for both spiked-in 
miRNA Cel-miR-39. PCR levels without anticoagulants were set at 100%. Concentrations of 
0.01 IU UH/ml urine or higher were sufficient to completely inhibit RT-qPCR (fig. 3a). 
Heparinase I is a bacterial enzyme able to degrade approximately 80% of highly-
sulfated disaccharides polymers. This enzyme has recently been re-established as a 
potential treatment to counteract RT-qPCR inhibition in the analysis of miRNA in plasma.
[15, 22] To develop more general standards and optimize incubation conditions for RNA 
isolated from urine, heparinase I was added in different concentrations during cDNA 
synthesis. The effect of heparinase I treatment was assessed using the PCR results from 
spiked-in miRNA Cel-miR-39 and the endogenous miRNAs miR-30e and miR-92a. Five 
µl of total RNA, isolated from urine of two individuals that displayed high levels of  RT-
PCR inhibition, were co-incubated with variable amounts of heparinase I, and Cq values 
were converted to percentages relative to the co-incubation with 12 IU of heparinase I. 
Twelve IU of heparinase I is considered the optimal amount during co-incubation in RNA 
isolated from plasma.[22] However, non-linear fitting of the data showed that for RNA 
isolated from urine, co-incubation of 6 IU of heparinase I is already sufficient to reduce 
the inhibiting effect of heparin in RT-qPCR analysis of urinary RNA (fig. 3b).
A B
figure 2. Variation in spike-in and endogenous mirna detection. RT-qPCR results of endogenous miR-
30e and miR-92a (A) and of spiked-in Cel-miR-39 and miR-238 (B) presented as Cq values in non-heparin-
ized individuals (closed circles), and heparinized individuals (closed squares).  Bars indicate median with 
interquartile range. *** p<0.001.
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Variation in urinary mirna detection of heparinized individuals is strongly 
reduced  after heparinase i treatment
To validate the effect of heparinase I treatment in our cohorts, RNA samples from heparin-
ized (n=20) and non-heparinized individuals (n=15) were co-incubated with or without 
6 IU of heparinase I during cDNA.  Subsequently,  qPCR was performed for Cel-miR-39, 
miR-30e and miR-92a (fig. 3C). For Cel-miR-39,  detection levels in the non-heparinized 
group did not improve after heparinase I treatment (fig. 3C, left panel). Similar results 
were observed for miR-30e and miR-92a in the non-heparinized individuals (fig. 3C, 
middle and right panel, respectively). For the group of combined heparinized individu-
als, however, levels of detection improved significantly after treatment with heparinase 
I and the range in Cq values was strongly decreased with approximately 4 to 7 cycles 
(fig. 3C, left panel). For the endogenous miRNAs miR-30e and miR-92a, the Cq range 
was not so much reduced using heparinase I, but overall Cq values were lowered signifi-
cantly. As a result these samples ended well within the more reliable detection range 
(fig. 3C, middle and right panel, respectively).  When not treated with heparinase I, 
8 samples gave results for miR-92a that were above the upper limit of detection that 
we considered as reliable (cut-off at Cq≤35). After heparinase I treatment, only 2 out of 
these 7 remained above the limit of detection (fig. 3C, right panel). Treatment of RNA 
samples with 6 IU of heparinase I for 1 hr at 30°C prior to cDNA synthesis did not further 
improve PCR results (data not shown).
Diagnostic measurement of heparin in urine and correlation with rt-qPCr 
inhibition
Depending on the molecular size and dosage of the molecule, heparin is removed from 
the body via two distinct mechanisms, of which renal clearance is the most prominent 
route.[16] To confirm the presence of UH and LMWH in urine, a chromogenic assay, 
developed by Larsen et al. to monitor heparin in plasma,[23] was modified and used to 
measure heparin in urine of 11 hospitalized individuals. The urine samples were ranked, 
based on the heparin concentration (fig. 3D, black bars) indicating that  this assay 
shows high potential to detect heparin in other fluids then plasma. When compared 
with the inhibition of RT-qPCR in three different miRNA assays (fig. 3D, white bars) 
we show that the concentration of LMWH in urine correlated well with the degree of 
inhibition of miRNA levels by RT-qPCR (fig. 3e). These results demonstrate the relation 
between presence of heparin in urine and its inhibitory effects on RT-qPCR. 
Protamine-sulfate is not applicable as a heparin antagonist for in vitro studies
As sample contamination with heparin clearly obscures RT-qPCR results, the use of a 
heparin antidote during analysis is essential. Heparinase I is only able to cleave a specific 
substrate, the2-O-sulfo-α-L-iduronic acid/2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-
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figure 3. Heparin inhibits rt-qPCr analysis in urinary mirna samples in a dose-dependent manner 
and can be neutralized with 6 iu heparinase i. (A) RT-qPCR inhibition of 50 amol synthetic Cel-miR-39 
at increasing amounts of unfractionated heparin (UH) and nadroparin (LMWH). PCR levels without antico-
agulants were set at 100%. Values represent the  mean ± SD. (B) Minimally required amount of  heparinase 
I to reach a plateau of RT-qPCR improvement. Cq levels were converted to miRNA expression levels for Cel-
miR-39, miR-30e, and miR-92a. Data were obtained from two LMWH contaminated urinary RNA samples. 
Results obtained with 12 IU heparinase I were set to 100%. Data points represent the  mean ± SD . (C) Effect 
of co-incubation with (+) or without (-) 6 IU heparinase I during cDNA synthesis in the non-heparinized 
group (n=15) and heparinized group (n=20). Left panel shows the effect of heparinase I on detection of 
the spiked-in Cel-miR-39, middle panel the effect on endogenous miR-30e, and the right panel on miR-92a. 
** p<0.01, *** p<0.001. (D) LMWH concentration (IU LMWH/ml) (closed bars) and  average RT-PCR inhibi-
tion (open bars) in eleven urine samples (1-11). (E) Correlation analysis between LMWH concentration and 
the average ΔCq.  ΔCq was calculated as the difference in Cq values with or without treatment with 6 IU 
heparinase I.
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sulfate disaccharide bond leaving other bonds unaffected. Protamine-sulfate is clinically 
available to counteract the (adverse) effects of anticoagulants. To investigate the applica-
tion of protamine-sulfate in vitro,  the effect on LMWH-induced RT-qPCR inhibition was 
determined for the spiked-in synthetic Cel-miR-238. Protamine-sulfate treatment was 
either applied prior to the RNA isolation procedure, (fig. 4, a-D), or directly mixed with 
the synthetic Cel-miR-238 and LMWH to test the application in isolated RNA (fig. 4, e-H). 
For the samples A-D, 50 amol of Cel-miR-238 was mixed with the indicated amounts of 
LMWH and protamine sulfate, and the miRNAs were subsequently isolated using the miR-
Neasy isolation kit. The sample without the addition of LMWH and protamine (fig. 4, a), 
displayed a normal detection of the Cel-miR-238, whereas Cel-miR-238 was not detectable 
in samples that contained LMWH (fig. 4, b-C). The results of this experiment showed that 
protamine-sulfate is not able to neutralize LMWH prior to RNA isolation, even when pres-
ent in excess amount (fig. 4, C). Protamine-sulfate alone, present prior to isolation of RNA, 
had no effect on  the detection of Cel-miR-238 (fig. 4, D). However, protamine-sulfate is a 
highly basic, low molecular weight protein and therefore, lack of heparin inhibition could 
also be caused by reversing the ion pair formation of protamine with LMWH during the 
RNA isolation procedure. To determine if protamine-sulfate is useful in neutralizing LMWH 
during the actual RT-qPCR procedure, 50 amol of Cel-miR-238 was reverse transcribed and 
amplified in the presence or absence of LMWH and protamine-sulfate (fig. 4, e-f). Only 
when present in equal amount of units, protamine-sulfate was capable of neutralizing the 
inhibitory effect of LMWH (fig. 4, e). Non-equal amounts (fig. 4, g), but also the presence 
of only protamine-sulfate, completely inhibits the detection of Cel-miR-238 (fig. 4, H). 
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figure 4. effect of protamine treatment on rt-PCr results. Urine samples of healthy controls were con-
taminated with 10 IU LMWH where indicated and either counteracted with 50 IU protamine sulfate prior to 
RNA isolation using the miRNeasy kit (A-D), or RNA samples were contaminated with the indicated amount 
of LWMH and protamine sulfate prior to RT (E-H). Results are presented in Cq. ND: Not Detected
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Heparin treatment affects rt-qPCr in urine, but not in paired kidney biopsies
The detection and analysis of miRNAs for biomarker purposes in the context of kidney 
transplantation and organ survival has also gained considerable attention.[24] Our 
observation that urine can be contaminated with heparin and thereby interfere with 
miRNA detection raised the question whether this will also affect miRNA detection in 
kidney biopsies. To answer this question, RNA from 7 paired urine samples and kidney 
biopsies was analyzed for the effect of 6 IU heparinase I during RT. Urinary RNA samples 
were analyzed for the endogenous microRNAs miR-30e, and miR-92a and the spiked-in 
Cel-miR-39 and Cel-miR-238 as described before. RNA from biopsies was analyzed for the 
spike-in Cel-miR-54, and the endogenous miRNAs miR-21 and miR-192. The latter two 
being highly expressed miRNAs in kidney.[25, 26] Small nucleolar RNA from SNORD43 
(indicated as RNU43) was selected as the reference RNA for biopsy material. Levels of 
synthetic Cel-miRs and endogenous miRNAs were converted to relative expression levels 
as described previously.[5] Ratios were obtained by dividing results of relative expres-
sion levels of untreated samples with that of levels of the same sample after heparinase 
I treatment. Urinary miRNAs (fig. 5a) clearly showed a ratio <1, indicative for LMWH 
contamination, although to various extend. fig. 5b shows the ratios of the concomitant 
biopsies were all  around 1 for RNU43, Cel-miR-54, miR-21, and miR-192 with small inner 
quartile ranges (0.87±0.1, 1.05±0.16, 0.93±0.26, 0.91±0.11, respectively), indicative for 
very low or even complete absence of RT-qPCR inhibiting compounds.
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figure 5. measurement of mirna expression in kidney biopsies is not affected by the presence of 
heparin in urine.  Paired urine (A) and kidney biopsies (B) were tested by RT-qPCR for the presence of 
heparin. The y-axis indicates the ratio of the RT-qPCR results of every sample with or without the incubation 
with 6 IU heparinase I. Bars indicate median with interquartile range.
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DisCussion
In this study we showed that endogenous miRNAs in urine are protected from degrada-
tion, but that these samples can be contaminated with compounds that inhibit RT-qPCR, 
and in that way can influence the analysis of biomarkers like miRNAs. This is especially 
evident for hospitalized individuals who systemically receive doses of heparin, either 
with UH or LMWH. UH and LMWH can be directly measured in urine, and clearly cor-
relates with the inhibition of detection levels of miRNA. The presence of UH and LMWH 
is a result of co-isolation with, but independent of the presence of, RNA. This inhibition 
could not be counteracted using the clinically used antidote Protamine sulfate, neither 
prior to isolation nor at the level of RT-qPCR. Heparinase I, on the other hand, amelio-
rated detection of microRNAs almost to levels detected in non-contaminated samples.
LMWH is routinely administered to hospitalized individuals in our center who have no 
contra-indications for the use of anticoagulants. Most of the LMWH fraction is excreted 
via the urine and therefore, upon analysis of this fluid, caution should be taken in the 
interpretation of RT-qPCR results. A heparin flush, however, is also performed prior 
to organ procurement.[27] With the rapid binding of heparin to endothelial cells and 
macrophages, especially at higher dosages,  the inhibitory effect of this compound on 
RT-qPCR might also be observed in the analysis of blood and urine from the recipient as 
well as in other transplantation-related fluids.[28]
As the inhibitory effect of heparin on viral replication and reverse transcription of RNA 
is already known for decades,[9, 10, 29] the development of PCR and its application as 
a highly sensitive method for analysis of polynucleotides also requires that more at-
tention is paid to inhibitory components that can obscure results obtained using this 
method. Recent studies have shown that heparin, in addition to the quantification of 
mRNA from tissue[12] and plasma,[30] also affects the quantification of miRNAs in hu-
man blood samples.[15, 30] It was shown that heparinase I treatment of RNA samples 
isolated from plasma significantly increased the detection of both spiked-in Cel-miR-39 
and cholangiocarcinoma associated, endogenous, miRNAs.[22]
As there are no well-established reference transcripts identified for normalization of 
miRNA in fluids up to this moment,[31, 32] the only available option to compare samples 
for specific miRNAs is by correcting for input volume and the use of synthetic miRNAs, 
absent in mammalian species, to monitor RT-qPCR efficiency.[33] Although PCR inhibi-
tion is significantly reduced upon treatment with heparinase I, small variations in the Cq 
levels of the spiked-in Cel-miR-39 remained present. This suggests that other inhibitory 
compounds might be present as well. 
PCR inhibitors come in many forms and classes. Both organic or inorganic substances 
can affect PCR outcome and they are found in a variety of biological fluids, environmental 
materials and food (reviewed in [11]). Heparin is a mixture of highly sulfated, repeating 
208 Chapter 9
disaccharide units, that vary in weight from 3-30 kDa. The most common disaccharide 
unit is the the 2-O-sulfo-α-L-iduronic acid/ 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-
O-sulfate disaccharide. This is the primary substrate for  Bacteroides eggerthii Heparinase 
I. Other disaccharide moleclules, however, are insensitive to degradation by Heparinase 
I. This possible incomplete degradation of heparin, however, might be a factor respon-
sible for the remaining PCR inhibition. This effect, referred to as the “heparin effect”, can 
be a result of the disease state of the patient.[34, 35] Especially in liver diseases and liver 
transplantation coagulation is affected, and it is postulated that heparin-like compo-
nents can also be of endogenous origin. The heparin effect was already observed in the 
90’s, when coagulation was inhibited in a pig model for liver transplantation without the 
use of heparin.[36]
In conclusion, our study shows that heparin is excreted to urine, where it impairs miRNA 
detection by RT-qPCR in a dose-dependent manner. Heparin levels in urine  correlated 
very well with the inhibitory effect. Protamine-sulfate, the clinical antidote for heparin, 
is not suitable for use in the in vitro situation, but heparinase I treatment of RNA samples 
during RT-qPCR provides an excellent alternative to counteract the inhibitory effect of 
heparin. Our results, in combination with already published data, clearly emphasizes 
the need for a thorough examination of the (more recent) medical and pharmaceutical 
history of patients and controls when using RT-PCR for identification or validation of 
biomarkers. However, it is also well imaginable that the same characteristics that are 
responsible for the binding of RNA to the column matrix during the isolation procedure 
are probably also responsible for the binding of heparin. Detection of synthetic miRNAs 
that are spiked into a sample that consists only of water with heparin during the miR-
Neasy isolation procedure is also strongly inhibited (data not shown). Choosing an RNA 
isolation procedure that is devoid of nucleotide-binding columns might therefor also 
be considered to reduce RT-qPCR inhibition. It is therefore eminent that, in the develop-
ment of a biomarker, not only standardization of sampling time, work-up and storage 
are monitored but, for molecular analysis of samples, the isolation of the molecule of 
interest and the medication history of the patient also requires the necessary attention. 
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Liver transplantation (LT) has become victim of its own success. In the last decades, 
the number of patients on the waiting list for transplantation has expanded due to a 
growing demand and the limited availability of transplantable donor organs. In the 
Netherlands, this has led to the increased use of grafts obtained from circulatory death 
donors (DCD), despite the fact that these grafts are of inferior quality compared to those 
donated after brain death (DBD). Prolonged warm ischemia during graft procurement 
causes extensive ischemia-reperfusion injury to hepatocytes and cholangiocytes in DCD 
liver grafts. Therefore, these grafts have a higher risk to develop serious complications 
already early after liver transplantation, like primary non-function (PNF), early allograft 
dysfunction (EAD) and non-anastomotic biliary strictures (NAS). The latter is also known 
as ischemic-type biliary lesions (ITBL) or ischemic cholangiopathy. However, grafts of 
impaired quality like DCD are necessary to deal with the rising organ shortage and cur-
rently, potentially transplantable organs are rejected based on clinical characteristics 
(such as high donor age) and evaluation by the procuring surgeon. This problem is 
highlighted in fig. 1, which shows the number of organs used for LT in the Netherlands 
in 2015, based on numbers from the Dutch transplantation registry. In 2015, 130 post 
mortal donors were DBD, which were effectuated for transplantation in general in 97% 
and specifically for LT in 79% (fig. 1a). Although the number of DCDs was almost two-
fold higher (n=218), the percentage of effectuated donors was much less (64%) and the 
liver was transplanted in only in 22% of the cases (fig. 1a). Thus, from the total number 
of liver transplantations executed in the Netherlands in 2015, 32% were performed with 
a DCD graft (fig. 1b). Based on the numbers from fig. 1a, the contribution of DCD grafts 
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figure 1. (A) Number of post mortal donors and effectuated transplantations and LT’s in The Netherlands 
in 2015. Of all potential DBD organ donors (n=130), the liver was transplanted in 79% of the cases. Of all 
potential DCD organ donors (n=218), the liver was transplanted in only 22%. (B) In 2015, 152 liver transplan-
tations were performed. Approximately 32% of the transplantations concerned a DCD graft. Data originate 
from the Dutch Transplantation Foundation registry.
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in LT could however be much higher. If effective biomarkers would be available, this 
could contribute to a more objective assessment of graft quality and potentially expand 
the donor pool. The research in this thesis was performed to evaluate conventional and 
novel biomarkers on their performance to assess graft quality and to predict outcome in 
LT. A short overview of all chapters is provided in table 1.  
table 1. Overview of thesis chapters.
Ch. main findings strengths limitations Clinical relevance suggestions 
future research
2 Overview of 
biomarkers to 
assess graft 
quality during 
conventional 
and machine 
preservation.
Systematic review. 
Both human and 
experimental 
studies. Markers 
prior to graft 
implantation.
No meta-analysis 
due to incomparable 
studies and 
differences in 
outcome definitions. 
Most studies miss 
validation, low 
evidence. 
Early assessment 
of graft quality. 
Objective. 
Expanding the 
donor pool for LT 
by selecting grafts 
with favourable 
biomarker profiles. 
More validation 
studies. Meta-
analysis on 
performance 
of separate 
biomarkers. Better 
definitions for 
outcome analysis. 
3 No increased risk 
of microthrombi 
formation in DCD 
grafts during 
preservation or 
development of 
NAS.  
Large number of 
biopsies collected 
at different time 
points during 
preservation. In 
triplo staining for 
microthrombi. Both 
extended criteria 
DCD grafts and 
transplanted livers 
included. 
Small cohort size 
and number of 
included livers. 
Possible sampling 
bias in transplanted 
livers. No biopsies 
from all time points 
available. 
Undermines the 
hypothesis of 
microthrombi 
formation in 
development 
of NAS. No 
histological 
evidence for 
fibrinolytic therapy 
during LT.
Include larger 
number of 
transplanted 
livers. Comparison 
with paired bile 
duct specimens. 
Perform a RCT 
for preventive 
use of fibrinolytic 
therapy. 
4 FUT2 non-secretor 
status is a risk 
factor for NAS in 
patients with PSC. 
Donor-recipient 
mismatch gives 
additional risk for 
NAS. 
Large cohort size. 
Validation of earlier 
findings in non-
transplanted PSC 
patients. Combined 
donor-recipients 
data. 
Relative low 
percentage of 
PSC patients and 
combined donor-
recipient data. 
Possible overlap NAS 
and recurrence PSC. 
Provides insight 
in underlying 
mechanism of NAS 
in PSC patients. 
Potential graft 
allocation based on 
genetic profile in 
PSC patients. 
Validate findings 
in PSC patients. 
Perform 
additional basic 
research to check 
for bacterial 
translocation 
and aggravated 
immune 
response. 
5 Overview of 
extracellular 
miRNAs as 
biomarker in 
liver disease and 
transplantation.
Broad topic focused 
on extracellular 
miRNAs in the field 
of hepatology. 
Human studies. 
No systematic 
search. 
Limited amount 
of publications 
regarding 
extracellular miRNAs 
as biomarker in LT. 
Evaluates 
usefulness 
of miRNAs as 
biomarker in 
clinical setting. 
Expand miRNA 
research in 
the setting of 
LT. Perform a 
systematic review 
or meta-analysis. 
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Part i: biomarkers in liVer transPlantation
The various definitions of biomarkers and the potential of conventional markers in the 
context of LT are highlighted in the general introduction, chapter 1. In particular liver 
enzymes like aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are 
commonly used dynamic markers in serum for monitoring hepatocellular injury follow-
ing LT with increased levels at time of complications such as PNF, EAD and rejection. 
table 1. Overview of thesis chapters. (continued)
Ch. main findings strengths limitations Clinical relevance suggestions 
future research
6 Impaired graft 
excretory function 
and graft injury 
causes polarized 
release of HDmiRs 
and CDmiRs into 
bile and blood. 
Longitudinal 
analysis of large 
number of paired 
bile and blood 
samples during 
follow-up after 
LT. Validation of 
previous findings in 
serum . 
Small cohort size, 
less suitable for 
analysing biomarker 
performance. 
No in vitro 3D-model 
for polarized release. 
Provides insight 
in the biology of 
miRNA release. 
Shows the potential 
of bile as biofluid 
to measure 
biomarkers. 
Further 
investigate 
polarized release 
in a 3D model or 
organoid. 
Investigate biliary 
miRNA profiles in 
cholangiopathies 
like NAS. 
7 High levels of 
perfusate HDmiR/
CDmiR ratios 
at time of graft 
preservation are 
predictive of NAS. 
Non-invasive 
measurement. 
Independent 
predictor. Large 
quantities 
available. Potential 
cholangiocyte-
specific markers.  
Limited number of 
miRNAs analysed. 
Small cohort size. 
No validation. No 
measurement 
performed on 
conventional 
markers in perfusate. 
Early prediction 
of NAS. 
Cholangiocyte-
specific marker. 
Demonstrates the 
use of perfusates 
as biofluid for 
biomarker studies. 
Perform 
microarray 
analysis on graft 
perfusates. 
Validate findings 
in separate 
cohort. Apply 
measurements 
in machine 
perfusion.
8 Sample 
contamination 
with heparin 
potentially inhibits 
perfusate miRNA 
measurement. 
Re-evaluation of 
previous findings 
in ch. 7. 
Optimized 
detection of 
miRNAs in 
perfusate. No 
effect on predictive 
capacity of HDmiR/
CDmiR ratios.
Small difference with 
previous study. No 
direct evidence for 
presence of heparin. 
Create awareness 
for inhibitory 
effects and false 
results when 
samples are 
contaminated with 
heparin. 
Correct for 
inhibitory effects 
in samples with 
heparinase I. 
9 Excretion of 
heparin into urine 
inhibits miRNA 
detection by 
RT-qPCR. Sample 
treatment with 
heparinase I 
counteracts 
inhibition. 
Comparison 
between 
heparinized and 
non-heparinized 
patients, availability 
of healthy controls. 
Different 
concentrations of 
heparinase I tested. 
No data on co-
isolation of heparin 
and possible 
inhibition by other 
RNA isolation 
techniques. 
Optimize miRNA 
detection in 
body fluids like 
urine. Better 
understanding of 
heparin excretion 
via urine. 
Investigate 
whether 
inhibition of RT-
qPCR by heparin 
is a factor in other 
RNA isolation 
protocols. 
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For cholestatic injury, gamma-glutamyl transferase (GGT) and alkaline phosphatase 
(ALP) are serum markers that indicate biliary obstruction caused by anastomotic biliary 
strictures (AS) or NAS. Finally, markers as bilirubin, albumin and prothrombin-time are 
usually indicative for graft function. All these markers concern dynamic biomarkers, 
which measurement levels fluctuate depending on the pathophysiological state of the 
liver graft. Beside dynamic markers in blood and serum, histological characteristics in 
tissue are used to determine the degree of rejection, like the Banff score (also known as 
the rejection activity index). The disadvantage of histology is the invasive obtainment of 
liver tissue and the local representation, while serum markers are more informative on 
the entire status of the graft. Moreover, the increase of serum markers is usually faster 
than changes in histology. Therefore, histology in general is a less dynamic marker. Mark-
ers such as GGT and ALP have a delayed increase following liver transplantation and are 
therefore less useful as early markers for severe biliary injury such as NAS. MicroRNAs 
(miRNAs) were identified as potential early markers in the context of biliary complica-
tions, as further discussed in part III of this chapter. Finally, the option to determine 
genetic profiles in donors and recipients that could be predictive for outcome are dis-
cussed. Genetic polymorphisms are static factors that do not change during the course 
of disease or after LT and therefore are considered as risk factors rather than biomarkers. 
Due to the increased use of extended criteria grafts and rising incidence of associated 
complications, transplant centres throughout the world investigate different strategies 
to improve graft quality and outcome in LT recipients. A biomarker-based evaluation of 
graft quality prior to implantation helps to identify grafts with an increased risk for PNF, 
EAD, NAS, or other complications. A novel strategy to optimize graft preservation and 
performance is machine perfusion. Chapter 2 provides a systemic review on studies 
that investigated biomarkers to assess graft quality during conventional and machine 
preservation in LT. Since 2010, various techniques of machine perfusion have made their 
way into the clinic and the first results in human seem promising. Another advantage 
of machine perfusion is that it creates a time window for measuring biomarkers. Beside 
comparing different techniques of machine perfusion, chapter 2 discusses the pros and 
cons of different biomaterials. Biopsies provide histological evidence of graft quality 
(mainly cellular injury) and a large amount of cells for analysis of biomarker expression. 
The disadvantages, however, are the invasive collection with tissue disruption, the local 
representation and the possibility of inter and intra-observer variability. In contrast, pres-
ervation solutions that are used to flush the liver graft, so-called perfusates, are available 
in larger amounts during different techniques of preservation. Perfusate collection is 
non-invasive and it gives a better representation of the entire graft. Machine perfusion 
at higher temperatures also allows the collection of bile. The production and composi-
tion of bile is especially interesting to assess graft function. Unfortunately, preservation 
at lower temperatures does not trigger liver grafts to produce bile and quantity can be 
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low. An important conclusion of the study was that although many studies, including 
ours, show discriminative potential of a variety of biomarkers for graft injury and func-
tion, robust validation in larger cohorts are missing. First, cohort sizes are small due to 
the limited number of annually performed LTs. Also, prospective collection and storage 
of biomaterials can be time consuming, logistically challenging and the use of novel 
measurement techniques can be expensive. All these factors contribute to the lack of 
validation in biomarker studies, while this is actually a crucial step before biomarkers 
can be applied in the clinic. Importantly, most studies investigated biomarker perfor-
mance in DBD grafts, which usually have lower biomarker levels at baseline compared 
to DCD grafts. Therefore, the cut-off values for biomarker levels to predict complications 
in DBD grafts are often different from DCD grafts[1, 2]. Finally, the variations in outcome 
definitions make it difficult to perform a reliable meta-analysis. Introducing an interna-
tional guideline on the definition of common complications in LT could improve the 
comparability between study populations[3].   
Part ii: risk faCtors for biliary ComPliCations
Biomarkers can serve multiple purposes. Outcomes can be defined by biomarkers cross-
ing beyond a predetermined cut-off level, which is for instance the case with EAD. Less 
dynamic markers, such as histology or genetic markers like polymorphisms, can however 
be interpreted as risk factors for outcome. In Part II of this thesis, we investigated two 
factors which could be possibly useful as a risk factor to predict the development of NAS 
following LT. 
formation of microthrombi as an underlying cause for nas: fact or fable?
In chapter 3, we investigated whether DCD grafts have an increased tendency to form 
microthrombi in their microvascular circulation during graft preservation. In the last 
decade, researchers have hypothesized whether the additional first warm ischemia and 
vascular stasis in DCD grafts causes microthrombi formation in the peribiliary vascular 
plexus, which could subsequently lead to the development of NAS. According to Vir-
chow’s triad, three factors are mainly responsible for the formation of thrombi; hyperco-
agulability, endothelial cell injury and disturbed blood flow. These events can induce a 
coagulation cascade with activation of platelets via two independent pathways. In the 
collagen pathway, exposure of sub-endothelial collagen initiates platelet activation. In 
the tissue factor pathway, thrombin is generated by tissue factor derived from the vessel 
wall or from flowing blood[4]. The formation of a thrombus in LT, in particular hepatic 
artery thrombosis (HAT), has been associated with the number of arterial anastomoses, 
aberrant arterial anatomy, low donor and recipient body weight, previous abdominal 
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surgery, CMV-mismatch, re-LT and prolonged operation time[5, 6]. Insufficient flush-
ing of the graft during organ retrieval and prior to implantation is believed to further 
increase this risk. In order to prevent the formation of microthrombi, some transplant 
centres therefore apply potentially harmful intraoperative fibrinolytic therapy that could 
cause major bleedings in transplant recipients. 
The rationale for our study was to determine whether there is actual evidence of mi-
crothrombi formation in liver tissue that could justify intraoperative fibrinolytic therapy. 
Beside conventional staining with hematoxylin-eosin, we also stained for Von Willebrand 
Factor VIII, a marker for endothelial cell activation earlier in the coagulation cascade, and 
Fibrin Lendrum which occurs at the end of the cascade. Our study did not show convinc-
ing evidence of microthrombi formation at different time points during graft preserva-
tion, despite thorough histological evaluation of intrahepatic biopsies obtained from 
multiple liver segments from extended criteria DCD grafts that were rejected for human 
LT. In transplanted livers, the presence of microthrombi was not increased compared to 
matched DBD grafts, nor was their number higher after graft reperfusion or in grafts that 
developed NAS. Although some biopsies showed partial positive staining for Von Wil-
lebrand Factor 8, paired staining’s with Fibrin Lendrum and hematoxylin-eosin remained 
negative. This suggests that DCD grafts do not appear to have a significantly increased 
tendency for microthrombi formation at time of graft preservation. However, it does 
not rule out the possibility of microthrombi formation at a later stage during follow-up. 
An important limitation of our study consisted of the possibility of sampling bias - in 
particular in transplanted livers, where we could only collect wedged shaped biopsies 
from the left lateral segment. And despite the large number of sections analysed on the 
presence of microthrombi, biopsies were collected from a small number of liver grafts. 
Nevertheless, our findings are in concordance with other histological studies that mainly 
evaluated microthrombi formation and cholangiocyte injury of extra- and intrahepatic 
bile ducts[7-10]. Moreover, a study by Vendrell et al. showed that DCD induces hyperfi-
brinolysis, further undermining the hypothesis that DCD grafts would have an increased 
tendency to form microthrombi[11].
With two studies showing potential benefit [12, 13] and two other studies that could 
not demonstrate any effect[14, 15], the results of interventional studies remain incon-
clusive in demonstrating beneficial effect of intraoperative fibrinolytic therapy on the 
development of NAS. All these studies were however based on retrospective analyses, 
while a randomized controlled trial should be performed to provide the strongest 
evidence on whether fibrinolytic therapy is successful in preventing microthrombi and 
associated NAS. For now, we conclude that the histological evidence for microthrombi is 
marginal and together with the conflicting results in clinical studies, we discourage the 
use of intraoperative fibrinolytic therapy during LT.     
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injury to the peribiliary glands as a possible cause for nas
Although we did not investigate the involvement of the peribiliary glands (PBGs), the 
findings from other research groups make this topic worthwhile in the discussion of 
factors causing NAS. Already in 1994, Nakanuma et al. described how PBGs might be 
a niche containing stem cells for regeneration of cholangiocytes[16]. An elegant study 
from DiPaola et al. using confocal microscopy in mice, demonstrated that PBGs populate 
the submucosal compartment of the entire extrahepatic biliary tract, with exception 
of the gallbladder[17]. The PBGs form intramural epithelial networks between several 
segments of the large bile ducts and are connected with the luminal surface through 
small canals. Furthermore, this study found an increase in cellular proliferation in PBGs 
in response to bile duct ligation. Recently, Carpino et al. found hyperplasia of the PBGs 
expanding up to the surface epithelium in bile ducts from patients suffering from se-
vere primary sclerosing cholangitis (PSC) with biliary fibrosis[18]. These PBGs expressed 
hedgehog pathway components and markers of senescence and autophagy. Expression 
of the cystic-fibrosis transmembrane receptor was decreased, making cholangiocytes 
less protected against toxic bile salts via the so-called ‘bicarbonate umbrella’, which will 
be discussed later. Importantly, there was epithelial-to-mesenchymal transition, a risk 
factor for potential malignant degeneration in PSC.     
These findings are in concordance with an earlier study from the group of Porte from 
Groningen, the Netherlands[19]. Beside loss of the epithelial lining of the luminal bile 
duct surface, this group found increased expression of Ki-67 and keratin-19 in the PBGs 
of explanted donor livers obtained from recipients with severe NAS. In patients who 
received surgical intervention for cholangitis, the expression of Ki-67 and keratin-19 was 
more pronounced in cholangiocytes. The authors suggest that in case of mild biliary 
injury, a first-line regenerative mechanism is induced by cholangiocytes, but in case of 
extensive injury, a second-line of regeneration is activated by PBGs. This lead to the for-
mulation of a new paradigm within the pathophysiologic mechanisms of NAS; namely 
that of insufficient regenerative capacity of cholangiocytes due to injury of the PBGs 
located in the larger bile ducts[20]. Subsequently, Op den Dries et al. investigated injury 
to PBGs in a large series of extrahepatic bile duct specimens from transplanted DBD and 
DCD grafts[7]. They found a higher rate of vascular injury, mural stroma necrosis, and 
deep PBG injury in bile ducts from grafts which later developed NAS compared to those 
that did not develop NAS. Interestingly, not deep PBG injury, but vascular injury was 
significantly higher in DCD grafts. This suggests that solely PBG injury does not explain 
the higher incidence of NAS in DCD grafts, but that vascular injury and diminished blood 
supply could add to the risk in DCDs. Notably, histological injury at the distal end of 
the extrahepatic bile duct was representative for injury of the larger intrahepatic bile 
ducts[21].    
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fucosyltransferase-2 dysfunction in the pathophysiology of biliary disease
Genetic polymorphisms are often used as a biomarker to predict outcome. In Chapter 
4, we investigated whether a single-nucleotide polymorphism (SNP) in the fucosyltrans-
ferase-2 gene (FUT2) is a risk factor for the development of NAS. The mutation rs608133 
(G>A), identified through a genome-wide association study, is a prevalent polymorphism 
that occurs in approximately 20% of the general population but which has also been 
associated with PSC[22, 23]. The mutation causes a dysfunctional FUT2 protein, result-
ing in reduced glycosylation of surface epithelial cells. It is believed that this reduced 
glycosylation impairs the barrier function of cells against pathogens[24]. Because of the 
clinical similarities that exist between NAS and PSC, the question raised if the highly 
prevalent rs608133 mutation of the FUT2 gene in LT donors or recipients could be a 
risk factor for NAS. We therefore retrospectively genotyped donor and recipient DNA 
samples from a total of 418 LT procedures on FUT2 secretor status. Donor FUT2 status 
was not associated with the development of NAS. In PSC patients, however, recipient 
FUT2 non-secretor status (AA-genotype) was the strongest independent risk factor for 
NAS (HR 2.34, P=0.034), with the biggest effect during the first five years of follow-up. 
FUT2 status was not a risk factor in LT recipients without PSC as underlying disease.   
FUT2 dysfunction has also been correlated to inflammatory bowel diseases (IBD) like 
Crohn’s disease and ulcerative colitis, which can coexist with PSC[25, 26]. It is thought 
that the impaired barrier function and less diverse bacterial composition of the intesti-
nal epithelium in FUT2 non-secretors causes a ‘leaky gut’, with passage of bacteria and 
pathogens into the circulation[27-29]. To investigate the role of bacterial translocation, 
we analysed the coexistence of IBD in our cohort of recipients with underlying PSC and 
the relation with FUT2 secretor status. With an incidence of 56%, there was a strong 
correlation between PSC and ulcerative colitis. We could however not demonstrate that 
coexistent PSC and IBD occurred more frequently in FUT2 non-secretors, nor was the in-
cidence of NAS higher in this group. This could be due to the limited number of patients 
with coexisting PSC and IBD in our study cohort. This made it also hard to investigate 
whether colectomy had a preventive effect on the occurrence of NAS, as was suggested 
by another study concerning PSC[30].
The results from chapter 4 could also indicate that an aggravated immune response 
was triggered by FUT2 mismatching. Analyses of combined donor-recipient genotypes 
revealed that incidence of NAS was highest (80%) among PSC recipients with FUT2 non-
secretor status (AA) who received a liver graft from a FUT2 secretor donor (GG or GA). 
An experimental study in transgenic mice supports this hypothesis, demonstrating an 
increased immune response and impaired graft survival of skin and hearts with overex-
pression of fucosyltransferase into wildtype recipients[31]. Furthermore, our results do 
not exclude that cholangiocytes from the recipient possibly repopulate the donor bile 
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duct. This type of chimerism has been demonstrated before, but not in the context of 
NAS[32]. 
Aside from the intestinal epithelium, FUT2 non-secretors also have an altered gly-
cosylation of cholangiocytes and bacterial composition of bile, which could both con-
tribute to the development of NAS[22]. The altered glycocalyx layer affects the alkaline 
environment of cholangiocytes that is normally sustained by the bicarbonate umbrella 
and makes them more vulnerable for toxic bile salts[33, 34]. In addition, altered bile 
composition has been linked to a higher incidence of cholangitis, biliary complications 
and shortened transplantation-free survival[35-37]. Our study does not provide direct 
evidence for increased bile salt toxicity in FUT2 non-secretors, but it remains an interest-
ing topic for future research.  
Finally, the detection of biomarkers which biosynthesis normally depends on FUT2 
enzyme activity can be influenced by FUT2 genotype. This was shown by Wannhoff et 
al. for cancer antigen 19-9 (CA 19-9), a biomarker that is often used for the screening 
of cholangiocarcinoma in PSC patients[38]. It appears that PSC patients with FUT2 
non-secretor status have higher serum levels of CA 19-9 compared to FUT2 secretors. 
In order to gain a better biomarker performance in terms of sensitivity, specificity and 
positive/negative predictive value, cut-off values for CA 19-9 should be higher in FUT2 
non-secretors. So researchers should be aware of genotype-dependent biomarker levels 
in future studies.   
other polymorphisms associated with nas and PsC following liver 
transplantation
Besides FUT2, other SNPs have also been investigated in the context of NAS following 
LT. Ten Hove et al. showed that a mutation in the gene coding for matrix metallopro-
teinase-2 (MMP-2) of either donors or recipients increased the risk to develop NAS[39]. 
MMP-2 is a tissue-remodelling enzyme that regulates matrix degradation and has been 
associated with liver fibrosis and cirrhosis. A polymorphism present in both donor and 
recipient had a synergistic effect and further increased the risk of NAS (HR 3.48). Serum 
levels of MMP-2 were however not affected by the SNP. A subsequent study from the 
same research group showed that the polymorphism was associated with worse out-
come in PSC recipients in terms of the need of LT or higher mortality[40]. 
Another SNP associated with NAS is that of chemokine receptor CCR5 (CCR5-Δ32 
mutation)[41]. CCR5 is expressed on various cells of the innate as well as the adaptive 
immune system. For instance, homo- and heterozygote carriers of the mutation have 
impaired chemotaxis of regulatory T-cells. CCR5-Δ32 in recipients but not in donors 
increases the risk to develop NAS with 4-fold. The mutation in recipients was shown 
to be an independent risk factor for NAS, which was strongest in patients with PSC. 
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Unfortunately, no clear stratified analysis was performed on the effects of CCR5- Δ32 in 
non-PSC recipients. 
All these studies on genetic polymorphisms and the development of NAS described 
above, including our own, showed a strong association with PSC. This leads to the 
discussion whether the occurrence of NAS in these cohorts are in fact recurrence of 
the underlying disease. In fact, multiple studies have identified PSC as a risk factor for 
the development of NAS[42, 43]. The criteria for diagnosing recurrent PSC, which were 
formulated in 1999, consist of (i) a confirmed diagnosis of PSC prior to LT, with (ii) intra 
and/or extrahepatic biliary strictures, beading and irregularity after 90 days of follow-up 
demonstrated with cholangiography, or fibrous cholangitis and/or fibro-obliterative 
lesions with or without ductopenia, biliary fibrosis or biliary cirrhosis demonstrated by 
histology[44, 45]. Established ductopenic rejection, HAT, single anastomotic strictures, 
NAS before post-operative day 90, and ABO-incompatibility are described as factors 
excluding recurrent PSC. Despite this clear description, the diagnosis of recurrent PSC 
is not always obvious in clinical practice. First of all, in a minority of cases, the diagnosis 
of PSC becomes clear after histological evaluation on the explant liver by the patholo-
gist. Furthermore, the typical beading seen on cholangiography is often a result of 
progressive recurrent disease, but more isolated intrahepatic strictures and associated 
dilatations are seen in earlier stages. Sometimes, the first symptoms of recurrent disease 
actually present before post-operative day 90. And also through histological examina-
tion of for instance needle biopsies, distinguishing recurrent PSC from other conditions 
like chronic rejection can be challenging[46, 47].      
Because of the difficulties in differentiating recurrent PSC from NAS, it deserves rec-
ommendation to perform a stratified analysis for separate PSC and non-PSC recipients 
in transplantation cohorts, next to the usually performed overall analysis. Certain SNPs 
associated with recurrent PSC or NAS can be used for risk profiling in patients and pro-
vide more insight into the underlying mechanism or pathophysiology of complications 
following LT. Furthermore, the knowledge that certain graft-recipient matches (or mis-
matches) can lead to unfavourable outcomes could possibly influence future allocation 
of donor organs, which is currently mainly based on recipient MELD-score and blood 
type. 
risk factors for biliary complications put in perspective
The paragraphs above illustrate a coherent set of risk factors that appear to reinforce 
each other’s impact on the development of NAS. In short, bile duct injury starts with 
prolonged graft ischemia, explaining the higher incidence of NAS in DCD grafts[48]. 
Bile duct vitality strongly depends on blood supply through the hepatic artery, but di-
minished blood flow through the portal vein has also been associated with NAS[10, 49, 
50]. Reperfusion worsens injury to the biliary epithelium and PBGs, not only disturbing 
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cholangiocyte regeneration but also the integrity of the biliary glycocalyx and bicarbon-
ate umbrella which normally protect against toxic bile salts. Patients suffering from PSC 
more often have a perturbed biliary glycocalyx, which is permeable for pathogens like 
bacteria. This can cause enhanced bacterial translocation from the intestine to the liver, 
but also an aggravated immune response when a FUT2 secretor graft is implanted into 
a FUT2 non-secretor recipient. 
Part iii: miCrornas as noVel biomarker in liVer transPlantation
Part III of this thesis focused on the use of microRNAs (miRNAs or miRs) as biomarkers for 
graft function and injury in the setting of LT. As an introduction to this part, chapter 5 
provides an overview of the literature regarding miRNAs in liver disease and transplan-
tation, with special attention for extracellular miRNAs. After the discovery of miRNAs in 
2001, an explosive amount of research has been published regarding their capacities as 
biomarker, but also their involvement in different pathologies. MiRNAs are 20-23 nucleo-
tide long non-coding RNAs that can regulate gene expression at a post-transcriptional 
level. The fact that cell-type abundant miRNAs are present in the circulation and other 
body fluids, wherein they remain fairly stable against degradation, made them a popular 
subject for non-invasive biomarker research in the last decade. A possible explanation 
for the stability of miRNAs in fluids is that they are embedded in- or attached to other 
cellular components. For example, in response to injury, extracellular miRNAs were 
found in vesicles and smaller exosomes, lipoproteins, or bound to argonaute-2. In the 
field of hepatology, serum miRNA levels are indicative for liver injury in patients with vi-
ral hepatitis, non-alcoholic fatty liver disease, liver fibrosis, malignancy, and more. In the 
context of LT, however, the amount of literature on extracellular miRNAs as biomarker is 
more scarce. 
micrornas as biomarker for hepatocyte and cholangiocyte injury post-
transplantation
Hepatocytes and cholangiocytes have different miRNA expression patterns. An elegant 
study by Chen et al. used laser capture microdissection to select cholangiocytes and 
hepatocytes from liver tissue for separate genome-wide microArray analysis on miR-
NAs[51]. Based on the results of this study, our group was one of the first to investigate 
the release of hepatocyte-derived miRNAs (HDmiRs) into serum at time of liver injury an 
acute rejection after liver transplantation[52]. The main findings of this study were that 
expression of HDmiR-122 and HDmiR-148a was significantly reduced in post-reperfusion 
biopsies when warm ischemia was prolonged. Inversely, serum samples collected dur-
ing the first month of recipient follow-up showed increased levels of HDmiR-122 and 
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HDmiR-148a at time of injury and strongly correlated with AST and ALT values. In fact, 
serum HDmiR levels were already significantly elevated when transaminase levels were 
still <50 IU/L, and peak HDmiR levels were 24 hours ahead of peak serum HDmiR levels 
in recipients with histology proven acute rejection. These results suggests that HDmiRs 
are an earlier and perhaps more sensitive marker for liver injury then the classic serum 
transaminases, which are currently the golden standard as a biomarker to assess liver 
injury. 
In order to gain more insight in the biology of miRNA dynamics during various (patho)
physiological hepatic conditions after LT, we further investigated miRNA release into 
bile and serum in chapter 6. For this study, we not only tested HDmiRs (HDmiR-122 and 
-148a), but we also selected cholangiocyte-derived miRNAs (CDmiRs) that were previ-
ously identified by Chen et al. (CDmiR-30e, -200c and -222)[51]. The tissue-abundancy 
of these miRNAs was confirmed in liver biopsies and bile duct specimens that were 
collected during LT. HDmiR-122 was most abundant in liver tissue, while CDmiR-222 had 
the highest expression in common bile duct tissue. Overall, miRNA levels were higher 
in bile then in paired serum samples. Fractionation experiments demonstrated that the 
majority of extracellular miRNAs in bile were present in an unpelletable fraction and 
protected against degradation for at least 1-4 hours through protein-conjunctions. A 
strong correlation was found between excretion of HDmiR-122 and bilirubin into bile, 
with high levels of biliary HDmiR-122 during good excretory function. Biliary levels 
of HDmiR-122 however drastically lowered if graft excretory function was impaired. 
Interestingly, inverse dynamics were observed for CDmiR-222, with low biliary levels at 
time of good excretory function that increased when excretory function was impaired. 
Changes in excretory function were mainly reflected in biliary miRNA levels, without 
significant changes in paired serum samples. In case of liver injury and acute rejection, 
however, changes in serum were predominant; at time of injury, biliary HDmiR-122 levels 
decreased with simultaneously an increase in serum levels. Again, CDmiR-222 showed 
opposite dynamics. 
Based on these results, it appears that release of HDmiRs and CDmiRs into bile and 
blood is polarized, depending on graft function and the degree of injury. Furthermore, 
the opposite dynamics between HDmiRs and CDmiRs suggests an active release mecha-
nism rather than simple leakage from injured cells. The excretion of miRNAs into bile 
during proper function indicates a role in biliary homeostasis; previous studies showed 
that expression of miR-506, miR-222 and miR-199a-3p for instance influence the activity 
of anion exchanger 2 and farnesoid-X receptor[53, 54]. Furthermore, our study shows 
the potential use of bile as a biomaterial and biliary miRNAs to assess graft function in 
the setting of LT. Limitations of our study consisted of the small number of transplant 
recipients from whom bile and serum samples were collected (n=10) and the absence of 
a 3D experimental model to validate the hypothesis that release of HDmiRs and CDmiRs 
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is polarized. With the ongoing developments in organ tissue engineering, this goal can 
hopefully be realized in the near future[55, 56]. 
Regarding involvement of miRNA in cholangiopathies, cholangiocarcinoma is the most 
extensively studied disease[57]. In these studies, bile is the most frequently used biofluid 
for miRNA analysis, followed by serum. At the gene-regulatory level, miRNA expression in 
tissue has been linked with target genes involved with fibrosis, apoptosis, proliferation, 
invasion, inflammation, migration, tumour growth, oncogenesis, chemo-resistance and 
other pathophysiological factors[57]. Remarkably, much less is known about miRNAs in 
cholangiopathies as primary biliary cirrhosis (PBC), PSC and biliary atresia. In particular 
knowledge on miRNA regulation in the pathophysiology of PSC could be informative for 
NAS, seen their overlap in clinical presentation. In the context of PSC, miR-7a has been 
associated with cholangiocyte proliferation[58]. Other research mainly describes miRNA 
patterns in bile and serum to distinguish PSC from cholangiocarcinoma, which can be 
difficult based on brush cytology [59, 60]. By further unravelling the regulatory aspects 
of CDmiRs, these miRNAs could form the basis of novel therapeutic targets in NAS or 
other cholangiopathies, which was successful for HDmiRs in viral hepatitis[61, 62]. 
micrornas as a biomarker for cholangiocyte injury before transplantation
Markers for cholangiocyte injury and NAS are scarce. Most studies concern histological 
bile duct specimens, which were extensively described earlier. Because of the surgical 
trauma and local representation associated with biopsy sampling, we were seeking 
for a cholangiocyte-specific biomarker that could be measured non-invasively prior to 
graft implantation. Therefore, the study from chapter 7 was initiated to determine if 
extracellular miRNAs are released into perfusates that are used to flush the graft and 
whether these miRNAs could be an early marker for NAS. Levels of HDmiRs (miR-122 and 
-148a) and CDmiRs (miR-30e, -222 and -296) in perfusate supernatant from grafts that 
developed ITBL (n=20) were compared with those that did not develop biliary complica-
tions (n=37). In order to correct for any possible differences in perfusate concentrations, 
ratios of HDmiRs/CDmiRs were used for analyses. Recipients from a graft with high 
HDmiR/CDmiR ratios in the perfusate, mainly due to low CDmiR levels, had a 3 to 6-fold 
increased risk to develop ITBL during follow-up. The discriminative value of HDmiR/
CDmiR ratios was fairly good with C-statistics ranging between 0.74-0.77, although a 
substantial overlap in biomarker levels existed between the ITBL and non-ITBL group. 
A possible explanation for the lower CDmiR levels in perfusate from the ITBL group is 
the loss of cholangiocytes[7]. However, paired tissue biopsies (n=24), which performed 
less well as a predictive biomarker, did not show a lower expression of CDmiRs. This 
observation could be explained by possible sampling bias of the biopsies, which were 
wedges of liver tissue from the left lateral segment. Perhaps CDmiR levels in perfusate 
correlate better with their expression in bile duct tissue, which should be investigated in 
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future research. Furthermore, because of the high abundancy, small changes in miRNA 
expression in tissue might remain insignificant, while the change in perfusate is much 
bigger. 
Increased CDmiR release into bile during injury, as demonstrated in chapter 6, could 
also explain the lower levels of CDmiRs in perfusate. The rationale that CDmiRs are 
released to the biliary lumen formed the basis of one other study investigating miRNA 
patterns in the context of ITBL; Lankisch et al. reported on miRNA profiles in bile ob-
tained from patients with different types of biliary complications, with specific attention 
for patients who developed ITBL[63]. They suggest that modifications in the biliary 
epithelium as in ITBL are best reflected in the composition of bile, whereas choledo-
cholithiasis mainly causes obstruction of bile. The investigators screened for relevant 
miRNAs by profiling whole bile samples that were obtained by endoscopic retrograde 
cholangiography (ERC) from LT recipients with varying severity in ITBL (n=4) versus 
recipients with solely anastomotic strictures (n=4). Out of 905 miRNAs, they identified 
seven miRNAs of interest which were validated in a larger cohort of patients (ITBL n=37, 
anastomotic strictures n=39 and patients with bile duct stones n=12). This way, three 
miRNAs, miR-517a, miR-892a and miR-106a*, were identified that were significantly 
different in bile from recipients with ITBL compared to recipients with bile obstruction 
caused by anastomotic strictures or bile duct stones. However, these miRNAs could not 
distinguish for severity of ITBL. This study was limited by the relative low abundance of 
miRNAs (high CT values), as well as a low sensitivity and specificity for diagnosing ITBL. 
Furthermore, due to the absence of a multivariate analysis, it remains to be determined 
whether the identified miRNAs in bile are independent of other patients characteristics. 
fractions of extracellular mirnas; more than an elaborate way to detect injury?
Reasoning that injury of hepatocytes and cholangiocytes causes active or passive 
miRNA release from cells, we used biliary and perfusate supernatant to analyse extracel-
lular miRNAs in chapter 6 and 7. MiRNAs were however also present in other cell-free 
fractions, like organelles and small vesicles as exosomes. The percentage of miRNAs in 
these fractions was low, with less than 1% of miRNAs residing in small vesicles.
There is much discussion on which fraction of bile, perfusate or other biofluids should 
be analysed for studying extracellular miRNAs. Lankisch et al. used unfractionated, 
whole bile samples for miRNA analysis. Consequently, it remained unclear whether the 
potentially relevant miRNAs identified in bile were present in cells or in the liquid frac-
tion. Shigehara et al., who were the first to report on diagnostic miRNA profiles in bile for 
cholangiocarcinoma, showed that a majority of detected miRNAs were in fact present 
in cells, whereas much lower miRNA levels were found in biliary fractions containing mi-
crovesicles[64]. Previous studies reporting on microvesicles and exosomes in bile showed 
that these fractions are loaded with distinct miRNAs. For instance, Li et al. designed a 
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diagnostic miRNA assay for cholangiocarcinoma using isolated biliary microvesicles[65]. 
Analysis of miRNAs in biliary exosomes can be informative on cholangiocyte-regulatory 
mechanisms and transmissions of disease[66-68]. Most likely, there is no right or wrong in 
the decision to analyse extracellular miRNAs in exosomes or supernatant, depending on 
the research question. But researchers should be aware that the choice for a certain frac-
tion could lead to a different performance of miRNAs as biomarkers; certain miRNAs will 
have predictive value in exosomes but not in supernatant and vice versa[69]. Moreover, 
the presence of miRNAs might differ between distinct populations of exosomes[70]. Our 
decision to analyse biliary and perfusate supernatant was mainly driven by the fact that 
exosomal miRNAs only represented a minority and that such a design carries the risk of 
overlooking more abundant though significant miRNAs[71]. 
The question remains whether extracellular miRNAs are not just an elaborate way of 
detecting cellular leakage, that could also be determined by conventional markers like 
AST and ALT? As discussed in chapter 2, perfusate levels of AST and ALT are predic-
tive of EAD and PNF following LT. Moreover, Den Dulk et al. showed that peak levels 
of serum ALT >1300 IU/L following LT were predictive of NAS in DCD grafts.[2] So why 
perform expensive and labour intensive measurements on miRNAs? An argument in 
favour of miRNAs consist of the rapid elevation in biofluids that is more sensitive than 
liver transaminases[52, 72]. Furthermore, CDmiRs are more specific for cholangiocyte 
injury compared to transaminases, which are mainly present in hepatocytes. The cor-
relation between peak serum ALT and NAS probably results from severe ischemic injury 
that affected both hepatocytes and cholangiocytes. Release of CDmiRs could however 
also relate to other factors associated with cholangiocyte injury, which should be in-
vestigated in future research. Finally, given the fact that miRNAs are present in other 
extracellular fragments make them suitable for studying underlying mechanisms of 
injury. The optimized and accelerated detection of miRNAs, which will be discussed in 
the following paragraphs, makes them more attractive for clinical use in LT.    
effect of heparin on microrna detection
One of the major advantages of miRNAs over messenger RNA as a biomarker is their 
stability at room temperature, shown in chapter 6 and 7, and after repeated cycles of 
freezing and thawing[52]. Disadvantages concerning the measurement of miRNAs are 
the time consuming RNA isolation procedure and reverse-transcriptase quantitative 
PCR (RT-qPCR). Although RT-qPCR is a sensitive technique that is capable of measuring 
very small amounts of miRNAs and other genes, factors have been described that can 
inhibit qPCR and obtain false results. Chapter 8 and 9 of this thesis focus on such PCR 
inhibitor, namely heparin, and the effects of sample contamination on miRNA detec-
tion. Chapter 8 is a re-analysis of our study described in chapter 7, after we suspected 
that perfusate samples contained traces of heparin that was administered during graft 
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procurement. Heparin makes a strong connection with endothelial cells and therefore, 
it might still be present in the liver even after multiple flushes with preservation solu-
tion[73]. We repeated qPCR on miRNAs after performing the RT-step with heparinase I, 
an enzyme that counteracts the inhibitory effects of heparin[74]. This slightly improved 
the detection of miRNAs in perfusates, suggesting the presence of small amounts of 
heparin that affected the measurement of miRNAs in a similar degree. However, the ef-
fect on the detection of HDmiR-148a was significantly stronger; this could be explained 
by some samples that showed Ct values above the reliable cut-off level of 35 cycles prior 
to heparinase I treatment, but which improved drastically for a minority of samples. In 
addition, the possible contamination with heparin did not affect the predictive capac-
ity of miRNAs as reported earlier in chapter 7, because HDmiR/CDmiR ratios did not 
significantly change within and between samples. This encourages the use of miRNA 
ratios rather than single miRNAs to avoid the risk of false results whenever there is doubt 
on the presence of heparin in samples. 
More technical aspects on the inhibitory effects of heparin and counteracting 
heparinase I were studied in chapter 9. Beside bile and blood, other perhaps more 
easily obtainable body fluids like urine are gaining interest for non-invasive biomarker 
measurement. Urinary miRNAs were proven stable biomarkers in kidney transplantation 
and hepatopancreatobiliary malignancies[75-78]. Most studies investigating urinary 
miRNAs collected samples from hospitalized patients, who often receive prophylactic 
anticoagulant  therapy such as unfractionated or low molecular weight heparin (UH 
and LMWH, respectively). Heparin is partly excreted by the kidneys into urine, but its 
potential inhibitory effect on miRNA measurement in this medium has not been investi-
gated before. For our study, we investigated urinary supernatant that was collected from 
healthy kidney donors and liver transplant recipients, with heparinized and non-hepa-
rinized individuals in both groups. The detection of urinary miRNAs through RT-qPCR 
was inhibited in a dose-dependent manner in samples from heparinized individuals. 
This caused strong variation in urinary miRNA levels that could significantly influence 
outcome analysis in biomarker studies. This variation was however strongly reduced 
after treating samples with heparinase I, which almost completely negates the inhibi-
tory effects from heparin. Measurement of miRNA expression in tissue was not affected 
by systemic heparin administration. Inhibition of RT-qPCR results from co-isolation of 
heparin with RNA, which could differ between various RNA isolation methods. In our 
study, RNA isolation was based on molecular size, allowing other molecules like LMWH 
to pass the column and end up in the isolate. Protocols that use a different approach 
to isolate miRNAs, like electrochemical magnetic beads, might experience less trouble 
from heparin contamination[79]. The results from this study indicate that in hospital-
ized patients who receive systemic administration of anticoagulants, the possibility of 
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sample contamination with heparin should always be investigated when performing 
biomarker research.
optimizing microrna detection and validation
Optimized miRNA detection and validation depend on various other factors that 
deserve mentioning. Challenges already present themselves in the discovery phase; 
on which material should one perform a miRNA Array for the discovery of potentially 
interesting miRNAs? Many studies choose to perform an Array on tissue samples from 
small identification cohorts (usually 4 to 7 patients per group) and to validate the most 
significantly up or downregulated miRNAs in a larger validation cohort. Performing 
an Array on tissue in order to validate in body fluids like serum and bile can however 
give disappointing results; some tissue miRNAs are barely detectable in body fluids. 
Furthermore, tissue samples can contain a variety of cells, which can lead to inequalities 
within groups and lead to insignificant results in validation cohorts, even when using 
similar biomaterial[80]. This problem can be circumvented for instance by selecting cell 
types through laser capture microdissection, instead of using whole biopsies for miRNA 
isolation[51]. 
Second, the work-up of tissue and biofluids can differ between transplant centres, 
making it harder to compare results of biomarker performance. This is particularly the 
case for the collection of perfusates. Not only the type of preservation solution, but also 
the volume and ways to flush the graft differs between hospitals. Moreover, the choice 
of biomaterial could have consequences for the quality of isolated RNA; formalin-fixed 
paraffin embedded (FFPE) tissue biopsies were considered inferior compared to snap-
frozen biopsies for RNA isolation. However, in the last years it has become clear that FFPE 
biopsies are also a valuable source for miRNA research[81-83].     
Finally, an increasing amount of research is invested in accelerating and simplifying 
the isolation and detection of miRNAs. With normal RT-qPCR, which is currently the 
golden standard for miRNA detection, it is unattractive for physicians to apply miRNAs in 
clinical liver transplantation due to the time consuming and labour intensive technical 
procedure. But novel techniques seem promising in accelerating miRNA detection. For 
example, Liu et al. recently developed a biosensor which can directly detect miRNAs in 
a label-free and real-time manner, through the measurement of the light phase change 
caused by the formation of the double-stranded structure between the complementary 
DNA capture probe and the target miRNA. This way, the detection of urinary miRNAs 
took approximately 15 minutes[84]. This is just one example of many innovative de-
velopments to fasten and optimize miRNA detection. With the upcoming technology 
of machine preservation to optimize graft quality, early detection of biliary injury via 
accelerated miRNA measurement in recirculating perfusates would be of great interest 
to evaluate graft performance. 
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ConClusions anD future PersPeCtiVes 
The studies described in this thesis contribute to a better evaluation of graft quality 
and the potential of various biomarkers for accurately assessing the risk to develop seri-
ous complications following LT. The introduction of machine perfusion creates a time 
window in which perfusate biomarkers can be measured to evaluate graft performance 
of marginal grafts. But also the production and composition of bile are informative 
on graft function. It appears that DCD grafts do not have an increased tendency to 
form microthrombi during graft preservation and the intraoperative administration of 
fibrinolytic therapy in order to prevent NAS therefore seems unjustified. Genetic pre-
disposition is an additional risk factor for NAS in LT recipients who also suffer from PSC 
as underlying disease. Recipient-donor mismatch in FUT2 secretor status could further 
increase the risk of early development of NAS. Therefore, adapted allocation based on 
genetic screening of donors and PSC recipients could optimize graft performance in this 
group. With the increasing use of extended criteria grafts, more objective and sensitive 
biomarkers are demanded to predict severe biliary complications like NAS. MicroRNAs, 
in particular CDmiRs, showed potential to early predict the development of NAS during 
graft preservation. The application of miRNAs into clinical practice will however depend 
on optimizing and accelerating measurement techniques. Novel developments in this 
field seem promising and miRNAs in biofluids can become a valuable addition to current 
classic biomarkers. With the use of objective biomarkers, we aim to expand the donor 
pool and increase the number of effectuated DCD in the very near future.
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Levertransplantatie is het slachtoffer geworden van zijn eigen succes. De afgelopen tien 
jaar is het aantal patiënten op de wachtlijst steeds verder gestegen door het groeiende 
tekort aan en de toenemende vraag naar transplanteerbare organen. In Nederland heeft 
dit heeft geleid tot een toename in het gebruik van organen verkregen via donatie na 
circulatiestilstand (donation after circulatory death (DCD)), ondanks dat deze organen 
van slechtere kwaliteit zijn vergeleken met organen verkregen bij donatie na hersen-
dood (donation after brain death (DBD)). Door de langere, warme ischemietijd tijdens 
de orgaanuitname procedure ontstaat er uitgebreidere ischemie-reperfusie schade aan 
de hepatocyten en cholangiocyten van DCD organen. Daarom hebben ontvangers van 
dergelijke levers een hoger risico op het ontwikkelen van ernstige complicaties vlak na 
levertransplantatie, zoals primaire non-functie (PNF), vroege transplantaat dysfunctie 
(early allograft dysfunction (EAD)) en non-anastomotische galwegstricturen (NAS). Deze 
laatste staan ook wel bekend als ischemie-achtige galweg laesies (ischemic-type biliary 
lesions (ITBL)) of ischemische cholangiopathie. 
Het transplanteren van levers van minder goede kwaliteit, zoals bij DCD, is echter 
onvermijdelijk vanwege het toenemende orgaantekort. Momenteel worden dergelijke 
levers vaak en wellicht onterecht afgewezen voor levertransplantatie op basis van 
ongunstige klinische karakteristieken, zoals een hoge donorleeftijd of op basis van de 
empirische beoordeling door de chirurg. Dit probleem blijkt uit de cijfers van de Neder-
landse Transplantatie Stichting. In 2015 waren er 130 potentiële DBD donoren, waarvan 
97% bruikbaar waren voor transplantatie in het algemeen en 79% voor levertransplanta-
tie. Hoewel het aantal DCD donoren bijna tweemaal zo hoog was (218), was slechts 64% 
van deze donoren geschikt voor orgaantransplantatie en werd in slechts 22% van de 
gevallen de lever getransplanteerd. Kortom, van het totale aantal levertransplantaties 
uitgevoerd in Nederland in 2015 (n=152) werd dat in 32% gedaan met een DCD lever. 
Dit percentage zou op basis van bovenstaande getallen echter veel hoger kunnen zijn. 
Een objectievere beoordeling van de kwaliteit van het levertransplantaat met behulp 
van biomarkers zou kunnen bijdragen aan het vergroten van het donorpotentieel. Het 
onderzoek beschreven in dit proefschrift had daarom tot doel om conventionele en 
nieuwe biomarkers te evalueren op hun vermogen om de kwaliteit van het transplan-
taat en de uitkomst na levertransplantatie te voorspellen. 
Deel i: biomarkers in leVertransPlantatie
In hoofdstuk 1 worden de verschillende definities van de term biomarker besproken 
en wordt een overzicht gegeven van de gangbare markers in de context van levertrans-
plantatie. Leverenzymen zoals aspartaat aminotransferase (AST) en alanine aminotrans-
ferase (ALT) worden vaak gebruikt als dynamische markers in serum om hepatocellulaire 
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schade na levertransplantatie te monitoren. Deze markers zijn verhoogd in serum ten 
tijde van complicaties als PNF, EAD en rejectie. Bij schade door cholestase zijn gamma-
glutamyl transferase (GGT) en alkalisch fosfatase (ALP) serummarkers die kunnen wijzen 
op galwegobstructie, bijvoorbeeld ten gevolge van anastomotische galwegstricturen 
of NAS. Tenslotte zijn er markers die iets zeggen over de functie van het transplantaat, 
zoals bilirubine, albumine en protrombinetijd. Al deze markers zijn dynamische markers, 
waarvan de meetwaardes fluctueren naar gelang de pathofysiologische toestand van 
het levertransplantaat. Behalve dynamische markers in bloed en serum kunnen ook 
histologische karakteristieken gebruikt worden om de mate van rejectie te bepalen, zo-
als de Banff-score of de rejection activity index. Nadelen van het gebruik van histologie 
zijn echter dat het verkrijgen van het biopt gepaard gaat met weefselinvasie en dat 
een biopt slechts een lokale representatie geeft van de toestand van de lever, terwijl 
serummarkers meer zeggen over de toestand van de lever als geheel. Bovendien stijgen 
serummarkers normaliter sneller dan dat er veranderingen in histologie kunnen worden 
waargenomen. Daarom is histologie over het algemeen een minder dynamische marker. 
Surrogaat markers voor cholangiocyt schade zoals GGT en ALP hebben een vertraagde 
stijging na levertransplantatie en zijn daarom minder geschikt als vroege marker voor 
ernstige galwegschade zoals NAS. De toepassing van MicroRNAs (miRNAs) als poten-
tiële vroege markers voor galwegcomplicaties wordt apart besproken in deel III van dit 
hoofdstuk. 
Tenslotte wordt in hoofdstuk 1 ingegaan op genetische profielen in donoren en 
ontvangers waarmee de uitkomst na levertransplantatie beter voorspeld kan worden. 
Genetische polymorfismen zijn statische factoren die niet veranderen gedurende het 
beloop van een ziekte of na levertransplantatie, en kunnen dus eigenlijk niet als bio-
markers maar meer als risicofactoren worden beschouwd.  
Door het toenemend gebruik van donoren met uitgebreidere criteria en de daarmee 
gepaard gaande complicaties, worden wereldwijd door transplantatiecentra strategieën 
onderzocht om de kwaliteit van het transplantaat en de uitkomst in ontvangers te ver-
beteren. Een op biomarkers gebaseerde evaluatie van de kwaliteit van het transplantaat 
voorafgaand aan implantatie zou donorlevers kunnen opsporen met een verhoogd 
risico op PNF, EAD, NAS, of andere complicaties. Een andere moderne strategie om 
preservatie van het transplantaat te optimaliseren is machineperfusie. Hoofdstuk 2 is 
een systematisch review van studies die biomarkers hebben onderzocht om de kwaliteit 
van het transplantaat te bepalen gedurende conventionele- en machinepreservatie in 
levertransplantatie. Sinds 2010 zijn verschillende technieken van machineperfusie geïn-
troduceerd in de klinische praktijk en de eerste resultaten in humane levertransplantatie 
zijn veelbelovend. Een bijkomend voordeel van het gebruik van machineperfusie is dat 
het extra tijd creëert voor het meten van biomarkers om de kwaliteit van het transplan-
taat objectief te kunnen beoordelen. Behalve een vergelijking van de verschillende 
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machineperfusie technieken worden in hoofdstuk 2 tevens de voor- en nadelen van 
het gebruik van verschillende biomaterialen voor het meten van leverschade tegen 
elkaar afgewogen. Met behulp van biopten kan histologisch bewijs worden verkregen 
van voornamelijk cellulaire schade, en kan een groot aantal cellen verkregen worden 
voor de analyse van de expressie van biomarkers. Nadelen bestaan echter uit de in-
vasieve aard waarmee de biopten worden verkregen, de lokale representatie en de kans 
op inter- en intra-individuele variabiliteit van de beoordeling. Dit in tegenstelling tot 
preservatievloeistoffen die gebruikt worden om het transplantaat mee te spoelen, zo-
genaamde perfusaten. Perfusaten zijn in grote volumina aanwezig tijdens verschillende 
preservatietechnieken, kunnen non-invasief verzameld worden en geven een betere 
representatie van het gehele transplantaat. Daarnaast biedt machineperfusie op hogere 
temperaturen de mogelijkheid om gal te verzamelen. De productie en samenstelling 
van gal is in het bijzonder interessant om de functie van het transplantaat te bepalen. 
Helaas produceert de lever vrijwel geen gal bij preservatie op lagere temperaturen. Een 
belangrijke conclusie van hoofdstuk 2 is dat hoewel veel studies, evenals de studies be-
schreven in dit proefschrift, een discriminerend vermogen aantonen van verschillende 
biomarkers, robuuste validatie in grotere cohorten vaak achterwege blijft. Allereerst zijn 
de onderzochte studiecohorten vaak klein door het lage aantal levertransplantaties dat 
op jaarbasis wordt uitgevoerd. Daarnaast is het prospectief verzamelen en opslaan van 
biomaterialen tijdrovend, logistiek uitdagend en het toepassen van nieuwe meettech-
nieken vaak kostbaar. Al deze factoren dragen bij aan het gebrek aan validatie bij 
biomarker studies, hoewel dit cruciaal is voordat biomarkers daadwerkelijk toegepast 
kunnen worden in de klinische praktijk. Een ander belangrijk punt betreft het feit dat 
veel studies enkel biomarkers hebben onderzocht in DBD levertransplantaties. De gren-
swaardes voor biomarkers om complicaties in DBD levertransplantaties te voorspellen 
zijn echter niet zomaar toepasbaar in DCD levertransplantaties[1, 2]. Tenslotte maakt de 
variatie in uitkomstdefinities tussen verschillende studies het moeilijk om een betrou-
wbare meta-analyse uit te voeren. Het introduceren van internationale richtlijnen voor 
uitkomstdefinities van veel voorkomende complicaties bij levertransplantaties zou de 
vergelijkbaarheid van studies ten goede kunnen komen[3]. 
Deel ii: risiCofaCtor Voor galwegComPliCaties
Biomarkers kunnen meerdere doelen dienen. De uitkomst van een transplantatie kan 
gedefinieerd worden door biomarkers die boven een vooraf gestelde grenswaarde 
stijgen, zoals het geval is bij EAD. Minder dynamische biomarkers, zoals histologie of ge-
netische polymorfismen, kunnen daarentegen geïnterpreteerd worden als risicofactor 
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voor een bepaalde uitkomst. In deel II van dit proefschrift zijn twee markers onderzocht 
die een mogelijke risicofactor zijn voor het ontwikkelen van NAS na levertransplantatie. 
De vorming van microtrombi als onderliggende oorzaak van nas: feit of fabel?
In hoofdstuk 3 is onderzocht of DCD levers een verhoogde neiging hebben om mi-
crotrombi te vormen in hun microvasculatuur ten tijde van preservatie. In de laatste 10 
jaar is door meerdere groepen onderzocht of de extra warme ischemietijd en vasculaire 
stase in DCD levers leidt tot het ontstaan van microtrombi in de peribiliaire vasculaire 
plexus van de galwegen. Dit zou vervolgens leiden tot het ontstaan van NAS. Volgens 
de triade van Virchow zijn drie factoren verantwoordelijk voor de vorming van een 
trombus; hypercoagulatie, schade aan endotheelcellen en een verstoorde bloedstroom. 
Deze gebeurtenissen kunnen een coagulatie cascade induceren waarbij bloedplaatjes 
geactiveerd worden via twee onafhankelijke mechanismen. Bij de collageen route 
initieert de blootstelling van sub-endotheliaal collageen de activatie van bloedplaatjes. 
Bij de weefselfactor route wordt trombine gegenereerd door weefselfactoren afkomstig 
uit de vaatwand of het bloed[4]. Het risico op de vorming van een trombus bij lever-
transplantatie, met name van de arteria hepatica (HAT), is gerelateerd aan het aantal 
arteriële anastomosen, afwijkende arteriële anatomie, een laag gewicht van de donor 
of ontvanger, voorgaande buikchirurgie, CMV-mismatch, re-transplantatie en verlengde 
operatietijd[5, 6]. Er wordt gedacht dat onvoldoende spoelen van het transplantaat ti-
jdens orgaanuitname en voorafgaand aan implantatie het risico op microtrombi verder 
verhoogt. Om de vorming van microtrombi te voorkomen gebruiken sommige trans-
plantatiecentra potentieel gevaarlijke intra-operatieve fibrinolytica, die grote bloedin-
gen kunnen veroorzaken in patiënten. 
De gedachte achter onze studie was om te bepalen of er eigenlijk wel bewijs is voor 
de vorming van microtrombi in leverweefsel die de toepassing van fibrinolytica zou 
kunnen rechtvaardigen. Voor de studie in hoofdstuk 3 werden levercoupes, naast een 
conventionele kleuring met hematoxyline-eosine, ook gekleurd voor Von Willebrand 
Factor VIII (een marker voor endotheel activatie vroeg in de coagulatie cascade), en 
Fibrine Lendrum dat zich aan het eind van deze cascade bevindt. Onze studie leverde 
geen overtuigend bewijs voor de vorming van microtrombi gedurende verschillende ti-
jdspunten van preservatie. Dit ondanks grondige evaluatie van intrahepatische biopten 
die waren verkregen uit verschillende leversegmenten van uitgebreide criteria DCD le-
vers die waren afgewezen voor levertransplantatie. Maar ook in getransplanteerde DCD 
levers was het aantal microtrombi niet verhoogd ten opzichte van vergelijkbare DBD 
levers, noch was het aantal microtrombi verhoogd na reperfusie of in levers die NAS 
ontwikkelden. Hoewel in sommige coupes een deel van het vasculaire lumen positief 
kleurde voor Von Willebrand Factor VIII, bleven gepaarde coupes negatief voor Fibrine 
Lendrum en waren geen trombi waarneembaar met hematoxyline-eosine. DCD levers 
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lijken dus geen verhoogde neiging te hebben om microtrombi te vormen ten tijde 
van preservatie, die de verhoogde incidentie van NAS in deze organen zou verklaren. 
De vorming van microtrombi op een later moment tijdens de follow-up is echter niet 
uitgesloten. 
Een belangrijke limitatie van onze studie is de mogelijkheid van sampling bias, met 
name in getransplanteerde levers waar enkel biopten van het linker laterale segment 
werden afgenomen. En ondanks het grote aantal coupes dat geanalyseerd is op de 
aanwezigheid van microtrombi, zijn deze van slechts een klein aantal levers verzameld. 
Desalniettemin komen onze resultaten overeen met andere histologische studies die 
de vorming van microtrombi en cholangiocyt schade van intra- en extrahepatische 
galwegen evalueerden[7-10]. Een onderzoek van Vendrell et al. laat bovendien zien dat 
DCD levertransplantatie hyperfibrinolyse veroorzaakt, wat de hypothese van verhoogde 
vorming van microtrombi en hypercoagulatie in DCD verder ondermijnt[11]. 
Met twee studies die een mogelijke voordelig effect aantonen[12, 13] en twee andere 
studies waarin geen effect wordt gezien[14, 15], lijkt er geen overtuigend bewijs te zijn 
voor een preventief effect van intra-operatieve fibrinolytica op NAS in interventiestudies. 
Alle studies betreffen echter retrospectieve analyses, terwijl een gerandomiseerde trial 
uitgevoerd zou moeten worden om het sterkste bewijs te leveren. Voor nu concluderen 
we dat het histologisch bewijs voor de vorming van microtrombi marginaal is. Dit, in 
combinatie met de tegenstrijdige resultaten in klinische studies, maakt dat we het 
gebruik van intra-operatieve fibrinolytica tijdens levertransplantatie afraden.
schade aan de peribiliaire klieren als mogelijke oorzaak van nas
Hoewel de betrokkenheid van de peribiliaire klieren (peribiliary glands (PBG)) bij de 
ontwikkeling van NAS niet is onderzocht in dit proefschrift, maken de resultaten van 
andere onderzoeksgroepen dit onderwerp wel de moeite van discussie waard. Al in 
1994 beschreven Nakanuma et al. dat PBGs een niche zouden zijn die stamcellen bevat 
voor de regeneratie van cholangiocyten[16]. Een elegante studie van DiPaola et al., 
welke gebruik maakte van confocale microscopie in muizen, laat zien dat PBGs zich be-
vinden in het submucosale compartiment van de gehele extrahepatische galweg, met 
uitzondering van de galblaas[17]. De PBGs vormen intramurale epitheliale netwerken 
tussen verschillende segmenten van de grote galwegen en staan in verbinding met 
het galweglumen via kleine kanalen. Verder laat deze studie zien dat de proliferatie 
van cellen in PBGs toeneemt na ligatie van de galweg. Onlangs vonden Carpino et al. 
hyperplasie van PBGs die zich uitbreidde tot het oppervlakte epitheel van de galwegen 
in patiënten met primaire scleroserende cholangitis (PSC) en biliaire fibrose[18]. Deze 
PBGs brachten componenten van de hedgehog route en markers van senescence en 
autofagie tot expressie. De expressie van de cystische-fibrose transmembraan receptor 
was echter verminderd, waardoor de cholangiocyten minder beschermd waren tegen 
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toxische galzouten door middel van de zogenaamde ‘bicarbonate umbrella’, welke later 
in dit hoofdstuk nog aan bod zal komen. Belangrijk was de aanwezigheid van epitheliale 
naar mesenchymale transitie, een risicofactor voor maligne degeneratie in PSC. 
Deze bevindingen zijn in overeenstemming met een eerdere studie door de groep 
van Porte uit Groningen, Nederland[19]. Behalve verlies van het luminale galwege-
pitheel vond deze groep een verhoogde expressie van Ki-67 en keratine-19 in PBGs 
van geëxplanteerde donorlevers van patiënten met ernstige NAS. In patiënten die 
chirurgische interventie nodig hadden vanwege cholangitis was de expressie van Ki-67 
en keratine-19 meer uitgesproken in cholangiocyten. Op basis van deze bevindingen 
suggereren de auteurs dat in geval van milde galwegschade een eerstelijns regenera-
tie plaatsvindt door cholangiocyten, maar dat in geval van uitgebreidere schade een 
tweedelijns regeneratie geactiveerd wordt door PBGs. Dit heeft geleid tot een nieuw 
paradigma binnen de levertransplantatie, namelijk dat insufficiënte regeneratie van 
cholangiocyten door schade aan de PBGs in de grotere galwegen ten grondslag ligt aan 
NAS[20]. Vervolgens bestudeerden Op den Dries et al. de schade aan PBGs in een grote 
serie extrahepatische galwegbiopten van getransplanteerde DBD en DCD levers[7]. 
Zij vonden een hogere mate van vasculaire schade, necrose van het murale stroma en 
schade aan de dieper gelegen PBGs in levers welke later NAS ontwikkelden. Interessant 
genoeg bleek niet de schade aan PBGs, maar de vasculaire schade significant verhoogd 
in DCD levers. Dit suggereert dat de hogere incidentie van NAS in DCD levers toch 
zou kunnen voortkomen uit de vasculaire schade en verminderde bloedvoorziening. 
De histologische schade die werd gezien in de distale extrahepatische galweg bleek 
bovendien representatief voor de grotere intrahepatische galwegen[21].    
fucosyltransferase-2 dysfunctie in de pathofysiologie van galwegziekten
Genetische polymorfismen worden vaak toegepast als biomarker om de uitkomst van 
een levertransplantatie te voorspellen. In hoofdstuk 4 hebben we onderzocht of een 
single-nucleotide polymorfisme (SNP) in het fucosyltransferase-2 gen (FUT2) een risico-
factor is voor het ontwikkelen van NAS. De mutatie rs608133 (G>A), die gevonden is bij 
een genoomwijde associatie studie, is een prevalent polymorfisme dat voorkomt onder 
20% van de algemene populatie, maar die ook in verband is gebracht met PSC[22, 23]. 
De mutatie veroorzaakt een dysfunctioneel FUT2 eiwit, wat resulteert in verminderde 
glycosylering van oppervlakte epitheliale cellen. Men denkt dat deze verminderde gly-
cosylering de barrière functie van cellen tegen pathogenen verlaagt[24]. Vanwege de 
klinische overeenkomsten tussen NAS en PSC rees de vraag of deze mutatie van het FUT2 
gen in levertransplantatiedonoren en ontvangers een risicofactor zou kunnen zijn voor 
NAS. Daarop hebben we retrospectief een genotypering van de FUT2 secretor status 
uitgevoerd op het DNA van donoren en ontvangers van in totaal 418 levertransplantatie 
procedures. De donor FUT2 status was niet geassocieerd met de ontwikkeling van NAS. 
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In patiënten met PSC bleek echter dat een FUT2 non-secretor status van de ontvanger 
(AA-genotype) een onafhankelijke risicofactor was voor NAS (HR 2.34, P=0.034), waarbij 
het sterkste effect werd gezien in de eerste vijf jaar na transplantatie. FUT2 status was 
geen risicofactor voor levertransplantatiepatiënten die een andere onderliggende 
ziekte dan PSC hadden. 
FUT2 dysfunctie is ook gecorreleerd aan inflammatoire darmziekten (IBD), zoals 
de ziekte van Crohn en colitis ulcerosa, die kunnen voorkomen in combinatie met 
PSC[25, 26]. Er wordt gedacht dat de verlaagde barrièrefunctie en de minder diverse 
bacteriële samenstelling van het darmepitheel leiden tot een ‘lekkende darm’ in FUT2 
non-secretors, waardoor bacteriën en pathogenen door de darmwand kunnen passeren 
naar de circulatie[27-29]. Om de rol van bacteriële translocatie te onderzoeken, hebben 
we het gelijktijdig voorkomen van IBD geanalyseerd in ons cohort van patiënten met 
onderliggend PSC en de relatie met FUT2 secretor status. Er was een sterke correlatie 
tussen PSC en het gelijktijdig bestaan van colitis ulcerosa, met een incidentie van 56%. 
We konden echter niet aantonen dat FUT2 non-secretor status vaker voorkwam bij 
patiënten met gecombineerd PSC en IBD, noch was de incidentie van NAS verhoogd in 
deze groep. Mogelijk was het aantal patiënten met gelijktijdig voorkomen van PSC en 
IBD in ons cohort te klein om dit verband goed te onderzoeken. Dit belemmerde tevens 
een betrouwbare analyse van het preventieve effect van colectomie op het ontwikkelen 
van NAS, wat aangetoond is in voorgaande studies betreffende PSC[30].  
De resultaten van hoofdstuk 4 zouden ook kunnen duiden op een verhoogde im-
muunrespons, veroorzaakt door ongunstige FUT2 combinaties. Analyse van gecom-
bineerde donor- en ontvangergenotypen liet zien dat de incidentie van NAS het hoogste 
was (80%) onder PSC patiënten met een FUT2 non-secretor status (AA), die een donor 
lever ontvingen van een FUT2 secretor donor (GG of GA). Een experimentele studie 
in transgene muizen ondersteunt deze hypothese. Hierbij werd door een verhoogde 
immuunrespons een verkorte transplantaatoverleving aangetoond van huid en hart-
weefsel met overexpressie van fucosyltransferase, welke getransplanteerd werden naar 
wild-type ontvangers[31]. Daarnaast sluiten de resultaten van onze studie niet uit dat 
cholangiocyten uit de resterende galweg van de ontvanger de nieuwe donor galweg 
repopuleren. Dit type chimerisme is al eens eerder aangetoond, maar niet in de context 
van NAS[32].  
Behalve het darmepitheel hebben FUT2 non-secretors ook een veranderde glycosyl-
ering van cholangiocyten en een veranderede bacteriële samenstelling van gal, welke 
beiden kunnen bijdragen aan het ontwikkelen van NAS[22]. Een veranderde samenstell-
ing van de glycocalyx beïnvloedt het alkaline milieu van cholangiocyten, welke normali-
ter in stand wordt gehouden door de ‘bicarbonate umbrella’. Dit maakt cholangiocyten 
meer kwetsbaar voor toxische galzouten[33, 34]. Bovendien is een veranderde samen-
stelling van de gal in verband gebracht met een hogere incidentie van cholangitis, 
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galwegcomplicaties en een verkorte transplantatievrije overleving[35-37]. Onze studie 
levert echter geen direct bewijs voor een verhoogde toxiciteit door galzouten in FUT2 
non-secretors, hoewel dit een interessant onderwerp blijft voor toekomstig onderzoek. 
Tenslotte blijkt dat de detectie van biomarkers die afhankelijk zijn van synthese door 
FUT2 enzymactiviteit, beïnvloed kan worden door het FUT2 genotype. Dit is aangetoond 
door Wannhoff et al. voor kanker antigen 19-9 (CA 19-9), welke vaak toegepast wordt als 
biomarker bij de screening op cholangiocarcinoom in patiënten met PSC[38]. Het blijkt 
dat PSC patiënten met een FUT2 non-secretor status hogere serumwaardes hebben 
van CA 19-9 vergeleken met FUT2 secretors. Om een betere voorspelbaarheid van deze 
biomarker te verkrijgen in termen van sensitiviteit, specificiteit en postief- of negatief 
voorspellende waarde, zou de grenswaarde van CA 19-9 hoger moeten liggen in FUT2 
non-secretors. Dus onderzoekers moeten zich bewust zijn van mogelijke genotype-
afhankelijkheid van biomarker waardes in toekomstige studies. 
andere polymorfismen geassocieerd met nas en PsC in levertransplantatie
Naast FUT2 zijn ook andere SNPs onderzocht in de context van NAS na levertransplan-
tatie. Ten Hove et al. lieten zien dat een mutatie in het gen coderend voor matrix metal-
loproteinase-2 (MMP-2) in zowel donoren als ontvangers een verhoogd risico geeft op 
het ontwikkelen van NAS[39]. MMP-2 is een enzym dat matrixdegradatie in weefsels 
reguleert en in verband is gebracht met leverfibrose en cirrose. Een polymorfisme aan-
wezig in zowel de donor als de ontvanger heeft een synergistisch effect en vergroot het 
risico op NAS (HR 3.48). Serumwaardes van MMP-2 veranderden echter niet door de SNP. 
Een vervolgstudie van dezelfde onderzoeksgroep liet zien dat het polymorfisme ook 
geassocieerd is met slechtere uitkomsten in termen van transplantatie-vrije overleving 
en mortaliteit in PSC patiënten[40]. 
Een andere SNP gerelateerd aan NAS is die van chemokine receptor CCR5 (CCR5-Δ32 
mutatie)[41]. CCR5 wordt tot expressie gebracht op verschillende cellen van zowel het 
aangeboren als het verworven immuunsysteem. Homo- en heterozygote dragers van 
de mutatie hebben bijvoorbeeld een verminderde chemotaxis van regulatoire T-cellen. 
CCR5-Δ32 in ontvangers, maar niet in donoren, geeft een viervoudig verhoogd risico op 
het ontwikkelen van NAS. De mutatie in ontvangers is een onafhankelijke risicofactor 
voor NAS, met name in patiënten met PSC. Helaas is er geen duidelijke gestratificeerde 
analyse uitgevoerd op het effect van de mutatie in niet-PSC patiënten. 
Al deze studies betreffende genetische polymorfismen en de ontwikkeling van NAS, 
inclusief onze eigen studie, tonen een sterke associatie aan met PSC. Dit leidt tot de 
discussie of de presentatie van NAS in deze studiecohorten in feite een terugkeer van 
de onderliggende ziekte is. Meerdere studies hebben aangetoond dat PSC een risicofac-
tor is voor het ontwikkelen van NAS[42, 43]. De criteria voor recidief PSC, welke zijn 
geformuleerd in 1999, bestaan uit; (i) een bestaande diagnose van PSC voorafgaand aan 
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levertransplantatie, met (ii) intra- en/of extrahepatische galweg stricturen, kralensnoer 
aspect of irregulariteiten, optredend na tenminste 90 dagen follow-up en aangetoond 
met cholangiografie, of fibreuze cholangitis en/of fibro-obliteratieve laesies met of 
zonder ductopenie, met histologische aangetoonde biliaire fibrose of biliaire cirrose[44, 
45]. Criteria die recidief PSC excluderen bestaan uit vastgestelde ductopene rejectie, 
HAT, enkelvoudige anastomotische stricturen, NAS optredend voor dag 90 na lever-
transplantatie en ABO-incompatibiliteit. Ondanks deze duidelijke beschrijving blijkt de 
diagnose van recidief PSC in de praktijk niet altijd even gemakkelijk. Ten eerste wordt 
de primaire diagnose van PSC in een minderheid van de gevallen pas duidelijk na een 
grondige histologische evaluatie van het leverexplantaat door de patholoog. Daarnaast 
wordt het typische kralensnoer aspect van PSC, zoals te zien is met cholangiografie, vaak 
pas duidelijk in een verder gevorderd stadium van de ziekte, terwijl meer geïsoleerde 
intrahepatische stricturen en dilataties vaker voorkomen in een vroeger stadium. Soms 
worden de eerste symptomen van de ziekte al duidelijk voor de 90e postoperatieve dag. 
En op basis van histologisch onderzoek op naaldbiopten kan het lastig zijn om recidief 
PSC te onderscheiden van andere aandoeningen zoals chronische rejectie[46, 47]. 
Vanwege het moeilijke onderscheid tussen recidief PSC en NAS verdient het de aan-
beveling om, indien mogelijk, altijd een gestratificeerde analyse uit te voeren voor apart 
PSC en niet-PSC patiënten in transplantatie cohorten. Bepaalde SNPs geassocieerd met 
recidief PSC en NAS kunnen gebruikt worden voor het in kaart brengen van risicopro-
fielen in patiënten. Bovendien verschaffen dergelijke SNPs meer inzicht in de onder-
liggende mechanismen en pathofysiologie van complicaties na levertransplantatie. 
De kennis dat bepaalde donor-ontvanger combinaties kunnen leiden tot ongunstige 
uitkomsten kan in de toekomst van invloed zijn op de toewijzing van donor organen, die 
momenteel vooral wordt bepaald door de MELD-score en de bloedgroep. 
risicofactoren voor galwegcomplicaties in perspectief
De bovenstaande paragrafen beschrijven een samenhangend geheel van risicofacto-
ren die elkaars invloed op de ontwikkeling van NAS lijken te versterken. Samengevat 
lijkt galwegschade te ontstaan door verlengde ischemie van het transplantaat, wat de 
hogere incidentie van NAS verklaart in DCD levers[48]. De vitaliteit van de galweg is 
sterk afhankelijk van bloedvoorziening door de arteria hepatica, maar verminderde 
bloedtoevoer vanuit de vena porta is ook in verband gebracht met NAS[10, 49, 50]. De 
hierop volgende reperfusie vergroot de schade aan het galwegepitheel en de PBGs. Dit 
tast niet alleen de regeneratie van cholangiocyten aan, maar ook de integriteit van de 
biliaire glycocalyx en ‘bicarbonate-umbrella’, die normaliter cholangiocyten beschermt 
tegen het toxische effect van galzouten. Patiënten met PSC hebben vaker een verstoorde 
biliaire glycocalyx, die daardoor makkelijker doordringbaar wordt voor pathogenen zo-
als bacteriën. Dit kan vervolgens een verhoogde translocatie veroorzaken van bacteriën 
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vanuit de darm naar de lever, maar kan ook leiden tot een versterkte immuunrespons als 
een lever van een FUT2 secretor donor geïmplanteerd wordt in een FUT2 non-secretor 
ontvanger. 
Deel iii: miCrornas als nieuwe biomarkers in leVertransPlantatie
Deel III van dit proefschrift richt zich op de toepassing van microRNAs (miRNAs of 
miRs) als biomarkers voor transplantaatfunctie en schade  bij levertransplantatie. Als 
introductie op dit onderwerp wordt in hoofdstuk 5 een overzicht gegeven van de liter-
atuur betreffende miRNAs in leverziekten en levertransplantatie, met speciale aandacht 
voor extracellulaire miRNAs. Na hun ontdekking in 2001 is het aantal publicaties over 
miRNAs als biomarkers explosief toegenomen, maar ook over de betrokkenheid bij 
andere pathologieën. MiRNAs zijn 20-23 nucleotiden lange, niet-coderende RNAs die 
post-transcriptioneel genexpressie kunnen reguleren. In het bloed, maar ook in andere 
lichaamsvloeistoffen, bevinden zich cel-specifieke miRNAs die stabiel zijn en beschermd 
blijven tegen degradatie. Dit maakt miRNAs een populair onderwerp voor non-invasief 
biomarker onderzoek. Een mogelijke verklaring voor de stabiliteit van miRNAs in 
lichaamsvloeistoffen is dat ze ingebed zijn in, of gebonden zijn aan, andere cellulaire 
componenten. Extracellulaire miRNAs zijn bijvoorbeeld gevonden in vesikels en klei-
nere exosomen, gebonden aan lipoproteïnen, of gebonden aan het eiwit argonaute-2 
in reactie op schadelijke processen. Binnen de hepatologie geven serumwaardes van 
miRNAs informatie over leverschade in patiënten met virale hepatitis, non-alcoholische 
leververvetting, leverfibrose, maligniteit en meer. In de context van levertransplantatie 
is de hoeveelheid literatuur over extracellulaire miRNAs als biomarkers echter schaars. 
micrornas als markers voor schade aan hepatocyten en cholangiocyten post-
levertransplantatie
Hepatocyten en cholangiocyten brengen verschillende miRNAs tot expressie. Een el-
egante studie uitgevoerd door Chen et al. gebruikte laser-capture microdissectie om 
cholangiocyten en hepatocyten te isoleren uit leverweefsel, waarna voor deze cellen 
afzonderlijk met behulp van genoomwijde microarray analyse werd bepaald welke 
miRNAs aanwezig waren[51]. Gebaseerd op de resultaten van Chen et al. heeft onze 
groep als eerste het vrijkomen van hepatocyt-afgeleide miRNAs (HDmiRs) in serum 
onderzocht op het moment van leverschade en acute rejectie na levertransplantatie[52]. 
De belangrijkste bevindingen van deze studie waren dat expressie van HDmiR-122 en 
HDmiR-148a significant verlaagd was in post-reperfusie biopten wanneer de warme-
ischemie tijd verlengd was. Omgekeerd bleken de waardes van deze miRNAs te stijgen 
in serum en sterk te correleren met AST en ALT waardes gedurende de eerste maand na 
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levertransplantatie. Sterker, de waardes van HDmiRs waren al significant verhoogd in se-
rum wanneer de transaminaselevels nog <50 IU/L waren. De piekwaardes van HDmiRs in 
serum liepen 24 uur voor op de piekwaardes van serum transaminases in patiënten met 
histologisch bewezen acute rejectie. Deze resultaten suggereren dat serum HDmiRs een 
vroegere en misschien zelfs sensitievere marker voor leverschade zijn dan de klassieke 
serum transaminases, welke momenteel nog de gouden standaard zijn als biomarker 
voor leverschade. 
Om meer inzicht te verkrijgen in de biologie en dynamiek van miRNAs, hebben we 
in hoofdstuk 6 het vrijkomen van miRNAs in gal en serum onderzocht gedurende ver-
schillende (patho)fysiologische condities van de lever na transplantatie. In deze studie 
zijn behalve HDmiR-122 en -148a ook cholangiocyt-afgeleide miRNAs (CDmiRs) getest, 
welke tevens zijn geïdentificeerd door de eerder genoemde studie van Chen et al. (CD-
miR-30e, -200c en -222)[51]. De weefsel-specificiteit van deze miRNAs werd bevestigd 
in leverbiopten en galwegweefsels die verzameld werden gedurende levertransplan-
tatie. In leverweefsel was HDmiR-122 het meest overvloedig, terwijl in galwegweefsel 
CDmiR-222 het hoogst tot expressie kwam. Over het algemeen waren miRNA waardes 
in gal hoger dan in gepaarde serummonsters. Fractioneringsproeven lieten zien dat de 
meerderheid van extracellulaire miRNAs in gal aanwezig waren in de niet te pelleteren 
fractie, en dat ze hierin  gedurende tenminste 1-4 uur beschermd werden tegen degra-
datie door verbindingen met proteïnes. Er werd een sterke correlatie gevonden tussen 
de excretie van HDmiR-122 en bilirubine naar gal, met hoge niveaus van HDmiR-122 
als de lever een goede excretiefunctie had. De waardes van HDmiR-122 in gal daalden 
drastisch wanneer de excretiefunctie van de lever verminderde. Interessant was de 
observatie dat CDmiR-222 waardes in gal een omgekeerde dynamiek vertoonden, met 
lagere waardes ten tijde van goede excretiefunctie en een stijging als de excretiefunctie 
verminderde. Veranderingen in excretiefunctie werden het duidelijkst weerspiegeld 
in miRNA waardes in gal, zonder significante veranderingen van miRNAs in gepaarde 
serummonsters. Leverschade en acute rejectie werden echter het duidelijkst weerspie-
geld door serum miRNAs. Ten tijde van schade stegen waardes van HDmiR-122 in gal 
en tegelijkertijd nog sterker in serum. Opnieuw vertoonde CDmiR-222 een tegenoverg-
estelde dynamiek.
Op basis van deze resultaten lijkt het erop dat het vrijkomen van HDmiRs en CDmiRs 
in gal en bloed gepolariseerd is, afhankelijk van de transplantaatfunctie en de mate van 
schade. De tegenovergestelde dynamiek tussen HDmiRs en CDmiRs lijkt bovendien 
meer te berusten op een actief mechanisme van uitscheiding dan op slechts passieve 
lekkage vanuit beschadigde cellen. De excretie van miRNAs naar gal gedurende goede 
transplantaatfunctie kan wijzen op een rol van miRNAs in de biliaire homeostase. Voor-
gaande studies hebben bijvoorbeeld laten zien dat expressie van miR-506, miR-222 en 
miR-199a-3p invloed hebben op de activiteit van anion exchanger 2 en de farnesoid-x 
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receptor[53, 54]. Verder laat onze studie de potentie van het gebruik van gal zien als me-
dium om met biliaire miRNAs de functie van het transplantaat te bepalen. Beperkingen 
van onze studie bestonden uit het kleine aantal patiënten van wie gal en serummon-
sters werden verzameld (n=10) en de afwezigheid van een 3D experimenteel model om 
het gepolariseerd vrijkomen van HDmiRs en CDmiRs te valideren. Met de voortdurende 
recente ontwikkelingen wat betreft het opbouwen en groeien van orgaanweefsel in het 
laboratorium kan dit laatste doel hopelijk in de nabije toekomst gerealiseerd worden 
[55, 56]. 
De betrokkenheid van miRNAs in cholangiopathieën is voornamelijk onderzocht bij 
cholangiocarcinomen[57]. In deze studies is gal de meest gebruikte bron voor miRNA 
analyse, gevolgd door serum. De expressie van miRNAs in weefsel is vooral gerelateerd 
aan de regulatie van doelwitgenen die betrokken zijn bij fibrose, apoptose, proliferatie, 
invasie, inflammatie, migratie, tumor groei, oncogenese, chemo-resistentie en andere 
pathofysiologische factoren. Opmerkelijk genoeg is er minder bekend over miRNAs in 
andere cholagiopathieën zoals primaire biliaire cirrose, PSC en biliaire atresie. De kennis 
over miRNA regulatie in de pathofysiologie van PSC zou in het bijzonder van belang 
kunnen zijn voor een beter begrip van NAS, gezien de overeenkomsten in klinische 
presentatie. In de context van PSC is miR-7a gerelateerd aan cholangiocytprolifera-
tie[58]. Andere studies beschrijven vooral miRNA profielen in gal en serum om PSC te 
onderscheiden van cholangiocarcinoom, wat lastig kan zijn op basis van slechts borstel-
cytologie[59, 60]. Door de regulerende aspecten van CDmiRs verder te ontrafelen 
kunnen deze miRNAs de basis vormen van nieuwe therapeutische doelwitten in NAS 
of andere cholangiopathieën, wat eerder al succesvol is gebleken voor HDmiRs in virale 
hepatitis[61, 62].  
micrornas als potentiële markers voor cholangiocytschade voorafgaand aan 
levertransplantatie
Markers voor schade aan cholangiocyten en het voorspellen van NAS zijn schaars. De 
meeste studies betreffen onderzoek naar galwegweefsels, welke hiervoor al uitvoerig 
beschreven zijn. Vanwege het chirurgische trauma en de lokale representativiteit geas-
socieerd met het verzamelen van biopten, zochten we naar een cholangiocytspecifieke 
biomarker die non-invasief gemeten kon worden voorafgaand aan implantatie van de 
donorlever. De studie in hoofdstuk 7 is geïnitieerd om te bepalen of extracellulaire 
miRNAs vrijkomen in perfusaten die gebruikt worden om het transplantaat te spoelen 
en of deze miRNAs een vroege marker zouden kunnen zijn voor NAS. Waardes van 
HDmiRs (miR-122 en -148a) en CDmiRs (miR-30e, -222 en -296) in het supernatant van 
perfusaten verkregen van levers die ITBL ontwikkelden (n=20) werden vergeleken met 
die van levers die geen galwegcomplicaties ontwikkelden (n=37). Om te corrigeren 
voor mogelijke verschillen in concentratie tussen perfusaten, werden ratio’s van HD-
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miRs/CDmiRs gebruikt voor analyse. Ontvangers van een donorlever die hoge HDmiR/
CDmiR ratio’s bevatte in het perfusaat, met name door lage CDmiR waardes, hadden 
een drie- tot zesmaal verhoogd risico op het ontwikkelen van ITBL tijdens follow-up. 
Het onderscheidend vermogen van HDmiR/CDmiR ratio’s was redelijk, met C-statistiek 
waardes tussen de 0.74-0.77. Er bestond echter wel een substantiële overlap in bio-
marker waardes tussen de ITBL en de niet-ITBL groep. 
Een mogelijke verklaring voor de lagere CDmiR waardes in perfusaten van de ITBL 
groep zou het verlies aan cholangiocyten kunnen zijn[7]. Analyse van gepaarde leverbi-
opten (n=24), welke overigens minder goed presteerden als voorspellende biomarker, 
liet echter geen verminderde weefselexpressie zien van CDmiRs. Deze observatie is op 
zijn beurt weer te verklaren door de manier waarop de biopten zijn verzameld; dit waren 
namelijk wigbiopten van leverweefsel afkomstig van het linker laterale segment. Welli-
cht dat CDmiRs in perfusaat beter correleren met de expressie in galwegweefsel, dat 
meer cholangiocyten bevat. Dit moet toekomstig onderzoek nog uitwijzen. Verder zou 
het kunnen dat door hun overvloedigheid in weefsel kleine veranderingen in miRNA 
expressie niet significant zijn, terwijl de effecten van kleine veranderingen duidelijker 
naar voren komen in cel-armere perfusaten. Daarnaast zou het vrijkomen van CDmiRs 
in gal gedurende galwegschade, zoals aangetoond in hoofdstuk 6, de lagere waardes 
van CDmiRs in perfusaten kunnen verklaren. De redenering dat CDmiRs vrijkomen in het 
galweglumen vormde de basis van een andere studie die profielen van miRNAs onder-
zocht in de context van ITBL. Lankisch et al. hebben miRNA profielen in gal beschreven 
bij patiënten met verschillende soorten galwegcomplicaties, met specifieke aandacht 
voor ITBL[63]. Zij opperden dat veranderingen in het galwegepitheel zoals bij ITBL 
het best weerspiegeld worden in de samenstelling van de gal, terwijl complicaties als 
choledocholithiasis voornamelijk voor een obstructie van gal zorgen. De onderzoekers 
screenden op relevante miRNAs in ongefractioneerde galmonsters die waren verkregen 
door middel van endoscopische retrograde cholangiografie (ERC) bij levertransplan-
tatiepatiënten met ernstige ITBL (n=4) versus patiënten met enkele anastomotische 
stricturen (n=4). Uit een pool van 905 miRNAs identificeerden zij zeven potentiële 
miRNAs van belang, die vervolgens gevalideerd werden in een groter patiëntencohort 
(ITBL n=37, anastomotische stricturen n=39 en patiënten met galstenen n=12). Zo 
resteerden drie relevante miRNAs, miR-517a, miR-892a en miR-106a*, welke significant 
verschillende waardes hadden in gal van patiënten met ITBL ten opzichte van patiënten 
met anastomotische stricturen en galstenen. Deze miRNAs waren echter niet in staat om 
onderscheid te maken in de ernst of de mate van ITBL. Limitaties van de studie betref-
fen de relatief lage niveaus van miRNAs, als ook de lage sensitiviteit en specificiteit van 
miRNAs bij het voorspellen van ITBL. En door het achterwege laten van een multivariate 
analyse blijft het onbekend of de geïdentificeerde miRNAs in gal voorspellers zijn voor 
ITBL, onafhankelijk van andere patiëntkarakteristieken. 
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fracties extracellulaire mirnas: meer dan een ingewikkelde manier om schade 
te meten?
Redenerend dat schade aan hepatocyten en cholangiocyten leidt tot het actief of passief 
vrijkomen van miRNAs uit cellen, hebben we in hoofdstuk 6 en 7 de aanwezigheid van 
extracellulaire miRNAs geanalyseerd in het supernatant van gal en perfusaten. MiRNAs 
waren echter ook aanwezig in andere cel-vrije fracties, zoals organellen en kleinere 
vesikels zoals exosomen. Het percentage miRNAs dat zich in deze fracties bevond was 
echter laag, met minder dan 1% van de miRNAs aanwezig in kleinere vesikels. 
Er is veel discussie gaande over de vraag welke fractie van gal, perfusaat of andere 
biovloeistoffen geanalyseerd dient te worden bij de bestudering van extracellulaire 
miRNAs. Lankisch et al. gebruikten ongefractioneerde galmonsters voor miRNA anal-
yse. Daarom blijft het onduidelijk welke van de door hen geïdentificeerde miRNAs in 
gal aanwezig waren in cellen of in de vloeibare fractie. Shigehara et al., die als eerste 
diagnostische miRNA profielen in gal beschreven voor cholangiocarcinoom, vonden 
een meerderheid van de gedetecteerde miRNAs in cellen, terwijl een veel lagere ho-
eveelheid teruggevonden werd in de fractie met microvesikels[64]. Voorgaande studies 
betreffende microvesikels en exosomen in gal laten zien dat deze fracties wel degelijk 
verschillende miRNAs kunnen bevatten. Li et al. hebben bijvoorbeeld een diagnostische 
miRNA assay ontworpen voor cholangiocarcinoom, gebruikmakend van geïsoleerde 
microvesikels in gal[65]. Analyse van miRNAs in exosomen in gal kan waarschijnlijk meer 
informatie opleveren over cholangiocyt-regulerende mechanismen en transmissie van 
ziekte[66-68]. Waarschijnlijk is er geen goed of fout in het besluit om exosomen of su-
pernatant te analyseren op extracellulaire miRNAs, afhankelijk van de onderzoeksvraag. 
Maar onderzoekers dienen er rekening mee te houden dat de keuze om een bepaalde 
fractie te analyseren, kan leiden tot verschillen in de prestatie van miRNAs als biomarkers. 
Sommige miRNAs zullen namelijk voorspellende waarde hebben in exosomen maar niet 
in supernatant en vice versa[69]. Bovendien kan de aanwezigheid van miRNAs afwijken 
tussen verschillende populaties exosomen[70]. Ons besluit om het supernatant van gal 
en perfusaten te analyseren werd voornamelijk gedreven door het feit dat slechts een 
minderheid van de miRNAs zich in exosomen bevond en dat een dergelijke studieopzet 
het risico met zich meebrengt dat andere belangrijke miRNAs over het hoofd zouden 
worden gezien[71]. 
De vraag blijft of extracellulaire miRNAs een ingewikkelde manier zijn om simpele 
cellekkage te detecteren, die ook gemakkelijker bepaald zou kunnen worden met con-
ventionele markers als AST en ALT. Zoals besproken in hoofdstuk 2 zijn waardes van 
AST en ALT in perfusaten immers voorspellend voor het optreden van EAD en PNF na 
levertransplantatie. Bovendien laten Den Dulk et al. zien dat piekwaardes van serum ALT 
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>1300 IU/L voorspellend zijn voor NAS na DCD levertransplantatie[2]. Dus waarom zou 
men dan een dure en arbeidsintensieve meting verrichten naar miRNAs? Een argument 
in het voordeel van miRNAs is de vroege stijging in biovloeistoffen, die meer sensitief 
lijkt te zijn dan die van levertransaminasen[52, 72]. Daarnaast zijn CDmiRs meer specifiek 
voor schade aan cholangiocyten dan transaminasen die voornamelijk aanwezig zijn in 
hepatocyten. De correlatie tussen piek serum ALT en NAS komt dan ook waarschijnlijk 
voort uit ernstige ischemische schade die zowel hepatocyten als cholangiocyten aan-
tast. Het vrijkomen van CDmiRs kan echter ook gerelateerd zijn aan andere factoren die 
samenhangen met cholangiocyt schade, wat moet blijken uit toekomstig onderzoek. 
Tenslotte, het feit dat miRNAs ook aanwezig zijn in andere extracellulaire fracties maakt 
ze meer geschikt voor het bestuderen van onderliggende mechanismen van schade. 
Een versnelde en geoptimaliseerde detectie van miRNAs, welke in een latere paragraaf 
nog aan bod zal komen, maakt ze aantrekkelijker en beter toepasbaar bij klinische 
levertransplantatie.    
Het effect van heparine op de detectie van micrornas
Een van de grote voordelen van miRNAs boven messenger RNA als biomarker is hun sta-
biliteit op kamertemperatuur, zoals aangetoond in hoofdstuk 6 en 7, en hun stabiliteit 
na herhaalde cycli van vriezen en ontdooien. Nadelen zijn de tijdsintensieve procedures 
van RNA isolatie en reverse-transcriptase kwantitatieve PCR (RT-qPCR). Hoewel RT-qPCR 
een sensitieve techniek is die zeer kleine hoeveelheiden miRNAs en andere genen kan 
meten, zijn er factoren beschreven die qPCR kunnen inhiberen en zodoende foutieve 
resultaten opleveren. Hoofdstuk 8 en 9 van dit proefschrift focussen op een dergelijke 
PCR-inhiberende component, namelijk heparine, en het effect ervan op miRNA detectie. 
Hoofdstuk 8 is een re-analyse van onze studie beschreven in hoofdstuk 7, nadat we 
vermoedens kregen dat perfusaten sporen konden bevatten van heparine die was toe-
gediend gedurende de orgaanuitname procedure. Heparine gaat een sterke verbinding 
aan met endotheelcellen en kan daarom nog steeds aanwezig zijn in de donorlever, zelfs 
na veelvuldig spoelen met preservatie vloeistof[73]. We analyseerden onze monsters 
opnieuw met qPCR, maar ditmaal nadat de RT-stap was uitgevoerd in aanwezigheid van 
heparinase I, een enzym dat heparine afbreekt[74]. Dit gaf een lichte verbetering van de 
detectie van vrijwel alle miRNAs in perfusaten, wat er op duidt dat kleine hoeveelheden 
heparine aanwezig waren die de eerste meting van verschillende miRNAs in eenzelfde 
mate hebben beïnvloed. Het effect was echter sterker bij de detectie van HDmiR-148a. 
Dit kan verklaard worden doordat de niveaus van HDmiR-148a in sommige monsters, 
voorafgaand aan de behandeling met heparinase I, boven de detectielimiet was, maar 
waarvan de detectie in een aantal monsters na behandeling met Heparinase I drastisch 
verbeterde. Een mogelijke vervuiling met heparine had echter geen effect op de voor-
spellende waarde van miRNAs zoals beschreven in hoofdstuk 7, want HDmiR/CDmiR 
ratio’s veranderden niet significant tussen de monsters. Het verdient dus aanbeveling 
om bij de analyse van miRNA ratio’s te bepalen in plaats van enkelvoudige miRNA’s 
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om het risico op foutieve resultaten te vermijden wanneer er mogelijk heparine in de 
monsters aanwezig is.
In hoofdstuk 9 zijn meer technische aspecten met betrekking tot de inhiberende 
effecten van heparine en het tegengaan hiervan met heparinase I bestudeerd. Naast gal 
en bloed is er steeds meer interesse voor het bepalen van non-invasieve biomarkers in 
andere, wellicht nog gemakkelijker te verkrijgen lichaamsvloeistoffen. MiRNAs in urine 
blijken stabiele biomarkers te zijn bij niertransplantatie en hepato-pancreato-biliaire 
maligniteiten[75-78]. De meeste studies die miRNAs in urine onderzochten, verza-
melden monsters van gehospitaliseerde patiënten die vaak profylactisch anticoagu-
lantia ontvingen, zoals ongefractioneerde- of laag-moleculair-gewicht heparine (UH en 
LMWH, respectievelijk). Heparine wordt deels uitgescheiden naar de urine door de nie-
ren, maar potentiële inhiberende effecten op de detectie van miRNAs in urine zijn nog 
niet eerder onderzocht. Voor onze studie hebben we het supernatant van urinemonsters 
onderzocht die waren verkregen van gezonde nierdonoren en levertransplantatie ont-
vangers, met gehepariniseerde en niet-gehepariniseerde individuen in beide groepen. 
De detectie van miRNAs in urine met RT-qPCR was sterk geïnhibeerd en dosis afhankelijk 
in monsters van gehepariniseerde individuen. Dit veroorzaakte een sterke variatie in 
de waardes van miRNAs in urine en zou dus kunnen leiden tot vertekende uitkomsten 
bij biomarker studies. De variatie nam echter sterk af wanneer monsters tijdens de 
RT-stap behandeld werden met heparinase I, waardoor de inhiberende effecten van 
heparine bijna volledig teniet werden gedaan. De detectie van miRNAs in weefsel werd 
niet beïnvloed door systemische toediening van heparine. De inhibitie van de RT-qPCR 
reactie komt voort uit de co-isolatie van heparine met het RNA. De mate van heparine 
co-isolatie varieert waarschijnlijk tussen verschillende isolatie methoden. In onze studie 
is RNA geïsoleerd op basis van molecuul grootte, waarbij ook andere moleculen zoals 
LMWH de isolatie kolom kunnen passeren en terecht kunnen komen in het geïsoleerde 
materiaal. Protocollen die een andere aanpak hebben voor de isolatie van miRNAs, zoals 
elektrochemische magnetische bolletjes, ondervinden mogelijk minder problemen van 
heparine vervuiling in RNA monsters[79]. De resultaten uit onze studie wijzen er echter 
op dat in gehospitaliseerde patiënten die systemisch anticoagulantia toegediend krij-
gen, monsters gebruikt wordendie bij biomarker onderzoek gecontamineerd kunnen 
zijn met heparine, met mogelijke effecten op de uitkomst van het onderzoek.
optimalisatie en validatie van mirna detectie 
Geoptimaliseerde detectie en validatie van miRNAs is tevens afhankelijk van verschil-
lende andere factoren die aandacht verdienen. Een van de vragen die opkomt is op 
welk materiaal een miRNA array uitgevoerd dient te worden voor het identificeren 
van potentieel interessante miRNAs. In veel studies wordt gekozen om een array uit te 
voeren op weefsel van een klein identificatie cohort (zo’n vier tot zeven patiënten per 
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groep) en om de meest significante miRNAs te valideren in een groter validatie cohort. 
Het uitvoeren van een array op weefsel om later te valideren in lichaamsvloeistoffen 
zoals serum en gal kan echter teleurstellende resultaten opleveren. Sommige miRNAs in 
weefsels zijn nauwelijks detecteerbaar in lichaamsvloeistoffen. Daarnaast bevat weefsel 
vaak een grote variatie aan celtypen, wat kan leiden tot ongelijkheid binnen groepen 
en niet significante resultaten in validatie cohorten, zelfs bij gebruik van vergelijkbare 
biomaterialen[80]. Dit probleem kan wellicht vermeden worden door bijvoorbeeld 
celtypen te selecteren door middel van  laser capture microdissectie, in plaats van het 
gebruik van hele biopten voor de isolatie van miRNAs[51].  
Ten tweede kan het opwerken van weefsels en biovloeistoffen verschillen tussen 
transplantatiecentra, wat het vergelijken van de bruikbaarheid van biomarkers be-
moeilijkt. Dit is vooral het geval bij het verzamelen van perfusaten. Niet alleen het type 
preservatie vloeistof, maar ook het volume en de manier waarop het transplantaat wordt 
gespoeld verschilt tussen ziekenhuizen. Bovendien kan de keuze van het biomateriaal 
gevolgen hebben voor de kwaliteit van het geïsoleerde RNA. Formaline-gefixeerde 
biopten ingebed in paraffine (FFPE) worden als inferieur beschouwd voor de isolatie 
van RNA vergeleken met direct bevroren biopten. De laatste jaren is echter duidelijk 
geworden dat ook FFPE biopten een waardevolle en betrouwbare bron vormen voor 
miRNA onderzoek[81-83]. 
Tenslotte richt steeds meer onderzoek zich op het versnellen en vereenvoudigen 
van de isolatie en detectie van miRNAs. De normale RT-qPCR techniek, momenteel 
de gouden standaard voor miRNA detectie, maakt het voor clinici onaantrekkelijk 
om miRNAs toe te passen tijdens levertransplantatie vanwege de tijdrovende en ar-
beidsintensieve procedure. Maar nieuwere technieken om miRNA detectie te versnellen 
lijken veelbelovend. Liu et al. hebben bijvoorbeeld onlangs een biosensor ontwikkeld 
die direct miRNAs kan detecteren door middel van lichtfase veranderingen tussen 
complementaire DNA probes en doelwit miRNA. Op deze manier duurt de detectie van 
miRNAs in urine ongeveer 15 minuten[84]. Dit is slechts een voorbeeld van de vele in-
novatieve ontwikkelingen om miRNA detectie te versnellen en optimaliseren. Met de 
opmars van machine preservatie om de kwaliteit van het transplantaat te optimaliseren, 
wordt vroeg-detectie van galwegschade met behulp van versnelde miRNA metingen in 
recirculerende perfusaten extra interessant. 
Conclusies en toekomstperspectieven
De studies beschreven in dit proefschrift dragen bij aan een betere evaluatie van de 
kwaliteit van het transplantaat en de prestatie van potentiële biomarkers om accuraat 
het risico op complicaties na levertransplantatie te voorspellen. De introductie van 
machineperfusie creëert extra tijd waarin biomarkers in perfusaat gemeten kunnen 
worden voor de evaluatie van levers afkomstig uit kwalitatief marginale donoren. Maar 
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ook de productie en samenstelling van gal geven informatie over transplantaatfunctie. 
DCD levers lijken geen verhoogde neiging te hebben op het vormen van microtrombi 
gedurende transplantaat preservatie. Daarom lijkt het intra-operatief toedienen van 
fibrinolytica ter preventie van NAS niet gerechtvaardigd. Genetische predispositie 
is een extra risicofactor op het ontwikkelen van NAS in levertransplantatie patiënten 
die tevens PSC als onderliggend lijden hebben. Donor-ontvanger mismatch in FUT2 
secretor status verhoogt het risico op vroege ontwikkeling van NAS nog sterker. Een 
aangepaste toewijzing van donorlevers op basis van genetische screening van donoren 
en PSC patiënten zou daarom kunnen bijdragen aan betere uitkomsten in deze groep. 
Met de toenemende hoeveelheid levers afkomstig van uitgebreide criteria donoren zijn 
meer objectieve en sensitieve biomarkers noodzakelijk om ernstige galwegcomplicaties 
als NAS te voorspellen. MiRNAs, in het bijzonder CDmiR, hebben potentie als vroege 
voorspellers van NAS al ten tijde van transplantaat preservatie. De toepassing van miR-
NAs in de klinische praktijk is echter afhankelijk van het optimaliseren en versnellen van 
detectie technieken. Nieuwe ontwikkelingen in dit veld lijken veelbelovend en miRNAs 
in biovloeistoffen kunnen een waardevolle toevoeging zijn naast de klassieke biomark-
ers. Met objectieve biomarkers kan de donorvoorraad en het aantal geëffectueerde DCD 
donoren voor levertransplantatie in de nabije toekomst hopelijk worden vergroot. 
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2013 Voorjaarsvergadering NVGE, Veldhoven
2013 Bootcongres NTV, Nijmegen
2012 Dutch liver retreat, NVH, Spier
2012 Bootcongres NTV, Maastricht
2012 Voorjaarsvergadering NVGE, Veldhoven, Nederland
2011 24e Symposium Experimenteel Onderzoek Heelkundige Specialismen 
(SEOHS), Amsterdam
National conferences, participation
2015 Chirurgendagen, Nederlandse vereniging voor Heelkunde (NVvH), 
Veldhoven
2013 Chirurgendagen, Nederlandse vereniging voor Heelkunde (NVvH), 
Veldhoven
2012 25e Symposium Experimenteel Onderzoek Heelkundige Specialismen 
(SEOHS), Amsterdam
Teaching activities
2014 Supervisor Clinical review writing in transplantation, Medicine, 
Erasmus MC 
2013 Supervisor Clinical review writing in transplantation, Medicine, 
Erasmus MC
2013 Lecturer, gastroenterology- and hepatology minor, Medicine, Erasmus 
MC
2013 Internship supervisor of a third year laboratory student, Erasmus MC 
2012 Research supervisor of a minor student in Medicine, Erasmus MC
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scientific awards and grants 
2015 Travel grant (€1000) KNAW Van Walree beurs
Travel grant (€500), Erasmus Trustfonds 
Travel grant (€500) Gerrit Jan Mulder stichtin.
Travel grant (€500), NVGE
2014 Travel Scholarship ($10.000), ILTS 
Rising star award ($1500), ILTS 
Novartis Transplantation Award (€1500), NTV 
2013 Travel grant (€500), Erasmus Trustfonds
Genzyme Speakers award, NTV
2012 Best research idea (€3500), NVH
Best Master Thesis award (€500), NIHES
Young Investigator’s Award ($1000), ILTS 
2011 Young Investigator’s Award ($1000), ILTS
other academic activities 
2014-current Member of the Basic Science Committee of the ILTS 
2012-current Invited reviewer for scientific journals (Liver Transplantation, Liver 
International, Transplant International) 
2011-2014 Student-member of the committee of (bio)medical sciences of the 
Royal Dutch Academy of Sciences (KNAW)
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DankwoorD
Na vier jaar zwoegen is “het boekje” eindelijk af! Wat begon als een afstudeerproject voor 
mijn Research Master, mocht uitgebreid worden tot een volwaardig wetenschappelijk 
proefschrift. Voor deze unieke kans die zich tijdens mijn geneeskunde studie voordeed 
ben ik velen nog steeds dankbaar, want het succesvol volbrengen van een promotie 
onderzoek is niet mogelijk zonder de steun, toewijding en inspanning van anderen. De 
patiënten en de overleden donoren die schuilgaan achter de data gepresenteerd in dit 
proefschrift zijn dan wel onzichtbaar, zij vormen de basis van transplantatie onderzoek. 
Daarnaast wil ik graag nog een aantal mensen persoonlijk bedanken.  
Zeergeleerde heer van der laan, beste Luc, ik had me geen betere copromotor kun-
nen wensen. Tijdens mijn bijbaantje in het levertransplantatie studententeam was je 
vooral de man die mijn declaratieformulier moest ondertekenen nadat er bij nacht en 
ontij weer eens biopten gehaald moesten worden van de OK. Maar amper een jaar later 
leerde ik je kennen als een ietwat chaotische maar fantastisch creatieve wetenschapper! 
Dank voor alle vrijheid die je me hebt gegeven tijdens het onderzoek, je aanstekelijke 
enthousiasme voor nieuwe projecten, de wekelijkse sparringssessies, de gevaarlijke 
autorit uit Leuven, je dansmoves op de Michael Jackson coverband in San Francisco en 
de Mexicaanse lunches in het buitenland. Dank ook voor de rustmomenten die je me 
hebt gegeven tijdens de coschappen en dat ik altijd mocht binnenlopen als ik in de 
buurt was, al was het maar om even van alle laatste nieuwtjes op de hoogte te blijven.    
Hooggeleerde heer iJzermans, beste professor, zelfs in een latere fase van mijn 
onderzoekstraject was u bereid om zich over me te ontfermen als supervisor. Hoewel de 
kleurenschema’s nooit helemaal aan de eisen voldeden (‘groen betekent gepubliceerd 
of geaccepteerd!’) werden de deadlines netjes gehaald dankzij uw strakke begeleiding. 
En als ik nieuwe resultaten van een studie presenteerde, wist u altijd wel minstens drie 
nieuwe vervolgonderzoeken te bedenken, waarna ik me vervolgens zorgen kon maken 
over hoe ik al dat werk nog gedaan moest krijgen in één promotie. 
Hooggeleerde heer metselaar, beste professor, samen met Luc was u een stabiele 
factor tijdens het onderzoek. Ik kan me nog goed herinneren hoe u mij het voorstel deed 
om fulltime onderzoek te gaan doen en dat ik er een weekendje over mocht nadenken, 
omdat ik een week later eigenlijk zou starten met coschappen. Dank voor uw directheid, 
het heeft altijd tot verbetering geleid, zelfs toen ik op mijn eerste internationale congres 
een dag voor de presentatie nog alle powerpoint slides moest aanpassen! Ook veel 
dank voor de bereidwilligheid om altijd te helpen met het beoordelen van ERCP’s van 
transplantatiepatiënten, desnoods met het sportjournaal op de achtergrond. 
Hooggeleerde heer kazemier, beste Geert, zonder jou was dit proefschrift met mijn 
naam op de voorkant er misschien nooit geweest. Toen ik als student mijn eerste stap in 
de OK zette, heb je me letterlijk aan de hand meegenomen om me rond te leiden (of om 
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te zorgen dat ik geen bedreiging vormde voor het steriele veld). Jij was tevens degene 
die me heeft overgehaald om translationeel onderzoek te gaan doen, ook al had ik 
gezworen nooit meer een pipet aan te willen raken. Je bent de meest toegewijde en kri-
tische arts die ik ken en een grote inspiratiebron. Dank dat je destijds zoveel vertrouwen 
in mij had, het is toekomst bepalend geweest. En dank voor de levenslessen tijdens de 
vele cappuccino’s bij Doppio; een auto bezitten is een primaire levensbehoefte (de rode 
Beetle is helaas niet meer), en een Ipad winnen is inderdaad beter dan er een kopen. 
Hooggeleerde heer tilanus, beste professor, assisteren tijdens een levertransplan-
tatie was altijd een feestje als u aan tafel stond! Vooral de kritische vragen (‘wat is het 
verschil tussen een Hagenees en een Hagenaar?’) en instructies om mee te kijken bij 
een operatie (‘leun maar voorover over mijn schouder, maar niet in de patiënt vallen!’). 
Als geen ander wist u mij als ‘jonge collega’ op m’n gemak te stellen, of dit nou op de OK 
was of tijdens mijn eerste stafdag-diner. Tijdens het onderzoek hield u altijd een oogje in 
het zeil, om zeker te zijn dat de ‘s’ weggestreept kon worden. Dank dat u de taak op zich 
heeft willen nemen om mijn verdediging in goede banen te leiden!
Hooggeleerde heer looijenga en hooggeleerde mevrouw baan, dank dat u beiden 
zitting heeft genomen in de leescommissie en alle hoofdstukken uit deze pageturmer 
heeft willen doorlezen.  
Hooggeleerde heer Porte, beste Robert, als voorloper in het onderzoek naar galweg-
complicaties na levertransplantatie ben je onmisbaar als opponent, dank dat je hiervoor 
helemaal naar Rotterdam wilt afreizen! Ik heb genoten van onze gesprekken tijdens de 
vele nationale en internationale congressen die je altijd bezoekt. Meest memorabel was 
wellicht het bootcongres in Amsterdam, waarbij pogingen om de taxichauffeur midden 
op het Leidseplein te laten parkeren helaas mislukten. 
Veel dank aan alle levertransplantatiechirurgen die bereid waren om midden in de 
nacht nog extra weefsels af te nemen voor het onderzoek. Zeergeleerde heer Polak, 
beste Wojciech, dank voor de fijne samenwerking met het microthrombi onderzoek en 
het daarbij behorende “noodzakelijke” overleg bij de Starbucks ;). Zeergeleerde heer de 
Jonge, beste Jeroen, samen youtube filmpjes kijken maakte het wachten bij de experi-
menten van de anesthesie in de toren een stuk dragelijker. weledelgeleerde mevrouw 
tran, beste Khe, dank voor je excellente restaurant keuzes in Chicago! Zeergeleerde 
mevrouw terkivatan, beste Turkan, dank voor je (waarschijnlijk zelf onopgemerkte) 
support die je me eens gaf in voorbereiding op een marathon aan praatjes die ik moest 
houden bij het Bootcongres. Zeergeleerde mevrouw Hartog, beste Hermien, dank voor 
de oprechte en diepgaande gesprekken in Chicago en natuurlijk de vlucht ernaartoe en 
weer terug! Veel succes met je carrière binnen de transplantatie chirurgie!
Collega-onderzoekers uit de van der Laan-groep, dank voor alle hulp in de roller-
coaster van de afgelopen jaren! weledelgeleerde mevrouw de ruiter, beste Petra, 
wat had ik zonder jouw hulp op het MDL-lab gemoeten?! Dank voor al je hulp als ik 
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weer eens tegen een deadline aanliep, maar ook voor de fietstocht over de golden-gate 
bridge en weer terug, de congressen en tripjes. Zeergeleerde heer roest, beste Henk, 
jij wist altijd weer met een nieuwe lab-techniek op de proppen te komen waarmee veel 
artikelen tot een hoger niveau zijn getild. Dank voor je hulp bij het heparinase-project. 
Zeergeleerde mevrouw Verstegen, beste Monique, in jouw kundige handen gaan 
die lever organoïden echt nog wel groeien, misschien kun je me als post-doc nog wat 
adviezen geven voor de toekomst! weledelgeleerde mevrouw toxopeus, lieve Eel, het 
microRNA onderzoek heeft ons beide soms tot wanhoop gedreven, jou misschien nog 
wel het meest. Des te meer bewonder ik je en om hoe je met tegenslagen in onderzoek 
om wist te gaan. Je gaat een fantastisch chirurg worden, succes met je opleiding en het 
afronden van het boekje! Zeergeleerde heer farid, beste Waqar, jij hebt me de tips 
and tricks van het microRNA onderzoek bijgebracht, waarvoor dank. Het kon soms wat 
knallen tussen ons, maar dat heeft niet tot mindere publicaties geleid. Veel succes met je 
heelkunde opleiding in Maastricht! Zeergeleerde mevrouw fouraschen, beste Suomi, 
samen met Waqar heb je me begeleid tijdens de eerste fase van mijn onderzoek. Hoe 
hield je het toch vol daar beneden in de faculteit? Dank voor alle gezellige momenten! 
weledelgeleerde mevrouw selten, beste Jasmijn, ik weet nog goed hoe we elkaar 
hebben ontmoet tijdens de chirurgendagen, wat super dat je naar Rotterdam bent 
gekomen! Ik zie je nog steeds als toekomstig HPB-chirurg in Parijs, veel succes met alles. 
Beste sjoerd, je toewijding en inzet als student voor het studententeam en het lever-
transplantatie onderzoek zijn bewonderenswaardig, veel succes met de afronding van 
de studie geneeskunde! Very learned mrs. ramakrishnaiah, dear Veda, thanks for your 
help with the fractionation experiments, I wish you all the best in Arnhem. Very learned 
mr. Pan, dear abdullah, you are one of the most intelligent and fastest researchers I 
know. One day you will probably also learn to speak ‘Nederlands’ fluently!   
Niet zelden moest ik tijdens mijn onderzoek een beroep doen op de expertise van 
specialisten uit andere disciplines. Zeergeleerde mevrouw Hansen, beste Bettina, 
dank voor het delen van je statistische kennis, alleen al het installeren van SAS op mijn 
computer bleek een onmogelijke opgave. Zeergeleerde heer de bruin, beste Ron, het 
artikel over alpha-1-antitrypsine staat wellicht niet in mijn boekje, het gaat er zeker ko-
men. Dank voor je hulp bij de in vivo experimenten waar jij als geen ander bedreven 
in bent. Zeergeleerde heer grüne, beste Frank, de TEG-data hebben het helaas niet 
gehaald in het microthrombi artikel, toch heb ik genoten van je uitleg en je hulp bij het 
verbeteren van mijn vocabulaire Duits!
Collega-onderzoekers van het MDL-lab, dank voor alle mooie borrels, weekendjes 
weg, lunches, put-put op vrijdag, en beer of the month! Hooggeleerde heer Peppelen-
bosch, beste Michael, dank dat je ons onderzoekers al die gekkigheid liet uithalen in je 
mooie laboratorium en voor de onnavolgbare speeches tijdens promotieceremonies. 
Zeergeleerde heer kwekkeboom, beste Jaap, veel dank dat ik gebruik mocht maken 
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van de DNA-samples voor het FUT2 stuk, excuses voor mijn onzedige gevloek zo nu 
en dan op het lab. Mijn kamergenoten op de zesde verdieping van de onderzoek to-
ren; zeergeleerde mevrouw de mare-bredemeijer, lieve Em, wat bewonder ik je om 
je skills om te multitasken! Promoveren, kinderen opvoeden, en dat alles binnen de 
deadlines. Dank voor je luisterend oor op het laboratorium, de bootcongressen, mijn 
afscheidscadeau toen ik wegging van het lab. Veel succes in het SFG! Zeergeleerde 
heer Hoekstra, beste elmer, er zit alleen maar goedheid in jou. Altijd relaxed en in 
voor een feestje, hopelijk doen we dat in de toekomst nog eens over, succes in Leiden. 
weledelgeleerde heer de groen, beste Rik, dank voor het leuke weekend in Cadzand 
met de collega’s en je karaoke kunsten bij de borrels, succes met de afronding van je 
boekje. Zeergeleerde mevrouw spaan, beste Michelle, London baby! Wat gaaf dat je 
die stap genomen hebt. Zeergeleerde heer utomo, beste Wesley, we hadden beiden 
dezelfde kwelgeest op het lab, ik had met je te doen ;). De lekkere lunch van Cindy moet 
alles iedere dag weer goedgemaakt hebben. Veel geluk samen in de toekomst! Zeergel-
eerde mevrouw tjon, beste Angela, dank voor je altijd oprechte interesse in anderen, je 
wordt een fantastische internist. weledelgeleerde mevrouw van der aa, beste Evelyn, 
samen met Elmer en Rik organisator van vele feestjes, succes met je onderzoek. Very 
learned mr. shi, dear Xiao-Lei, you know how hard it was to arrange the Thursday morn-
ing meetings. And not rarely, we were both working at the lab untill late in the evening if 
there was a deadline. Good luck in China with your career. Al mijn andere MDL-collega’s; 
bedankt voor de mooie tijd!!  
Collega-onderzoekers van de afdeling heelkunde, het waren mooie jaren! Bedankt 
voor alle koffietjes, lunches, stafdagen, chirurgendagen en mooie skiweekenden. 
Zeergeleerde heer lafranca, beste Jeff, dat autorijden, met name in z’n achteruit, ga je 
nog wel onder de knie krijgen ;). Dank voor de borrels en italiaanse etentjes. weledel-
geleerde mevrouw Janki, beste Shiro, als ik weer eens wat vrije tijd had wist jij altijd 
wel een plekje in de Z-flat voor me vrij te houden, door jouw skills heb ik zelfs een thesis-
outline bij een van de meetings met de professor weten te overhandigen. Zeergeleerde 
mevrouw booy, beste Steeph, m’n maatje tijdens het onderzoek, als geen ander kende 
jij de stress van coschappen lopen en tegelijk het onderzoek afronden. Wat fantastisch 
dat we in de toekomst wéér collega’s gaan worden, maar dan binnen de KNO! Dat er nog 
maar vele wijntjes gaan volgen (of Breezers!).
Collega-onderzoekers uit Groningen, zeergeleerde mevrouw op den Dries, beste 
Sanna, gewaardeerde collega aan de andere kant van de wereld. Ik heb je boekje vaak 
gebruikt als leidraad voor het schrijven van de mijne en miste je aanwezigheid bij de 
laatste congressen. Dank dat je me aan een woonruimte hebt geholpen in Groningen 
voor mijn semi-artsstage! Zeergeleerde mevrouw arshad, lieve Freeha, naast collega 
onderzoeker uit Groningen ben je een huisgenootje en een goede vriendin geworden! 
Ik ken maar weinigen die zo integer en gepassioneerd hun vak uitoefenen als jij. Tegelijk 
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hebben we het onderzoek afgerond, ik ben trots dat ik je paranimf mocht zijn! Veel suc-
ces met je carrière als SEH-arts. 
During my PhD, I was given the opportunity to perform research at the laboratory 
for hepatobiliary surgery in Zürich. Highly learned mr. Clavien and highly learned 
mr. Dutkowski, thank you both for your hospitality and introducing me into the world 
of hypothermic oxygenated machine perfusion. I had a lovely time! Very learned mrs. 
schlegel, dear Andrea, without your efforts, my short time in Zürich would probably 
have been less efficient. Thanks for all the late night dinners, I still quietly laugh when I 
think about ‘there’s a donor, I need to transplant’ as a replacement for ‘there’s a fracture, 
I need to fix it’.  
Hooggeleerde heer beuers en hooggeleerde heer oude-elferink, dank voor de 
samenwerking bij het FUT2 onderzoek, ik ben voortaan een groot fan van wetenschap-
pelijk speed daten geworden! Very learned mr. maroni, dear Luca, I still use the Ipad 
we’ve both won during the Dutch liver retreat, it was worth skipping the party! I wish 
you all the best in Italy.
Achter iedere succesvolle promovendus staat een succesvolle (co)promotor… maar 
nog belangrijker, een betrouwbare secretaresse!! Ik had het genoegen om hulp vanuit 
drie verschillende hoeken te krijgen. Beste Carola Zandijk, in de laatste fase van mijn 
promotie was jij cruciaal, dank voor je snelle optreden als er weer en formulier onder-
tekend en verstuurd moest worden, of als ik snel een afspraak nodig had bij de prof. 
Beste marion Hoogendoorn, ik kan er nog steeds om lachen dat we beiden over die 
verkeerde terugvlucht datum hebben heengekeken! Dank voor je inspanningen toen ik 
in het buitenland zat. Beste leonie morée, moeder van het MDL-lab, zelfs ieder feestje 
ben je er bij! Dank voor je hulp op alle vlakken en je luisterend oor.
Beste stafleden en (pre-)AIOS van de afdeling KNO in het UMCG, er gaat niets boven 
Groningen, bedankt voor de leuke en leerzame tijd, ik verheug me om mijn onderzoek 
en opleiding voort te zetten bij jullie afdeling. Waar een ontmoeting tijdens een lever-
transplantatie congres wel niet toe kan leiden. 
Lieve collega-coassistenten van co-groep 14.35, de afgelopen twee jaar met jullie 
waren dolle pret! weledelgeleerde mevrouw van bekkum, lieve Saar, altijd was je 
bereid te helpen met indicaties of opdrachten voorbereiden als ik nog een deadline 
van mijn onderzoek moest wegwerken. Wat was het lekker om aan het eind van de dag 
samen wat stoom af te blazen op de tennisbaan. weledelgeerde mevrouw bril, lieve 
San, samen gestrand in Goes en vriendinnetjes gebleven. Je bent de slimste persoon die 
ik ken, wat heerlijk dat we ook nog wat onderzoek hebben mogen doen samen! Zonder 
je hulp was het FUT2 stuk nooit op tijd afgekomen. 
Lieve weledelgeleerde studie-vriendinnetjes, manon gijtenbeek, stefanie eind-
hoven, maartje van ’t Hof, rosanne ebbing, ingrid Coolen, Josianne ten berge, het 
onderzoek is af! Dank voor de noodzakelijk afleiding tussen het onderzoek door. Manon 
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en Stefanie, ik zal onze tijd in Boston nooit vergeten, vooral ook het weekendtripje naar 
Cape Cod en de beruchte Tea Party niet. 
weledelgeleerde heer römers, beste Luuk, het is een geruststellende gedachte om 
een goede vriend en collega te hebben die altijd wel wat goodies heeft om stressvolle 
momenten te tackelen ;). Gelukkig heb ik het nog niet nodig gehad! Bedankt voor je 
gezelligheid de afgelopen jaren. 
Tussen al het onderzoeks- en geneeskunde geweld is het fijn om af en toe in de om-
geving te zijn van mensen die ook eens over iets anders willen praten; weledelgeleerde 
vrienden max Posthumus, tim van der Heijden, Julia Drissen, renskje de wit en 
kristianne lie kwie, ieder jaar leef ik weer toe naar onze weekendjes weg, ik hoop dat 
deze traditie nog lang in stand blijft! Spin the bottle, linksaf slaan, trekgeit, planken, op 
zich wel leuk, Francesinha, associaties waarbij ik nog steeds spontaan in een lachstuip 
kan schieten en waarvan er ongetwijfeld nog velen zullen volgen in de toekomst!
Een bijzonder woord van dank aan mijn paranimfen. weledelgeleerde heer van den 
bossche, beste Wouter, als ik denk aan geneeskunde denk ik automatisch aan onze 
avonden op de snijzaal, de baanbrekende onderzoeken die we bedachten tijdens onze 
wekelijkse borrels, de exquise dinertjes, de skivakanties… ‘Alles is beter boven de cla-
vicula’ en ‘je weet wat ik daar van vind, Tessa’, zijn enkele van je gevleugelde uitspraken. 
Je zult zonder twijfel een fantastisch neurochirurg worden, maar onthoud goed; ‘brain 
surgery ain’t exactly rocket science!’ weledelgeleerde mevrouw romijn, lieve Tessa, 
zonder jou zou Wouter nooit zo goed z’n taak als paranimf kunnen uitvoeren! Ik kijk nu 
alweer uit naar de gezamenlijke skilessen. Dank voor je hulp in aanloop naar en op de 
grote dag zelf en dank voor de logeerkamer die altijd beschikbaar is. weledelgeleerde 
heer Verhoeven, lieve Jan, grote broer, ik kan me geen verdediging voorstellen zonder 
jou aan mijn zijde. We zijn totaal verschillend, maar je bent een voorbeeld en mijn beste 
vriend. Als ik me weer eens in een non-stop, geïsoleerde schrijfmodus bevond wist jij me 
daar uit te trekken door samen chinees te gaan eten of naar de film te gaan. Beloof me 
dat we dat we dat nog vaak gaan doen, ook al zal het aantal kilometers in woonafstand 
toe gaan nemen! Ik wens je veel geluk samen met Lieke, maar pas op dat je geen vet hart 
krijgt daar in 020 ;). 
Het laatste woord is aan mijn drie belangrijkste steunpilaren. weledelgeleerde heer 
Venmans, beste ome Arno, zolang als ik me kan heugen kwam je wekelijks bij ons eten 
en vertelde je over nieuwe wetenschappelijke ontdekkingen, de verre reizen, over het 
studeren aan de universiteit en schonk je me met sinterklaas zelfs mijn eerste (en tot nu 
toe enige) microscoop. Je hebt de onderzoeker in mij aangemoedigd en me gestimu-
leerd om kansen te benutten als die zich voordoen, waarvoor dank. Ik kom graag nog 
een keer naar je live-piano spel op de vleugel luisteren! lieve pap en mam, of ik nou 
van studie wisselde, onderzoek ging doen, weer eens ging verhuizen, of nog een stukje 
maand over had aan het einde van mijn geld; jullie steun was altijd onvoorwaardelijk. 
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Hoe kan ik jullie hier ooit voor bedanken? Het tuinhuisje lijkt me gewoonweg niet vol-
doende... Lieve mam, als geen ander weet jij dat de geneeskunde ook een donkere kant 
heeft, maar met je optimisme weet je iedere tegenslag weer te boven te komen. Lieve 
ome Arno, pap en mam, zonder jullie steun was dit boekwerk nooit afgekomen, dank 
voor alles!  
En dan nu: BUBBELS!!!
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Cornelia Johanna (given name Renée) Verhoeven was born on April 21st 1987 in Tilburg, 
The Netherlands. After graduating from secondary school in 2005, she studied Dutch 
law at Tilburg University. In 2007 she also started to study medicine at the Erasmus 
University Medical Center, Rotterdam, The Netherlands. During her study in 2009, she 
qualified for participating in a Research Master Programme of The Netherlands Institute 
for Health Sciences, for which she attended the Summer Programme at Harvard School 
of Public Health in Boston, United States of America in 2011. 
After completing her Research Master in 2012, she was allowed to extend her research 
into the current PhD project on biomarkers in liver transplantation at the department of 
Surgery (promotor: Prof.dr. J.N.M. IJzermans) and the department of Gastroenterology 
and Hepatology (promotor: Prof.dr. H.J. Metselaar). In 2014 she performed research at 
the laboratory of Hepatobiliary and Transplantation surgery at the UniversitätsSpital 
Zürich, Switzerland (supervisors: Prof.dr. P.A. Clavien and Prof.dr. P. Dutkowski). As mem-
ber of the committee of (bio)medical sciences of the Royal Dutch Academy of Sciences 
(KNAW), she was responsible for accreditation of Research Master programmes in the 
Netherlands from 2011 through 2015. Currently, she holds a position as member of the 
basic science committee of the International Liver Transplantation Society.
In August 2016, while finishing her PhD thesis, she obtained her medical doctors’ 
degree at the Eramus University Medical Center. She will continue her scientific and 
clinical career as a post-doctorate researcher in Head and Neck oncology and as resident 
in Ear-, Nose-, and Throat Surgery at the University Medical Center in Groningen, The 
Netherlands, under supervision of Prof.dr. B.F.A.M. van der Laan.
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